CA2163995A1 - Spiro-substituted azacycles as neurokinin antagonists - Google Patents
Spiro-substituted azacycles as neurokinin antagonistsInfo
- Publication number
- CA2163995A1 CA2163995A1 CA002163995A CA2163995A CA2163995A1 CA 2163995 A1 CA2163995 A1 CA 2163995A1 CA 002163995 A CA002163995 A CA 002163995A CA 2163995 A CA2163995 A CA 2163995A CA 2163995 A1 CA2163995 A1 CA 2163995A1
- Authority
- CA
- Canada
- Prior art keywords
- spiro
- piperidine
- dichlorophenyl
- methylamino
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed are spiro-substituted azacycles of formula (I), tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma. In particular compounds of formula (I) are shown to be neurokinin antagonists.
Description
WO 94t29309 PCT/US94/0~45 2 1 63q95 TITLE OF THE INVENTION
SPIRO-SUBSTITUTED AZACYCLES AS NEUROK~IN
ANTAGONISTS
The invention disclosed herein is directed to certain spiro-substituted azacycles useful as tachykinin receptor antagonists. In particular, the compounds disclosed herein are neurokinin receptor antagonists.
The tachykinins, substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), are structurally similar members of a family of neuropeptides. Each of these is an agonist of the receptor types, neurokinin-1 receptor (NK-1), neuorokinin-2 receptor (NK-2) and neuorokinin-3 receptor (NK-3), which are so defined according to their 5 relative abilities to bind tachykinins with high affinity and to be activated by the natural agonists SP, NKA and NKB respectively.
The tachykinins are distinguished by a conserved carboxyl-terminal sequence Phe-X-Gly-Leu-Met-NH2. More specifically, substance P is a pharmacologically-active neuropeptide that is produced 20 in mamm~ls and possesses a characteristic amino acid sequence:
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 Neurokinin A possesses the following amino acid sequence:
His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2.
Neurokinin B possesses the following amino acid sequence:
SPIRO-SUBSTITUTED AZACYCLES AS NEUROK~IN
ANTAGONISTS
The invention disclosed herein is directed to certain spiro-substituted azacycles useful as tachykinin receptor antagonists. In particular, the compounds disclosed herein are neurokinin receptor antagonists.
The tachykinins, substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), are structurally similar members of a family of neuropeptides. Each of these is an agonist of the receptor types, neurokinin-1 receptor (NK-1), neuorokinin-2 receptor (NK-2) and neuorokinin-3 receptor (NK-3), which are so defined according to their 5 relative abilities to bind tachykinins with high affinity and to be activated by the natural agonists SP, NKA and NKB respectively.
The tachykinins are distinguished by a conserved carboxyl-terminal sequence Phe-X-Gly-Leu-Met-NH2. More specifically, substance P is a pharmacologically-active neuropeptide that is produced 20 in mamm~ls and possesses a characteristic amino acid sequence:
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 Neurokinin A possesses the following amino acid sequence:
His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2.
Neurokinin B possesses the following amino acid sequence:
3 Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2.
(Chang et al., Nature New Biol. 232, 86 (1971); D.F. Veber et al., U.s.
Patent No. 4,680,283).
21 639~5 The neurokinin receptors are widely distributed throughout the m~mm~lian nervous system (especially brain and spinal ganglia), the circulatory system and peripheral tissues (especially the duodenum and jejunum) and are involved in regulatmg a number of diverse biological processes. This includes sensory perception of olfaction, vision, audition and pain, movement control, gastric motility, vasodilation, salivation, and micturition (B. Pernow, Pharmacol. Rev., 1983, 35, 85-141). The NK1 and NK2 receptor subtypes are implicated in synaptic transmission (Laneuville et al., Life Sci., 42: 1295-1305 (1988)).
Substance P acts as a vasodilator, a depressant, stimulates salivation and produces increased capillary permeability. It is also capable of producing both analgesia and hyperalgesia in animals, depending on dose and pain responsiveness of the ~nim~l (see R.C.A.
Frederickson et al., Science, 199, 1359 (1978); P. Oehme et al., Science, 208, 305 (1980)) and plays a role in sensory transmission and pain perception (T.M. Jessell, Advan. Biochem. Psychopharmacol. 28, 189 (1981)). In particular, substance P has been shown to be involved in the tr~nsmission of pain in migraine (see B.E.B. Sandberg et al., Journal of Medicinal Chemistry, 25, 1009 (1982)), and in arthritis (Levine et al.
Science, (1984) 226, 547-549).
In the airways, it has been indicated that NK1 receptors are associated with microvascular leakage and mucus secretion, while NK2 receptors regulate smooth muscle contraction. Also, it has been shown that both substance P and neurokinin A are effective in inducing airway constriction and edema. Based on such findings, it is believed that substance P and neurokinin A may be involved in the pathogenesis of neurogenic infl~mm~tion, including allergic diseases such as asthma.
(Frossard et al., Life Sci., 49, 1941-1953 (1991); Advenier, et al., Biochem. Biophys. Res. Comm., 184(3), 1418-1424 (1992)).
In experimental studies, sensory neuropeptides, especially tachykinins such as substance P and neurokinin A, can bring about many of the pathophysiological features of asthma. Neurokinin A is a very potent constrictor of human airways in vitro, and substance P causes mucus secretion in the airways. (Barnes P.J., Lancet, pp 242-44 (1986);
Rogers D.R., Aursudkij B., Barnes P.J., Euro. J. Pharmacol, 174, 283-86 (1989)).
Inhalation of bradykinin causes bronchoconstriction in asthmatic patients but not in normal subjects. (Fuller R.W., Dixon C.M.S., Cuss F.M.C., Barnes P.J., Am Rev Respir Dis, 135, 176-80 (1987)). Since the bradykinin-induced bronchoconstriction is partly opposed by anticholinergic agents and since bradykinin is only a weak constrictor of human airways in vitro, it has been suggested that the bronchoconstrictor response is partly mediated by a neural reflex.
Bradykinin stimulates vagal afferent C fibers and causes broncho-constriction in dogs. (Kaufman M.P., Coleridge H.M., Coleridge J.C.G., Baker D.G., J. Appl. Physio., 48, 511-17 (1980)). In guinea-pig air~vays, bradykinin causes a bronchoconstrictor response by way of cholinergic and sensory-nerve-mediated mech~ni~m.s. (Ichinoe M., Belvisi M.G., Barnes P.J., J. Pharmacol. Exp. Ther., 253, 594-99 (1990). Bradykinin-induced bronchoconstriction in human airways may therefore be due partly to tachykinin released from sensory nerve terminals via axon reflex mech~ni~m~. Clinical trials have shown that a dual NK-1/NK-2 antagonist (such as FK-224) protects against bradykinin induced bronchocontriction in asthmatic patients. (Ichinoe, M. et al., Lancet,, vol. 340, pp 1248-1251 (1992)).
The tachykinins have also been implicated in gastro-intestinal (GI) disorders and diseases of the GI tract, such as infl~mm~tory bowel disease, ulcerative colitis and Crohn's disease, etc.
(see Mantyh et al., Neuroscience, 25 (3), 817-37 (1988) and D. Regoli in "Trends in Cluster Headache" Ed. F. Sicuteri et al., Elsevier Scientific Publishers, Amsterdam, 1987, pp. 85-95).
It is also hypothesized that there is a neurogenic mechanism for arthritis in which substance P may play a role (Kidd et al., "A
Neurogenic Mech~nism for Symmetric Arthritis" in The Lancet, 11 November 1989 and Gronblad et al., "Neuropeptides in Synovium of Patients with Rheumatoid Arthritis and Osteoarthritis" in J. Rheumatol.
(1988) 15(12) 1807-10). Therefore, substance P is believed to be involved in the inflammatory response in diseases such as rheumatoid wo 94/29309 2 1 6 3 9 9 5 PCT/US94/0554~
arthritis and osteoarthritis (O'Byrne et al., in Arthritis and Rheumatism (1990) 33, 1023-8). Other disease areas where tachykinin antagonists are believed to be useful are allergic conditions (Hamelet et al., Can. J.
PhaImacol. Physiol. (1988) 66, 1361-7), immunoregulation (Lotz et al., Science (1988) 241, 1218-21, Kimball et al., J. Immunol. (1988) 141 (10) 3564-9 and A. Perianin, et al., Biochem. Biophys. Res. Commun.
161, 520 (1989)) vasodilation, bronchospasm, reflex or neuronal control of the viscera (Mantyh et al., PNAS (1988) 85, 3235-9) and, possibly by arresting or slowing ~-amyloid-mediated neurodegenerative changes (Yankner etal., Science, (1990) 250, 279-82) in senile dementia of the Alzheimer type, Alzheimer's disease and Downs Syndrome.
Substance P may also play a role in demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis (J. Luber-Narod et al., poster presented at C.I.N.P. XVIIIth Congress, 28th June-2nd July, 1992). Antagonists selective for the substance P and/or the neurokinin A receptor may be useful in the treatment of asthmatic disease (Frossard et al., Life Sci., 49, 1941-1953 (1991); Advenier, et al., Biochem. Biophys. Res. Comm., 184(3), 1418-1424 (1992)).
SUMMARY OF THE INVENTION
This invention is directed to compounds of forrnula I.
X' W
~) m The invention is also concerned with pharmaceutical folmulations with these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders.
21 6~995 The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of infl~mm~tory diseases, pain or migraine and asthma.
This invention is directed to compounds of formula I.
X' `W
o ~Z~) m I N
or a pharmaceutically acceptable salt thereof, wherein the nitrogen expressly shown above is optionally quaternized with Cl 4alkyl or phenylCl 4alkyl or is optionally present as the N-oxide (N+O-), and wherein:
20 l and m are each independently 0, 1, 2, 3, 4, or 5, with the proviso that 1 +misequalto 1,2,3,4,or5;
R1 is selected from a group consisting of:
( 1 ) hydrogen, (2) linear or brarlched C1 8 alkyl, linear or branched C2 8 alkenyl, or linear or branched C2 8 alkynyl, wherein the C1 8 alkyl, C2 g alkenyl or C2 g alkynyl is optionally mono, di, tri or tetra substituted, the substitutents independently selected from:
3 0 (a) hydroxy, (b) oxo, (c) cyano, (d) halogen which is defined to include Br, Cl, I, and F, (e) trifluoromethyl, WO 94/29309 2 1 6 3 q ~ 5 PCT/US94/05545 (f) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from ( 1 ) phenyl, (2) hydroxy, (3) Cl 3alkyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (7) -NR6COR7, wherein R6 and R7 are o independently selected from:
(a) hydrogen, (b) C1 6 alkyl, or mono or disubstituted C1 6 alkyl, the substitutents independently selected from (1) phenyl,unsubstituted or substituted with hydroxy, C1 3alkyl, cyano, halogen, trifluoromethyl or C1 4alkoxy, (2) hydroxy, (3) oxo, (4) cyano, (S) halogen, (6) trifluoromethyl, (c) phenyl, pyridinyl or thiophene or mono, di or trisubstituted phenyl, pyridinyl or thiophene, the substitutents independently selected from ( 1 ) hydroxy, (2) Cl 4alkyl, (3) cyano, 3 (4) halogen, (5) trifluoromethyl, (d) C1 3alkyloxy, or WO 94/2930g PCTIUS94/05545 2 1 639~5 R6 and R7 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or disubstituted, the substituents independently selected from (a) hydroxy, (b) oxo, (c) cyano, o (d) halogen, (e) trifluoromethyl, (8) -NR6C02R7, (9) -NR6CONHR7, (10) -NR6S(O)jR7, wherein j is 1 or 2, (11) -CONR6R7, (1 2) -COR6, (1 3) -C02R6, (14) -OR6, (15) -S(O)kR6 wherein k is 0, 1 or 2, (16) heteroaryl, wherein heteroaryl is selected from the group consisting of:
( 1 ) benzimidazolyl, (2) benzofuranyl, (3) benzoxazolyl, 2 5 (4) furanyl, (5) imidazolyl, (6) indolyl, (7) isoxazolyl, (8) isothiazolyl, 3 (9) oxadiazolyl, (10) oxazolyl, ( 1 1 ) pyrazinyl, (12) pyrazolyl, (1 3) pyridyl, (14) pyrimidyl, (1 S) pyrrolyl, ( 16) quinolyl, (17) tetrazolyl, (18) thiadiazolyl, (1 9) thiazolyl, (20) thienyl, and (21 ) triazolyl, wherein the heteroaryl is unsubstituted or mono, di or trisubstituted, the substituents independently selected from, (a) hydroxy, (b) oxo, (c) cyano, s (d) halogen, (e) trifluoromethyl, (g) -NR6R7, (h) -NR6COR7, (i) -NR6C02R7, (j) -NR6CONHR7, (k) -NR6S(O)jR7, (I) -CONR6R7, (m) -COR6, (n) -C02R6, 2 5 (o) -OR6, (p) -S(O)kR6, (q) heteroaryl, wherein heteroaryl is selected from the group consisting of:
( 1 ) benzimidazolyl, 3 (2) benzofuranyl, (3) benzoxazolyl, (4) furanyl, (5) imidazolyl, (6) indolyl, wo 94/29309 2 1 6 3 9 9 5 PCT/US94/05545 - (7) isoxazolyl, (8) isothiazolyl, (9) oxadiazolyl, (10) oxazolyl, (11) pyrazinyl, (12) pyrazolyl, (1 3) pyridyl, ( 14) pyrimidyl, (15) pyrrolyl, o (16) quinolyl, (1 7) tetrazolyl, (1 8) thiadiazolyl, (19) thiazolyl, (20) thienyl, (21) triazolyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from ( 1 ) phenyl, 2 o (2) hydroxy, (3) oxo, (4) cyano, (5) halogen, (6) trifluoromethyl, wherein the nitrogen of definition R1 2(g) as defined above is optionally quaternized with C1 4alkyl or phenylC1 4alkyl or is optionally present as the N-oxide (N+O-);
W is selected from the group consisting of 3 ( 1 ) a covalent bond (2) C1-3 alkyl, unsubstituted or substituted with (a) oxo, (b) hydroxy (C) OR6, (d) halogen, (e) trifluoromethyl, (f) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from ( 1 ) hydroxy, (2) cyano, (3) halogen, (4) trifluoromethyl, 3) S(O)k, (4) (C1-3 alkyl)-S(O)k, (5) S(O)k-(C1 -2 alkyl), (6) S(O)k-NH, (7) S(O)j-NH(C1 -2 alkyl), (8) S(O)j-NR6, (9) S(O)j-NR6-(C1-2 alkyl), (10) CONH, (11) CONH-(C1-2 alkyl), (12) CONR6, ( 13) CONR6-(C 1-2 alkyl), (14) CO2, ( 15) CO2-(C 1-2 alkyl);
Q = NR2, O, S, S(O), or SO2, with the proviso that when W is a covalent bond and X is C1 3alkyl, then Q must be NR2;
R2 is selected from a group consisting of:
2 5 ( 1 ) hydrogen, (2) C1-g linear or branched aLkyl, unsubstituted, monosubstituted or multiply substituted with (a) -OR6, (b) = o, 3 0 (c) -NHCOR6, (d) -NR6R7, (e) -CN, (f) -halogen, (g) -CF3, 2 1 639~
(h) -phenyl, unsubstituted or substituted, wherein the substitutents are selected from the group consisting of ( 1 ) hydroxy, (2) cyano, (3) halogen, (4) trifluoromethyl, (3) S(O)Rg, wherein R8 is C1-6 linear or branched alkyl, unsubstituted, mono di or trisubstituted with o (a) hydroxy, (b) oxo, (c) cyano, (d) -OR6, (e) -NR6R7, (f) -NR6COR7, (g) -halogen, (h) -CF3, (i) -phenyl or mono, di or trisubstituted phenyl, the substituents independently selected from 2 o ( 1 ) hydroxy, (2) oxo, (3) cyano, (4) -NHR6, (5) -NR6R7, 2 5 (6) -NR6COR7, (7) -halogen, (8) -CF3, and (9) Cl 3 alkyl, (4) S02R8, 3 0 (5) COR8, (6) C02R8;
(7) CONR7R8;
X is selected from the group consisting of 21 63'3~
( 1 ) a covalent bond (2) C1 3 alkyl, unsubstituted or substituted with (a) oxo, (b) OR6, (c) halogen, (d) trifluoromethyl, (e) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) OR6, (2) halogen, and (3) trifluoromethyl, (3) S(O)k, (4) (Cl -3 alkyl)S(O)k, (5) S(O)k(C 1-2 alkyl), (6) NHS(O)j, (7) NH(C1-2 alkyl)S(O)j, (8) S(O)jNR6, (9) S(O)j-NR6-(C1-2 alkyl), (10) NHCO, (1 1 ) NHCO-(C1-2 alkyl), (12) NR6CO, (13) NR6-(Cl-2 alkyl)CO, (14) O(CO), and (15) (C1-2 alkyl)O(CO), Y-Z considered together are 2 adjoining atoms of the ring ~Z
said ring being an phenyl, naphthyl or heteroaryl group, with the heteroaryls selected *om the group consisting of:
( l ) benzimidazolyl, (2) benzofuranyl, (3) benzoxazolyl, wo 94/29309 2 1 6 3 9 9 5 PCT/US94/05545 (4) furanyl, (S) imidazolyl, (6) indolyl, (7) isoxazolyl, (8) isothiazolyl, (9) oxadiazolyl, ( 10) oxazolyl, (11 ) pyrazinyl, (12) pyrazolyl, (13) pyridyl, (14) pyrimidyl, (15) pyrrolyl, (16) quinolyl, (1 7) tetrazolyl, (18) thiadiazolyl, (19) thiazolyl, (20) thienyl, (21 ) triazolyl, and wherein the aryl or heteroaryl group is unsubstituted, 20 mono, di or tri substituted, the substitutents selected from:
(a) hydrogen, (b) C1 6 alkyl, branched or unbranched, unsubstituted or mono or disubstituted, the substituents being selected from hydrogen and hydroxy, 2 5 (c) oxo (d) OR6, wherein R6 is as defined immediately above, (e) halogen, (f) trifluoromethyl, (g) nitro, 3 (h) cyano, (i) NHR6, (j) NR6R7~
(k) NHCOR6, (1) NR6COR7, 21 6:~q5 (m) NHC02R6, (n) NR6C02R7, (o) NHS(0)jR6, (p) NR6S(O)jR7, (q) CONR6R7, (r) C0R6, (s) C02R6, (t) S()jR6, (u) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(a) benzimidazolyl, (b) benzofuranyl, (c) benzoxazolyl, (d) furanyl, (e) imidazolyl, (f) indolyl, (g) isoxazolyl, (h) isothiazolyl, (i) oxadiazolyl, (j) oxazolyl, (k) pyrazinyl, (l) pyrazolyl, (m) pyridyl, (n) pyrimidyl, 2 5 (o) pyrrolyl, (p) quinolyl, (q) tetrazolyl, (r) thiadiazolyl, (s) thiazolyl, 3 (t) thienyl, (u) triazolyl, and wherein the heteroaryl is unsubstituted mono or di substituted, the substitutents selected from ( 1 ) hydrogen, wo 94/29309 2 1 6 3 9 9 5 PCT/US94/05545 (2) C1 6 alkyl, branched or unbranched, unsubstituted or mono or disubstituted, the substituents being selected from hydrogen and hydroxy, (3) oxo, (4) OR6, (S) trifluoromethyl, (6) nitro, (7) cyano, (8) NHR6, o (9) NR6R7, (10) NHCOR6, ( 1 1 ) NR6COR7, ( 12) NHC02R6, (1 3) NR6C02R7, (14) NHS(O)jR6, (1 5) NR6S(O)jR7, (16) CONR6R7, (17) COR6, (18) C02R6, (19) S(O)jR6~ and (20) phenyl.
One subclass of this invention consists of structures tabulated below linked to R1 (as detailed immediately above) via the 25 broken bond, and optionally substituted at the positions indicated by numbers 1-8 with (a) hydroxy, (b) oxo, (c) cyano, 3 (d) -NR6R7, (e) -NHCOR6R7, (f) -halogen, (g) -CF3, 21 639q5 (h) -phenyl or mono, di or trisubstituted phenyl, the substituents independently selected from (a) through (g) and Cl 3 alkyl;
the tabulated structures being s 21 63q95 ~H ~,S~ Me ~)~H
4 ~?3 ~ ~
~ ~ ~r ~)~ Me ~ OMe~;
~e ~Me ~r ~
~N~Me ~N`Me ~,`Me 2 1 63~q5 Me Me ~N Me ~ ~N
~r ~
~r O
Me Me " Me ~ ~ N
Me 3~ ~
~ 5 ~ ~ ~S=O
4 ~3, 4 ~3' [~ [~
2 1 639~
~H ~' Me ~ H
~
/ N N / N
~Me ~)~OMe ~,r ~ ~/Me N N N
~N~ Me ~ ` Me ~` Me 21 63q~5 Me Me 7 Me ~~O
Me Me ~ ~ ~N
~ Me 2s ~~=O
/N /N /N /N
WO 94/29309 PCT/US94/0554;
2 1 639q5 ~ ~0~ /,0 5 Ç~
O O
~ Me ~ OMe g~
~ O
~r ~ ~N~ Me ~N` Me ~ Me 21 63q95 Me O Me ~N~ Me ~r ~
Me Me 1l Me ~ N
Me ~ ~r ~r N ~ ~ ~
WO 94/29309 PCT/US94/0554~
2 1 ~39~5 `"S"
o o ~ Me ~J~OMe ~_' ~ ~ ~
~e ~e ~e ~N~ Me ~N` Me ~ Me 21 639q5 ~ ~N
~ ~r Me Me R Me N~ [ ~N N~ N~N
~ Me ~ ~r 25 ~ ~o O~. ~, ~
/~J~Me/~)~OMe I~N/
~ ~
MeMe Me N~ ~ N~ N~
2 5 N~N ~ MeN~ ~N~ Me ~ ` Me WO 94129309 21 6 39 q 5 PCT/US94/05545 Me Me ~, ~ N~l N/
~r ~Ar ~r Me Me ,, Me / ~N ~s~N/
N~5 N~ N~,~, ~r ~r ~
O
~r ~r~r ~r N~ N~ N/~ N~
~ ~r ~Ar O~ // )~
~N
~)~ Me ~ OMe ~Me ~ ~
~N~Me ~`Me g~ Me ~r ~r WO 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 Me Me ~~Me ~r ~r Me Me 1l Me ~ 0 ~S
~r 25 ~ ~=O
~S~ Me ~N ~ [~
~ N;~ ~;
Me Me Me ~0 ~ ~ O
~ ~r ~N~Me ~`Me $~ ~ `Me WO 94/29309 PCT/US94/0554~
2 ~ 6;~9~5 N` Me ~ ~ $
~r ~
~r 3 Me Me R Me // Me a O 0 ~N ~ lNH
~r 25 ~ ~=O
S~H ~N'S`Me ~N)~H
~N ~ ~
O O Me ~ ~
Me ~M
~r ~Ar S~ S S S~
\~X~ Me ~N` M ;~N~ Me Me b' Me S~ ~ ~N
Me Me 1I Me S~- O S~lS S~
~;~ Me ~r ~r 5~ S~ 5~ 5~=
N~ N~ 'S`Me N~N~H
~N ~ ~
O O
~N~ Me ~ OMe ~N N N
b~
~r ~nAr ~N5~N. ~ ~\ S
~ I I
Me 3 Me c~N`Me ~ ~N~
Me Me 1l Me N~ N~ N~N
/
~r ~
~' N~
wo 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 As is clear from the examples and schemes, the designation:
~) l or ~) m in formula I is interchangeable with (CH2)l or (CH2)m respectively. As appreciated by those of skill in the art, halo as used herein are intended to include chloro, fluoro, bromo and iodo.
Exemplifying the invention are the compounds of the examples including the group consisting of (a) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(t-butoxycarbonyl (methylamino)) butyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine);
(b) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(c) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-2 o piperidine);
(d) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(e) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-2 5 methylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(f) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
3 o (g) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-trifluoromethyl-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4' piperidine);
(h) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichloro-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
21 63qq5 (i) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-trifluoromethyl-phenylacetyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4 '-piperidine);
(j) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-5 isopropyloxy-phenylacetyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(k) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzenesulfonyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(l) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -benzyoxycarbonyl-spiro(indoline-3,4'-piperidine);
(m) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,S-dimethyl-benzoyl)(methylamino))butyl)-spiro(indoline-3 ,4'-piperidine);
(n) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -propionyl-spiro(indoline-3 ,4'-piperidine);
(o) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino)) butyl)-1-formyl-spiro(indoline-3,4'-20 piperidine);
(p) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -t-butylcarbonyl-spiro(indoline-3 ,4'-piperidine);
(q) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-2 5 benzoyl)(methylamino))butyl)- 1 -methylaminocarbonyl-spiro(indoline-3,4'-piperidine);
(r) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -ethoxycarbonyl-spiro(indoline-3 ,4'-piperidine);
3 (s) 1 '(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3 ,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -ethanesulfonyl-spiro(indoline-3,4'-piperidine);
WO 94/29309 2 1 6 3 9 q ~ PCT/US94/05545 (t) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -i-propanesulfonyl-spiro(indoline-3,4'-piperidine);
(u) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-5 benzoyl)(methylarnino))butyl)-1'-methyl-1-methanesulfonyl-spiro-indoline-3,4'-piperidinium iodide;
(v) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3-methylbenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(w) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5-bis(trifluoromethyl)benzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(x) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5-dimethylbenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro-5 (indoline-3 ,4'-piperidine);
(y) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5-dichlorobenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro-(indoline-3 ,4'-piperidine);
2 o (aa) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3 ,5-difluorobenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro-(indoline-3 ,4 '-piperidine);
(ab) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-fluoro-5-25 (trifluoromethyl)benzoyl)(methylamino))butyl)-1-methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(ac) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(1-naphthoyl)-(methylamino))butyl)- l -methanesulfonyl-spiro(indoline-3,4'-piperidine);
3 (ad) 1 '-(2-((S)-(3 ,4-dichlorophenyl))- 1 -(N-(2-chloro-phenylsulfonyl)-(methylamino))-4-butyl)- 1 -methylsulfonyl-spiro-(indoline-3 ,4'-piperidine);
WO 94/29309 21 6 39 ~ 5 PCT/US94/05545 (ae) 1 '-(2-((S)-(3,4-dichlorophenyl))- 1 -(N-(3-chloro-phenylsulfonyl)-(methylamino))-4-butyl)- 1 -methylsulfonyl-spiro-(indoline-3 ,4'-piperidine);
(af) 1 '-(2-((S)-(3 ,4-dichlorophenyl))- 1 -(N-(4-chloro-5 phenylsulfonyl)-(methylamino))-4-butyl)- 1 -methylsulfonyl-spiro-(indoline-3,4'-piperidine);
(ag) 1 '-(2-((S)-(3,4-dichlorophenyl))- 1 -(N-(3,5-dichloro-phenylsulfonyl)-(methylamino))-4-butyl)- 1 -methylsulfonyl-spiro-(indoline-3 ,4'-piperidine);
(ah) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3-fluoro-5-(trifluoromethyl)benzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine);
(ai) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine).
(aj) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-bromo-5-methylbenzoyl)(methylarnino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4' -piperidine);
(ak) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -(2-aminoacetyl)-spiro-20 (indoline-3,4'-piperidine);
(al) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -methyl-spiro(indol-2-one-3,4'-piperidine);
(am) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-2 5 dichlorobenzoyl)(methylamino))butyl)- 1 -methyl-spiro(isoindol- 1 -one-3,4'-piperidine);
(an) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)-spiro(2-oxo-tetrahydroquinoline-4,4'-piperidine); and 3 (ao) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3 ,5-dichloro-benzoyl)(methylamino))butyl)- 1 -methyl-spiro(2-oxo-tetrahydro-quinoline-4,4'-piperidine).
21 639~5 In an alternative embodiment the above compounds may be co-administered with a ~2-agonist such as Bambuterol, US 4,419,364 issued to Draco on 12/6/83; Bitolterol mesylate, US 4,138,581 issued to Sterling 2/6/79; Carbuterol, US 3,763,232 issued to SmithKline 10/2/73;
Clenbuterol, US 3,536,712 issued to Boehringer Ingelheim 10/27/70;
Dopexamine, US 4,645,768 issued to Fisons 2/24/87; Formoterol, US
3,994,974 issued to Yamanouchi 11/30/76; Mabuterol, US 4,119,710 issued to Boehringer Ingelheim 10/10/78; Pirbuterol hydrochloride US
3,700,681 issued to Pfizer 10/24/72; Procaterol hydrochloride US
4,026,897 issued to Otsuka 5/31/77; Ritodrine hydrochloride US
3,410,944 issued to North American Philips 11/12/68; Brosaterol, US
4,276,299 issued to Zambon 6/30/81 and US 4,520,200 issued to Zambon 5/28/85; Cimaterol, US 4,407,819 issued to American Cyanamid 10/4/83; Docarpamine, US 4,228,183 issued to Tanabe 10/14/80; Salmeterol, US 4,992,474 i~sued to Glaxo 2/21/91 and US
5,091,422 issued to Glaxo 2/25/92.
The compounds of formula I are particularly useful in the treatment of diseases or conditions that are advantageously treated by concomitant antagonism of both NK1 and NK2 receptors or NK1, NK2 and NK3 receptors. These diseases include neuropathy, such as diabetic or peripheral neuropathy and chemotherapy-induced neuropathy;
asthma; osteoarthritis; rheumatoid arthritis; and migraine.
In a second alternative embodiment the compounds of formula I may be co-~lmini~tered with another NKl or NK2 antagonist such as those described in Appln No. DO-139125, filed 08-Jun-78, Pub. 12-Dec-79; Appln No.
EP-82568, filed 22-Dec-81, Pub. 29-Jun-83; Appln No. EP-490379, filed 13-Dec-90, Pub. 17-Jun-92; Appln No. EP-353732, filed 05-Aug-88, Pub. 07-Feb-90; Appln No. EP- 161007, filed 13 -Jan-84, Pub. 13-Nov-85; Appln No. EP-385-43, filed 28-Feb-89, Pub. 05-Sep-90; Appln No. WO8301251, filed 09-Oct-81, Pub. 14-Apr-83; Appln No. BE-894602, filed 09-Oct-81, Pub. 31-Jan-83; Appln No. DE3205991, filed 19-Feb-82, Pub. 01-Sep-83; Appln No. EP-327009, filed 02-Feb-88, Pub. 09-Aug-89; Appln No. EP-336230, filed 05-Apr-88, Pub. 11 -Oct-q q 5 89; Appln N o. 394989, filed 28-Apr-89, Pub. 31-Oct-90; Appln No.
AU9068010, filed 22-Dec-89, Pub. 27-Jun-91; Appln No. EP-482539, filed 24-Oct-90, Pub. 29-Apr-92; Appln No. EP-443132, filed 10-Dec-90, Pub. 28-Aug-91; Appln No. EP-498069, filed 21-Dec-90, Pub. 12-Aug-92; Appln No. W09222569, filed 19-Jun-91, Pub. 23-Dec-92;
Appln No. JO4297492, filed 24-Oct-91, Pub. 21-Oct-92; Appln No.
US4997853, filed 02-Dec-88, Pub. 05-Mar-91; Appln No. EP-272929, filed 24-Dec-86, Pub. 29-Jun-88; Appln No. EP-360390, filed 25-Jul-88, Pub. 28-Mar-90; Appln No. US3862114, filed 22-Nov-71, Pub. 21-Jan-75; Appln N o. EP-219258, filed 30-Sep-85, Pub. 22-Apr-87, Appln N o. US4742156, filed 30-Sep-85, Pub. 03-May-88; Appln No. EP-401177, filed 29-May-89, Pub. 05-Dec-90; Appln N o. W09202546, filed 03-Aug-90, Pub. 20-Feb-92; Appln No. EP-176436, filed 26-Sep-84, Pub. 02-Apr-86; Appln No. US4680283, filed 26-Sep-84, Pub. 14-lS Ju1-87; Appln No. WO9220661, filed 22-May-91, Pub. 26-Nov-92;
Appln No. EP-520555, filed 24-Jun-91, Pub. 30-Dec-92; Appln No.
EP-347802, filed 20-Jun-88, Pub. 27-Dec-89; Appln No. EP-412542, filed 10-Aug-89, Pub. 13-Feb-91; Appln No. W09005729, filed 23-Nov-88, Pub. 31-May-90; Appln No. W09005525, filed 23-Nov-88, Pub. 31-May-90; Appln No. EP-436334, filed 04-Jan-90, Pub. 10-Jul-91; Appln No. WO9118878, filed 31-May-90, Pub. 12-Dec-91; Appln N o. W 0 9118899, filed 01-Jun-90, Pub. 12-Dec-91; Appln No.
WO9201688, filed 23-Jul-90, Pub. 06-Feb-92; Appln No. W09206079, filed 28-Sep-90, Pub. 16-Apr-92; Appln N o. WO9212152, filed 03-Jan-91, Pub. 23-Ju1-92; Appln No. WO9212151, filed 10-Jan-91, Pub. 23-Ju1-92; WO9215585, filed 01-Mar-91, Pub. 29-Apr-92; Appln No.
W0022-676, filed 22-May-91, Pub. 26-Nov-92; Appln No.
WO9221677, filed 31 -May-91, Pub. 10-Dec-92; Appln No.
WO9300331, filed 20-Jun-91, Pub. 07-Jun-93; Appln No. W09300330, filed 21-Jun-91, Pub. 07-Jan-93; Appln No. WO9109844, filed l 1-Jul-91, Pub. 11-Jul-91; Appln N o. EP-429366, filed 23-Nov-89, Pub. 29-May-91; Appln No. EP-430771, filed 23-Nov-89, Pub. 05-Jun-91;
Appln No. EP-514274, filed 17-May-91, Pub. 19-Nov-92; Appln No.
EP-514276, filed 17-May-91, Pub. 19-Nov-92; Appln No. EP-514275, WO 94/29309 2 1 6 3 ~ q 5 PCT/US94/0554~
filed 17-May-91, Pub. 19-Nov-92; Appln No. EP-514273, filed 17-May-91, Pub. 19-Nov-92; Appln No. EP-428434, filed 06-Nov-89, Pub.
(Chang et al., Nature New Biol. 232, 86 (1971); D.F. Veber et al., U.s.
Patent No. 4,680,283).
21 639~5 The neurokinin receptors are widely distributed throughout the m~mm~lian nervous system (especially brain and spinal ganglia), the circulatory system and peripheral tissues (especially the duodenum and jejunum) and are involved in regulatmg a number of diverse biological processes. This includes sensory perception of olfaction, vision, audition and pain, movement control, gastric motility, vasodilation, salivation, and micturition (B. Pernow, Pharmacol. Rev., 1983, 35, 85-141). The NK1 and NK2 receptor subtypes are implicated in synaptic transmission (Laneuville et al., Life Sci., 42: 1295-1305 (1988)).
Substance P acts as a vasodilator, a depressant, stimulates salivation and produces increased capillary permeability. It is also capable of producing both analgesia and hyperalgesia in animals, depending on dose and pain responsiveness of the ~nim~l (see R.C.A.
Frederickson et al., Science, 199, 1359 (1978); P. Oehme et al., Science, 208, 305 (1980)) and plays a role in sensory transmission and pain perception (T.M. Jessell, Advan. Biochem. Psychopharmacol. 28, 189 (1981)). In particular, substance P has been shown to be involved in the tr~nsmission of pain in migraine (see B.E.B. Sandberg et al., Journal of Medicinal Chemistry, 25, 1009 (1982)), and in arthritis (Levine et al.
Science, (1984) 226, 547-549).
In the airways, it has been indicated that NK1 receptors are associated with microvascular leakage and mucus secretion, while NK2 receptors regulate smooth muscle contraction. Also, it has been shown that both substance P and neurokinin A are effective in inducing airway constriction and edema. Based on such findings, it is believed that substance P and neurokinin A may be involved in the pathogenesis of neurogenic infl~mm~tion, including allergic diseases such as asthma.
(Frossard et al., Life Sci., 49, 1941-1953 (1991); Advenier, et al., Biochem. Biophys. Res. Comm., 184(3), 1418-1424 (1992)).
In experimental studies, sensory neuropeptides, especially tachykinins such as substance P and neurokinin A, can bring about many of the pathophysiological features of asthma. Neurokinin A is a very potent constrictor of human airways in vitro, and substance P causes mucus secretion in the airways. (Barnes P.J., Lancet, pp 242-44 (1986);
Rogers D.R., Aursudkij B., Barnes P.J., Euro. J. Pharmacol, 174, 283-86 (1989)).
Inhalation of bradykinin causes bronchoconstriction in asthmatic patients but not in normal subjects. (Fuller R.W., Dixon C.M.S., Cuss F.M.C., Barnes P.J., Am Rev Respir Dis, 135, 176-80 (1987)). Since the bradykinin-induced bronchoconstriction is partly opposed by anticholinergic agents and since bradykinin is only a weak constrictor of human airways in vitro, it has been suggested that the bronchoconstrictor response is partly mediated by a neural reflex.
Bradykinin stimulates vagal afferent C fibers and causes broncho-constriction in dogs. (Kaufman M.P., Coleridge H.M., Coleridge J.C.G., Baker D.G., J. Appl. Physio., 48, 511-17 (1980)). In guinea-pig air~vays, bradykinin causes a bronchoconstrictor response by way of cholinergic and sensory-nerve-mediated mech~ni~m.s. (Ichinoe M., Belvisi M.G., Barnes P.J., J. Pharmacol. Exp. Ther., 253, 594-99 (1990). Bradykinin-induced bronchoconstriction in human airways may therefore be due partly to tachykinin released from sensory nerve terminals via axon reflex mech~ni~m~. Clinical trials have shown that a dual NK-1/NK-2 antagonist (such as FK-224) protects against bradykinin induced bronchocontriction in asthmatic patients. (Ichinoe, M. et al., Lancet,, vol. 340, pp 1248-1251 (1992)).
The tachykinins have also been implicated in gastro-intestinal (GI) disorders and diseases of the GI tract, such as infl~mm~tory bowel disease, ulcerative colitis and Crohn's disease, etc.
(see Mantyh et al., Neuroscience, 25 (3), 817-37 (1988) and D. Regoli in "Trends in Cluster Headache" Ed. F. Sicuteri et al., Elsevier Scientific Publishers, Amsterdam, 1987, pp. 85-95).
It is also hypothesized that there is a neurogenic mechanism for arthritis in which substance P may play a role (Kidd et al., "A
Neurogenic Mech~nism for Symmetric Arthritis" in The Lancet, 11 November 1989 and Gronblad et al., "Neuropeptides in Synovium of Patients with Rheumatoid Arthritis and Osteoarthritis" in J. Rheumatol.
(1988) 15(12) 1807-10). Therefore, substance P is believed to be involved in the inflammatory response in diseases such as rheumatoid wo 94/29309 2 1 6 3 9 9 5 PCT/US94/0554~
arthritis and osteoarthritis (O'Byrne et al., in Arthritis and Rheumatism (1990) 33, 1023-8). Other disease areas where tachykinin antagonists are believed to be useful are allergic conditions (Hamelet et al., Can. J.
PhaImacol. Physiol. (1988) 66, 1361-7), immunoregulation (Lotz et al., Science (1988) 241, 1218-21, Kimball et al., J. Immunol. (1988) 141 (10) 3564-9 and A. Perianin, et al., Biochem. Biophys. Res. Commun.
161, 520 (1989)) vasodilation, bronchospasm, reflex or neuronal control of the viscera (Mantyh et al., PNAS (1988) 85, 3235-9) and, possibly by arresting or slowing ~-amyloid-mediated neurodegenerative changes (Yankner etal., Science, (1990) 250, 279-82) in senile dementia of the Alzheimer type, Alzheimer's disease and Downs Syndrome.
Substance P may also play a role in demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis (J. Luber-Narod et al., poster presented at C.I.N.P. XVIIIth Congress, 28th June-2nd July, 1992). Antagonists selective for the substance P and/or the neurokinin A receptor may be useful in the treatment of asthmatic disease (Frossard et al., Life Sci., 49, 1941-1953 (1991); Advenier, et al., Biochem. Biophys. Res. Comm., 184(3), 1418-1424 (1992)).
SUMMARY OF THE INVENTION
This invention is directed to compounds of forrnula I.
X' W
~) m The invention is also concerned with pharmaceutical folmulations with these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders.
21 6~995 The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of infl~mm~tory diseases, pain or migraine and asthma.
This invention is directed to compounds of formula I.
X' `W
o ~Z~) m I N
or a pharmaceutically acceptable salt thereof, wherein the nitrogen expressly shown above is optionally quaternized with Cl 4alkyl or phenylCl 4alkyl or is optionally present as the N-oxide (N+O-), and wherein:
20 l and m are each independently 0, 1, 2, 3, 4, or 5, with the proviso that 1 +misequalto 1,2,3,4,or5;
R1 is selected from a group consisting of:
( 1 ) hydrogen, (2) linear or brarlched C1 8 alkyl, linear or branched C2 8 alkenyl, or linear or branched C2 8 alkynyl, wherein the C1 8 alkyl, C2 g alkenyl or C2 g alkynyl is optionally mono, di, tri or tetra substituted, the substitutents independently selected from:
3 0 (a) hydroxy, (b) oxo, (c) cyano, (d) halogen which is defined to include Br, Cl, I, and F, (e) trifluoromethyl, WO 94/29309 2 1 6 3 q ~ 5 PCT/US94/05545 (f) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from ( 1 ) phenyl, (2) hydroxy, (3) Cl 3alkyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (7) -NR6COR7, wherein R6 and R7 are o independently selected from:
(a) hydrogen, (b) C1 6 alkyl, or mono or disubstituted C1 6 alkyl, the substitutents independently selected from (1) phenyl,unsubstituted or substituted with hydroxy, C1 3alkyl, cyano, halogen, trifluoromethyl or C1 4alkoxy, (2) hydroxy, (3) oxo, (4) cyano, (S) halogen, (6) trifluoromethyl, (c) phenyl, pyridinyl or thiophene or mono, di or trisubstituted phenyl, pyridinyl or thiophene, the substitutents independently selected from ( 1 ) hydroxy, (2) Cl 4alkyl, (3) cyano, 3 (4) halogen, (5) trifluoromethyl, (d) C1 3alkyloxy, or WO 94/2930g PCTIUS94/05545 2 1 639~5 R6 and R7 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or disubstituted, the substituents independently selected from (a) hydroxy, (b) oxo, (c) cyano, o (d) halogen, (e) trifluoromethyl, (8) -NR6C02R7, (9) -NR6CONHR7, (10) -NR6S(O)jR7, wherein j is 1 or 2, (11) -CONR6R7, (1 2) -COR6, (1 3) -C02R6, (14) -OR6, (15) -S(O)kR6 wherein k is 0, 1 or 2, (16) heteroaryl, wherein heteroaryl is selected from the group consisting of:
( 1 ) benzimidazolyl, (2) benzofuranyl, (3) benzoxazolyl, 2 5 (4) furanyl, (5) imidazolyl, (6) indolyl, (7) isoxazolyl, (8) isothiazolyl, 3 (9) oxadiazolyl, (10) oxazolyl, ( 1 1 ) pyrazinyl, (12) pyrazolyl, (1 3) pyridyl, (14) pyrimidyl, (1 S) pyrrolyl, ( 16) quinolyl, (17) tetrazolyl, (18) thiadiazolyl, (1 9) thiazolyl, (20) thienyl, and (21 ) triazolyl, wherein the heteroaryl is unsubstituted or mono, di or trisubstituted, the substituents independently selected from, (a) hydroxy, (b) oxo, (c) cyano, s (d) halogen, (e) trifluoromethyl, (g) -NR6R7, (h) -NR6COR7, (i) -NR6C02R7, (j) -NR6CONHR7, (k) -NR6S(O)jR7, (I) -CONR6R7, (m) -COR6, (n) -C02R6, 2 5 (o) -OR6, (p) -S(O)kR6, (q) heteroaryl, wherein heteroaryl is selected from the group consisting of:
( 1 ) benzimidazolyl, 3 (2) benzofuranyl, (3) benzoxazolyl, (4) furanyl, (5) imidazolyl, (6) indolyl, wo 94/29309 2 1 6 3 9 9 5 PCT/US94/05545 - (7) isoxazolyl, (8) isothiazolyl, (9) oxadiazolyl, (10) oxazolyl, (11) pyrazinyl, (12) pyrazolyl, (1 3) pyridyl, ( 14) pyrimidyl, (15) pyrrolyl, o (16) quinolyl, (1 7) tetrazolyl, (1 8) thiadiazolyl, (19) thiazolyl, (20) thienyl, (21) triazolyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from ( 1 ) phenyl, 2 o (2) hydroxy, (3) oxo, (4) cyano, (5) halogen, (6) trifluoromethyl, wherein the nitrogen of definition R1 2(g) as defined above is optionally quaternized with C1 4alkyl or phenylC1 4alkyl or is optionally present as the N-oxide (N+O-);
W is selected from the group consisting of 3 ( 1 ) a covalent bond (2) C1-3 alkyl, unsubstituted or substituted with (a) oxo, (b) hydroxy (C) OR6, (d) halogen, (e) trifluoromethyl, (f) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from ( 1 ) hydroxy, (2) cyano, (3) halogen, (4) trifluoromethyl, 3) S(O)k, (4) (C1-3 alkyl)-S(O)k, (5) S(O)k-(C1 -2 alkyl), (6) S(O)k-NH, (7) S(O)j-NH(C1 -2 alkyl), (8) S(O)j-NR6, (9) S(O)j-NR6-(C1-2 alkyl), (10) CONH, (11) CONH-(C1-2 alkyl), (12) CONR6, ( 13) CONR6-(C 1-2 alkyl), (14) CO2, ( 15) CO2-(C 1-2 alkyl);
Q = NR2, O, S, S(O), or SO2, with the proviso that when W is a covalent bond and X is C1 3alkyl, then Q must be NR2;
R2 is selected from a group consisting of:
2 5 ( 1 ) hydrogen, (2) C1-g linear or branched aLkyl, unsubstituted, monosubstituted or multiply substituted with (a) -OR6, (b) = o, 3 0 (c) -NHCOR6, (d) -NR6R7, (e) -CN, (f) -halogen, (g) -CF3, 2 1 639~
(h) -phenyl, unsubstituted or substituted, wherein the substitutents are selected from the group consisting of ( 1 ) hydroxy, (2) cyano, (3) halogen, (4) trifluoromethyl, (3) S(O)Rg, wherein R8 is C1-6 linear or branched alkyl, unsubstituted, mono di or trisubstituted with o (a) hydroxy, (b) oxo, (c) cyano, (d) -OR6, (e) -NR6R7, (f) -NR6COR7, (g) -halogen, (h) -CF3, (i) -phenyl or mono, di or trisubstituted phenyl, the substituents independently selected from 2 o ( 1 ) hydroxy, (2) oxo, (3) cyano, (4) -NHR6, (5) -NR6R7, 2 5 (6) -NR6COR7, (7) -halogen, (8) -CF3, and (9) Cl 3 alkyl, (4) S02R8, 3 0 (5) COR8, (6) C02R8;
(7) CONR7R8;
X is selected from the group consisting of 21 63'3~
( 1 ) a covalent bond (2) C1 3 alkyl, unsubstituted or substituted with (a) oxo, (b) OR6, (c) halogen, (d) trifluoromethyl, (e) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) OR6, (2) halogen, and (3) trifluoromethyl, (3) S(O)k, (4) (Cl -3 alkyl)S(O)k, (5) S(O)k(C 1-2 alkyl), (6) NHS(O)j, (7) NH(C1-2 alkyl)S(O)j, (8) S(O)jNR6, (9) S(O)j-NR6-(C1-2 alkyl), (10) NHCO, (1 1 ) NHCO-(C1-2 alkyl), (12) NR6CO, (13) NR6-(Cl-2 alkyl)CO, (14) O(CO), and (15) (C1-2 alkyl)O(CO), Y-Z considered together are 2 adjoining atoms of the ring ~Z
said ring being an phenyl, naphthyl or heteroaryl group, with the heteroaryls selected *om the group consisting of:
( l ) benzimidazolyl, (2) benzofuranyl, (3) benzoxazolyl, wo 94/29309 2 1 6 3 9 9 5 PCT/US94/05545 (4) furanyl, (S) imidazolyl, (6) indolyl, (7) isoxazolyl, (8) isothiazolyl, (9) oxadiazolyl, ( 10) oxazolyl, (11 ) pyrazinyl, (12) pyrazolyl, (13) pyridyl, (14) pyrimidyl, (15) pyrrolyl, (16) quinolyl, (1 7) tetrazolyl, (18) thiadiazolyl, (19) thiazolyl, (20) thienyl, (21 ) triazolyl, and wherein the aryl or heteroaryl group is unsubstituted, 20 mono, di or tri substituted, the substitutents selected from:
(a) hydrogen, (b) C1 6 alkyl, branched or unbranched, unsubstituted or mono or disubstituted, the substituents being selected from hydrogen and hydroxy, 2 5 (c) oxo (d) OR6, wherein R6 is as defined immediately above, (e) halogen, (f) trifluoromethyl, (g) nitro, 3 (h) cyano, (i) NHR6, (j) NR6R7~
(k) NHCOR6, (1) NR6COR7, 21 6:~q5 (m) NHC02R6, (n) NR6C02R7, (o) NHS(0)jR6, (p) NR6S(O)jR7, (q) CONR6R7, (r) C0R6, (s) C02R6, (t) S()jR6, (u) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(a) benzimidazolyl, (b) benzofuranyl, (c) benzoxazolyl, (d) furanyl, (e) imidazolyl, (f) indolyl, (g) isoxazolyl, (h) isothiazolyl, (i) oxadiazolyl, (j) oxazolyl, (k) pyrazinyl, (l) pyrazolyl, (m) pyridyl, (n) pyrimidyl, 2 5 (o) pyrrolyl, (p) quinolyl, (q) tetrazolyl, (r) thiadiazolyl, (s) thiazolyl, 3 (t) thienyl, (u) triazolyl, and wherein the heteroaryl is unsubstituted mono or di substituted, the substitutents selected from ( 1 ) hydrogen, wo 94/29309 2 1 6 3 9 9 5 PCT/US94/05545 (2) C1 6 alkyl, branched or unbranched, unsubstituted or mono or disubstituted, the substituents being selected from hydrogen and hydroxy, (3) oxo, (4) OR6, (S) trifluoromethyl, (6) nitro, (7) cyano, (8) NHR6, o (9) NR6R7, (10) NHCOR6, ( 1 1 ) NR6COR7, ( 12) NHC02R6, (1 3) NR6C02R7, (14) NHS(O)jR6, (1 5) NR6S(O)jR7, (16) CONR6R7, (17) COR6, (18) C02R6, (19) S(O)jR6~ and (20) phenyl.
One subclass of this invention consists of structures tabulated below linked to R1 (as detailed immediately above) via the 25 broken bond, and optionally substituted at the positions indicated by numbers 1-8 with (a) hydroxy, (b) oxo, (c) cyano, 3 (d) -NR6R7, (e) -NHCOR6R7, (f) -halogen, (g) -CF3, 21 639q5 (h) -phenyl or mono, di or trisubstituted phenyl, the substituents independently selected from (a) through (g) and Cl 3 alkyl;
the tabulated structures being s 21 63q95 ~H ~,S~ Me ~)~H
4 ~?3 ~ ~
~ ~ ~r ~)~ Me ~ OMe~;
~e ~Me ~r ~
~N~Me ~N`Me ~,`Me 2 1 63~q5 Me Me ~N Me ~ ~N
~r ~
~r O
Me Me " Me ~ ~ N
Me 3~ ~
~ 5 ~ ~ ~S=O
4 ~3, 4 ~3' [~ [~
2 1 639~
~H ~' Me ~ H
~
/ N N / N
~Me ~)~OMe ~,r ~ ~/Me N N N
~N~ Me ~ ` Me ~` Me 21 63q~5 Me Me 7 Me ~~O
Me Me ~ ~ ~N
~ Me 2s ~~=O
/N /N /N /N
WO 94/29309 PCT/US94/0554;
2 1 639q5 ~ ~0~ /,0 5 Ç~
O O
~ Me ~ OMe g~
~ O
~r ~ ~N~ Me ~N` Me ~ Me 21 63q95 Me O Me ~N~ Me ~r ~
Me Me 1l Me ~ N
Me ~ ~r ~r N ~ ~ ~
WO 94/29309 PCT/US94/0554~
2 1 ~39~5 `"S"
o o ~ Me ~J~OMe ~_' ~ ~ ~
~e ~e ~e ~N~ Me ~N` Me ~ Me 21 639q5 ~ ~N
~ ~r Me Me R Me N~ [ ~N N~ N~N
~ Me ~ ~r 25 ~ ~o O~. ~, ~
/~J~Me/~)~OMe I~N/
~ ~
MeMe Me N~ ~ N~ N~
2 5 N~N ~ MeN~ ~N~ Me ~ ` Me WO 94129309 21 6 39 q 5 PCT/US94/05545 Me Me ~, ~ N~l N/
~r ~Ar ~r Me Me ,, Me / ~N ~s~N/
N~5 N~ N~,~, ~r ~r ~
O
~r ~r~r ~r N~ N~ N/~ N~
~ ~r ~Ar O~ // )~
~N
~)~ Me ~ OMe ~Me ~ ~
~N~Me ~`Me g~ Me ~r ~r WO 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 Me Me ~~Me ~r ~r Me Me 1l Me ~ 0 ~S
~r 25 ~ ~=O
~S~ Me ~N ~ [~
~ N;~ ~;
Me Me Me ~0 ~ ~ O
~ ~r ~N~Me ~`Me $~ ~ `Me WO 94/29309 PCT/US94/0554~
2 ~ 6;~9~5 N` Me ~ ~ $
~r ~
~r 3 Me Me R Me // Me a O 0 ~N ~ lNH
~r 25 ~ ~=O
S~H ~N'S`Me ~N)~H
~N ~ ~
O O Me ~ ~
Me ~M
~r ~Ar S~ S S S~
\~X~ Me ~N` M ;~N~ Me Me b' Me S~ ~ ~N
Me Me 1I Me S~- O S~lS S~
~;~ Me ~r ~r 5~ S~ 5~ 5~=
N~ N~ 'S`Me N~N~H
~N ~ ~
O O
~N~ Me ~ OMe ~N N N
b~
~r ~nAr ~N5~N. ~ ~\ S
~ I I
Me 3 Me c~N`Me ~ ~N~
Me Me 1l Me N~ N~ N~N
/
~r ~
~' N~
wo 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 As is clear from the examples and schemes, the designation:
~) l or ~) m in formula I is interchangeable with (CH2)l or (CH2)m respectively. As appreciated by those of skill in the art, halo as used herein are intended to include chloro, fluoro, bromo and iodo.
Exemplifying the invention are the compounds of the examples including the group consisting of (a) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(t-butoxycarbonyl (methylamino)) butyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine);
(b) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(c) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-2 o piperidine);
(d) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(e) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-2 5 methylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(f) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
3 o (g) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-trifluoromethyl-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4' piperidine);
(h) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichloro-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
21 63qq5 (i) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-trifluoromethyl-phenylacetyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4 '-piperidine);
(j) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-5 isopropyloxy-phenylacetyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(k) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzenesulfonyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(l) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -benzyoxycarbonyl-spiro(indoline-3,4'-piperidine);
(m) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,S-dimethyl-benzoyl)(methylamino))butyl)-spiro(indoline-3 ,4'-piperidine);
(n) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -propionyl-spiro(indoline-3 ,4'-piperidine);
(o) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino)) butyl)-1-formyl-spiro(indoline-3,4'-20 piperidine);
(p) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -t-butylcarbonyl-spiro(indoline-3 ,4'-piperidine);
(q) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-2 5 benzoyl)(methylamino))butyl)- 1 -methylaminocarbonyl-spiro(indoline-3,4'-piperidine);
(r) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -ethoxycarbonyl-spiro(indoline-3 ,4'-piperidine);
3 (s) 1 '(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3 ,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -ethanesulfonyl-spiro(indoline-3,4'-piperidine);
WO 94/29309 2 1 6 3 9 q ~ PCT/US94/05545 (t) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -i-propanesulfonyl-spiro(indoline-3,4'-piperidine);
(u) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-5 benzoyl)(methylarnino))butyl)-1'-methyl-1-methanesulfonyl-spiro-indoline-3,4'-piperidinium iodide;
(v) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3-methylbenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(w) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5-bis(trifluoromethyl)benzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(x) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5-dimethylbenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro-5 (indoline-3 ,4'-piperidine);
(y) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5-dichlorobenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro-(indoline-3 ,4'-piperidine);
2 o (aa) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3 ,5-difluorobenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro-(indoline-3 ,4 '-piperidine);
(ab) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-fluoro-5-25 (trifluoromethyl)benzoyl)(methylamino))butyl)-1-methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(ac) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(1-naphthoyl)-(methylamino))butyl)- l -methanesulfonyl-spiro(indoline-3,4'-piperidine);
3 (ad) 1 '-(2-((S)-(3 ,4-dichlorophenyl))- 1 -(N-(2-chloro-phenylsulfonyl)-(methylamino))-4-butyl)- 1 -methylsulfonyl-spiro-(indoline-3 ,4'-piperidine);
WO 94/29309 21 6 39 ~ 5 PCT/US94/05545 (ae) 1 '-(2-((S)-(3,4-dichlorophenyl))- 1 -(N-(3-chloro-phenylsulfonyl)-(methylamino))-4-butyl)- 1 -methylsulfonyl-spiro-(indoline-3 ,4'-piperidine);
(af) 1 '-(2-((S)-(3 ,4-dichlorophenyl))- 1 -(N-(4-chloro-5 phenylsulfonyl)-(methylamino))-4-butyl)- 1 -methylsulfonyl-spiro-(indoline-3,4'-piperidine);
(ag) 1 '-(2-((S)-(3,4-dichlorophenyl))- 1 -(N-(3,5-dichloro-phenylsulfonyl)-(methylamino))-4-butyl)- 1 -methylsulfonyl-spiro-(indoline-3 ,4'-piperidine);
(ah) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3-fluoro-5-(trifluoromethyl)benzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine);
(ai) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine).
(aj) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-bromo-5-methylbenzoyl)(methylarnino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4' -piperidine);
(ak) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -(2-aminoacetyl)-spiro-20 (indoline-3,4'-piperidine);
(al) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -methyl-spiro(indol-2-one-3,4'-piperidine);
(am) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-2 5 dichlorobenzoyl)(methylamino))butyl)- 1 -methyl-spiro(isoindol- 1 -one-3,4'-piperidine);
(an) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)-spiro(2-oxo-tetrahydroquinoline-4,4'-piperidine); and 3 (ao) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3 ,5-dichloro-benzoyl)(methylamino))butyl)- 1 -methyl-spiro(2-oxo-tetrahydro-quinoline-4,4'-piperidine).
21 639~5 In an alternative embodiment the above compounds may be co-administered with a ~2-agonist such as Bambuterol, US 4,419,364 issued to Draco on 12/6/83; Bitolterol mesylate, US 4,138,581 issued to Sterling 2/6/79; Carbuterol, US 3,763,232 issued to SmithKline 10/2/73;
Clenbuterol, US 3,536,712 issued to Boehringer Ingelheim 10/27/70;
Dopexamine, US 4,645,768 issued to Fisons 2/24/87; Formoterol, US
3,994,974 issued to Yamanouchi 11/30/76; Mabuterol, US 4,119,710 issued to Boehringer Ingelheim 10/10/78; Pirbuterol hydrochloride US
3,700,681 issued to Pfizer 10/24/72; Procaterol hydrochloride US
4,026,897 issued to Otsuka 5/31/77; Ritodrine hydrochloride US
3,410,944 issued to North American Philips 11/12/68; Brosaterol, US
4,276,299 issued to Zambon 6/30/81 and US 4,520,200 issued to Zambon 5/28/85; Cimaterol, US 4,407,819 issued to American Cyanamid 10/4/83; Docarpamine, US 4,228,183 issued to Tanabe 10/14/80; Salmeterol, US 4,992,474 i~sued to Glaxo 2/21/91 and US
5,091,422 issued to Glaxo 2/25/92.
The compounds of formula I are particularly useful in the treatment of diseases or conditions that are advantageously treated by concomitant antagonism of both NK1 and NK2 receptors or NK1, NK2 and NK3 receptors. These diseases include neuropathy, such as diabetic or peripheral neuropathy and chemotherapy-induced neuropathy;
asthma; osteoarthritis; rheumatoid arthritis; and migraine.
In a second alternative embodiment the compounds of formula I may be co-~lmini~tered with another NKl or NK2 antagonist such as those described in Appln No. DO-139125, filed 08-Jun-78, Pub. 12-Dec-79; Appln No.
EP-82568, filed 22-Dec-81, Pub. 29-Jun-83; Appln No. EP-490379, filed 13-Dec-90, Pub. 17-Jun-92; Appln No. EP-353732, filed 05-Aug-88, Pub. 07-Feb-90; Appln No. EP- 161007, filed 13 -Jan-84, Pub. 13-Nov-85; Appln No. EP-385-43, filed 28-Feb-89, Pub. 05-Sep-90; Appln No. WO8301251, filed 09-Oct-81, Pub. 14-Apr-83; Appln No. BE-894602, filed 09-Oct-81, Pub. 31-Jan-83; Appln No. DE3205991, filed 19-Feb-82, Pub. 01-Sep-83; Appln No. EP-327009, filed 02-Feb-88, Pub. 09-Aug-89; Appln No. EP-336230, filed 05-Apr-88, Pub. 11 -Oct-q q 5 89; Appln N o. 394989, filed 28-Apr-89, Pub. 31-Oct-90; Appln No.
AU9068010, filed 22-Dec-89, Pub. 27-Jun-91; Appln No. EP-482539, filed 24-Oct-90, Pub. 29-Apr-92; Appln No. EP-443132, filed 10-Dec-90, Pub. 28-Aug-91; Appln No. EP-498069, filed 21-Dec-90, Pub. 12-Aug-92; Appln No. W09222569, filed 19-Jun-91, Pub. 23-Dec-92;
Appln No. JO4297492, filed 24-Oct-91, Pub. 21-Oct-92; Appln No.
US4997853, filed 02-Dec-88, Pub. 05-Mar-91; Appln No. EP-272929, filed 24-Dec-86, Pub. 29-Jun-88; Appln No. EP-360390, filed 25-Jul-88, Pub. 28-Mar-90; Appln No. US3862114, filed 22-Nov-71, Pub. 21-Jan-75; Appln N o. EP-219258, filed 30-Sep-85, Pub. 22-Apr-87, Appln N o. US4742156, filed 30-Sep-85, Pub. 03-May-88; Appln No. EP-401177, filed 29-May-89, Pub. 05-Dec-90; Appln N o. W09202546, filed 03-Aug-90, Pub. 20-Feb-92; Appln No. EP-176436, filed 26-Sep-84, Pub. 02-Apr-86; Appln No. US4680283, filed 26-Sep-84, Pub. 14-lS Ju1-87; Appln No. WO9220661, filed 22-May-91, Pub. 26-Nov-92;
Appln No. EP-520555, filed 24-Jun-91, Pub. 30-Dec-92; Appln No.
EP-347802, filed 20-Jun-88, Pub. 27-Dec-89; Appln No. EP-412542, filed 10-Aug-89, Pub. 13-Feb-91; Appln No. W09005729, filed 23-Nov-88, Pub. 31-May-90; Appln No. W09005525, filed 23-Nov-88, Pub. 31-May-90; Appln No. EP-436334, filed 04-Jan-90, Pub. 10-Jul-91; Appln No. WO9118878, filed 31-May-90, Pub. 12-Dec-91; Appln N o. W 0 9118899, filed 01-Jun-90, Pub. 12-Dec-91; Appln No.
WO9201688, filed 23-Jul-90, Pub. 06-Feb-92; Appln No. W09206079, filed 28-Sep-90, Pub. 16-Apr-92; Appln N o. WO9212152, filed 03-Jan-91, Pub. 23-Ju1-92; Appln No. WO9212151, filed 10-Jan-91, Pub. 23-Ju1-92; WO9215585, filed 01-Mar-91, Pub. 29-Apr-92; Appln No.
W0022-676, filed 22-May-91, Pub. 26-Nov-92; Appln No.
WO9221677, filed 31 -May-91, Pub. 10-Dec-92; Appln No.
WO9300331, filed 20-Jun-91, Pub. 07-Jun-93; Appln No. W09300330, filed 21-Jun-91, Pub. 07-Jan-93; Appln No. WO9109844, filed l 1-Jul-91, Pub. 11-Jul-91; Appln N o. EP-429366, filed 23-Nov-89, Pub. 29-May-91; Appln No. EP-430771, filed 23-Nov-89, Pub. 05-Jun-91;
Appln No. EP-514274, filed 17-May-91, Pub. 19-Nov-92; Appln No.
EP-514276, filed 17-May-91, Pub. 19-Nov-92; Appln No. EP-514275, WO 94/29309 2 1 6 3 ~ q 5 PCT/US94/0554~
filed 17-May-91, Pub. 19-Nov-92; Appln No. EP-514273, filed 17-May-91, Pub. 19-Nov-92; Appln No. EP-428434, filed 06-Nov-89, Pub.
22-May-91; Appln No. EP-474561, filed 09-May-90, Pub. 11-Mar-92;
Appln No. EP-512901, filed 03-May-91, Pub. 11-Nov-92; Appln No.
EP-512902, filed 03-May-91, Pub. 11 -Nov-92; Appln No. EP-515240, filed 03-May-91, Pub. 25-Nov-92; Appln No. US4472305, filed 17-May-83, Pub. 18-Sep-84; Appln No. US4839465, filed 20-Jan-87, Pub.
13-Jun-89; Appln No. EP-101929, filed 28-Ju1-82, Pub. 07-Mar-84;
Appln No. WO9102745, filed 16-Aug-89, Pub. 07-Mar-91; Appln No.
US3912711, filed 03-Ju1-72, Pub. 14-Oct-75; Appln No. US4059693, filed 11 -Jun-76, Pub. 22-Nov-77; Appln No. US4481139, filed 13-Apr-83, Pub. 06-Nov-84; Appln No. US7358073, filed 24-Oct-88, Pub. 19-Dec-89; Appln No. US7261627, filed 24-Oct-88, Pub. 07-Mar-89, which are hereby incorporated by reference.
The compounds of formula I are useful in the prevention and treatment of a wide variety of clinical conditions (as detailed in this specification) which are characterized by overstimulation of the tachykinin receptors, in particular NK1, NK2 and NK3.
These conditions may include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; neurodegenerative disorders such as AIDS related dementia, senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelin~ting diseases such as multiple sclerosis and amyotrophic lateral sclerosis and other neuropathological disorders such as diabetic or peripheral neuropathy, AIDS related neuropathy, chemotherapy-induced neuropathy, and neuralgia; respiratory diseases such as chronic obstructive airways disease, bronchopneumonia, bronchospasm and asthma; infl~mm~tory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis and rheumatoid arthritis; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis;
WO 94/29309 ~ ~ 6 ~ ~ ~ 5 PCT/US94/05545 addiction disorders such as alcholism; stress related somatic disorders;
reflex sympathetic dystrophy such as shoulder/hand syndrome;
dysthymic disorders; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or 5 suppression such as systemic lupus erythematosis; gastrointestinal (GI) disorders and diseases of the GI tract such as disorders associated with the neuronal control of viscera such as ulcerative colitis, Crohn's disease and incontinence; disorders of bladder function; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease; and pain or nociception, for example, that is attributable to or associated with any of the foregoing conditions especially the tr~nsmission of pain in migraine. Hence, these compounds are readily adapted to therapeutic use for the treatment of 5 physiological disorders associated with the overstimulation of the tachykinin receptors, in particular NK1, NK2 and NK3.
The compounds of the present invention are particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as, for exarnple: neuropathy, such 20 as diabetic or peripheral neuropathy and chemotherapy-induced neuropathy; asthma; osteoarthritis; rheumatoid arthritis; and migraine.
For the treatment of any of these diseases compounds of Formula I may be a~lministered orally, topically, parenterally, ICV, by inhala~ion spray or rectally in dosage unit formulations containing 25 conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intracisternal injection or infusion techniques. In addition to the treatment of warm-blooded ~nim~ls such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the 30 compounds of the invention are effective in the treatment of humans.
The pharmaceutical compositions cont~ining the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or 2 1 63~95 elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring 5 agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by S known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Patents 4,256,108;
20 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or 25 kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous 3 suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethyl-cellulose, sodium alginate, polyvinyl- pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an WO 94/29309 2 1 ~ 3 ~ 9 5 PCT/US94/05545 alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already 2s mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation 2 1 63~95 products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The compounds of formula I may also be ~clministered in the form of suppositories for rectal a-l-ninistration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of Formula I are employed.
(For purposes of this application, topical application shall include mouth washes and gargles.) 3 In the treatment of a condition associated with an excess oftachykinins, an appropriate dosage level will generally be about 0.001 to 50 mg per kg patient body weight per day which can be a~lministered in single or multiple doses. Preferably, the dosage level will be about 0.01 to about 25 mg/kg per day; more preferably about 0.05 to about 10 WO 94/29309 PCT/US94/0~545 2 ~ 6~3~ 95 mg/kg per day. A suitable dosage level may be about 0.001 to 25 mg/kg per day, about 0.005 to 10 mg/kg per day, or about 0.005 to 5 mg/kg per day. Within this range the dosage may be 0.005 to 0.05, 0.05 to 0.5 or 0.5 to 5.0 mg/kg per day. The compounds may be a~lmini~tered on a 5 regimen of 1 to 4 times per day, preferably once or twice per day.
TACHYK~IN ANTAGONISM ASSAY
The compounds of this invention are useful for antagonizing tachykinins, in particular substance P and neurokinin A in the treatment of gastrointestinal disorders, central nervous system disorders, infl~mm~tory diseases, pain or migraine and asthma in a m~mmal in need of such treatment. This activity can be demonstrated by the following assay.
A. Receptor Expression in COS
To express the cloned human neurokinin-1 receptor (NKlR) transiently in COS, the cDNA for the human NKlR was cloned into the expression vector pCDM9 which was derived from pCDM8 20 (INVITROGEN) by inserting the ampicillin resistance gene (nucleotide 1973 to 2964 from BLUESCRIPT SK+) into the Sac II site.
Transfection of 20 ~g of the plasmid DNA into 10 million COS cells was achieved by electroporation in 800 ~l of transfection buffer (135 mM NaCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 2.4 mM K2HPO4, 0.6 mM
25 KH2PO4, 10 mM glucose, 10 mM HEPES pH 7.4) at 260 V and 950 uF
using the IBI GENEZAPPER (IBI, New Haven, CT). The cells were incubated in 10% fetal calf serum, 2 mM glllt~mine, 100U/ml penicillin-streptomycin, and 90% DMEM media (GIBCO, Grand Island, NY) in 5% C2 at 37C for three days before the binding assay.
30 Similar methods were used to express the NK2 receptor.
B. Stable Expression in CHO
To establish a stable cell line expressing the cloned human NKlR, the cDNA was subcloned into the vector pRcCMV
(INVITROGEN). Transfection of 20 ,ug of the plasmid DNA into CHO
5 cells was achieved by electroporation in 800 ~l of transfection buffer suplemented with 0.625 mg/ml Herring sperm DNA at 300 V and 950 uF using the IBI GENEZAPPER (IBI). The transfected cells were incubated in CHO media (10% fetal calf serum, 100 U/ml pennicilin-streptomycin, 2 mM glutamine, 1/500 hypoxanthine-thymidine (ATCC), 90% IMDM media (JRH BIOSCIENCES, Lenexa, KS), 0.7 mg/ml G418 (GIBCO)) in 5% CO2 at 37C until colonies were visible. Each colony was separated and propagated. The cell clone with the highest number of human NKlR was selected for subsequent applications such as drug screening.
15 Similar methods were used to express the human NK2 receptor.
C. Assay Protocol usin~ COS or CHO
The binding assay of human NKlR expressed in either COS
or CHO cells is based on the use of 125I-substance P (125I-SP, from 20 DU PONT, Boston, MA) as a radioactively labeled ligand which competes with unlabeled substance P or any other ligand for binding to the human NKlR. Monolayer cell cultures of COS or CHO were dissociated by the non-enzymatic solution (SPECIALTY MEDIA, Lavallette, NJ) and resuspended in appropriate volume of the binding 25 buffer (50 mM Tris pH 7.5, 5 mM MnCl2~ 150 mM NaCl, 0.04 mg/ml bacitracin, 0.004 mg/ml leupeptin, 0.02 mg/ml BSA, 0.01 mM
phosphoramidon) such that 200 ~11 of the cell suspension would give rise to about 10,000 epm of speeifie 125I-SP binding (approximately 50,000 to 200,000 cells). In the binding assay, 500 ul of cells were added to a 30 tube containing 20 ~l of 1.5 to 0.25 nM of 125I-SP and 5 ~l of unlabeled substance P or any other test compound in DMSO. The tubes were incubated at 4C or at room temperature for 1 hour with gentle shaking. The bound radioactivity was separated from unbound radioactivity by GF/C filter (BRANDEL, Gaithersburg, MD) which was WO 94/29309 PCT/US94/0~545 pre-wetted with 0.1% polyethylenimine. The filter was washed with 3 ml of wash buffer (50 mM Tris pH 7.5, 5 mM MnCl2, 150 mM NaCl) three times and its radioactivity was determined by gamma counter. A
similar assay was used for NK2 except 125I-NKA was used as the ligand.
The activation of phospholipase C by NKlR may also be measured in CHO cells expressing the human NKlR by determining the accumulation of inositol monophosphate which is a degradation product of IP3. CHO cells are seeded in 12-well plate at 250,000 cells per well.
After incubating in CHO media for 4 days, cells are loaded with 0.025 uCi/ml of 3H-myoinositol by overnight incubation. The extracellular radioactivity is removed by washing with phosphate buffered saline.
LiCl is added to the well at final concentration of 0.1 mM with or without the test compound, and incubation is continued at 37C for 15 min. Substance P is added to the well at final concentration of 0.3 nM
to activate the human NKlR. After 30 min of incubation at 37C, the media is removed and 0.1 N HCl is added. Each well is sonicated at 4C
and extracted with CHCl3/methanol (1:1). The aqueous phase is applied to a 1 ml Dowex AG lX8 ion exchange column. The column is washed with 0.1 N formic acid followed by 0.025 M ammonium formate-0.1 N
formic acid. The inositol monophosphate is eluted with 0.2 M
ammonium formate-0.1 N formic acid and quantitated by beta counter.
Similar methods were used to assess antagonism at the NK2 receptor, except NKA was used as the stimulating agonist.
The compounds of of Formula I as Exemplified in the EXAMPLES below have been found to displace radioactive ligand for the NK-1 receptor at a concentration range of 0.01 nM to 1.0 ,uM, for the NK-2 receptor, 0.01 nM to S ~M, and for the NK-3 receptor, 1.0 nM to 10 ~lM.
Several methods for preparing the compounds of this invention are illustrated in the following Schemes and Examples.
The compounds of the present invention are prepared by alkylating azacycle 1, in which R1 = H, under appropriate conditions (Scheme 1). The required azacycle starting materials are prepared WO 94/29309 PCT/US94/0554~
2 1 6~ 9 ~
using methods described in the literature; such as described in Ong, H.
H. et al, Journal of Medicmal Chemistry, 1983,26, 981-986, and Nargund, R. e~ al, USSN 08/147,226 (November 3, 1993), EP
93309867.5 hereby encorporated by reference. None of the compounds in these references are claimed to be neurokinin antagonists.
Thus, azacycle 1 (R1=H) is combined with the appropriate aldehyde and the intermediate imine is reduced to the tertiary amine chemically (e.g. using sodium cyanoborohydride) or catalytically (e.g.
using hydrogen and palladium on carbon or Raney nickel catalyst) (Scheme 1). The aldehyde needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention the preparation of a representative aldehyde is described in Hale, J.J.; Finke, P.E.; MacCoss, M. Bioorganic &
Medicinal Chemistry Letters 1993,3, 319-322.
In an alternative embodiment of the present invention, azacycle 1 (Rl=H) can be alkylated with an alkyl halide or alkyl sulfonate ester (with or without an added base to neutralize the mineral acid or sulfonic acid by-product) to give the desired compound (Scheme 1). The alkyl halide or alkyl sulfonate needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention an aldehyde, prepared as described above, can be reduced to an alcohol with sodium borohydride, diisobutylaluminum hydride or lithium aluminum hydride, and the product alcohol converted to either the aL~yl halide using methods described in March J. "Advanced Organic Chemistry", 25 3rd ed., John Wiley & Sons, New York, pp. 382-384 (1985), or alkyl sulfonate ester using methods described in March J. "Advanced Organic Chemistry", 3rd ed., John Wiley & Sons, New York, p. 444 (1985).
In an alternative embodiment of the present invention, 1 (R1 = H) can be acylated to give the tertiary amide and subsequent 30 reduction with a strong reducing agent (e.g. diborane including borane dimethylsulfide; and, lithium alllminllm hydride) will give the desired compound (Scheme 1). The acylating agent needed for this reaction can be prepared by methods generally known in the chemical literature; for ~l 63q95 the purposes of the present invention an aldehyde, prepared as described above, can be oxidized using such commonly used reagents as permanganate in acid or silver oxide, and the resulting acid activated as an acid chloride or mixed anhydride which can be used to acylate I (Rl 5 = H). The product amide can in and of itself be a neurokinin antagonist or can be reduced with a strong reducing agent, such as diborane or lithium aluminum hydride, to give the tertiary amine.
Optionally, compound 1 formed in the alkylation step may be further modified in subsequent reactions. In one illustration of such an approach,the aldehyde fragment contained a t-butoxycarbonylamino group (Example 2). After reductive ~min~tion, the t-butoxycarbonyl protecting group is removed by treatment with a strong acid such as trifluoroacetic acid or formic acid and the resulting amine is acylated to furnish the desired compounds (Example 3). Alternatively, the 5 protecting group may also be present in the azacycle portion as illustrated with a benzyloxycarbonyl group in Example 6. Thus an azacycle cont~ining a benzyloxycarbonylindoline (prepared in Example 4) is alkylated with an aldehyde in the presence of a reducing agent.
Next, the protecting group is removed to liberate a free amine 20 (Example 7) and the amine is further reacted to provide additional analogs (Example 8).
2 1 63~95 SCHEM:E 1 RCHO, [H]
X W R 1 X X' W
~;;z~)m ~
RCO~\ ~trong [H]
~X-Q`W
~ )m O R
~1 63995 In an alternative embodiment of the present invention, the allyl acid 2 (described in Hale et al; see above) can be converted into the N-methyl methoxy amide 3, which is then treated with an alkyl or aryl metal reagent, for example methyllithium or butyllithium, to provide 5 the ketone 4 (Scheme 2). The ketone can be converted into an imine which can then be reduced to secondary amine 5 chemically, (e.g using sodium cyanoborohydride or sodium borohydride), or catalytically (e.g.
using hydrogen and palladium on carbon or Raney nickel catalyst).
Acylation under standard conditions, for example with an acid chloride, provides amide 6. The allyl group in 6 can be oxidatively cleaved to aldehyde 7 with osmium tetroxide followed by sodium periodate or with ozone at low temperature. Reductive ~min~tion of aldehyde 7 with azacycle 1 can then be carried out under the conditions described above.
Substituted spiro(indoline-3,4'-piperidine) derivatives can 5 be prepared as shown in Scheme 3 starting from the appropriately substituted phenylhydrazines. Following the Fischer indole reaction and reduction of the intermediate imine with a mild reducing agent such as sodium borohydride, the indoline nitrogen can be reacted with an electrophile such as an acyl chloride or a sulfonyl chloride. The 20 protecting group on the piperidine nitrogen, for example a benzyloxycarbonyl group, can be removed by treatment with hydrogen in the presence of palladium on carbon or by exposure to trimethylsilyl iodide, to give the deprotected substituted spiro(indoline-3,4'-piperidine).
2 1 63qq5 E DAC O
HOBT-H20 ~N,OMe OH HN(Me)(OMe) HCI - ~e RLi, -78C or Cl' ~ Cl/~3 RMgBr, rt `\ R R6NH3CI ~N,H (BOC)2o Cl/~ C~
Cl 4 Cl 5 1 ) OSO4 N,BOC acetone/ tBuOH/H20 H N,BOC
- R 3:1 CIJ~3 Cl 6 Cl 7 CF3CO2H Amine HCI C ~ ~
anisole, CH2C12 NaBH3CN - R 7 Cl/~
Cl 8 2 1 63~5 O OBn 1) pyridine, toluene ~OBn + ~ 2) CF3CO~H, 60C ~) NH3CI CHO 3) NaBH4, MeOH H
~ OBn N HCI Me3Sil; HCI N
~ ~ H2, Pd/C; HCI
R ~ R
Preparation of spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) derivatives is shown in Scheme 4. Reaction of N-Boc protected 4-piperidone with the lithium salt of methyl phenyl sulfoxide followed by base-mediated elimin~tion-rearrangement and basic cleavage provides the indicated allylic alcohol. The alcohol can be 30 converted to the rearranged allylic chloride with thionyl chloride in toluene in the presence of 2,6-lutidine as a proton scavenger.
Displacement of the chloride with functionalized 2-bromothiophenol provides the allylic sulfide, which can be cyclized under radical conditions to give the illustrated spiro(2,3-dihydrobenzothiophene-3,4'-wo 94/29309 2 1 6 3 9 9 5 PCT/US94/05545 piperidine). Cleavage of the t-butoxycarbonyl group under standard conditions, such as trifluoroacetic acid, then provides the desired spirocycle.
Boc Boc methyl phenyl N
~N~ sulfoxide ~ KOtBu, tBuOH
LDA, THF HO ~ 50C
OC ~S~O
R ~
Boc Boc ~ SH
N N Br ~ ~ SOCI2, PhMe ~ K2CO3, 40C
OH 2,6-lutidine Cl Boc N~ Boc I~J Br Bu3SnH, AIBN ~N~ 1 ) TFA
S~¦~ PhH, 80C ~ 2) HCI, MeOH
H HCI R
N
30 ~
R
2 1 6~9~5 Spiro(2,3-dihydrobenzofuran-3,4'-piperidine) derivatives can be prepared as illustrated in Scheme 5. Treatment of an appropiately substituted ester of 2-fluorophenylacetate with mechloret~mine hydrochloride under basic conditions provides the 5 piperidine product, which on treatment with a strong reducing agent such as lithium aluminum hydride produces the corresponding 4-(hydroxymethyl) compound. Cyclization with base provides the benzofuran derivative, and cleavage of the N-methyl group can then be carried out using l-chloroethyl chloroformate or other suitable N-o demethylating agents.
21 639~5 N NaH
MeO Cl Cl f ~ F
O N
Me ~I LiAlH4, THF
DMF HO ~
R ~ F
Cl ~ Me Me O Cl 1 ,2-dichloroethane, reflux ~NH-HCI
Compounds with alternate arrangements of the amide bond 30 can be prepared as shown in Scheme 6. The illustrated acid can be homologated under Arndt-EisteIt conditions to give the chain-extended acid, which can be derivatized under standard acylating conditions with, for example, an aniline derivative, to give the corresponding amide.
Oxidative cleavage of the olefin with osmium tetroxide or ozone then 21 639~5 provides the aldehyde intermediate suitable for coupling as described earller.
R R
~1 1) (COCI)2 ~OH 2) CH2N2, Et20 ~N2 R
AgN03 ~s~H
H20 o 1) (COCI)2 e` ,~
R
1 ) OSO4, H20, tBuOH
N-Me-morpholine-N-oxide ~\'q 2) NalO4, H20, THF ~ Me O ~5~ N
Me 2 ~ 63~95 In addition, ketone derivatives can be prepared by an extension of the chemistry given above, as shown in Scheme 7. A
second Arndt-Eistert chain extension provides the illustrated heptenoic acid derivative, which after conversion into its N-methoxy-N-methyl 5 amide, can be reacted with an aryl organometallic reagent, such as an aryl magnesium bromide, to provide the ketone. Routine oxidative cleavage then gives the desired aldehyde, which can be coupled with a spiro-piperidine derivative as described above.
R
1) (C )2 ~ 2) CH2N2 ~J~ OH
1) (COCI)2 ~q~
- Me 2) HN(Me)OMe ~ ~N~OMe ~ R' BrMg THF
1 ) OsO4, H2O, tBuOH
N-Me-morpholine-N-oxide R
2) NalO4, H2O, THF ~q '1~ 1~ R' R ~ J
2 ~ O
2 1 6399~
D~ 1) (COC~
s2) C H2N2 ~ ,I~,OH
101) (COc1)2 , ~q ~ Me 2) HN(Me)OMe l I
~N~ OM
BrMgJ3 THF ''' 1 ) OSO4, H20, tBuOH
N-Me-morpholine-N-oxide R
2) NalO4, H20, THF ~\~
,. ~ ~ R' R ~ ~
~ O
~ 1~ R' ~/
O
Alcohol containing antagonists can be prepared according to procedures given in Scheme 8. Formation of the N-methyl-N-methoxy amide of the indicated acid followed by oxidative cleavage of the olefin provides the intermediate aldehyde. Coupling with a spiro(indoline-3,4'-piperidine) derivative followed by addition of an organometallic reagent to the amide provides the illustrated ketone.
Treatment with a hydride reducing agent, such as sodium borohydride, 5 then yields the desired alcohol derivatives.
WO 94/29309 2 1 6 3 ~ ') 5 SCHE~'IE 8 O O
~OH ~N~ Me - 1) (coC1)2 . ,~, OMe l~;~ 2) HN(Me)OMe ~J
1 ) 0sO4,H20, tBuOH ~ N~ Me SO2CH3 N-Me-morpholine-N-oxlde ~ OMe ~< ~
2) NalO4, H20,THF R' R/~ NH HCI
MeOH, NaBH3CN R\,=< O R"MgCI
mol. sieves ~--NI--~`N'Me OMe Sl 02C H3 20 R~N ~--~` R~ NaBH4 R' SO2CH3 so2CH3 N N
R N~ R~ R~--~+ ~1 R' R' Formation of heterocycle substituted antagonists can be carried out according to the procedure given in Scheme 9 for substituted imidazoles. Reduction of the allyl acid with a strong reducing agent such as lithium aluminum hydride followed by in situ 5 formation of the trifluoromethanesulfonate of the formed alcohol allows for displacement of the triflate with a nucleophile such as 2-phenylimidazole. Oxidative cleavage under standard conditions provides the indicated aldehyde which can then be coupled under the conditions described above to the appropriate spiro derivative.
WO 94/Z9309 2 1 6 3 9 9 5 PCT/US94105~4~
LiAlH4 ~--OH (CF~SO2)0 T~F R' 2,6-lutidine R' 1 ) OSO4, H2O, tBuOH
N-Me-morpholine-N-oxide /_\ ~J 2) NalO4, tl2O, THF
HN~f N ~ N)~N
R' ~--N~N
2 0 \=~
R' Spiro(2-oxo- 1,2,3 ,4-tetrahydroquinoline-4,4'-piperidine) and spiro(1-oxo-1,2,3,4-tetrahydroisoquinoline-4,4'-piperidine) can be prepared as shown in Scheme 10. Starting from the indicated spiro(2-oxoindane-3,4'-piperidine) (described in Claremon, D.A. et al, 30 European Patent 0 431 943 943 A2, Ev~ns, B.E. et ~1, U.s. Patent 5~091.387, Davis, L. et al, U,s. Patent 4~420~485, all of which are incorporated by reference, and Parham et al, Journal of Or~anic Chemi~try, 41, 2628 (1976)), deprotection of the piperidine nitrogen is carried out by treatment with acid, for example trifluoroacetic acid, followed by protection as the trifluoroacetamide, and the product is WO 94/29309 ~ 1 ~ 3 q q 5 PCT/US94/05545 exposed to hydrazoic acid in the presence of sulfuric acid. Heating of this mixture effects a Schmidt rearrangement, to provide both the tetrahydroquinoline and the tetrahydroisoquinoline derivatives. These spiro compounds can then be separated and coupled to functionalized 5 aldehydes by the methodology given above.
--N Ot-Bu CF3C02H o~J
HN3, H2S04 rt to 45 deg C
--NH --NH
~~J + HN J
HN`~
Neurokinin antagonists with ether substituents can also be prepared by the route shown in Scheme 11. Thus, the allyl acid discussed earlier can be reduced to the corresponding alcohol with, for example, lithium aluminum hydride. This alcohol can be alkylated by a Williamson ether 30 synthesis, by deprotonation with a strong base such as sodium hydride or sodium hexamethyldisilazide followed by reaction with a benzyl halide such as benzyl bromide. The product can be processed through the oxidative cleavage steps described earlier to provide the aldehyde, which can then be coupled with a spirocycle kunder reductive amination conditions or else by reduction to the corresponding alcohol and conversion to the bromide. the bromide can then be used to alkylate a spirocycle under the conditions detailed above.
OH 4 ~ - OH
R~ R
1 ) OsO4, H20, tBuOH
,, n ~ N-Me-morpholine-N-oxide ~1 2) NalO4, H20, THF
~- ~oJ
2 0 R R' -,~
R
Accordingly in another aspect the invention encompasses a process of making compounds of formula I
21 639q5 X' `W
~Z ~) m as defined above, comprising the steps of:
(a) reacting a compound of formula A
~Q~
X W
~Z~>) m I N
H
A
in a suitable solvent such as acetonitrile or dimethylacetamide with a compound of formula Rl-xl wherein X1 is a leaving group such as bromo, chloro, tosyl or mesyl optionally in the presence of a suitable 2 5 base such as trialkylamine; or (b) reacting a compound of formula A in a second suitable solvent such as methanol or ethanol with a compound of the formula R-CH(O), wherein R-CH2 is R1 as defined above, in the presence of a reducing agent such as sodium cyanoborohydride or hydrogen and a palladium on carbon catalyst; or (c) reacting a compound of formula A in a halocarbon solvent such as methylene chloride with a compound of the formula R-C(O)X2 wherein X2 is a suitable leaving group such as bromo or chloro in the presence of a suitable base such as trialkylamine, to yield a compound of formula I.
3 -(S)-(3 ,4-Dichlorophenvl)-4-(N-(t-butoxycarbonyl)methylamino) butanal A solution of 10 g (41 mmol) of 3-(S)-(3,4-dichloro-phenyl)-4-methylamino-1-pentene in 100 mL of CH2C12 was cooled in an ice bath and treated with 5.8 mL (41 mmol) of triethylamine (Et3N) and 9 g (41 mmol) of di-t-butyl dicarbonate. The cold bath was removed after 5 min and the stirring was continued for 1 h. The reaction mixture was diluted with CH2Cl2 and washed with water, 1.2 15 N HCl, saturated NaHCO3 and brine. The solution was dried over Na2SO4 and concentrated to give 14.58 g of residual oil.
lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) o 1.36 (s, 9H), 2.33 (m, 2H), 2.60 & 2.70 (2s, 3H), 2.8-3.6 (m, 3H), 4.94 (m, 2H), 5.59 (m, lH), 6.9-7.4 (m, 3H).
The residue was dissolved in 80 mL of acetone, 40 mL of t-butanol and 40 mL of water. To this solution 1 mL of osmium tetroxide (4% solution in water) and 5.15 g (44 mmol) of 4-methylmorpholine N-oxide were added. After stirring for 26 h, the reaction was quenched with approximately 5 g of Na2SO3 and 25 concentrated to 25% of the original volume. The residue was partitioned between water and 1:1 ether (Et2o)~ ethyl acetate (EtOAc), the layers were separated and the aqueous layer was extracted with Et2O:EtOAc. Each organic layer was washed with water, brine and dried by filtering through Na2so4. The filtrate was concentrated to 30 afford the crude diol.
A solution of the diol in 120 mL of tetrahydrofuran (THF) and 40 mL of water was treated with 9.42 g (44 mmol) of sodium periodate. After stirring for 2 h, the reaction was diluted with Et2O:EtOAc and washed with water and brine. The organic layer was wo 94/29309 2 1 6 3 9 9 5 PCT/US94/0~545 dried (Na2SO4) and the filtrate was concentrated. The residue was purified by prepLC using 30% EtOAc/hexane to furnish 11.74 g (83%
yield for three steps) of the title compound as a thick oil.
lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) o 1.38 (s, 9H), 2.69 & 2.75 (2s, 3H), 2.6-3.65 (m, SH), 6.95-7.4 (m, 3H), 9.67 (s, lH).
0 1 '-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(t-butoxycarbonyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ~4 '-piperidine) To a solution of 0.76 g (2.2 mmol) of 3-(S)-(3,4-dichlorophenyl)-4-(N-(t-butoxycarbonyl)methylamino)butanal ( from Example 1) in 4 mL of methanol were added 0.608 g (2 mmol) of 1-methane-sulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride and 0.6 g of powdered 4 A molecular sieves. After 15 min a solution of 0.554 g (8.8 mmol) of NaCNBH3 in 8 mL of THF was dropwise added. Some gas evolution was obser~ed. After 2 h, when the reaction was complete by TLC, the mixture was filtered through a pad of celite, the reaction flask and the pad were rinsed with methanol. The filtrate was concentrated to approximately 5 ml and the residue was partitioned between saturated NaHCO3 and Et2o:EtoAc. The organic layer was washed with water, brine and dried over Na2so4. The filtrate was concentrated and the residue was chromatographed on a flash column using a gradient of 49:49:2 to 74:24:2 EtOAc:hexane: triethylamine to furnish 0.94 g (72%) of the title compound as a foam.
lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.37 (s, 9H), 1.6-3.6 (m, 15H), 2.61 & 2.72 (2s, 3H), 2.86 (s, 3H), 3.74 (s, 2H), 6.95-7.4 (m, 7H).
2163~95 1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 ,5-dimethylbenzoyl)(methylamino)) butyl)-1-methanesulfonyl-spiro(indoline-3 .4'-piperidine) Step A: 1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-1-methanesulfonyl-spiro(indoline-3 4'-piperidine) Cold trifluoroacetic acid (TFA, 4 mL) and 0.2 mL of anisole were added to 0.94 g (1.57 mmol) of 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(t-butoxycarbonyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) and the mixture was stirred in an ice bath until all the foam dissolved. After stirring the resulting solution at room temperature for 30 min, it was concentrated in vacuo. The residue was partitioned between 0.5 N NaOH and CH2C12 and the layers were separated. The organic layer was washed with brine, dried over Na2S04 and concentrated to give 0.7 g of foam which was used in the next step without purification.
lH NMR (CDC13, ppm ranges are given because of amide rotomers and line broadening) ~ 1.7-2.7 (m, 10H), 2.64 (s, 3H), 2.88 (s, 3H), 2.9-3.4 (m, SH), 3.70 (s, 2H), 6.8-7.4 (m, 7H).
Step B: 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 4'-piperidine) A solution of 0.12 g (0.52 mmol) of 3,5-dimethylbenzoic acid in 2 mL of CH2C12 containing 1 drop of DMF was treated with 85 ul of oxalyl chloride. (Caution-gas evolution!) After 20 min the solution was concentrated in vacuo and the residue was mixed with 0.2 g (0.4 mmol) of 1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-1-methane-sulfonyl-spiro(indoline-3,4'-piperidine) obtained from Step A, and 0.14 mL (1 mmol) of Et3N in 2 mL of CH2C12. After 1 h the reaction mixture was diluted with CH2C12 and washed with saturated NaHCO3, water, and brine. The CH2C12 solution was dried over Na2SO4, filtered and concentrated. Purification of the residue by prep ~1 639q5 TLC using 2% Et3N/EtOAc afforded 0.238 g (93% yield) of the title compound as a foam.
1H NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.6-2.4 (m, 10H), 2.27 (s, 6 H), 2.6-3.9 (m, 10H), 2.86 (s, 3H), 6.6-7.5 (m, 10H).
The following compounds were prepared by substituting the required acid chloride for 3,5-dimethylbenzoyl chloride in Step B.
1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methylamino)) butyl)-1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Mass Spectrum (FAB) 602 (37Cl + 35Cl isotope), 600 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 ,5-bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-5 spiro(indoline-3 ,4'-piperidine) Mass Spectrum (FAB) 738 (37Cl + 35Cl isotope), 736 (35Cl + 35Cl isotope).
1 '-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 -methylbenzoyl) 2 (methylamino))-butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) 1H NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.6-2.4 (m, 10H), 2.32 (s, 3H), 2.6-3.9 (m, 10H), 2.86 (s, 3H), 6.75-7.5 (m, 1 lH).
25 Mass Spectrum (FAB) 616 (37Cl + 35Cl isotope), 614 (35Cl + 35Cl isotope).
1 '-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 -chlorobenzoyl) (methylamino))-butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-3 piperidine) 1H NMR (CDC13, ppm ranges are given because of amide rotomers and line broadening) o 1.6-2.4 (m, 10H), 2.6-3.9 (m, 10H), 2.86 (s, 3H), 6.75-7.5 (m, 1 lH).
WO 94/29309 2 1 6 3 q 9 5 PCT/US94/05545 Mass Spectrum (FAB) 635 (37Cl + 35Cl isotope), 633 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3 -trifluoromethylbenzoyl) 5 (methyl-amino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 669 (37Cl + 35Cl isotope), 667 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl) (methylamino))-butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.6-2.4 (m, lOH), 2.6-3.9 (m, lOH), 2.86 (s, 3H), 5 6.75-7.5 (m, 1 OH).
Mass Spectrum (FAB) 671 (37Cl + 35Cl isotope), 669 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-trifluoromethylphenylacetyl) 20 (methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 684 (37Cl + 35Cl isotope), 682 (35Cl + 35CI
isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3-isopropyloxyphenylacetyl) 25 (methyl-amino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(benzenesulfonyl) (methylamino))-butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-30 piperidine)lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.65 (m, 3H), 1.8-2.3 (m, 7H), 2.62 (s, 3H), 2.7-3.05 (m, 4H), 2.86 (s, 3H), 3.3 (m, 2H), 3.74 (s, 2H), 7.0-7.7 (m, 12H).
WO 94/29309 2 l 6 3 9 ~ 5 PCT/US94/05545 Mass Spectrum (FAB) 637 (37Cl + 35Cl isotope), 635 (35Cl + 35Cl isotope).
The following compounds were also prepared by using the 5 appropriate acid chloride under the conditions given in Step B above:
1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3,5-difluorobenzoyl)(methyl-amino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Mass Spectrum (FAB) 638(37Cl + 35Cl isotope), 636(35Cl + 35Cl isotope).
1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 -fluoro-5 -(trifluoromethyl)-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Mass Spectrum (CI) 688 (37Cl + 35Cl isotope), 686 (35Cl + 35Cl 5 isotope).
1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-( 1 -naphthoyl)(methylamino))-butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) 1 H NMR (CDCl3, ppm ranges are given because of amide rotomers and 20 line broadening) d Mass Spectrum (FAB) (37Cl + 35Cl isotope), (35Cl + 35Cl isotope).
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(N-(2-chlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3 ,4'-piperidine) 25 Mass Spectrum: 200, 202, 228, 230, 279, 308, 310, 494, 496, 670, 672 (cluster).
1 '-(3-((S)-(3,4-Dichlorophenyl))- 1 -(N-(3-chlorophenylsulfonyl)-(methylamino))-4-butyl)- 1 -methylsulfonyl-spiro(indoline-3 ,4'-3 piperidiIle)Mass Spectrum: 200, 202, 228, 230, 279, 308, 310, 494, 496, 670, 672 (cluster).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-chlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum: 200, 228, 230, 279, 494, 496, 669 (cluster).
1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum: 228, 230, 279, 494, 496, 703, 705 (cluster).
l-Benzvloxycarbonyl-spiro(indoline-3.4'-piperidinium) hydrochloride A solution of 99 g (489 mmol) of 1'-methylspiro(indoline-3,4'-piperidine) (prepared according to Ong, H. H. et al, J. Med. Chem., 1983, 26, 981-986) in 1 L of CH2Cl2 and 82 mL (539 mmol) of Et3N
l5 was cooled to 0-5C with an ice bath and 77 mL (539 mmol) of benzyl chloroformate was added over 30 min keeping the reaction temperature below 10C. After stirring for 2 h 19 mL (136 mmol) of Et3N and 15 mL (105 mmol) of benzyl chloroformate were added since the reaction was incomplete and stirred for 2 h. At this time, additional 19 mL (136 20 mmol) of Et3N and 15 mL (105 mmol) of benzyl chloroformate were added. After 1 h, when a TLC indicated a complete reaction, the solution was concentrated in vacuo and the residue was partitioned between ether and saturated NaHCO3. The layers were separated, the organic layer was washed with saturated NaHCO3 and brine, and dried 25 over MgSO4. The filtrate was concentrated and the residue was chromatographed on 2 kg of silica gel using 1-5% MeOH/CH2Cl2 to obtain 117 g (71 %) of 1 -benzyloxycarbonyl- 1 '-methylspiro(indoline-3,4'-piperidine) as a yellow oil.
The yellow oil was dissolved in 800 mL of 1,2-30 dichloroethane and cooled in ice bath as 50 mL (463 mmol) of 1-chloroethyl chloroformate keeping the tempera~ure below 10C. The resulting solution was heated to reflux. Gas evolution was noticed when the reaction temperature reached 70-75C. After 1 h the solution was cooled, concentrated to ca. 250 mL in vacuo and 700 mL of methanol WO 94/29309 2 1 6 3 ~ 9 5 PCT/US94/05545 was added. The mixture was refluxed for 1.5 h and gas evolution was observed. The reaction was cooled to room temperature and concentrated in vacuo to a wet solid. The solid was slurried with cold methanol, the solid was filtered, washed with cold methanol and dried.
5 The filtrates and the washing were combined and concentrated to a brown foam. The brown foam and the filtered solid were suspended in CH2Cl2, washed with 2.5 N NaOH and the CH2Cl2 solution was dried.
The residue was chromatographed on 2 kg of silica gel using a gradient of 94:5:1 to 89:10:1 CH2Cl2, methanol, NH40H to isolate 91.3 g of free base as a brown oil. The oil was dissolved in 1 L of EtOAc by adding methanol (ca. 10 mL) and HCl gas was passed through the solution.
After stirring the acidic solution for 10 min, it was concentrated to a foam. The foam was triturated with ether and the solid was filtered, washed with more ether and dried to furnish 91.5 g (73%) of title 5 compound as a light yellow solid.
EXAMPLE S
3 -((S)-(3 ,4-Dichlorophenyl))-4-((3 ,5 -dimethylbenzoyl)methylamino)-20 butanal The title compound was prepared using the proceduresdescribed in Example 1 by substituting 3,5-dimethylbenzoyl chloride for di-t-butyl dicarbonate.
lH NMR (CDCl3, ppm ranges are given because of amide rotomers and 25 line broadening) ~ 2.27 (s, 6H), 2.6-3.9 (m, 8H), 6.5-7.5 (m, 6H), 9.73 (s, lH).
1 '-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 ,5 -dimethylbenzoyl)(methyl-3 amino))butyl)- 1 -benzyoxycarbonyl-spiro(indoline-3 ~4'-piperidine) The title compound was prepared from 3-((S)-(3,4-dichlorophenyl))-4-((3,5-dimethylbenzoyljmethylamino)butanal (Example S) and 1-benzyloxycarbonyl-spiro(indoline-3,4'-21 63q~5 piperidinium) hydrochloride (Example 4) following the procedure of Example 2.
lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.6-2.35 (m, 10H), 2.27 (s, 6H), 2.6-3.9 (m, 10H), 5.23 & 5.3 (2 s, 2H), 6.6-7.6 (m, 15H).
Mass Spectrum (FAB) 686 (37Cl + 35Cl isotope), 684 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) (methylamino))butyl )-spiro(indoline-3,4'-piperidine) To a solution of 1.23 g (1.8 mmol) of 1'-(3-((S)-(3,4-dichlorophenyl))-4-(3,5-dimethylbenzoyl(methylamino))butyl)- 1 -benzyoxycarbonyl-spiro(indoline-3,4'-piperidine) (Example 6) in 10 mL of ethanol and 0.8 mL of acetic acid (HOAc) was added 0.15 g of 10% Pd/C. The resulting mixture was hydrogenated on a Parr apparatus for 20 h. The catalyst was filtered and washed with EtOH.
The combined filtrate was concentrated in vacuo and the residue was dissolved in CH2Cl2. The CH2Cl2 solution was washed with dilute (ca 0.5 N) NaOH and brine, and dried by filtering through Na2SO4. The filtrate was concentrated to furnish 1.03 g (quantitative) of the title compound as a foam which was used in the next reaction without purification.
1H NMR (CDCl3, ppm ranges are given because of amide rotomers and 2s line broadening) ~ 1.6-2.45 (m, 10H), 2.27 (s, 6H), 2.6-3.9 (m, 10H), 6.5-7.5 (m, 10H).
Mass Spectrum (FAB) 552 (37Cl + 35Cl isotope), 550 (35Cl + 35Cl isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl) (methylamino))butyl)- 1 -acetvl-spiro(indoline-3.4'-piperidine) 2~ 63~5 Acetyl chloride (16 uL) was added to a solution of 0.1 g (0.18 mmol) of 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)-spiro(indoline-3,4'-piperidine) (Example 7) in 4 mL of CH2Cl2 containing 30 mL of pyridine. After stirring for 5 2 h, the reaction mixture was diluted with CH2Cl2 and washed with saturated NaHCO3, water, brine and dried. ~he residue after concentration of the filtrate was purified by prep TLC using 5%
Et3N/EtOAc as an eluent to afford 90 mg (84%) of the title compound.
lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.55-2.5 (m, 10H), 2.22 (s, 3H), 2.27 (s, 6H), 2.6-3.9 (m, 10H), 6.6-7.5 (m, 9H), 8.17 (d, lH, J = 12Hz).
Mass Spectrum (FAB) 594 (37Cl + 35Cl isotope), 592 (35Cl + 35Cl isotope).
The following analogs were prepared by substituting the appropriate acylation reagent for acetyl chloride in the above procedure.
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl)(methyl-amino))butyl)- 1 -propionyl-spiro(indoline-3,4'-piperidine) 20 Mass Spectrum (FAB) 608 (37Cl + 35Cl isotope), 606 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) (methylamino)) butyl)-1-formyl-spiro(indoline-3,4'-piperidine) 25 Mass Spectrum (FAB) 580 (37Cl + 35Cl isotope), 578 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl) (methylamino)) butyl)-1-t-butylcarbonyl-spiro(indoline-3,4'-piperidine) 30 Mass Spectrum (FAB) 636 (37Cl + 35Cl isotope), 634 (35Cl + 35Cl isotope).
WO 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl) (methylamino)) butyl)-1-methylaminocarbonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 609 (M+H, 37Cl + 35Cl isotope), 607 (M+H, 5 35Cl + 35CI isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) (methylamino)) butyl)-1-ethoxycarbonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 624 (37CI + 35Cl isotope), 622 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) (methylamino)) butyl)-1-ethanesulfonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 643 (37Cl + 35Cl isotope), 641 (35Cl + 35Cl l 5 isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl) (methylamino)) butyl)-l-i-propanesulfonyl-spiro(indoline-3,4'-piperidine) 20 Mass Spectrum (FAB) 657 (37Cl + 35Cl isotope), 655 (35Cl + 35Cl isotope).
The following compound can also be prepared under the conditions given above:
25 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-fluoro-5-(trifluoromethyl)-benzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) (CI) 652 (37Cl + 35Cl isotope), 650 (35Cl +35Cl isotope).
An alternative method (method B) is given below:
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl)(methyl-amino))butyl)- l -acetyl-spiro(indoline-3,4'-piperidine) l -Acetyl-spiro(indoline-3,4'-piperidine) 2 T ~3~5 Acetyl chloride (1.4 mL, 19.9 mmol) was added to a solution of 5.35 g (16.6 mmol) of 1'-benzyloxycarbonyl-spiro(indoline-3,4'-piperidine) in 33 mL of CH2Cl2 and 3.2 mL (23.2 mmol) of Et3N
5 keeping the temperature between 0-5C by cooling in ice bath. After 10 min the cold bath was removed and reaction was stirred for 30 min at which time a TLC indicated complete reaction. The solution was diluted with CH2Cl2 and washed with water, brine and dried over Na2SO4. The filtrate was concentrated to a thick oil and the oil was dissolved in 40 mL of EtOH. Acetic acid (3 mL) and 0.8 g of 10%
Pd/C were added to the solution and the resulting mixture was hydrogenated on a Parr apparatus for 3 h. The catalyst was filtered and washed with EtOAc and the combined filtrate was concentrated. The residue was partitioned between CH2Cl2 and water and 2N NaOH was 5 added to this mixture until the aqueous layer was basic. The layers were separated and the aqueous layer was extracted with CH2Cl2. The combined organic layer was washed with brine, dried over Na2SO4 and the filtrate was concentrated to give 2.93 g (77%) of the title compound sufficiently pure for use in the next reaction.
1 '-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 ,5 -dimethylbenzoyl)(methyl-amino)) butyl)-1-acetyl-spiro(indoline-3.4'-piperidine) To a solution of 0.284 g (0.75 mmol)of 3-((S)-(3,4-dichlorophenyl))-4-(N-(3 ,S -dimethylbenzoyl)(methylamino))butanal 25 (Example 5) in 2 mL of MeOH were added 0.166 g (0.72 mmol) of 1-acetyl-spiro(indoline-3,4'-piperidine), 0.5 g of powdered 4 A molecular sieves and 10 drops (ca. 0.1 mL) of acetic acid. After stirring the mixture for 1.5 h a solution of 0.189 g (3 mmol) of NaCNBH3 in 3 mL
of THF was added. Some gas evolution was observed. After 30 min 30 when the reaction was complete by TLC the mixture was filtered through a pad of celite, the reaction flask and the pad were rinsed with MeOH. The filtrate was concentrated to approximately 3 mL and the residue was diluted with EtOAc. The EtOAc solution was washed with water, brine and dried over Na2so4. The filtrate was concentrated and 21 639~5 the residue was chromatographed on a flash column using 50% EtOAc-hexane followed by 2% Et3N-EtOAc and finally 93:5:2 EtOAc: MeOH:
Et3N to isolate 0.317 g (74%) of the title compound as a white foam.
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(3,5-dimethylbenzoyl(methylamino)) butyl)- 1 '-methyl- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidinium) iodide A solution of 53 mg (0.084 mmol) of 1'-(3-((S)-(3,4-dichlorophenyl))-4-(3,5-dimethylbenzoyl(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) in 5 drops of MeOH
was diluted with 1 mL of ether and 0.5 mL of methyl iodide was added.
The reaction mixture was stirred overnight while a solid was formed.
5 The yellowish solid was allowed to settle and the supernatent was removed. The solid was washed with ether and dried to furnish 51 mg (78%) of the title compound.
1'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(3-methylbenzoyl) (methyl-amino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 2s Step 1: N-Methoxy-N-methyl-2-(S)-(3,4-dichlorophenyl)-4-pentenamide A mixture of 306 mg (1.25 mmol) of (2S)-(3,4-dichlorophenyl)-4-pentenoic acid (prepared according to the procedure of Hale, J.J.; Finke, P.E.; MacCoss, M. Bioorganic & Medicinal 30 Chemistry Letters 1993,3, 319-322) and 202 mg (1.50 mmol) of 1-hydroxybenzotriazole hydrate in 10 mL of methylene chloride was cooled to 0C and treated with 287 mg (1.50 mmol) of 1-(3-dimethyl-aminopropyl)-3-ethylcarbodiimide. The cooling bath was removed and after 45 min. a solution of 365 mg (3.75 mmol) of N,O-dimethyl-~163~5 hydroxylamine hydrochloride and 522 ~1 (3.75 mmol) of triethylamine in 10 mL of methylene chloride was added via cannula. The mixture was then stirred at 22C for 4 hours and then quenched with 10 mL of water and diluted with 8 mL of methylene chloride. The layers were 5 separated and the aqueous layer was extracted with methylene chloride (2 x 10 mL). The combined organic layers were washed with 10 mL of brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 75 g of silica gel using 1:9 v/v ethyl acetate/ hexane as the eluant afforded 319 mg (89%) of the title o compound as a clear oil.
lH NMR (400 MHz, CDCl3) ~ 2.40 (pentet, lH), 2.75 (pentet, lH), 3.13 (s, 3H), 3.52 (s, 3H), 3.99-4.01 (m, lH), 4.96-5.05 (m, 2H), 5.63-5.70 (m, lH), 7.15 (dd, lH), 7.35 (d, lH), 7.41 (d, lH).
Mass Spectrum (FAB): m/z 290 (M+H, 37Cl + 35Cl isotope, 50%), 288 5 (M+H, 37Cl + 37Cl isotope, 100%).
Step 2: 3-(S)-(3.4-dichlorophenyl)-5-hexen-2-one A solution of 319 mg (1.11 mmoL) of N-methoxy-N-methyl-2-(S)-(3,4-dichlorophenyl)-4-pentenamide (from Step 1 above) 20 in 10 mL of dry tetrahydrofuran was cooled to -70C and treated with 1.0 mL (1.40 mmol) of methyllithium and stirred between -70C to -40C. After 3 hours, the reaction was quenched with 5 mL of water, and diluted with 10 mL of ethyl acetate. The layers were separated and the organic layer was washed with water (3 x 10 mL). The aqueous 25 layers were extracted with 10 mL of ethyl acetate. The combined organic layers were washed with 10 mL of saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 44 g of silica gel using 1:3 v/v ethyl acetate/hexane as the eluant afforded 250 mg (93%) 3 of the title compound as a clear oil.
lH NMR (400 MHz, CDCl3) o 2.07 (s, 3H), 2.36 (pentet, lH), 2.72 (pentet, lH), 3.64 (t, lH), 4.95-5.01 (m, 2H), 5.55-5.65 (m, lH), 7.03 (dd, lH), 7.30 (d, lH), 7.39 (d, lH).
2 1 639q5 Mass Spectrum (FAB): m/z 245 (M+H, 37Cl + 35Cl isotope, 30%), 243 (M+H, 37Cl + 37Cl isotope, 50%), 155 (60%), 119 (100%).
Step 3: N-Methyl 3-(S)-(3,4-dichlorophenyl)-5-hexen-2-(RS)-amine A mixture of 102 mg (0.42 mmol) of 3-(S)-(3,4-dichlorophenyl)-5-hexen-2-one (from Step 2 above), 170 mg (2.52 mmol) of methylamine hydrochloride, and 234 ,ul (1.68 mmol) of triethylamine in 4.0 mL of methanol was treated with 16 mg (0.25 mmol) of sodium cyanoborohydride and stirred at 22C for 20 hours.
Saturated aqueous sodium bicarbonate solution (1.0 mL) was added and the resulting milky mixture was diluted with 5.0 mL of ethyl acetate and 5.0 mL of water. The layers were separated and the organic layer was washed with water (3 x 5 mL). The aqueous layers were extracted with 10 mL of ethyl acetate. The combined organic layers were washed with 10 mL of saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 42 g of silica gel using 10:1 v/v ether/ hexane as the eluant afforded 64 mg of the higher Rf isomer (Isomer A) and 22 mg of a lower Rf isomer (Isomer B) both as yellow oils.
lH NMR (400 MHz, CDCl3); Isomer A: o 1.04 (d, 3 H), 2.29-2.35 (m, 4 H), 2.50-2.68 (m, 3H), 4.86-4.95 (m, 2H), 5.48-5.56 (m, lH), 7.01 (dd, lH), 7.26 (d, lH), 7.34 (d, lH); Isomer B: ~ 0.86 (d, 3H), 2.32-2.50 (m, 4H), 2.51-2.53 (m, lH), 2.68-2.73 (m, 2H), 4.88-4.98 (m, 2H), 5.54-5.61 (m, lH), 6.97 (dd, lH), 7.22 (d, lH), 7.33 (d, lH).
Mass Spectrum (Isomer A) (FAB): m/z 260 (M+H, 37Cl + 35Cl isotope, 70%), 258 (M+H, 35Cl + 35Cl isotope, 100%).
Step 4: N-Methyl-N-t-butoxycarbonyl-3-(S)-(3,4-dichlorophenyl)-5 -hexen-2-(RS )-amine A solution of 1.1 g (4.1 mmol) of N-methyl-(3-(S)-(3,4-dichlorophenyl)-5-hexen-2-(R or S)-amine (Isomer B *om Step 3 above) in lO mL of dry methylene chloride was cooled to 0C and treated with 690 ~l (5.0 mmol) of triethylamine and 1.2 g (5.3 mmol) WO 94/29309 2 1 6 3 ~ 9 5 PCT/US94/05545 of di-tert-butyl dicarbonate. The cooling bath was removed and the reaction was stirred at 22C for 20 hours. The reaction was quenched with 10 mL of water and diluted with 25 mL of methylene chloride.
The layers were separated and the aqueous layer was extracted with 5 methylene chloride (2 x 10 mL). The combined organic layers were washed with 15 mL of brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 72 g of silica gel using 1 :3 v/v ethyl acetate/ hexane as the eluant afforded 1.4 g (95%) of the title compound as a yellow oil.
o l H NMR (400 MHz, CDCl3, ranges are given due to amide rotamers and line broadening) ~ 1.24-5.70 (22H), 6.88-7.40 (3H), 1.50 (s, 3H, N-CH3).
Mass Spectrum (FAB): m/z 358 (M+H, 37CI + 35Cl isotope, 30%), 302 (100%).
Step 5: N-Methyl-N-t-butoxycarbonyl-3-(S)-(3,4-dichlorophenyl)-4- (RS ) -amino-pentanal A solution of 1.4 g (3.9 mmol) of N-methyl-N-t-butoxy-carbonyl-3-(S)-(3,4-dichlorophenyl)-5-hexen-2-(RS)-amine (from Step 4 above) in 20 mL of 2:1:1 v/v/v acetone/t-butanol/water was treated with 30 mg (0.12 mmol) of osmium tetroxide. After 5 min., 691 mg (5.90 mmol) of N-methylmorpholine N-oxide was added and the resulting mixture was stirred at 22C for 4 hours. The reaction was quenched with 491 mg of sodium bisulfite and concentrated in vacuo to 25% of the original volume. The residue was partitioned between 20 mL of methylene chloride and 10 mL of water and the layers were separated. The aqueous layer was extracted with methylene chloride (2 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.
A solution of the crude diol in 24 mL of 3:1 v/v tetrahydrofuran/water was treated with 1.1 g (5.1 mmol) of sodium periodate and stirred at 22C for 20 hours. The reaction mixture was partitioned between 20 mL of ethyl ether and 10 mL of water and the layers were separated. The organic layer was washed with water (2 x 2 1 639~5 15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 68 g of silica gel using 4:1 v/v ethyl ether/hexane as the eluant afforded 372 mg of the higher Rf isomer (Isomer A) and 879 mg of a lower Rf isomer (Isomer B) both as 5 yellow oils.
1H NMR (400 MHz, CDCl3) Isomer B: o 1.19-1.34 (m, 13H), 2.45 (s, 3H, N-CH3), 2.68-2.81 (m, 2H), 3.28-3.34 (m, lH), 4.20-4.50 (m, lH), 6.98-7.32 (m, 3H), 9.60 (s, lH, -CHO).
Mass Spectrum (Isomer B) (FAB): m/z 360 (M+H, 37Cl + 35Cl isotope, 20%), 242 (100%).
Step 6: 1'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(t-butoxy-carbonyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ~4'-piperidine) A mixture of 217 mg (0.60 mmol) of N-methyl-N-t-butoxycarbonyl-3-(S)-(3,4-dichlorophenyl)-4-(RS)-amino-pentanal (from Step 5 above) and 262 mg (0.86 mmol) of 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride in 13 mL of methanol was treated with 115 mg (1.83 mmol) of sodium cyanoborohydride and 20 stirred at 22C for 20 hours. Saturated sodium bicarbonate solution (1.0 ml) was added and the resulting milky mixture was concentrated to 50% of its original volume. The residue was partitioned between 25 mL of ethyl acetate and 15 mL of water and the layers were separated.
The organic layer was washed with water (3 x 10 mL). The aqueous 25 layers were extracted with 20 mL of ethyl acetate. The combined organic layers were washed with 15 mL of brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromato-graphy on 42 g of silica gel using 5:95 v/v methanol/methylene chloride as the eluant afforded 329 mg (89%) of the title compound as a white 30 foam.
1H NMR (400 MHz, CDCl3, ranges are given due to amide rotamers and line broadening) ~ 1.20-2.90 (31H), 3.74 (s, 3H, N-SO2CH3), 7.05-7.41 (m, 8H).
21 63',q5 Mass Spectrum (FAB): m/z 612 (M+H, 37Cl + 35Cl isotope, 70%), 610 (M+H, 37Cl + 37Cl isotope, 100%).
Step 7: 1'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) To a solution of 329 mg (0.54 mmol) of 1'-(3-(S)-(3,4-dichlorophenyl)-4-N((R or S)-(t-butoxycarbonyl) (methylamino))pentyl) 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) (from Step 6 above) in 8.0 mL of dry methylene chloride at 0C was added 117 ~l (1.1 mmol) of anisole and 2.0 mL of trifluoroacetic acid. The cooling bath was removed and the reaction was stirred at 22C for 20 minutes. The reaction was concentrated in vacuo. The residue was partitioned between 10 mL of methylene 5 chloride and 5.0 mL of water. The organic layer was washed with 2N
NaOH (3 x 5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 42 g of silica gel using 5:95:0.5 v/v/v methanol/methylene chloride/ammonium hydroxide as the eluant afforded 221 mg (80%) of the title compound as a clear 20 oil.
1H NMR (400 MHz, CDCl3) ~ 1.05 (d, 3H, J = 6.2Hz), 1.62-2.85 (m, 17H), 2.30 (s, 3H, N-CH3), (7.03-7.37 (m, 7H).
Mass Spectrum (FAB): m/z 512 (M+H, 37Cl + 35Cl isotope, 70%), 510 (M+H, 37Cl + 37Cl isotope, 100%).
Step 8: 1'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(3-methyl-benzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline -3.4' -piperidine) The title compound was prepared from 1'-(3-(S)-(3,4-30 dichlorophenyl)-4-(R or S)-(methylamino)pentyl)-1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) (from Step 7 above) using a procedure identical to Example 3, Step (b), substituting m-toluoyl chloride for 3,5-dimethylbenzoyl chloride.
WO 94/29309 ~ 1 6 3 9 9 5 PCT/US94/05545 lH NMR (400 MHz, CDCl3, ranges are given due to amide rotamers and line broadening) ~ 1.42 (â, 3H, J = 6.7Hz), 1.60-2.30 (16H), 2.54 (s, 3H, Ph-CH3), 2.87 (s,3H, N-CH3),3.74 (s, 3H, N-SO2CH3),7.05-7.79 (m, 1 lH).
Mass Spectrum (FAB): m/z 630 (M+H,37Cl + 35Cl isotope,70%), 628 (M+H, 37Cl + 37Cl isotope, 100%).
1'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(3,5-bis(trifluoromethyl)-benzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) The title compound was prepared from 1'-(3-(S)-(3,4-dichlorophenyl)-4-(R or S)-(methylamino)pentyl)-1-methanesulfonyl-15 spiro(indoline-3,4'-piperidine) (from Example 1, Step 7 above) using a procedure identical to Example 3 Step (b), substituting 3,5-bis(trifluoromethyl)benzoyl chloride for 3,5-dimethylbenzoyl chloride.
lH NMR (400 MHz, CDCl3, ranges are given due to amide rotamers and line broadening) ~ 1.38-3.00 (22H), 3.74 (s, 3H, N-SO2CH3), 6.40-7.41 (m, lOH).
Mass Spectrum (FAB): m/z 752 (M+H,37Cl + 35Cl isotope, 40%),750 (M+H, 37Cl + 37Cl isotope, 60%), 241 (100%).
1'-(3-(S)-(3,4-Dichlorophenyl)-4-(R or S)-(3,5-dimethylbenzoyl(methyl-amino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ~4'-piperidine) The title compound was prepared from 1'-(3-(S)-(3,4-dichlorophenyl)-4-(R or S)-(methylamino)pentyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine) (from Example 1, Step 7 above) using a procedure identical to Example 3, Step (b).
21 63~5 lH NMR (400 MHz, CDCl3, ranges are given due to amide rotamers and line broadening) â 1.37-2.86 (28H), 3.74 (s, 3H, N-S02CH3), 6.24-7.41 (m, lOH).
Mass Spectrum (FAB): m/z 642 (M+H,37Cl + 35Cl isotope, 70%), 644 (M+H, 37Cl + 37Cl isotope, 100%).
(1'-(3-(S)-(3,4-Dichlorophenyl)-4-(R or S)-(3,5-dichlorobenzoyl-(methylamino))pentyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine) The title compound was prepared from 1'-(3-(S)-(3,4-dichlorophenyl)-4-(R or S)-(methylamino)pentyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine) (from Example 1, Step 7 above) using a procedure identical to Example 3, Step (b), substituting 3,5-dichloro-benzoyl chloride for 3,5-dimethylbenzoyl chloride.
lH NMR (400 MHz, CDCl3, ranges are given due to amide rotamers and line broadening) ~ 1.38-2.93 (22H), 3.73 (s, 3H, N-SO2CH3), 6.53-7.42 (m, lOH).
Mass Spectrum (FAB): m/z 684 (M+H,37Cl + 35Cl isotope,70%), 686 (M+H,37Cl + 37Cl isotope, 100%).
1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-bromo-5-methylbenzoyl)-2 5 (methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3.4'-piperidine) Step A: 3-Bromo-5-methylbenzoic acid To a solution of 0.38 g (1.44 mmol) of 3-bromo-5-methyl-benzyl bromide (prepared by NBS bromination of 3,5-dimethyl-3 bromobenzene) in 22 mL of MeCN and 50 mL of water was added 7.8 mL (28.8 mmol) of agueous sodium hypochlorite (13% active Cl). The mixture was allowed to stand in an ultrasonic cleaning bath for 14 h.
The reaction was acidified with HCl to pH 3 and extracted with CH2Cl2. The organic layer was washed with water, brine and dried WO 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 with Na2SO4. The filtrate was concentrated and the residue which was a mixture of the desired acid and the aldehyde was dissolved in 3 mL of acetone. The solution was treated with 6 N Jones reagent until the orange color persisted. After stirring for 20 min the excess reagent was 5 destroyed by adding few drops of i-PrOH. The solution was diluted with water and extracted with CH2Cl2. The CH2Cl2 layer was washed with brine, dried and the filtrate was concentrated. The residue was purified by prep TLC using 0.5:30:69.5 of HOAc:EtOAc:hexane to isolate 0.14 g (45 %) of 3-bromo-5-methylbenzoic acid.
Step B: 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-bromo-5-methylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3.4'-piperidine) 3-Bromo-5-methylbenzoic acid was used in the acylation 5 reaction according to the procedure of Example 3, Step B to obtain the title compound.
Mass Spectrum (CI) 696 (37Cl + 35Cl isotope), 694 (35Cl + 35Cl isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl)-(methvlamino))butyl)- 1 -(2-aminoacetyl)-spiro(indoline-3.4'-piperidine) A solution of 65 mg (0.31 mmol) of carbobenzyl-2s oxyglycine in 3 mL of CH2Cl2 was treated with 82 mg (0.41 mmol) of1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and 56 mg (0.41 mmol) of 1-hydroxybenzotriazole and 42 mg (0.41 mmol) of N-methylmorpholine. After 10 min 123 mg (0.21 mmol) of 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))-30 butyl)-spiro(indoline-3,4'-piperidine) (Example 7) was added and the reaction was stirred.for 2 h. The mixture was diluted with CH2Cl2 and washed with water, brine, dried and concentrated to give 0.184 g of residue. The residue in 10 drops of HOAc was dissolved in 3 mL of EtOH and the solution was hydrogenated on a Parr apparatus for 16 h.
2 1 639q5 The catalyst was filtered and washed with EtOAc. The filtrate was washed with 10% Na2co3~ brine and concentrated. The residue was purified by prep TLC using 30% MeOH-EtOAc to give 80 mg (59%) of the title compound.
Mass Spectrum (CI) 651 (37Cl + 35Cl isotope), 649 (35Cl + 35Cl isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl)-(methylamino))butyl)- 1 -methyl-spiro(indol-2-one-3,4'-piperidine) Step A: 1.1'-Dimethvl-spiro(indol-2-one-3.4'-piperidine) A solution of 0.1 g (0.68 mmol) of N-methyl-2-oxo-indole in 2 mL of THF was added to a well stirred suspension of 0.14 g (3.4 mmol) of NaH in 2 mL of THF with cooling in ice bath. After the gas evolution had stopped the cold bath was removed and the mixture was heated in a 50C bath for another 15 min. The reaction was allowed to cool to room temperature and 0.68 mL of DMSO was added and more gas evolution was observed. After stirring for 10 min, the reaction mixture was cooled in ice bath and 0.144 g of mechloreth~mine hydro-chloride was added. The mixture was warmed to room temperature and stirred overnight. Next morning, the reaction was quenched with water and extracted with EtOAc. The EtOAc extact was washed with brine, dried with Na2so4 and filtered. The filtrate was concentrated and the residue was purified by prep TLC using 89:10:1 EtOAc:MeOH:Et3N to furnish 25 mg (15%) of the title compound.
Step B: l-Methyl-spiro(indol-2-one-3.4'-piperidine) A solution of 25 mg (0.11 mmol) of 1,1'-dimethyl-spiro(indol-2-one-3,4'-piperidine) (from Step A above) in 1 mL of dry dichloroethane was treated with 0.023 mL (0.22 mmol) of 1-chloroethyl chloroformate (ACECl) under a dry N2 atmosphere. After 30 min at room temperature, the solution was kept in a 50C bath for 30 min.
The reaction mixture was cooled to room temperature, 2 mL of MeOH
was added and reheated to 60C. After 30 min the solution was cooled WO 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 and concentrated in vacuo. The residue was partitioned between water and EtOAc and the aqueous phase was adjusted to pH 9 by adding lN
NaOH. The layers were separated and the combined EtOAc solution was washed with brine and dried. The filtrate upon concentration gave 5 34 mg of a residue which was a mixture of the desired compound and the starting material, but was sufficiently pure to be used in the next reaction.
Step C: 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -methyl-spiro(indol-2-one-3 4'-piperidine) A reaction of 49 mg (0.13 mmol) of 3-((S)-(3,4-dichloro-phenyl))-4-(N-(3,5-dimethylbenzoyl)methylamino)butanal (Example 5) with 34 mg of impure 1-methyl-spiro(indol-2-one-3,4'-piperidine) 5 (from Step B) according to the procedure of Example 8, method B
furnished 32 mg of the title compound after purification by prep TLC.
Mass Spectrum (CI) 580 (37Cl + 35Cl isotope), 578 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)-(methylamino))butyl)- 1 -methyl-spiro(isoindol- 1 -one-3.4'-piperidine) Mass Spectrum (CI) 622 (37Cl + 35Cl isotope), 620 (35Cl + 35Cl 25 isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl)-3 (methylamino))butyl)-spiro(2-oxo-tetrahydroquinoline-4.4'-piperidine) Step A: l'-Trifluoroacetyl-spiro(1-indanone-3.4'-piperidine) Cold trifluoroacetic acid (15 mL) and 0.6 mL of anisole were added to 2 g (6.6 mmol) of 1'-t-butoxycarbonyl-spiro(1-indanone-21 63~95 3,4'-piperidine) and the resulting solution was stirred in ice bath for lh.
The reaction mixture was concentrated in vacuo and the residue was partitioned between CH2cl2 and 0.5 N NaOH. The organic layer was washed with brine, dried with Na2so4 and concentrated. The residual orange oil was dissolved in 10 mL of CH2cl2 and 1.92 mL (13.7 mmol) of Et3N, 1 mL (7.1 mmol) of trifluoroacetic anhydride and 3 crystals of DMAP were added. After stirring for 4 h, the reaction mixture was diluted with CH2Cl2 and washed with water, brine and dried. The solution was filtered and the filtrate was concentrated to yield 2.0 g (quantitative) of the desired product as a solid.
lH NMR (CDCl3) ~ 1.65 (d, 2H, J=14Hz), 2.05 (m, 2H), 2.67 (ABq, 2H), 2.89 (m, lH), 3.28 (m, lH), 4.1 l(d, lH, J=14Hz), 4.67 (dt, lH, J=14 and 2Hz), 7.5-7.8 (m, 4H).
Step B: 1'-Trifluoroactyl-spiro-(2-oxo-1,2,3,4-tetrahydro-quinoline-4,4'-piperidine) and 1'-trifluoroactyl-spiro-(1-oxo- 1~2~3 .4-tetrahvdroisoquinoline-4.4'-piperidine) To a mixture of 1.09 g (16.8 mmol) of Sodium azide in 1.2 mL of water and 6.6 mL of CHCl3 was added 0.46 mL of concentrated H2SO4 (36 N) keeping the temperature between 0-5C. (Caution!) After 10 min the cold bath was removed and the reaction was stirred for 3 h, at which time the CHCl3 layer was separated from the aqueous layer. The CHCl3 layer containing HN3 was dried and the filtrate was added to a solution of 2 g (6.7 mmol) of 1'-trifluoroacetyl-spiro(1-2s indanone-3,4'-piperidine) (from Step A) in 7 mL of CHCl3.
Concentrated H2SO4 (1.8 mL) was added to this solution and the reaction was allowed to age for 30 min. The mixture was heated in a 45C bath for 45 min and then stirred at room temperature for 16 h.
Next morning, the reaction mixture was poured into ice and the layers were separated. The aqueous layer was neutralized with aq. NaOH and extracted with EtOAc. The combined organic phases were washed with brine, dried and concentrated. The residue was chromatographed using 50-80% EtOAc-CH2Cl2 to isolate 0.34 g (16%) of 1'-trifluoroactyl-spiro(2-oxo-1,2,3,4-tetrahydroquinoline-4,4'-piperidine) and 0.13 g of WO 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 1 '-trifluoroactyl-spiro(1 -oxo- 1,23,4-tetrahydroisoquinoline-4,4'-piperidine). In addition, 0.72 g (36%) of the starting indanone was recovered.
lH NMR (CDCl3) Isomer A: ~ 1.82 (m, 2H), 1.96 (m, 2H), 2.75 (ABq, 2 H, J=14Hz), 3.16 (t, lH), 3.46 (t, lH), 3.9 (d, lH), 4.42 (d, lH), 6.8-7.3 (m, 4H), 8.49 (br s, lH); Isomer B: ~ 1.9-2.1 (m, 4H), 3.09 (t, lH), 3.42 (m, lH), 3.61 (ABq, 2H), 3.94 (d, lH), 4.45 (d, lH), 6.72 (br s, lH), 7.3-7.6 (m, 3H), 8.11 (d, lH).
Step C: Spiro-(2-oxo-1.2.3.4-tetrahydroquinoline-4.4'-piperidine) To a solution of 0.3 g (0.97 mmol) of 1'-trifluoroacetyl-spiro-(2-oxo-1,2,3,4-tetrahydroquinoline-4,4'-piperidine) (from Step B) in 4 mL of MeOH was added 0.16 g (2.9 mmol) of KOH in 1 mL of water. After stirring the reaction for 16 H the solution was 15 concentrated and the residue was partitioned between EtOAc and water.
The EtOAc layer was washed with brine, dried with Na2SO4 and concentrated to give 0.16 g (76%) of the title compound as a white solid.
lH NMR (CDCl3) ~ 1.6-2.0 (m, 4H), 2.72 (s, 2H), 2.95 (m, 4H), 6.7-20 7.4 (m, 4H), 8.4 (br s, lH).
Step D: 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)-spiro(2-oxo-tetrahydro-quinoline-4.4'-piperidine) The title compound was obtained by reductive ~min~tion of 3 -((S)-(3,4-dichlorophenyl))-4-((3,5-dimethylbenzoyl)methylamino)-butanal (Example 5) by spiro-(2-oxo-1,2,3,4-tetrahydroquinoline-4,4'-piperidine) obtained in Step C according to the procedure of Example 8, method B.
30 Mass Spectrum (CI) 580 (37Cl + 35Cl isotope), 578(35Cl + 35Cl isotope).
WO 94/29309 21 6 3~ q 5 PCT/US94/05545 1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 ,5-dichlorobenzoyl)(methyl-amino))butyl)- 1 -methyl-spiro(2-oxo-tetrahydroquinoline-4,4'-5 piperidine) Step A: 1-Methyl-spiro-(2-oxo-1,2,3,4-tetrahydroquinoline-4,4'-piperidine) To a solution of 0.15 g (0.48 mmol) of 1'-trifluoroacetyl-spiro-(2-oxo-1,2,3,4-tetrahydroquinoline-4,4'-piperidine) (from Example 18, Step B) in 1.7 mL of DMF was added 19 mg (0.77 mmol) of 95% NaH at 0C. After 15 min 0.063 mL (1 mmol) of methyl iodide was added and the reaction was allowed to warm to room temperature.
After stirring for 16 H the reaction was not complete, so an additional 5 0.015 mL of methyl iodide was added and the solution was heated in a 45C bath. After 2 H the reaction was cooled to room temperature and partitioned between EtOAc and water. The EtOAc layer was washed with brine, dried and the filtrate was concentrated. The residue was purified by prep TLC using 33% EtOAc-hexane to provide 1-methyl-2 1 '-trifluoroacetyl-spiro-(2-oxo- 1 ,2,3 ,4-tetrahydroquinoline-4,4'-piperidine). Hydrolysis of this trifluoroacetamide as described in Example 55, Step C furnished 71 mg (64%) of the title compound.
lH NMR (CDCl3) â 1.61 (d, 2H), 1.92 (m, 2H), 2.74 (s, 2H), 2.98 (m, 4H), 3.36 (s, 3H), 7.0-7.4 (m, 4H).
2s Step B: 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichloro-benzoyl)(methylamino))butyl)- 1 -methyl-spiro(2-oxo-tetrahydroquinoline-4 ~4'-piperidine The title compound was prepared by reaction of the amine 30 from Step A and 3-((S)-(3,4-dichlorophenyl))-4-((3,5-dichlorobenzoyl)-methylamino)butanal as described in Example 18, Step D.
Mass Spectrum (CI) 636 (37Cl + 35Cl isotope), 634 (35Cl + 35Cl isotope).
WO 94/29309 PCT/US94/05~45 4-Bromo-2-(S)-(4-fluorophenyl)- 1 -(N-(3,5-bistrifluoromethylbenzoyl)methylamino)butane .
Step A: 3-(S)-(4-Fluorophenyl)-4-(N-(3,5-5 bistrifluoromethylbenzoyl)methylamino)butanol.
A solution of 1.67 g (3.84 mmol) of 3-((S)-(4-fluorophenyl)-4-(N-(3,5-(bistrifluoromethyl)benzoyl)(methylamino))butanal (prepared from 4-fluorophenylacetic acid as described by J. Hale et. al., Bioorganic &
10 Medicinal Chemistry Letters 1993,3, 319-322) in 16 mL of absolute ethanol at 0 C was treated with 172 mg (4.55 mmol) of sodium borohydride. After stirring for 1 h at room temperature, the reaction was quenched with saturated NH4Cl and extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried 15 (MgSO4) and evaporated to give 1.59 of residual oil. Purification on a silica gel flash column (30:70 then 50:50 ethyl acetate:hexanes) provided 1.21 g (72%) of the title compound as a viscous oil.
Mass Spectrum (CI/NH3) M+H= 438.
Step B: 4-Bromo-2-(S)-(4-fluorophenyl)- 1 -(N-(3,5-bistrifluoromethylbenzoyl)methylamino)butane.
To a solution of 1.19 g (2.72 mmol) of 3-(S)-(4-fluorophenyl)-4-(N-25 (3,5-bistrifluoromethylbenzoyl)methylamino)butanol in 20 mL of acetonitrile was added 1.49 g (3.53 mmol) of triphenylphosphine dibromide. After 1.5 h the reaction was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (MgSO4) and concentrated to give 2.33 g of crude white solid.
30 Purification on a silica gel flash column (30:70 ethyl acetate:hexanes) gave 944 mg (69%) of the desired bromide as a viscous oil.
Mass Spectrum (CIJNH3) M+H=S00, 502 (79,81Br isotope).
WO 94/29309 PCT/US94/05~45 ~1 63~95 1 '-(3-(S)-(4-Fluorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine).
To 40 mg (0.08 mmol) of the bromide prepared in Example 20, Step B
and 0.21 ul (0.12 mmol) of N,N-diisopropylethylamine in 0.5 mL of acetonitrile was added 37 mg (0.16 mmol) of 1-acetyl-spiro(indoline-3,4'-piperidine). The resultant mixture was heated in a tightly capped vial at 50 C for four days. The solvent was evaporated and the residue was purified on a 1000 micron silica gel prep plate (93:5:2 ethyl acetate:methanol:triethylamine) to furnish 46.6 mg (90%) of the title compound as a white foam.
Mass Spectrum (CIINH3) M+H=650.
The compounds in Examples 22-26 were prepared as in Example 21 from the requisite bromide, prepared from the corresponding 20 phenylacetic acid as described in Example 20, and the required 1-substituted-spiro(indoline-3,4'-piperidine) .
1 '-(3 -(S )-(3 -Chlorophenyl)-4-(N-(3,5 -bistrifluoromethylbenzoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine).
Mass Spectrum (CI/NH3) M+H= 666, 668 (35,37Cl-isotope).
1 '-(3-(S)-(4-Chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine).
Mass Spectrum (CI/NH3) M+H= 666, 668 (35,37Cl-isotope).
1 '-(3-(S)-(3,4-Difluorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine).
Mass Spectrum (CI/NH3) M+H= 668.
l '-(3-(S)-(3,4-Methylenedioxyphenyl)-4-(N-(3,5-20 bistrifluoromethylbenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) .
Mass Spectrum (CI/NH3) M+H=712.
2s l '-(3-(RS)-(3,5-Dichlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-30 (methylamino))butyl)- l -methanesulfonyl-spiro(indoline-3,4'-piperidine).
Mass Spectrum (CI/NH3) M+H=736, 738 (35,37Cl-isotope).
WO 94/29309 PCT/US94/0~54~
2 1~ 6~995 1 '-(3 -(S)-(4-Chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-5 (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine).
The title compound was prepared as in Example 21 from 4-bromo-2-(S)-(4-chlorophenyl)- 1 -(N-(3,5-bistrifluoromethylbenzoyl)methylamino)butane and spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) hydrochloride except that 3 eq.
of diisopropylethylamine were used.
Mass Spectrum (CI/NH3) M+H=641,643 (35,37Cl-isotope).
1 '-(3 -(RS)-(4-Pyridyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-2 o (methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine).
The title compound was prepared from 3-(S)-(4-pyridyl)-4-(N-(3,5-bistrifluoromethyl-benzoyl)methylamino)butanal (prepared from 4-pyridylacetic acid as described by J. Hale et. al., Bioorganic &
25 Medicinal Chemistry Letters 1993,3, 319-322) by reductive amination as described in Example 2.
Mass Spectrum (CVNH3) M+H=633.
1 '-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(ethylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine).
2 1 639~5 Step A: 4-Bromo-2-(S)-(3,4-dichlorophenyl)-1-(N-(3,5-dimethylbenzoyl)methylamino)butane.
The title compound was prepared as in Example 20, Steps A and B, from 3-(S)-(3,4-dichlorophenyl)-4-(N-(3,5-dimethyl-benzoyl)ethylamino)butanal (prepared from 3,4-dichlorophenylacetic acid as described by J. Hale et. al., (Bioorganic & Medicinal Chemistry Letters 1993,3, 319-322) using ethylamine rather than methylamine to form the intermediate amide).
Mass Spectrum (CI/NH3) M = 454, 456 (79,81Br isotope).
Step B: 1'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(ethylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine).
The title compound was prepared from the bromide prepared in Step A
and 1-acetyl-spiro(indoline-3,4'-piperidine) as described in Example 21.
Mass Spectrum (CVNH3) M+H = 641, 643 (35,37Cl-isotope).
2s 5-Fluoro-spiro(2 3-dihydrobenzofuran-3.4'-piperidine) hydrochloride salt Step 1) 4-(2,5-Difluorophenyl)-4-methoxycarbonyl- 1 -methylpiperidine Methyl 2,5-difluorophenylacetate (4.8 g, 26 mmol) and mechloreth~mine hydrochloride (5.0 g, 26 mmol) in DMSO (15 mL) and THF (50 mL) at 0C was carefully treated with NaH (2.5 g, 104 mmol). The reaction was gradually warmed to reflux over 1 h and WO 94129309 2` 1 6 3 9 9 5 PCT/US94/05545 refluxed further for 1 h. The reaction was cooled to 0C, and 6N HCl (25 mL) was slowly added. The reaction was diluted with lN HCl (200 mL) and washed with hexane (200 mL). The aqueous layer was cooled to 0C and adjusted to pH 12 with solid K2co3. The product was extracted with ethyl acetate (200 mL), washed with brine (100 mL), dried (MgSO4), and concentrated to 4.1 g (59%) of the title compound as an oil.
H NMR (400 MHz, CDCl3) ~ 7.34 (dq, lH), 6.88 (m, lH) 6.78 (ddd, lH) 6.69 (minor NMe invertomer, dm), 6.59 (minor NMe invertomer, dd), 3.69 (s, 3H), 3.80 (minor invertomer, s), 2.71 (d, 2H), 2.48 (d, 2H), 2.38 (t, 2H), 2.25 (s, 3H), 2.10 (t, 2H) ppm.
Step 2) 4-(2,5-Difluorophenyl)-4-hydroxymethyl-1-methylpiperidine EtOH (5.1 mL, 86 mmol) was added to 0.5 M LiAlH4 in glyme (82 mL, 41 mmol) at 0C. 4-(2,5-difluorophenyl)-4-methoxycarbonyl- 1 -methylpiperidine (3.45 g, 12.8 mmol) in glyme (4 mL) was added.
Saturated aqueous sodium potassium tartrate (50 mL) was added along with Celite (10 g), and the mixture was mechanically stirred 1 h at room temp. The slurry was filtered, and the organic layer was extracted with lN HCl. The HCl was washed with EtOAc and then basified with 3N NaOH. The product was extracted with CH2Cl2, washed with 20% brine, dried (MgSO4), and concentrated to a crude solid, which was recrystallized (EtOAc) to yield 1.46 g (52%) of the title compound as colorless crystals.
IH NMR (400 MHz, CDC13) ~ 7.28 (dt, lH, J =7,9 Hz), 6.88 (ddd, lH, J=3,9,9 Hz), 6.81 (ddd, J=3,9,13 Hz), 3.76 (s, 2H), 2.59 (m, 2H), 2.32-2.20 (m, 4H), 2.23 (s, 3H), 1.96 (t, 2H, J=5 Hz) ppm.
WO 94129309 2 1 6 3 9 ~ 5 PCT/US94/0554~
Step 3) 5-Fluoro-1'-methyl-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) NaH (158 mg, 6.56 mmol) was added to 4-(2,5-difluorophenyl)-4-hydroxymethyl-1-methylpiperidine (1.45 g, 6.56 mmol) in DMF (20 mL). The slurry was heated to 90C for 6 h. The reaction was diluted with hexane (200 mL), washed with water (200 mL), brine (50 mL), dried (MgSO4), and concentrated to yield 1.21 g (92%) of the title compound as a white crystalline solid;
1H NMR (400 MHz, CDC13) ~ 6.98 (dd, lH), 6.54 (dt, lH), 6.48 (dd, lH), 4.37 (s, 2H), 2.84 (m, 2H), 2.31 (s, 3H), 1.97 (4H, pentuplet), 1.71 (m, 2H) ppm.
Step 4) 5-Fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) hydrochloride salt 5 -fluoro- 1 '-methyl-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine) (1.21 g, 5.48 mmol) in 1,2-dichloroethane (12 mL) at room temp was treated with 2-chloroethyl chloroformate (1 mL, 9 mmol). A white precipitate formed, and the reaction was refluxed 2 h. MeOH (12 mL) was added and refluxing was continued for 2 h. The reaction was concentrated to a crude solid, which was triturated with EtOAc (5 mL) and filtered to yield 1.27 g (95%) of the title compound as a white crystalline solid.
1H NMR (400 MHz, d6-DMSO) ~ 9.12 (s, lH), 9.04 (s, lH), 7.11 (dd, lH), 7.74-7.66 (m, 2H), 4.53 (s, 2H), 3.26 (d, 2H), 2.95 (t, 2H), 2.08 (t, 2H), 1. 79 (d, 2H) ppm.
Reaction of 5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) hydrochloride with 3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butanal according to the procedure WO 94/29309 2 1 6 3 q q 5 PCT/US94/05545 given in Example 8, Method B gave 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-5 -fluoro-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine). Removal of the BOC group and benzamide formation according to the procedure given in Example 3, 5 Steps A and B afforded the compounds listed in Examples 31-36:
l '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl) -(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) 15 Mass spectrum (CI): m/z = 611.2 (35Cl + 35Cl isotope + H+), 613.2 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-5 -fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 609.3 (35Cl + 35Cl isotope + H+), 611.3 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chlorobenzoyl)-(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) WO 94/29309 PCT/US94/0554~
21 639q5 Mass spectrum (CI): m/z = 575.2 (35Cl + 35Cl isotope + H+), 577.2 (37Cl + 35Cl isotope + H+), 579.2 (37Cl + 37Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-S-fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 569.3 (35Cl + 35Cl isotope + H+), 571.3 5 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-methylbenzoyl)-(methylamino))butyl)-5 -fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) 25 Mass spectrum (CI): m/z = 555.3 (35Cl + 35Cl isotope + H+), 557.3 (37Cl + 35Cl isotope + H+).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(benzoyl)-(methylamino))butyl)-S-fluoro-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine) WO 94/29309 2 1 6 3 ~ 9 5 PCT/US94/05545 Mass spectrum (CI): m/z = 541.3 (35Cl + 35Cl isotope + H+), 543.3 (37Cl + 35Cl isotope + H+).
Preparation of spiro(2,3-dihydrobenzofuran-3,4'-piperidine) hydrochloride was carried out by analogy to the procedure given in Example 30, starting with methyl 2-fluorophenylacetate. Reaction of spiro(2,3-dihydrobenzofuran-3,4'-piperidine) hydrochloride with 3-(S)-(3,4-dichlorophenyl)-4-(t-butoxycarbonyl-methylamino)butanal according to the procedure given in Example 8, Step B gave 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine). Removal of the BOC
group and benzamide formation according to the procedure given in 5 Example 3, Steps A and B afforded the compounds listed in Exarnples 37-43:
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(benzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 523.1 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-methylbenzoyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) 2 1 ~3995 Mass spectrum (CI): m/z = 537.2 (35Cl + 35CI isotope + H+), 539.2 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 551.2 (35Cl + 35Cl isotope + H+), 553.2 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chlorobenzoyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) 20 Mass spectrum (CI): m/z = 557.0 (35Cl + 35Cl isotope + H+).
25 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 591.0 (35Cl + 35Cl isotope + H+), 593.1 (37Cl + 35Cl isotope + H+).
WO 94/29309 PCT/US94/05~45 216~5`
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzofuran-3 ,4 '-piperidine) Mass spectrum (CI): m/z = 591.3 (35Cl + 35Cl isotope + H+), 593.2 5 (37Cl + 35Cl isotope + H+).
1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3 ,4'-piperidine) 15 Step 1) 1-t-Butoxycarbonyl-3-hydroxy-4-methylenepiperidine n-Butyl lithium (9.57 mL, 2.45M in hexane, 23.7 mmol) was added to a -78C solution of diisopropylamine (3.32 mL, 23.7 mmol) in THF (15 mL). After 30 min at -78C, methyl phenyl sulfoxide (3.32 g, 23.7 20 mmol) in THF (4 mL) was added. The solution was warmed to 0C and cooled back down to -78C. 1-t-butoxycarbonyl-4-piperidinone (4.69 g, 23.7 mmol) in TH~ (20 mL) was added. The reaction was warmed to room temp, quenched by addition of solid NH4Cl, concentrated in vacuo, and partitioned between H2O (100 mL) and EtOAc (100 mL).
25 The organic layer was washed with H2O (50 mL) brine (50 mL), dried (MgSO4), and concentrated in vacuo. The resultant oil was heated at 80C in t-butanol (50 mL) with potassium t-butoxide (3.4g, 30 mmol) for 2 h. Solid NH4Cl was added, and the reaction was concentrated in vacuo and partitioned between H2O (100 mL) and EtOAc (100 mL).
3 The EtOAc was washed with brine (50 mL), dried (MgSO4 ), concentrated in vacuo and purified by column chromatography (silica gel 60, 0-50% EtOAc/hexane) to yield 4.47 g (79%) of the title compound as a crystalline solid.
WO 94/29309 PCT/US94/0~45 2~ 6~995 lH NMR (400 MHz, DMSO-d6) â 5.21 (d,lH), 4.96 (s, lH), 4.77 (s, lH), 3.82 (t, 2H), 3.67 (dt, lH), 2.83 (dt, lH), 2.77-2.50 (brd d, lH), 2.26 (dt, lH), 2.01 (ddd, lH), 1.38 (s, 9H) ppm.
Step 2) 1-t-Butoxycarbonyl-3,4-didehydro-4-(chloromethyl)piperidine To 1-t-butoxycarbonyl-3-hydroxy-4-methylenepiperidine (5.329 g, 25.1 mmol) in toluene (120 mL) and 2,6-lutidine (3.1 mL, 26 mmol) at 0C
o was added SOCl2 (2.0 mL, 26 mmol). The reaction was heated at 40C
for 30 min, cooled to 0C, washed with 0C lN HCl (100 mL), 0.1 N
HCl (100 mL), H2O (100 mL), brine (50 mL), dried (MgSO4), and concentrated in vacuo to afford 5.18 g (89%) of allylic chloride as a yellow oil.
1H NMR (400 MHz, CDCl3) ~ 5.78 (s, lH), 4.04 (s, 2H), 3.95 (s, 2H), 3.55 (t, 2H, J=6 Hz), 2.24 (s, 2H), 1.45 (s, 9H) ppm.
Step 3) l -t-Butoxycarbonyl-4-((2-bromophenyl)thio)methyl- 1,2,5,6-tetrahydropyridine The allylic chloride (330 mg, 1.43 mmole) was dissolved in acetone (10 mL) and 2-bromothiophenol (172 ml, 1.43 mmole) and K2CO3 (390 mg, 2.86 mmole) were added. The reaction mixture was heated to 60C
for 1 h and then filtered though silica gel ( ether). The organic layer was concentrated in vacuo and purified by column chromatography (silica gel 60, hexanes/ethyl acetate 10/1) to give the title compound in 84% yield (460 mg).
Step 4) l'-t-Butoxycarbonyl-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine).
WO 94/29309 PCT/US94/0554~
21; ~ 39~5 The intermediate adduct from step 3 above (450 mg, 1.17 mmole) was dissolved in benzene (60 mL) and AIBN (10 mg) and tributyltin hydride (644 mL, 2.39 mmole) were added. This mixture was refluxed for 2 h and concentrated. The residue was dissolved in Et2O and Br2 was 5 added until the reaction solution turned to a brownish color. To this brownish solution at room temp was added DBU (650 mL) dropwise.
The resulting cloudy solution was filtered though silica gel and washed with Et2O. The Et2O solution was concentrated and the residue was purified by radial chromatography (silic gel 60, 10/1 hexanes/EtOAc) to give the title compound (157 mg) in 43% yield.
1H NMR (400 MHz, CDCl3) ~ 7.18 (d, 7 Hz, 1 H), 7.12 (t, 7 Hz, 1 H), 7.06 (m, 2 H), 4.11(m, 2 H), 3.30 (s, 3 H), 2.89 (m, 2 H), 1.79 (m, 4 H), 1.47 (s, 9 H) ppm.
Removal of the BOC group according to the procedure given in Example 3, Step A followed by reaction with 3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butanal 20 according to the procedure given in Example 8, Method B gave 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine). Removal of the BOC group and benzamide formation according to the procedures described in Example 3, Steps A and B
25 gave the compounds listed in Examples 45-46:
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) Mass spectrum (CI): m/z = 567.2 (35Cl + 35Cl isotope + H+), 569.2 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(4-Chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) Mass spectrum (CI): m/z = 533 (35Cl + 35Cl isotope + H+), 535 (37Cl + 35Cl isotope + H+).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine)- 1 -oxide.
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) (222 mg, 415 ~mol) in CH2Cl2 (500 ,uL) at -78C was treated with a solution of m-chloroperbenzoic acid (86 mg, 498 ,umol) in CH2C12 (1 25 mL). The reaction was poured into 0C saturated aqueous NaHSO3.
The organic layer was washed with saturated aqueous NaHCO3 (1 mL), brine (1 mL), dried (MgSO4), concentrated in vacuo and purified by column chromatography (silica gel 60, 0-100% acetone/CH2Cl2) to yield 54.3 mg (24%) of the title compound as a white foam.
1H NMR (500 MHz, CDC13) ~ 7.84 (d, lH, J=7.5 Hz), 7.60 (t, lH, J=7.5 Hz), 7.48 (t, lH, J=7.5 Hz), 7.44 (m, lH), 7.39 (dd, lH, J=2.0, 8.5 Hz), 7.32 (m, lH), 7.10-7.04 (rotamer multiplets, lH), 3.6-3.2 (m, 2H), 3.34, 3.32 (two doublets of one diastereomer, lH), 3.16, 3.14 (two WO 94/29309 PCT/US94/05~45 doublets of other diastereomer, lH), 3.1-2.8 (m, 3H), 2.75-2.65 (rotamer singlets, 3H), 2.3-1.7 (m, 10 H), 1.42 (s, 9H) ppm.
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthylmethyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4~-piperidine)- 1 -oxide.
The title compound was prepared by oxidizing 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-5 spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) as described in Example 47 above, and then removing the BOC group and N-benzoylating according to the procedures given in Example 3, Steps A
and B.
20 Mass spectrum (CI): m~z = 623.1 (35Cl + 35Cl isotope + H+).
2 5 1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3 ,4'-piperidine)- 1,1 -dioxide.
To 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-3 (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) (102 mg, 191 ~lmol) in MeOH (0.8 mL) at 0C was added Oxone (176 mg, 287 ~) in water (0.4 mL). After 30 min at room temp, the reaction was filtered through a plug of silica gel and concentrated to yield 39.5 mg (36%) of the title compound as a white foam.
WO 94/29309 2 1 6 3 9 ~ ~ PCT/US94/0~54~
1H NMR (500 MHz, CDCl3) o 7.72 (d, lH, J=7.5 Hz), 7.66 (t, lH, J=7.5 Hz), 7.51 (t, lH, J=7.3 Hz), 7.39 (t, lH, J=8.3 Hz), 3.65-3.25 (m, 2H), 3.38 (s, 2H), 3.15-2.85 (m, 3H), 2.76,2.66 (rotamer singlets, 3H), 2.25 (m, 2H), 2.15-1.95 (m, 3H), 1.95-1.65 (m, 5H), 1.40 (s, 9H) ppm.
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine)- 1,1 -dioxide.
lS The title compound was prepared by removing the BOC group and N-benzoylating (according to the procedures given in Example 3, Steps A
and B) the product from Example 49.
Mass spectrum (CI): m/z = 639.1 (35Cl + 35Cl isotope + H+).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine)- 1,1 -dioxide.
30 To 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) (10 mg, 20 ~mol) in MeOH (0.1 mL) at 0C was added 0.4 M aqueous Oxone (75 IlL, 30 !lmol). The reaction was warmed to room temp and stirred overnight. The reaction was concentrated in vacuo, partitioned WO 94/29309 ~ 3 9 9 5 PCT/US94/05545 between lN NaOH (1 mL) and CH2cl2 (1 mL). The organic layer was concentrated and purified by column chromatography (silica gel 60, 0-100% acetone/CH2Cl2) to yield 9.0 mg (90%) of the title compound as a clear filrn.
Mass spectrum (CI): m/z = 599.1 (35Cl + 35Cl isotope + H+), 601.1 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(4-Chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-15 piperidine)- 1,1 -dioxide.
This compound was prepared according to the procedure given in Example 51 above.
20 Mass spectrum (CI): m/z = 567 (35Cl + 35Cl isotope + H+), 565 (37Cl + 35Cl isotope + H+).
1 '-(3 -((S)-(4-Chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine)- 1 -oxide.
To 1'-(3-((S)-(4-chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) (25 mg, 47 ,umol) in MeOH (1.0 mL) at 0C was added a solution of Oxone (38 mg, 61 ~mol) in H2O (1.0 mL). The reaction was stirred 2 WO 94/29309 2 1 6 3 ~ ~ 5 PCT/US94/05545 min and quenched with 10% aqueous sodium bisulfite. The reaction mixture was diluted with H2O (10 mL), neutralized with sat. aqueous NaHCO3 (15 mL), extracted with CH2cl2 (3 x 25 mL), washed with brine (10 mL), dried (Na2so4)~ concentrated in vacuo, and purified by column chromatography (silica gel 60, 5-8% MeOH/CH2Cl2) to yield 25 mg (99%) of a colorless solid; Mass spectrum (CI): m/z = 549 (35Cl + 35Cl isotope + H+), 551 (37Cl + 35Cl isotope + H+).
l '-(3 -(S)-(4-Chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine), l-oxide.
The title compound was prepared by the oxone oxidation method 15 described in Example 53.
Mass Spectrum (CVNH3) M+H=657, 659 (35,37Cl-isotope).
1 '-(3-(S)-(4-Chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine), l, l-dioxide.
The title compound was prepared by the oxone oxidation method 25 described in Example 51.
Mass Spectrum (CVNH3) M+H=673, 675 (35,37Cl-isotope).
30 Substituted indoline spiropiperidine derivatives were obtained by employing substituted phenyl hydrazines and 1-benzyloxycarbonylpiperidine-4-carboxyaldehyde in the Fisher indole synthesis. Wlhen regioisomers were formed, they were separated as the 1 '-benzyloxycarbonyl- l -methanesulfonyl-spiro(indoline-3,4'-piperidine) derivative by chromatography (silica gel 60, THF/hexane). Preparation WO 94/29309 PCT/US94/05~45 ~1 63~5 of a representative substituted spiro(indoline-3,4'-piperidinium) hydrochloride is described below:
s EXAMPLE 56 1 '-Benzyloxycarbonyl-5 -fluoro-spiro(indoline-3,4'-piperidine) A slurry of 4-fluorophenylhydrazine hydrochloride (6.504 g, 40 mmol), pyridine (6.56 ml, 80 mmol), toluene (360 mL), acetonitrile (40 mL), and N-benzylcarboxy-4-piperidine carboxyaldehyde (9.88g, 40 mmol) was maintained at 0C for 1 h. Trifluoroacetic acid (18.5 mL, 240 mmol) was added, and the reaction was heated 20 h at 60C. The reaction was cooled to 0C, and methanol (40 mL) was added followed 5 by NaBH4 (1.51 g, 40 mmol). The cooling bath was removed and 30%
aqueous NH40H (100 mL) was added. The organic layer was separated, washed with 5% aqueous NH40H (100 mL) brine (50 mL), dried (MgSO4), and concentrated to a crude oil which was purified by column chromatography (SG 60 silica, 0-5% acetone/CH2Cl2) to yield 20 6.48 g (48%) of the title compound as a clear oil.
1H NMR (400 MHz, CDCl3): ~ 7.23-7.36 (m, SH), 6.76-6.71 (m, 2H), 6.58 (dd, lH, J=4.4, 8.0 Hz), 5.14 (s, 2H), 4.12 (br s, 2H), 3.49 (s, 2H), 2.95 (br s, 2H) 1.73 (br s, 4H) ppm.
2s 30 Step 1) l'-Benzyloxycarbonyl-S-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine) To a solution of 1'-benzyloxycarbonyl-5-fluoro-spiro(indoline-3,4'-piperidine) (6.48 g, 19.0 mmol) in CH2cl2 (19 mL) and pyridine (38 21 639~5 mmol, 3.1 mL) at 0C was added methanesulfonyl chloride (19 mmol, 1.52 mL). The reaction was warmed to room temp., diluted with ethyl acetate (200 mL), washed with lN aqueous HCl (100 mL) saturated aqeuous NaHCO3 (100 mL) brine (50 mL), dried (MgSO4), and 5 concentrated to 7.81 g (98%) of the title compound as a red foam.
lH NMR (400MHz, CDCl3) â 7.35 (m, 5H), 7.32 (dd, lH, J=4.2, 9.0 Hz), 6.90 (dt, lH, J=2.7, 8.8 Hz), 6.81 (lH, dd, J=2.6, 8.2 Hz), 5.14 (s, 2H), 4.22 (br s, 2H), 3.84 (s, 2H), 2.92 (br s, 2H), 2.88 (s, 3H), 1.79 (br s, 2H), 1.69 (d, 2H, 13 Hz) ppm.
Step 2) 5-Fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride salt To 1 '-benzyloxycarbonyl-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) (7.81 g, 18.7 mmol) in CHCl3 (18 mL) at room temp.
was added trimethylsilyl iodide (20.5 mmol, 2.93 ml). After 5 min, the rxn was cooled to 0C, and a 5M solution of HCl in methanol/methyl 20 acetate is added with vigorous stirring. The HCl solution was prepared by adding acetyl chloride (190 mmol, 14 ml) to methanol (20 mL) at 0C. 40 ml of EtOAc was added, and the slurry was vigorously stirred at 0C for 4 h. The solid was filtered off under dry nitrogen, washed with 0C ethyl acetate (10 mL) and then with hexane (10 mL), and dried 25 under vacuum to yield 4.77 g (80%) of the title compound as a light pink solid.
1H NMR (400 MHz, DMSO-d6) ~ 8.85 (br s, lH), 8.77 (br s, lH), 7.26 (dd, lH, J=4.4, 8.8 Hz), 7.11 (dt, lH, J=2.8, 8.8 Hz), 7.02 (dd, lH, 30 J=2.8, 8.4 Hz), 3.97 (s, 3H), 3.30 (m, 2H), 3.06 (m, 2H), 3.06 (s, 3H), 2.04 (m, 2H), 1.83 (d 2H, J=14 Hz) ppm.
The substituted 1-methanesulfonyl-spiro(indoline-3,4'-piperidinium) hydrochlorides could be reductively ~min~ted with 3-(S)-(3,4-dichlorophenyl)-4-(t-butoxycarbonyl-methylarnino)butanal according to the procedure described in Example 8, Method B. Removal of the BOC
5 group by the procedure given in Example 3, Step A provided intermediate secondary amine compounds described below which could then be benzoylated under conditions given in Example 3, Step B to give the indicated benzamide derivatives.
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(methylamino)butyl)- 1-methanesulfonyl-5 -methoxy-spiro(indoline-3 ,4'-piperidine) 1H NMR (CDC13, 400 MHz) ~ 7.37 (d, lH, J=8.2 Hz), 7.29 (d, lH), 7.25 (d, lH), 7.04 (dd, lH, J=2.1, 8.3 Hz), 6.72 (m, 2H), 3.76 (s, 3H), 3.73 (s, 2H), 2.87 (m, 2H), 2.82 (s, 3H), 2.78 (d, 2H, J=7.1 Hz), 2.41 (s, 3H), 2.32-2.18 (m, 2H), 2.05-1.85 (m, 5H), 1.7 (m, 3H) ppm.
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(methylamino)butyl)- 1-2 5 methanesulfonyl-5-methyl-spiro(indoline-3 ,4'-piperidine) 1H NMR (CDCl3, 400 MHz) o 7.37 (d, lH, J=6.2 Hz), 7.30 (d, lH, J=2.0 Hz), 7.24 (d, lH, J=10 Hz), 7.05 (dd, lH, J=2.0, 8.2 Hz), 7.00 (d, lH, J= 8.8 Hz), 6.95 (s, lH), 3.71 (dd, 2H, J=16, 5.4 Hz), 2.9 (m, 3H), 30 2.84 (s, 3H), 2.79 (d, 2H, J=7.4 Hz), 2.43 (s, 3H), 2.30 (s, 3H), 2.24 (m, lH), 2.05-1.85 (m, 5H),.1.75-1.60 (m, 3H) ppm.
2 1 63~5 5-Chloro- 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(methylamino)butyl)- 1-methanesulfonyl-spiro(indoline-3 ,4'-piperidine) lH NMR (CDCl3, 400 MHz) ~ 7.39 (d, lH, J=8.2 Hz), 7.29 (d, lH, J=2.1), 7.24 (s, lH), 7.17 (dd, lH, J=2.2, 8.5 Hz), 7.11 (d, lH, J=2.1 Hz), 7.05 (dd, lH, J=2.0, 8.3 Hz), 3.76 (dd, 2H, J=4.5, 25 Hz), 3.18 (p, lH), 2.10-2.85 (m, 4H), 2.87 (s, 3H), 2.61 (s, 3H), 2.47 (m, lH), 2.34 (m, lH), 2.15 (t, lH), 2.04 (m, 2H), 1.95-1.70 (m, SH) ppm.
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(methylamino)butyl)-S-fluoro- 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) lH NMR (CDCl3, 400 MHz) ~ 7.38 (d, lH), 7.3 (m, 2H), 7.05 (dd, lH), 7.91-7.85 (m, 2H), 3.75 (dd, 2H), 3.0-2.8 (m, 3H), 2.81 (d, 2H), 2.43 (s, 3H), 2.42 (m, lH), 2.34 (m, lH), 2.1-1.8 (m, SH), 1.7 (m, 3H) ppm.
1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(methylamino)butyl)-7-fluoro- 1 -2 ~ methanesulfonyl-spiro(indoline-3 ,4'-piperidine) lH NMR (CDCl3, 400 MHz) ~ 7.38 (d, lH), 7.29 (d, lH), 7.05 (m, 2H), 6.95 (m, 2H), 3.99 (dd, 2H), 3.25 (s, 3H), 2.9 (m, 2H), 2.81 (t, lH), 2.45 (s, 3H), 2.38 (m, lH), 2.28 (m, lH), 2.1-1.8 (m, 5H), 1.75 (m, 3H) ppm.
~ 1~ b3~95 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3 ,5-dimethylbenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-5-methyl-spiro(indoline-3 ,4'-piperidine) Mass spectrum (FAB): m/z = 64~.0 (35Cl + 35Cl isotope + H+).
5-Chloro-1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) 15 Mass spectrum (FAB): m/z = 648.1 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 ,5-dimethylbenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-5-methoxy-spiro(indoline-3,4'-piperidine) 25 Mass spectrum (FAB): m/z = 658 (35Cl + 35Cl isotope + H+).
1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 -methylbenzoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) WO 94/29309 PCT/US94/05~45 ~1 63995 Mass spectrum (CI): m/z = 632.2 (35Cl + 35Cl isotope + H+), 634.2 (37Cl + 35Cl isotope + H+).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spectrum (FAB): m/z = 688.0 (37Cl + 35Cl isotope + 35Cl +
35Cl isotope+ H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-20 (methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 646.1 (35Cl + 35Cl isotope + H+), 648.1 (37Cl + 35Cl isotope + H+).
2s 30 l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chlorobenzoyl)-(methylamino))butyl)-5-fluoro- l -methanesulfonyl-spiro(indoline-3,4'-piperidine) WO 94/29309 PCT/US94/0554~
21 63'tq5 Mass spectrum (CI): m/z = 652.2 (35Cl + 35Cl isotope + 35Cl + 35Cl isotope + H+), 656.2 (37Cl + 35Cl isotope + 37Cl + 35Cl isotope+ H+), 657.2 (37Cl + 37Cl isotope + 37Cl + 35Cl isotope+ H+),. 658.2 (37Cl +
37Cl isotope + 37Cl + 37Cl isotope+ H+).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-o bis(trifluoromethyl)benzoyl)-(methylamino))butyl)-5-fluoro- l -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 754.1 (35Cl + 35Cl isotope + H+), 756.1 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-20 (methylamino))butyl)-7-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 646.1 (35Cl + 35Cl isotope + H+), 648.1 (37Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-t-butoxycarbonyl)-30 (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) To 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-t-butoxycarbonyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) (1.32 g 2.15 mmol) in toluene (5 mL) at 0C was added WO 94/29309 2 1 6 3 ~ ~ 5 PCT/US94/05545 3.4M Red-Al/toluene (5.1 mL, 17.2 mmol). After 4 h at room temp, the reaction was cooled to 0C and quenched by cautious addition of lN
aqueous NaOH (2 mL). Cold saturated aqueous sodium potassium tartrate (30 mL) was added, and the biphasic mixture was mechanically 5 stirred at 0C for 1 h. The product was extracted with toluene (3 x 10 mL), washed with 50~ saturated aqueous sodium potassium tartrate (10 mL), H2O (10 mL), brine (10 mL), dried (MgSO4), and concentrated to roughly 5 mL volume, and cooled to 0C. Pyridine (705 !lL, 8.6 mmol) and acetic anhydride (410 ,uL, 4.3 mmol) were added. After 16 hours at room temp, the reaction was concentrated and purified by column chromatography (silica gel 60, 0-50% acetone/CH2Cl2) to yield 830 mg (72%) of the title compound as a white foam.
1H NMR (400 MHz, CDCl3) ~ 8.14 (dd, lH), 7.37 (d, lH), 7.28 (m, 15 lH), 7.1-7.0 (m, lH), 6.87 (m, 2H), 3.95, 3.81 (rotamer singlets, 2H), 3.53 (m, lH), 3.36 (m, 2H), 3.22 (m, lH), 3.01 (m, lH), 2.90 (m, lH), 2.82 (m, lH), 2.74, 2.63 (rotamer singlets, 3H), 2.39, 2.20 (rotamer singlets, 3H), 1.89 (m, 4H), 1.65 (m, 4H) ppm.
20 The corresponding 1 -acetyl-spiro(indoline-3,4'-piperidine) compounds were obtained by selectively removing the methanesulfonyl group with Red-Al and then treating with acetic anhydride/pyridine at the stage where the methylamino group is protected with BOC; a representative procedure is given in Example 72 above. The BOC group could be 25 removed using the procedure given in Example 3, step A to give intermediate methylamino compounds which were benzoylated according to Example 3, step B to give the compounds in Examples 73-90:
1 -Acetyl-5-chloro- l '-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-spiro(indoline-3,4'-piperidine) WO 94/29309 PCTIUS94/0~545 2t 639qF~
lH NMR (CDCl3, 400 MHz) ~ 7.83 (d, lH, J=6.6 Hz), 7.12 (d, lH, J=5.2 Hz), 7.09 (d, lH, J=2.0 Hz), 6.87 (dd, 2H, J=2.0, 10.0 Hz), 6.84 (s, lH), 2.81 (p, lH0, 2.75-2.55 (m, 4H), 2.27 (s, 3H), 2.12 (m, lH), 2.04 (m, lH), 1.95 (s, 3H), 1.9-1.7 (m, 3H), 1.6 (t, 2H), 1.5-1.4 (m, 3H) ppm.
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-5-methyl-spiro(indoline-3,4' -piperidine) H NMR (CDCl3, 400 MHz) ~ 8.05 (d, lH)~ 7.38 (d, lH), 7.30 (d, lH), 5 7.05 (dd, lH), 7.00 (d, lH), 6.92 (s, lH), 3.79 (s, 2H), 3.01 (p, 2H), 2.9 (m, 3H), 2.52 (s, 3H), 2.5-2.1 (m, 2H), 2.29 (s, 3H), 2.20 (s, 3H), 2.1-1.7 (m, 6H),. 1.65 (m, 2H) ppm.
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) 25 lH NMR (CDCl3, 400 MHz) ~ 8.14 (dd, lH), 7.38 (d, lH), 7.24 (s, lH), 7.05 (dd, lH), 6.88 (dt, lH), 6.82 (dd, lH). 3.96, 3.83 (rotamer singlets, 2H), 3.13 (p, lH), 3.04 (dd, 2H), 2.92 (dd, 2H), 2.69, 2.66 (rotamer singlets, 3H), 2.50 (p, lH), 2.33 (p, lH), 2.38, 2.20 (rotamer singlets, 3H), 2.13 (t, lH), 2.05 (m, lH), 1.7 (m, 4H), 1.73 (dd, 2H) 30 ppm-wo 94/29309 2 1 6 :~ 9 9 5 PCT/US94/05545 1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-6-fluoro-spiro(indoline-3,4'-piperidine) lH NMR (DMSO-d6, 500 MHz) â 7.76 (dd, lH), 7.58-7.53 (m, 2H), 7.26 (dd, lH), 7.21 (dd, lH), 6.80 (dt, lH), 3.93 (s, 2H), 2.98-2.86 (m, 3H), 2.82 (d, lH), 2.65 (d, lH), 2.38 (s, 3H), 2.19 (m, lH), 2.16 (s, 3H), 2.09 (m, lH), 2.05 (t, lH), 1.90 (t, 2H), 1.78-1.6 (m, 3H), 1.6-1.5 (m, 2H) ppm.
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-4-fluoro-spiro(indoline-3,4'-piperidine) lH NMR (DMSO-d6, 500 MHz) ~ 7.88 (d, lH), 7.63-7.58 (m, 2H), 7.29 (dd, lH), 7.19 (q, lH), 6.79 (t, lH), 3.86 (s, 2H), 3.23-3.13 (m, 3H), 2.97 (m, lH), 2.72 (m, lH), 2.52 (s, 3H), 2.26 (m, lH), 2.16 (s, 3H), 2.09 (t, 4H), 1.97 (p, 2H), 1.76-1.62 (m, 3H) ppm.
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)-(methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 588.2 (35Cl + 35Cl isotope + H+).
? 5 1 -Acetyl- 1 '-(3 -((S)-(3,4-dichlorophenyl))-4-(N-(3,5,-dimethylbenzoyl)-(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 610.2 (35Cl + 35Cl isotope + H+), 612.2 5 (37Cl + 35Cl isotope + H+).
.
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)-(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 582.3 (35Cl + 35Cl isotope + H+).
20 1 -Acetyl- l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5,-dimethylbenzoyl)-(methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 610.3 (35Cl + 35Cl isotope + H+) 1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)-30 (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 582.2 (35Cl + 35Cl isotope + H+).
1 -Acetyl- l '-5-chloro-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-5 dimethylbenzoyl)-(methylamino))butyl)-spiro(indoline-3,4'-piperidine) Mass spectrum (FAB): m/z = 626.0 (35Cl + 35Cl isotope + H+), 628.1 (37Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)-15 (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 616.2 (35Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)-(methylamino))butyl)-5 -fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 650.1 (35Cl + 35Cl isotope + H+).
l -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)-(methylamino))butyl)-5 -fluoro-spiro(indoline-3,4'-piperidine) WO 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 Mass spectrum (CI): m/z = 596.2 (35Cl + 35Cl isotope + H+), 598.3 (37Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 610.2 (35Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3 -((S)-(3,4-dichlorophenyl))-4-(N-(3-isopropoxybenzoyl)-(methylamino))butyl)-5 -fluoro-spiro(indoline-3,4'-piperidine) 20 Mass spectrum (CI): m/z = 640.3 (35Cl + 35Cl isotope + H+), 642.3 (37Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)-(methylamino))butyl)-5-fluoro-spiro(indoline-3,4' -piperidine) Mass spectrum (CI): m/z = 718.2 (35Cl + 35Cl isotope + H+), 720.2 (37Cl + 35Cl isotope + H+).
2 ~ 6 3 ~ ~ 5!
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-5 (methylamino))butyl)-S-methyl-spiro(indoline-3,4'-piperidine) Mass spectrum (FAB): m/z = 606.1 (35Cl + 35Cl isotope + H+), 608.2 (37Cl + 35Cl isotope + H+).
N-Napthoyl- methylamino derivatives (Examples 91 - 101) were prepared by analogy to the benzoyl derivatives, employing commercially available 1-napthoyl chlorides in place of benzoyl 15 chlorides:
1 -Acetyl- 1 '-(3 -((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-S -fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 650.3 (35Cl + 35Cl isotope + H+).
30 1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(1 -napthoyl)-(methylamino))butyl). S-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 632.2 (35Cl + 35Cl isotope + H+), 634.2 (37Cl + 35Cl isotope + H+).
21 ~qq5 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(1 -napthoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 668.2 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 20 Mass spectrum (CI): m/z = 668.2 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) Mass spectrum (CI): m/z = 607.2 (35Cl + 35Cl isotope + H+).
WO 94/29309 PCT/US94/0~45 21 63i~
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- l -napthoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) sulfone Mass spectrum (CI): m/z = 639.1 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- l -napthoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene -3,4'-piperidine) Mass spectrum (CI): m~z = 623.1 (35Cl + 35Cl isotope + H+).
2 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-5 -fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 609.3 (35Cl + 35Cl isotope + H+), 611.3 25 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- l -napthoyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) 2 1 63~
Mass spectrum (CI): m/z = 591.3 (35Cl + 35Cl isotope + H+), 593.3 (37Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine) o Mass spectrum (CI): m/z = 650.3 (35Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 650.3 (35Cl + 35Cl isotope + H+).
Benzylamine derivatives could be synthesized by reducing the benzamide of the 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) 25 derivatives described in some of the Examples. The methanesulfonyl group could be removed by heating with HBr/acetic acid/phenol and then be replaced with an acetyl group by treating with acetic anhydride/pyridine. Representative procedures and compounds are given in Examples 102 and 103 below:
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthylmethyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) (96 mg) was dissolved in lM Dibal-H in toluene (160 uL).
After 1/2 h, saturated aqueous sodium potassium tartrate (5 mL) and EtOAc (5 mL) were added and stirred vigorously for 2 h. The organic layer was washed with H2O (5 mL), brine (5 mL), dried (MgSO4), and concentrated to a crude oil, which was purified by column chromatography (silica gel 60, 0-10% acetone/CH2Cl2) to yield 55 mg (59%) of the title compound as a white foam; 1H NMR (400 MHz, CDCl3) ~ 8.09 (d, lH, J=8.5 Hz), 7.91 (d, lH, J=8.5 Hz), 7.53 (t, lH, 5 J=7.5 Hz), 7.38 (t, lH, J=7.5 Hz), 7.33 (dd, lH, J=4.3, 8,8 Hz), 7.22 (dd, lH, J=5.8, 7.8 Hz), 7.18 (d, lH, J=8.5Hz), 7.09 (d, J=2.0 Hz), 7.04 (dd, lH, J=7.5, 10. 0 Hz), 6.92 (dt, lH, J=2.5, 8.5 Hz), 6.88 (d, lH), 6.77 (dd, lH, J=1.8, 8.3 Hz), 3.85 (dd, lH, J=8.0 Hz), 3.76 (s, 2H), 3.75 (dd, lH, J=8.0 Hz), 2.88 (s, 3H), 2.80-2.66 (m, 3H), 2.62 (dd, lH, 20 J=8.8, 12.3 Hz), 2.51 (dd, lH, J=6.5, 12.5 Hz), 2.28 (s, 3H), 2.18-2.06 (m, 2H), 1.88-1.80 (m,4H), 1.65 (d, 2H, J=10.5 Hz) ppm;
Mass spectrum (CI): m/z = 672.4 (35Cl + 35Cl isotope + H+).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthylmethyl)-30 (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) 1 '-(3 -((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthylmethyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) (45.6 mg) and phenol (19 mg) in 30% HBr/HOAc (270 ~L) WO 94129309 2 1 6 3 ~ q ~ PCT/US94/05~4~
were heated to 70C for 6 h in a sealed vessel. The reaction was concentrated and partitioned between CH2Cl2 (1 ml) and lN NaOH (2 mL). The organic layer was eluted through a 3x3 cm silica gel plug with 0-100% acetonelcH2cl2 to yield 30 mg (74%) of the title 5 compound as a yellow oil.
1H NMR (400 MHz, CDCl3) ~ 8.09 (d, lH, J=8.0 Hz), 7.93 (d, lH, J=8.5 Hz), 7.52 (t, lH, J=7.5 Hz), 7.43 (t, lH, J=7.3 Hz), 7.22 (dd, lH, J=5.5, 7.5 Hz), 7.17 (d, lH, J=8.5 Hz), 7.06 (dd, lH, J=8.8, 10.3 Hz), 7.02 (d, lH, J=1.5 Hz), 6.87 (d, lH, J=3.5 Hz) 6.78 (dd, lH, J=2.3, 8.3 Hz), 6.75 (dd, lH, J=2.3, 7.8 Hz), 6.56 (dd, lH, J=4.0, 8.5 Hz) ppm;
Mass spectrum (CI): m/z = 594.3 (35Cl + 35Cl isotope + H+), 596.3 (37Cl + 35Cl isotope + H+) 2 1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1-napthylmethyl)-(methylamino))butyl)-5 -fluoro-spiro(indoline-3 ,4'-piperidine) 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthylmethyl)-2 5 (methylamino))butyl)-5-fluoro-spiro(indoline-3 ,4'-piperidine) ( 10 mg) in CH2C12 (100 !lL) was treated with one drop acetic anhydride and 1 drop pyridine. After 30 min, the reaction was eluted through a lx2 cm silica gel column using 0-100% acetone/CH2Cl2 plus 1% NH40H to yield 10 mg (93%) of the title compound as a clear film.
1H NMR (CDC13) ~ 8.17 (dd, lH, J=4.3, 8.8 Hz), 8.09 (d, lH, J=8.5 Hz), 7.91 (d, lH, J=8.0 Hz), 7.52 (t, lH, 7.3 Hz), 7.38 (t, lH, J=7.3 Hz), 7.22 (dd lH, 6.8, 7.0 Hz), 7.18 (d, lH, J=8.8 Hz), 7.07 (d, lH, J=2.0 Hz), 7.04 (dd, lH, J=8.0, 10.5 Hz), 6.91 (dt, lH, J=2.0, 9.0 Hz), 6.86 WO 94t29309 ~1 63 ~ ~ ~ PCT/US94/0554~
(dd, lH, J=2.0, 7.5 Hz), 6.76 (dd, lH, J=2.0, 8.5 Hz), 3.96, 3.81 (rotamer singlets, 3H), 3.85 (d, 1 H, J= 13 Hz), 3.75 (d, 1 H, J= 13 Hz), 2.84 (m, 2H), 2.74 (m, lH), 2.61 (dd, lH, J=8.5, 13Hz), 2.51 (dd, lH, J=7.0, 13 Hz), 2.43, 2.35 (rotamer singlets, 3H), 2.24 (s, 3H), 2.3-2.2 (m, 3H), 2.0-1.85 (m, 4H), 1.65 (m, 2H), 1.50 (m, lH) ppm;
Mass spectrum (CI): m/z = 636.4 (35Cl + 35Cl isotope + H+), 638.4 (37Cl + 35Cl isotope + H+).
1 '-(5-Fluoroindolyl-3-(2-ethanoyl))- 1 -methanesulfonyl-spiro(indoline-5 3 4 -piperidine) To a solution of l-methanesulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride (373 mg, 1.23 mmol), 5-fluoroindole-3-acetic acid (500 mg, 2.59 mmol), in DMF (15 mL) at room temp. was added N-methyl 20 morpholine (261 mg, 2.59 mmol), hyroxybenzotriazole (381 mg, 2.82 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (473 mg, 2.47 mmol). The reaction was stirred 48 h, diluted with H2O (250 mL), extracted with EtOAc (3 x 100 mL), washed with H2O (2 x 150 mL), brine (150 mL), dried (Na2SO4), concentrated in vacuo and 25 purified by column chromatography (SG 60 silica, 5% MeOH/CH2Cl2) to afford 486 mg (89%) of the title compound as a colorless oil.
lH NMR (500 MHz, CDCl3) o 8.39 (br s, lH), 7.37 (d, lH, J = 8.2 Hz), 7.34 (dd, lH, J = 9.6, 2.3 Hz), 7.29 (dd, lH, J = 8.9, 4.4 Hz), 7.23 (dt, 30 lH, J = 7.8, 1.2 Hz), 7.14 (d, lH, J = 2.3 Hz), 7.03 (t, lH, J = 7.3 Hz), 6.98 (dt, lH, J = 8.9, 2.5 Hz), 6.87 (d, lH, J = 7.5 Hz), 4.73 (d, lH, J =
13.7 Hz), 3.96 (d, lH, J = 14.0 Hz), 3.82-3.92 (m, 2H), 3.72-3.78 (m, lH), 3.13 (t, lH, J = 13.4 Hz), 2.91 (s, 3H), 2.73 (t, lH, J = 13.5 Hz), ;2 1 ~3995 1.83 (dt, lH, J = 13.5, 4.4 Hz), 1.65-1.75 (m, 2H), 1.52-1.58 (m, lH), 1.40 (dt, lH, J = 13.0, 4.3 Hz) ppm; Mass spec (CI) m/z 441 (M+H).
1 '-(2-(3-(5-Fluoroindolyl))ethyl))- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine).
To a solution of 1'-(5-fluoroindolyl-3-(2-ethanoyl))-1-methanesulfonyl-spiro(indoline-3,4'-piperidine) (100 mg, .226 mmol) in CH2C12 (8 mL) at -70C was added Dibal-H (lM in THF, 0.91 mL, .906 mmol). After 2.5 h the mixture was quenched by addition of 1 M NaOH (20 mL), 15 diluted with CH2cl2 and stirred vigorously for 15 min. The mixture was extracted with CH2Cl2 (3 x 50 mL), washed with brine (50 mL), dried (Na2SO4), concentrated in vacuo and purified by column chromatography (SG60 silica, 5% MeOH/CH2Cl2) to afford 66 mg (68%) of the title compound as a colorless solid.
lH NMR (500 MHz, CDCl3) â 8.20 (br s, lH), 7.42 (d, lH, J = 8.0 Hz), 7.20-7.30 (m, 4H), 7.06-7.14 (m, 2H), 6.93-6.97 (m, lH), 3.84 (s, 2H), 3.08 (d, 2H, J = 11.7 Hz), 2.94-3.00 (m, 2H), 2.93 (s, 3H), 2.71-2.77 (m, 2H), 2.19 (t, 2H, J = 12.3 Hz), 2.07 (dt, 2H, J = 13.2, 3.9 Hz), 1.75 25 (d, 2H, J = 13.0 Hz) ppm; Mass spec (CI) m/z 428 (M+H).
30 4-Fluoro-3,5-dimethylbenzoic acid Step 1) 1-Bromo-4-fluoro-3,5-dimethylbenzene wo 94/29309 21 6 3 q 9 5 PCT/US94/05545 - To a mixture of 4-Bromo-2,6-dimethylaniline (8.3 g, 42 mmol) at 5C
and H2O (50 mL) was added conc H2SO4 (6.25 mL). NaNO2 (4.1 g) was added in portions until an excess was indicated by starch iodide paper. Water (30 mL) was added to make the mixture homogeneous.
After transferring to a plastic container, HBF4 (50%, 13.7 g) was added dropwise with stirring. The resultant white precipitate was collected by vacuum filtration, washed with H2O (30 mL), MeOH (30 mL), and Et2O (60 mL), and dried over P2O5 under vacuum for 16 h. The solid was then heated in a glass flask with an open flame until all the solid had decomposed. The rem~ining liquid was diluted with Et2O (50 mL) and 0.5 M NaOH (30 mL). The organic layer was separated, washed with 0.5 M NaOH (25 mL), H2O (25 mL), brine (25 mL), dried (MgSO4), and concentrated in vacuo yielding 6.06 g (72%) of 1-bromo-4-fluoro-3,5-dimethylbenzene as a pale yellow liquid.
1HNMR(500MHZ,CDCl3)~7.17(d,2H,J=6.2Hz),2.21 (s,6H) ppm.
Step B) 4-Fluoro-3,5-dimethylbenzoic acid To a mixture of magnesium shavings (120 mg, 4.92 mmol) in THF (2 mL) was added a crystal of iodine followed by slow addition of a solution of the bromide (1.0 g, 4.92 mmol) in THF (3 mL). The 2s reaction mixture was heated to reflux for 1 h followed by cooling to room temp. and addition of CO2(s) (excess), stirred 1 h and quenched by addition of lM HCl (10 mL). The mixture was extracted with Et2O
(3 x 25 mL), washed with brine (25 mL), dried (MgSO4), and concentrated in vacuo to afford 0.82 g (99%) of the title compound as a pale yellow solid.
1H NMR (500 MHz, CDC13) ~ 7.81 (d, 2H, J = 6.7 Hz), 2.36 (s, 6H) ppm;
2~3~Y5 Mass spec (CI) m/z 168 (M-H).
The compounds of Examples 108-120 were prepared as per Example 3 5 Step B utilizing the previously prepared amines and the appropriate benzoic or naphthoic acids:
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chloro-4-fluorobenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) 15 Mass spec (CI) 656 (37Cl + 35Cl isotope + H+), 654 (35CI + 35CI
isotope + H+).
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(N-(3-chloro-4-fluorobenzoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Mass spec (CI) 674 (37Cl + 35Cl isotope + H+), 672 (35Cl + 35Cl isotope + H+).
1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(4-fluorobenzoyl)-(methylamino))butyl)- l -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Mass spec (CI) 620 (37Cl + 35Cl isotope + H+), 618 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluorobenzoyl)-(methylamino))butyl)-5-fluoro- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 618 (37Cl + 35Cl isotope + H+), 616 (35CI + 35Cl isotope + H+).
1 '-(3 -((S) -(3,4-Dichlorophenyl))-4-(N-(3 -chloro-4-fluorobenzoyl)-(methylamino))butyl)-5-fluoro- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 636 (37Cl + 35Cl isotope + H+), 634 (35CI + 35Cl isotope + H+).
2 s EXAMPLE 113 1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3,5-dimethylbenzoyl)-(methylamino))butyl)-5-fluoro- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 630 (37Cl + 35Cl isotope + H+), 628 (35Cl + 35Cl isotope + H+).
wo 94/29309 21 S 3 9 q 5 PCT/US94/05545 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3,5-dimethylbenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 648 (37Cl + 35Cl isotope + H+), 646 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3 -trifluoromethylbenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 688 (37Cl + 35Cl isotope + H+), 686 (35Cl + 35Cl isotope + H+).
l '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3,5 -dimethylbenzoyl)-2 5 (methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 612 (37Cl + 35Cl isotope + H+), 610 (35Cl + 35Cl isotope + H+).
21 ~3995 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3-trifluoromethylbenzoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 652 (37Cl + 35Cl isotope + H+), 650 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -naphthoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 634 (37Cl + 35Cl isotope + H+), 632 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -naphthoyl)-(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 670 (37Cl + 35Cl isotope + H+), 668 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(1 -naphthoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indolme-3,4'-piperidine) Mass spec (CI) 616 (37Cl + 35Cl isotope + H+), 614 (35Cl + 35Cl isotope + H+).
21 63q95 1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-5(methylamino))-4-phenyl-butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) The title compound was prepared in 6 steps from 2-(S)-(3,4-dichlorophenyl)-4-pentenoic acid using procedures identical to othose in Example 10, substituting phenyllithium for methyllithium in Example 10, Step 2.
Mass Spectrum (FAB): m/z 704 (M+H, 37Cl + 35Cl isotope, 100%), 706 (M+H, 37Cl + 37Cl isotope, 80%).
1 '-(4-(N-(3,5-Dimethylbenzoyl)-(methylamino))-4-(phenyl)butyl)- 1 -20acetyl-spiro(indoline-3,4'-piperidine) The title compound was prepared in 6 steps from 4-pentenoic acid using procedures identical to those in Example 10, substituting phenyllithium for methyllithium in Example 10, Step 2.
Mass Spectrum (FAB): m/z 524 (M+H, 37Cl + 35Cl isotope, 100%), 526 (M+H, 37CI + 37Cl isotope, 50%).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(1 -(2-phenylimidazolo))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) WO 94/29309 PCT/~lS94/0554~
21 b3~9G3 Step 1) 1-(2-Phenylimidazolo)-2-((S)-(3,4-dichlorophenyl))-4-pentene To a solution of 0.178 g (0.77 mmole) of 2-((S)-(3,4-dichlorophenyl))-4-penten-1-ol (prepared in Example 136, Step A) and 0.099 mL (0.85 mmole) of 2,6-lutidine in 1.5 mL of methylene chloride at -53 deg C
under nitrogen was added 0.136 mL (0.81 mmole) of trifluoromethanesulfonic anhydride. The solution was stirred between -30 deg C and -40 deg C for 15 min at which point 0.333 g (2.31 mmole) of 2-phenylimidazole was added. The temperature was allowed o to warm to -20 deg C briefly, and the mixture was then cooled to -60 deg C, stirred at that temperature for 1 hr, stirred at -20 deg Cfor 2 hr, and then held at 4 deg C for 16 hr. After stirring at room temperature for 8 hr, the mixture was treated with 10 mL of saturated sodium carbonate solution and 10 mL of ethyl acetate and the layers were separated. The aqueous phase was extracted with 2x15 mL of ethyl acetate and the combined aqueous layers were dried over sodium sulfate, filtered and concentrated in vacuo. The residue was partly purified by flash chromatography on 36 g of silica eluting with 500 mL
of 3:100 methanol:methylene chloride then 300 mL of 5:100:0.1 methanol:methylene chloride: ammonia water. The partly purified product fractions were flash chromatographed on 66 g of silica eluting with 1.2 L of 83:17 methylene chloride:ethyl acetate to give 85 mg (31%) of an oil.
1H-NMR (400 MHz, CDC13) ~ 2.26 (app. t, 2H), 2.85 (pentet, lH), 4.08 (dd, lH), 4.27 (dd, lH), 4.9-5.0 (m, 2H), 5.45-5.55 (m, lH), 6.59 (dd, lH), 6.79 (s, lH), 6.85 (d, lH), 7.18 (d, lH), 7.23-7.30 (m, 2H), 7.35-7.4 (m, 3H).
Mass Spectrum (FAB): m/z 359 (M+H, 65%), 357 (M+H, 100%), 145 (7%).
Step 2) 1 '-(2-((S)-(3,4-Dichlorophenyl))- 1 -(1 -(2-phenylimidazolo))-4-butyl)- l -methanesulfonyl-spiro(indoline-3,4'-piperidine) The title compound was prepared by employing the chemistry outlined in Examples 1 and 2, using 1-(2-phenylimidazolo)-2-((S)-(3,4-dichlorophenyl))-3-butene in place of 3-(S)-(3,4-dichlorophenyl)-4-methylamino-1-pentene, and beginning with the osmium tetroxide step.
H-NMR (400 MHz, CDCl3) ~ 1.55-2 (m, 8H), 2.08 (t, J = 7.3, 2H), o 2.63 (br d, J = 11, lH), 2.70 (br d, J = 8.3, lH), 2.86 (s, 3H), 2.9-3.0(m, lH), 3.71 (s, 2H), 4.13 (dd, J = 14, 8.8, lH), 4.25 (dd, J = 14, 6.2, lH), 6.66 (dd, J = 6.2, 2.1, lH), 6.79 (d, J = 1.3, lH), 6.94 (d, J = 2.1, lH), 7.03 (d, J = 1.3, lH), 7.05 (d, J = 6.4, lH), 7.15 (d, J = 6.5, lH), 7.15-7.25 (m, 2H), 7.35-7.45 (m, 6H) Mass Spectrum (FAB): m/z 609 (M+H, 25%), 279 (100%), 267 (50%), 212 (30%), 187 (35%).
1'-(3-((S)-(3,4-Dichlorophenyl))-4-((N-(R or S)-(3,5-dimethylbenzoyl)-(methylamino))pentyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) The title compound was prepared in 6 steps from (2S)-(3,4-dichlorophenyl)-4-pentenoic acid using procedures identical to those in Example lO, substituting l-acetyl-spiro(indoline-3,4'-piperidine) for 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) in Example 10, Step 6.
Mass Spectrum (FAB): m/z 606 (M+H, 37Cl + 35Cl isotope, 100%), 608 (M+H, 37CI + 37Cl isotope, 80%).
1'-(3-((S)-(3,4-Dichlorophenyl))-4-((N-(R or S)-(4-fluoro-1-napthyl)-(methylamino))pentyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) The title compound was prepared in 6 steps from (2S)-(3,4-dichlorophenyl)-4-pentenoic acid using procedures identical to those in Example 10, substituting 1-acetyl-spiro(indoline-3,4'-piperidine) for 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) in Example 10, Step 6, and substituting 4-fluoro-1-napthoyl chloride for benzoyl chloride.
Mass Spectrum (FAB): m/z 646 (M+H, 37Cl + 35Cl isotope, 30%), 204 (1 00%).
The following compounds described in Examples 126-129 were prepared by the method described in Scheme II and in Example 10, except that in step 2 ethylmagnesium chloride or - propylmagnesium chloride was used at room temperature instead 20 of methyllithium at -78C.
25 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(R or S)-(N-(3,5-dimethylbenzoyl)-(methylamino))hexyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) 1H-NMR (400 MHz, CDCl3) ~ 0.97 (t, 3H), 2.20 (s, 6H), 2.21 (s, 30 3H), 2.42-2.46 (s+m, 4H), 6.23 (s, 2H), 6.89 (s, lH), 7.04 (t, lH), 7.15-7.21 (m, 3H), 7.39 (t, 2H), 8.18 (d, lH).
Mass Spectrum (FAB) m/z 620 (m+).
WO 94/29309 PCT/US94/05~45 21 639~5 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(R or S)-(N-(3,5-dimethylbenzoyl)-(methylamino))hexyl)- 1 -acetyl-5-fluoro-5 spiro(indoline-3,4'-piperidine) 1H-NMR (400 MHz, CDCl3) ~ 0.96 (t, 3H), 2.20 (s, 9H), 2.45 (s, 3H), 3.81 (s, 2H), 6.24 (s, 2H), 6.84-6.89 (m, 3H), 7.19 (dd, lH), 7.39 (t, 2H), 8.13 (dd, lH).
Mass Spectrum (FAB) m/z 638 (m+).
1'-(3-(S)-(3,4-Dichlorophenyl)-4-(R or S)-(N-(3,5-dimethylbenzoyl)-(methylamino))heptyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) 20 lH NMR (400 MHz, CDC13) ~ 0.96 (t, 3H), 2.20 (s, 6H), 2.21 (s, 3H), 2.41-2.45 (s+m, 4H), 3.78 (s, 2H), 6.22 (s, 2H). 6.89 (s, lH), 7.03 (t, lH), 7.15-7.21 (m, 3H), 7.39 (t, 2H), 8.18 (d, lH).
Mass Spectrum (FAB): m/z 634 (m+).
1'-(3-(S)-(3,4-Dichlorophenyl)-4-(R or S)-(N-(3,5-3 0 dimethylbenzoyl)-(methylamino))heptyl)- 1 -acetyl-5-fluoro-spiro(indoline-3,4'-piperidine) 1H-NMR (400 MHz, CDCl3) ~ 0.97 (t, 3H), 2.20 (s, 9H), 2.44 (s, 3H), 3.81 (s, 2H), 6.22 (s, 2H), 6.83-6.88 (m, 3H), 7.18 (dd, lH), 7.38 (t, 2H), 8.13 (dd, lH).
WO 94/29309 2 1 6 3 q q 5 PCT/US94/05545 Mass Spectrum (FAB) m/z 652 (m~).
1'-(3-((S)-(3,4-Dichlorophenyl))-4-(R or S)-hydroxy-5-(3,5-dimethylphenyl)pentyl)- 1 -methane-sulfonyl-spiro(indoline-3,4'-piperidine) To a THF (3 mL) solution of 3,5-dimethylbenzylmagnesium chloride (generated from 290 mg (1.9 mmol) of 3,5-dimethylbenzyl chloride and 53 mg (2.2 mmol) of magnesium in THF) was added slowly 1'-(3-((S)-(3,4-dichlorophenyl))-3 -(N-methoxy-N-15 methylaminocarbonyl)propyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) (100 mg, 0.19 mmol, prepared by reacting the product obtained in Example 10, Step 1 under the oxidative cleavage conditions given in Example 1 followed by the coupling procedure given in Example 2) in 1 mL of THF. The reaction 20 mixture was stirred at 60C for 40 min and poured into 20 mL of lN HCl. The solution was extracted with 3 x 10 mL of EtOAc.
The organic extracts were combined, dried, and concentrated.
The product was purified by preparative TLC (30% EtOAc in CH2Cl2) to afford 20 mg of ketone.
25 To a MeOH (3 mL) solution of ketone (19.4 mg) was added sodium borohydride (7 mg). The mixture was stirred at 55C for lh and concentrated. The residue was purified by preparative TLC (4% MeOH in CH2Cl2) to give 15 mg of the higher Rf isomer (Isomer A) and 4 mg of a lower Rf isomer (Isomer B).
1H-NMR (400 MHz, CDCl3), Isomer A: d 1.71 (d, 2H), 1.92-2.12 (m, 6H), 2.23-2.29 (s+m, 9H), 2.50-2.60 (m, 2H), 2.72-2.76 (m, lH), 2.88 (s, 3H). 2.95 (d, 2H), 3.76 (s, 2H), 4.00-4.06 (m, lH), 6.69 (s, 2H), 6.83 (s, lH), 7.05 (d, lH), 7.19-7.24 (m, 3H), 7.37 (t, 2H), 7.44 (s, lH).
Mass spectrum (FAB) Isomer A, m/z 601 (m+), 603 (m++ 2).
lH-NMR (400 MHz, CDCl3), Isomer B: d 1.69 (d, 2H), 1.74-1.79 (m, lH), 1.83-1.90 (m, lH), 1.93-2.05 (m, 2H), 2.07-2.20 (m, 2H), 2.24-2.36 (s+m, 8H), 2.42-2.47 (m, lH), 2.55-2.58 (dd, lH), 2.66-2.72 (d+dd, 2H), 2.87 (s, 3H), 2.86-3.00 (m, 2H), 3.76 (s, 2H), 3.91-3.95 (m, lH), 6.72 (s, 2H), 6.82 (s, 2H), 7.13-7.19 (m, 2H), 7.18-7.21 (m, 2H), 7.36 (t, 2H).
Mass spectrum (FAB) Isomer B, m/z 601 (m+) 603 (m+ + 2).
1 '-(3 -(R)-(3,4-Dichlorophenyl)-5 -(N-3,5 -dimethylphenyl-2 0 methylamino)-S-oxo-pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Step 1) Diazomethyl-(2-(S)-(3,4-dichlorophenyl)-pent-4-en-yl)-ketone.
To a solution of 2-(S)-(3,4-dichlorophenyl)-pent-4-enoic acid (5.04g, 20.6mmol) in 60mL of dichloromethane was added oxalyl chloride 2.15mL (24.6mmol) and dimethylformamide (O.lmL) upon cooling in an ice-water bath. The cooling bath was then removed and 30 the reaction mixture was stirred at rt overnight. The solvent was removed under reduced pressure. The resulting material was diluted in ethyl acetate and concentrated in vacuo in order to remove residual HCl.
The residual crude acid chloride was dissolved in 70mL of ether and was slowly added to a lOOmL ether solution of diazomethane (77mmol).
After stirring for 2hr at rt, the solvent was removed under vacuum.
WO 94/29309 2 1 6 3 q ? ~i PCT/US94/0~545 The resulting yellow oil was chromatographed on silica gel column eluting with a gradient of hexane: ethyl acetate = 20: 1 to 3: 1 to give 4.66g (84%) of diazomethyl-(2-(S)-(3,4-dichlorophenyl)-pent-4-en-yl)-ketone.
H-NMR (CDCl3 400MHz): o 2.44(app. quint. lH), 2.82(app. qunit.
lH), 3.43(br s. lH), 4.98 & 5.02 (d of AB quart., 2H), 5.16 (br s, lH), 5.63(m, lH), 7.09 (dd, J=2.2Hz, 8.3Hz, lH), 7.34(d, J=2.2Hz, lH),7.38 (d J=8.3Hz).
Step 2) 3-(R)-(3,4-Dichlorophenyl)-hex-4-en-oic acid To a solution of the above diazoketone 4.56g (17.0mmol) in 15 340mL of tetrahydrofuran was added 170mL aquous solution of silver nitrate 3.02g (17.8mmol). After stirring at rt overnight, tetrahydrofuran was removed under reduced pressure. The remaining aqueous layer was extracted with two lOOmL portions of dichloromethane. The combined organic phases were washed with 20 brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. The resulting material was purified by silica gel column chromatography. Elution with dichloromethane: methanol = 10: 1 gave 3.94g (90%) of 3-(R)-(3,4-dichlorophenyl)-hex-4-en-oic acid.
25 Step 3) (N-(3,5-Dimethylphenyl)-N-methyl)-((3-(R)-(3,4-dichlorophenyl)-hex-5-en-yl)-amide The carboxylic acid from Step 2 (300mg, 1.16mmol) was dissolved in 5mL of dichloromethane. To it was added 0.131mL
30 (1.50mmol) of oxalyl chloride followed by the addition of a drop of dimethylformamide upon cooling in an ice-water bath. The cooling bath was then removed and the reaction mixture was stirred at rt for 2hr. The solvent and residual HCl was removed as described above.
The resulting crude acid chloride was then dissolved in 5mL of 21 63qq~
dichloromethane. To it was added N-methyl-3,5-dimethylaniline 313mg (3.32mmol) (Prepared from 3,5-Dimethylaniline following the procedure of Barluenga J., Bayon A.M., and Asensio G. J. Chem. Soc.
Chem. Comm. 1984 1334.) followed by the addition of triethylamine 5 0.5mL (3.6mmol) upon cooling in an ice-water bath. Then the cooling bath was removed and the reaction mixture was stirred at rt overnight.
The solvent was removed under reduced pressure. The residual solid material was dissolved in 15mL of ethyl acetate and 5mL of water. The organic phase was separated and aqueous phase was extracted with two o 7mL portions of ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. This crude material was chromatographed on silica gel eluting with a gradient of 10: 1 to 3: 1 hexane-ethyl acetate to give 386mg of (N-(3,5-dimethylphenyl)-N-methyl)-((3-(R)-(3,4-15 dichlorophenyl)-hex-5-en-yl)-amide (88%).
lH-NMR(CDCl3 400MHz): ~ 2.15-2.35 (m., 4H), 2.29 (s, 6H), 3.09 (s, 3H), 3.26 (quint, J=7.2Hz, lH), 4.88 (d, J=7.6Hz, lH), 4.92 (s, lH), 5.5 (m, lH), 6.45 (s, 2H), 6.91 (dd, J=2Hz, 7Hz, lH), 6.93 (s, lH), 7.30 (d, 20 J=g.3Hz, 1 H)-Step 4) 3-(R)-(3,4-Dichlorophenyl)-5-(N-(3,5-dimethylphenyl)-methylamino)-5-oxo-pentanal To 386mg (1.03mmol) of the product from the previous step was oxidized by osmium tetroxide to corresponding diol as described in Example 1 to give 413mg of crude diol. 381mg of this material was then dissolved in lOmL of benzene. To it was added lead tetraacetate 30 452mg (1.02mmol). After stirring for lhr at rt, 5mL of water was added to quench the reaction. The reaction mixture was extracted with two lOmL portions of ethyl acetate. The combined organic phases were dried over anhydrous magnesium sulfate, filtered, and concentrated.
The crude material was chromatographed on silica gel eluting with WO 94/29309 PCTIUS94/05~45 ~1 63995 hexane: ethyl acetate = 2: 1 to give 329mg of 3-(R)-(3,4-dichlorophenyl)-5 -(N-(3 ,5 -dimethylphenyl)-methylamino)-5 -oxo-pentanal (94% overtwo steps).
Step 5) 1'-(3-(R)-(3,4-Dichlorophenyl)-5-(N-3,5-dimethylphenyl-methylamino)-5-oxo-pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Following the procedure described in Example 2, 107mg (0.287mmol) of this aldehyde was treated with 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride to give 1 03mg (58 %
yield) of the title compound .
15 1H-NMR (CDCl3 400MHz): â 2.23 (s, 6H), 2.86 (s, 3H), 3.09 (s, 3H), 3.72 (s, 2H), 6.49 (s, 2H), 6.9-7.2 (s, 8H).
MS(CI): 628 (M++1: 35Clx2), 630 (M++1: 35Cl & 37Cl) 1 '-(3 -(R)-(3 ,4-Dichlorophenyl))-5 -(3 ,5 -dimethylphenyl)-5 -oxo-pentyl)-2 5 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Step 1) (N-Methoxy-N-methyl)-(3-(R)-(3,4-dichlorophenyl)-4-hexenyl)-amide To a solution of 3-(R)-(3,4-dichlorophenyl)-5-hexenoic acid (Example 132, Step 1) 744mg (2.87mmol) was added 1-hydroxybenzotriazole hydrate 465mg (3.44mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloroide 660mg (3.44mmol) with cooling in an ice-water bath. The cooling bath was 21 63~5 then removed. After stirring at rt for lhr, to it was added 5mL
dichloromethane suspension of N, O-dimethylhydroxyl amine hydrochloride 840mg (8.61mmol) and triethylamine 1.2mL (8.6mmol).
After stirring overnight, the solvent was removed under vacuum, 5 diluted with ethyl acetate and water. The organic phase was separated.
Aqueous phase was extracted twice with ethyl acetate. Combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, filtered, concentrated, chromatographed on silica gel eluting on a gradient of hexane: ethyl acetate = 5: 1 to 2: 1 to give o 762mg (88%) of (N-methoxy-N-methyl)-(3-(R)-(3,4,-dichlorophenyl)-4-hexenyl)-amide.
1H-NMR (CDCI3 400MHz): ~ 2.34(m, lH), 2.69 (App. d, 2H), 3.09 (s, 3H), 3.23 (quint. J=7.3Hz, lH), 3.56 (s, 3H), 4.95 (s, lH), 4.98 (app. d, 15 lH), 5.6 (m, lH),7.0 (dd, J=2.1Hz, 8.4Hz, lH),7.28 (d, J=2.1Hz, lH), 7.32 (d, J=8.3Hz, lH).
Step 2) 3-(R)-(3,4-Dichlorophenyl)-(N-methoxy-methylamino)-S-oxo-2 pentaIlal This above material was subjected to the osmium tetroxide oxidation to the corresponding diol as described in Example 1. The crude product was then treated with 1.23g (2.77mmol) of lead 25 tetraacetate as described in example 131, Step 4. Chromatographic purification on silica gel (eluant; dichloromethane: ethyl acetate = S: 1) afforded 618mg (81% two steps)of 3-(R)-(3,4-dichlorophenyl)-(N-methoxy-methylamino)-S -oxo-pentanal .
Step 3) 1'-(3-(R)-(3,4-Dichlorophenyl)-5-(N-methoxy-methylamino)-5-oxo-pentyl)- l -methanesulfonyl-spiro(indoline-3,4'-piperidine) ~ 1 6:~q95 - A sample of 332mg (1.09mmol) of the aldehyde from Step 2 above was subjected to reductive ~min~tion with 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride as described in Example 2 to give 369mg (61%) of 1'-(3-(R)-(3,4-dichlorophenyl)-5-(N-methoxy)-5 N-(methyl)amino)-5-oxo-pentyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine).
1H-NMR (CDCl3 400MHz): ~ 2.87 (s 3H), 3.10 (s, 3H), 3.60 (s, 3H), 7.0-7.4 (m, 7H).
Step 4) 1 '-(3-(R)-(3,4-Dichlorophenyl))-5-(3,5-dimethylphenyl)-5-oxo-pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) To a 1.2mL THF solution of the amide from Step 3 above (73mg, 0.13mmol) was added l.lmL of 0.7M 3,5-dimethylphenylmagnesium bromide solution in THF (prepared from 5-bromo-m-xylene and magnesium turnings in THF). Then the reaction mixture was heated to 500C. After stirring for 1.5hr, the reaction mixture was allowed to cool 20 down to rt and the reaction was quenched by sat NH4Cl aq solution.
THF was removed under reduced pressure, diluted with ethyl acetate.
The organic phase was separated and the aqueous phase was extracted twice with ethyl acetate. Combined organic phases were dried over anhydrous magnesium sulfate, filtered, concentrated, chromatographed 25 on silica gel eluting with a gradient of dichloromethane: ethyl acetate =
10: 1 to 1: 1 to give 55mg (70%) of the title compound.
lH-NMR (CDCl3 400MHz): â 2.34 (s, 6H), 2.86 (s, 3H), 3.23 (m, 2H), 3.74 (s, 2H), 7.0-7.5 (m, lOH).
MS (CI): 599 (M++1;35Clx2), 601 (M++1: 35Cl& 37Cl).
2l 63~5 1 '-(3-(R)-(3,4-Dichlorophenyl)-6-(3,5-dimethylphenyl)-5-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 70mg (0.126mmol) of 1'-(3-(R)-(3,4-dichlorophenyl)-5-(N-methoxy)-N-(methyl)amino)-5-oxo-pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4r-piperidine) (Example 132, Step 3) was treated with 0.8M THF solution of 3,5-dimethyl benzylmagnesium chloride as in the case of Example 132. The crude material was chromatographed on silica gel in the same solvent system to afford 33mg of the title compound (43%).
1H-NMR (CDCl3 400MHz): ~ 2.24 (s, 6H), 2.86 (s, 3H), 3.47 (s, 2H), 3.72 (s, 2H), 6.64 (s, 2H), 6.8-7.4 (m, 8H).
MS (CI): 613 (M++1: 35Clx2), 615 (M++1: 35CI& 37CI).
1 '-(3-(S)-(3,4-Dichlorophenyl)-6-(3,5-dimethylphenyl)-6-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 3-(R)-(3,4-Dichlorophenyl)-4-hexenoic acid (Example 131, Step 2) was converted into 4-(S)-(3,4-Dichlorophenyl)-5-heptenoic acid as in Example 131, Steps 1 and 2. 4-(S)-(3,4-dichlorophenyl)-4-heptenoic acid was converted to (N-methoxyl-N-methyl)-(4-(S)-(3,4-dichlorophenyl)-6-heptenyl)-amide followed by treatment with 3,5-dimethylphenylmagnesium bromide as described in Example 132, Step 4 to give the title compound.
1H-NMR (CDCl3 400MHz): ~ 2.32 (s, 6H), 2.80 (s, 3H), 3.74 (s, 3H), 7.0-7.4 (m, lOH).
WO 94/29309 2 1 6 3 q ~ j PCT/US94/05545 MS (CI): 613 (M++1: 35Clx2), 615 (M++1: 3~Cl& 37Cl).
1 '-(3-(S)-(3,4-Dichlorophenyl)-6-(3,5-dimethylphenyl)-5-(RS)-methyl-6-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Step 1) 4-(S)-(3,4-Dichlorophenyl)- 1 -(3,5-dimethylphenyl)-hept-6-ene-1 -one 1.42g (4.50mmol) of (N-Methoxy-N-methyl)-(4-(S)-(3,4-dichlorophenyl)-6-heptenyl)-amide (prepared in Example 134) was dissolved in 20mL of dry THF. To it added 10mL THF solution of 3,5-5 dimethylphenylmagnesium bromide prepared from 1.8g (9.6mmol) of 5-bromo-m-xylene and 463mg of magnesium turnings. After stirring for 2hr at rt, the reaction was quenched with saturated aqueous ammonium chloride solution. THF was removed under reduced pressure. The residual material was diluted with ethyl acetate. The 20 organic phase was separated, aqueous phase was extracted twice with ethyl acetate. Combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, filtered, concentrated, chromatogrpraphed on silica gel eluting with a gradient of hexane:
ethyl acetate = 10: 1 to 5: 1 to give 1.57g of 4-(S)-(3,4-25 dichlorophenyl)-1 -(3,5-dimethylphenyl)-hept-6-ene-1 -one (97%).
Step 2) 4-(R)-(3,4-Dichlorophenyl)-1-(3,5-dimethylphenyl)-2-(RS)-methyl-hept-6-ene- 1 -one Hexamethyldisilazane (0.108mL, 0.512mmol), and 0.089mL of hexamethylphosphoramide were dissolved in 2mL of dry THF. To it was added 0.306mL (0.49mmol) of n-butyllithium (1.6M hexane solution) after cooling in an ice-water bath. After stirring for 20min, WO 94129309 2 1 6 3 ~ ~ 5 PCT/US94/05545 the ice-water bath was replaced by a dry ice-acetone bath and 2mL of a dry THF solution of 4-(S)-(3,4-dichlorophenyl)-1-(3,5-dimethylphenyl)-hept-6-ene-1-one (154mg, 0.426mmol) was added via syringe. After stirring for lhr, 0.066mL (1.06mmol) of iodomethane 5 was added . The cooling bath was removed and the mixture stirred at rt overnight. The solvent was then removed under reduced pressure and the residual material was diluted in ethyl acetate and water. The organic phase was separated. The a~ueous phase was extracted twice with ethyl acetate. The combined organic phases were washed with o brine, dried over anhydrous magnesium sulfate, filtered, concentrated, and chromatographed on silica gel eluting with a gradient of hexane:
ethyl acetate = 10: 1 to 7: l to give l50mg of 4-(R)-(3,4-dichlorophenyl)- l -(3,5-dimethylphenyl)-2-(R &S)-methyl-hept-6-ene- 1 -one (94%). This was a 1 to 1 mixture of two diastereomers as revealed 5 by proton NMR.
H-NMR (CDCI3 400MHz): ~ 1.06 ( d, J=7Hz, l.5H), 1.14 ( d, J=6.7Hz, l.5H), 2.30, 2.31 (s, 6H), 2.5 (m, O.5H), 2.6 (m, O.5H), 3.1-3.2 (m, lH), 4.9 (m, 2H), 5.5 (m, lH), 6.8-7.4 (m, 6H).
Step 3) 3-(S)-(3,4-Dichlorophenyl)-5-(RS)-methyl-6-(3,5-dimethylphenyl)-6-oxo-hexanal The product from Step 2 above was subjected to osmium tetroxide oxidation followed by the treatment with sodium periodate as described in Example 1 to give 3-(S)-(3,4-dichlorophenyl)-5-(RS)-methyl-6-(3,5 -dimethylphenyl)-6-oxo-hexanal.
Step 4) l '-(3-(S)-(3,4-Dichlorophenyl)-6-(3,5-dimethylphenyl)-5-(RS)-methyl-6-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 21 6~qq5 This product from Step 3 above was subjected to reductive amination with 1-methanesulonyl-spiro(indoline-3,4'-piperidine) as described in Example 2 to give the title compound.
1H-NMR (CDCl3 400MHz): ~ 1.05 (d, J=7Hz),1.08 (d, J=6.7Hz), 2.30 & 2.32 (s, 6H), 2.89 (s, 3H), 3.72 (S, 2H), 6.8-7.0 (m, 10H).
MS (CI): 627 (M++1: 35Clx2), 629 (M++1: 35Cl& 37Cl).
1 '-(3 -(S )-(3,4-Dichlorophenyl)-4-(3,5 -(bistrifluoromethyl)benzyloxy)-l -acetyl -spiro(indoline-3,4 ' -piperidine) Step A: 2-(S)-(3,4-Dichlorophenyl)-4-penten-1-ol To a solution of 2-(S)-(3,4-dichlorophenyl)-4-pentenoic acid (7.0 gm) (prepared as described by J. Hale et. al., Bioorganic & Medicinal Chemistry Letters 1993,3, 319-322.) in ether (50 mL) at r.t. was added portionwise over 5 min solid lithium aluminum hydride (700 mg). The reaction was heated to 40 C for 3 hr and then stirred at r.t. for 16 hr.
The reaction was poured into water cont~ining 25 mL of 2N NaOH and extracted twice with ether. The ether layers were washed with brine, combined and dried over Na2SO4. Flash chromatograghy afforded the title compound (4.5 gm) as an oil. [a]D = +14 (EtOH, c = 1.5).
Step B: 2-(S)-(3,4-Dichlorophenyl)-1-(3,5-(bistrifluoromethyl)benzyloxy)-4-pentene To a solution of 2-(S)-(3,4-dichlorophenyl)-4-penten-1-ol (1.0 gm) in DMF (25 mL) was added sodium hydride (175 mg) while cooled in an ice bath. After 1 min, 3,5-(bistrifluoromethyl)benzyl bromide (2.0 gm) was added followed by a second portion of sodium hydride (175 mg).
After 1 hr, the reaction was poured into water and extracted twice with ether. The ether layers were washed with brine, combined and dried over Na2SO4. Flash chromatograghy (hexanes, then 2 and 5% ethyl acetate/hexanes) afforded the title compound (2.0 gm) as an oil.
2 1 6399~
NMR (CDCl3): ~ 2.30-2.40 and 2.50-2.60 (2 m, 2 H), 2.90-3.00 (m, l H), 3.55-3.65 (d of AB q, 2 H, J = 6 and 9 Hz), 4.54 (AB q, 2 H, J = 13 Hz), 4.90-5.00 (m, 2 H), 5.55-5.70 (m, 1 H), 7.04 (dd, I H, J = 2 and Hz), 7.30 (d, 1 h, J = 2 Hz), 7.36 (d, 1 h, J = 8 Hz), 7.64 (s, 2 h), 7.76 (s, 1 H).
Step C: 3-(S)-(3,4-Dichlorophenyl)-4-(3,5-(bistrifluoromethyl)benzyloxy)butan- 1 -ol o A solution of 2-(S)-(3,4-dichlorophenyl)-1-(3,5-(bistrifluoromethyl)benzyloxy)-4-pentene (1.5 gm) in methanol (50 mL) was cooled to -70 C in a dry ice/acetone bath and ozone bubbled thru for 15 min until a blue coloration was seen. The solution was purged with N2 for 10 min and sodium borohydride was added. The reaction was allowed to warm to r.t. and was stirred for 2 hr. The volatiles were removed in vacuo and the residue was flash chromatograghed (30 then 50% ethyl acetate/hexanes) to give the title compound as a clear oil.
NMR (CDCl3): ~ 1.78-1.88 and 2.00-2.10 (2 m, 2 H), 3.05-3.15 (m, 1 H), 3.45-3.55 (m, 1 H), 3.55-3.68 (2 m, 3 H), 4.55 (AB q, 2 H, J = 13 Hz), 7.04 (dd, 1 H, J = 2 and 8 Hz), 7.32 (d, 1 h, J = 2 Hz), 7.36 (d, 1 h, J = 8 Hz), 7.65 (s, 2 h), 7.76 (s, 1 H).
Step D: 4-Bromo-2-(S)-(3,4-dichlorophenyl)-1-(3,5-(bistrifluoromethyl)benzyloxy)butane 3-(S)-(3,4-Dichlorophenyl)-4 (3,5 (bistrifluoromethyl)benzyloxy)butan-1-ol from Step C (500 mg) was converted to the title compound (530 mg) with Ph3P-Br2 as described in Example 20, Step B.
Step E: 1'-(3-(S)-(3,4-Dichlorophenyl)-4-(3,5-(bistrifluoromethyl)benzyloxy)- 1 -acetyl-spiro(indoline-3,4r-piperidine).
4-Bromo-2-(S)-(3,4-dichlorophenyl)- 1 -(3,5 -(bistrifluoromethyl)benzyloxy)butane (30 mg) from Step D was converted to the title compound (42 mg) as described in Example 20, Step C.
2 1 ~39~5 NMR (CDCl3): ~ 1.48-2.05 (m,10 H),2.14 and 2.34 (2 s,3 H),2.10-2.25 (m,2 H),2.70-2.85 (m,2 H),2.90 (m, l H),3.48-3.58 (m,2 H), 3.70 and 3.84 (2 s,2 H),4.55 (AB q,2 H, J = 13 Hz),6.90-7.15 (m,4 h),7.33 (d, l h, J = 2 Hz),7.37 (d, l h, J = 8 Hz),7.66 (s,2 h),7.76 (s,1 H),8.18(d,1 h,8Hz).
Appln No. EP-512901, filed 03-May-91, Pub. 11-Nov-92; Appln No.
EP-512902, filed 03-May-91, Pub. 11 -Nov-92; Appln No. EP-515240, filed 03-May-91, Pub. 25-Nov-92; Appln No. US4472305, filed 17-May-83, Pub. 18-Sep-84; Appln No. US4839465, filed 20-Jan-87, Pub.
13-Jun-89; Appln No. EP-101929, filed 28-Ju1-82, Pub. 07-Mar-84;
Appln No. WO9102745, filed 16-Aug-89, Pub. 07-Mar-91; Appln No.
US3912711, filed 03-Ju1-72, Pub. 14-Oct-75; Appln No. US4059693, filed 11 -Jun-76, Pub. 22-Nov-77; Appln No. US4481139, filed 13-Apr-83, Pub. 06-Nov-84; Appln No. US7358073, filed 24-Oct-88, Pub. 19-Dec-89; Appln No. US7261627, filed 24-Oct-88, Pub. 07-Mar-89, which are hereby incorporated by reference.
The compounds of formula I are useful in the prevention and treatment of a wide variety of clinical conditions (as detailed in this specification) which are characterized by overstimulation of the tachykinin receptors, in particular NK1, NK2 and NK3.
These conditions may include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; neurodegenerative disorders such as AIDS related dementia, senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelin~ting diseases such as multiple sclerosis and amyotrophic lateral sclerosis and other neuropathological disorders such as diabetic or peripheral neuropathy, AIDS related neuropathy, chemotherapy-induced neuropathy, and neuralgia; respiratory diseases such as chronic obstructive airways disease, bronchopneumonia, bronchospasm and asthma; infl~mm~tory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis and rheumatoid arthritis; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis;
WO 94/29309 ~ ~ 6 ~ ~ ~ 5 PCT/US94/05545 addiction disorders such as alcholism; stress related somatic disorders;
reflex sympathetic dystrophy such as shoulder/hand syndrome;
dysthymic disorders; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or 5 suppression such as systemic lupus erythematosis; gastrointestinal (GI) disorders and diseases of the GI tract such as disorders associated with the neuronal control of viscera such as ulcerative colitis, Crohn's disease and incontinence; disorders of bladder function; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease; and pain or nociception, for example, that is attributable to or associated with any of the foregoing conditions especially the tr~nsmission of pain in migraine. Hence, these compounds are readily adapted to therapeutic use for the treatment of 5 physiological disorders associated with the overstimulation of the tachykinin receptors, in particular NK1, NK2 and NK3.
The compounds of the present invention are particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as, for exarnple: neuropathy, such 20 as diabetic or peripheral neuropathy and chemotherapy-induced neuropathy; asthma; osteoarthritis; rheumatoid arthritis; and migraine.
For the treatment of any of these diseases compounds of Formula I may be a~lministered orally, topically, parenterally, ICV, by inhala~ion spray or rectally in dosage unit formulations containing 25 conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intracisternal injection or infusion techniques. In addition to the treatment of warm-blooded ~nim~ls such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the 30 compounds of the invention are effective in the treatment of humans.
The pharmaceutical compositions cont~ining the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or 2 1 63~95 elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring 5 agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by S known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Patents 4,256,108;
20 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or 25 kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous 3 suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethyl-cellulose, sodium alginate, polyvinyl- pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an WO 94/29309 2 1 ~ 3 ~ 9 5 PCT/US94/05545 alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already 2s mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation 2 1 63~95 products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The compounds of formula I may also be ~clministered in the form of suppositories for rectal a-l-ninistration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of Formula I are employed.
(For purposes of this application, topical application shall include mouth washes and gargles.) 3 In the treatment of a condition associated with an excess oftachykinins, an appropriate dosage level will generally be about 0.001 to 50 mg per kg patient body weight per day which can be a~lministered in single or multiple doses. Preferably, the dosage level will be about 0.01 to about 25 mg/kg per day; more preferably about 0.05 to about 10 WO 94/29309 PCT/US94/0~545 2 ~ 6~3~ 95 mg/kg per day. A suitable dosage level may be about 0.001 to 25 mg/kg per day, about 0.005 to 10 mg/kg per day, or about 0.005 to 5 mg/kg per day. Within this range the dosage may be 0.005 to 0.05, 0.05 to 0.5 or 0.5 to 5.0 mg/kg per day. The compounds may be a~lmini~tered on a 5 regimen of 1 to 4 times per day, preferably once or twice per day.
TACHYK~IN ANTAGONISM ASSAY
The compounds of this invention are useful for antagonizing tachykinins, in particular substance P and neurokinin A in the treatment of gastrointestinal disorders, central nervous system disorders, infl~mm~tory diseases, pain or migraine and asthma in a m~mmal in need of such treatment. This activity can be demonstrated by the following assay.
A. Receptor Expression in COS
To express the cloned human neurokinin-1 receptor (NKlR) transiently in COS, the cDNA for the human NKlR was cloned into the expression vector pCDM9 which was derived from pCDM8 20 (INVITROGEN) by inserting the ampicillin resistance gene (nucleotide 1973 to 2964 from BLUESCRIPT SK+) into the Sac II site.
Transfection of 20 ~g of the plasmid DNA into 10 million COS cells was achieved by electroporation in 800 ~l of transfection buffer (135 mM NaCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 2.4 mM K2HPO4, 0.6 mM
25 KH2PO4, 10 mM glucose, 10 mM HEPES pH 7.4) at 260 V and 950 uF
using the IBI GENEZAPPER (IBI, New Haven, CT). The cells were incubated in 10% fetal calf serum, 2 mM glllt~mine, 100U/ml penicillin-streptomycin, and 90% DMEM media (GIBCO, Grand Island, NY) in 5% C2 at 37C for three days before the binding assay.
30 Similar methods were used to express the NK2 receptor.
B. Stable Expression in CHO
To establish a stable cell line expressing the cloned human NKlR, the cDNA was subcloned into the vector pRcCMV
(INVITROGEN). Transfection of 20 ,ug of the plasmid DNA into CHO
5 cells was achieved by electroporation in 800 ~l of transfection buffer suplemented with 0.625 mg/ml Herring sperm DNA at 300 V and 950 uF using the IBI GENEZAPPER (IBI). The transfected cells were incubated in CHO media (10% fetal calf serum, 100 U/ml pennicilin-streptomycin, 2 mM glutamine, 1/500 hypoxanthine-thymidine (ATCC), 90% IMDM media (JRH BIOSCIENCES, Lenexa, KS), 0.7 mg/ml G418 (GIBCO)) in 5% CO2 at 37C until colonies were visible. Each colony was separated and propagated. The cell clone with the highest number of human NKlR was selected for subsequent applications such as drug screening.
15 Similar methods were used to express the human NK2 receptor.
C. Assay Protocol usin~ COS or CHO
The binding assay of human NKlR expressed in either COS
or CHO cells is based on the use of 125I-substance P (125I-SP, from 20 DU PONT, Boston, MA) as a radioactively labeled ligand which competes with unlabeled substance P or any other ligand for binding to the human NKlR. Monolayer cell cultures of COS or CHO were dissociated by the non-enzymatic solution (SPECIALTY MEDIA, Lavallette, NJ) and resuspended in appropriate volume of the binding 25 buffer (50 mM Tris pH 7.5, 5 mM MnCl2~ 150 mM NaCl, 0.04 mg/ml bacitracin, 0.004 mg/ml leupeptin, 0.02 mg/ml BSA, 0.01 mM
phosphoramidon) such that 200 ~11 of the cell suspension would give rise to about 10,000 epm of speeifie 125I-SP binding (approximately 50,000 to 200,000 cells). In the binding assay, 500 ul of cells were added to a 30 tube containing 20 ~l of 1.5 to 0.25 nM of 125I-SP and 5 ~l of unlabeled substance P or any other test compound in DMSO. The tubes were incubated at 4C or at room temperature for 1 hour with gentle shaking. The bound radioactivity was separated from unbound radioactivity by GF/C filter (BRANDEL, Gaithersburg, MD) which was WO 94/29309 PCT/US94/0~545 pre-wetted with 0.1% polyethylenimine. The filter was washed with 3 ml of wash buffer (50 mM Tris pH 7.5, 5 mM MnCl2, 150 mM NaCl) three times and its radioactivity was determined by gamma counter. A
similar assay was used for NK2 except 125I-NKA was used as the ligand.
The activation of phospholipase C by NKlR may also be measured in CHO cells expressing the human NKlR by determining the accumulation of inositol monophosphate which is a degradation product of IP3. CHO cells are seeded in 12-well plate at 250,000 cells per well.
After incubating in CHO media for 4 days, cells are loaded with 0.025 uCi/ml of 3H-myoinositol by overnight incubation. The extracellular radioactivity is removed by washing with phosphate buffered saline.
LiCl is added to the well at final concentration of 0.1 mM with or without the test compound, and incubation is continued at 37C for 15 min. Substance P is added to the well at final concentration of 0.3 nM
to activate the human NKlR. After 30 min of incubation at 37C, the media is removed and 0.1 N HCl is added. Each well is sonicated at 4C
and extracted with CHCl3/methanol (1:1). The aqueous phase is applied to a 1 ml Dowex AG lX8 ion exchange column. The column is washed with 0.1 N formic acid followed by 0.025 M ammonium formate-0.1 N
formic acid. The inositol monophosphate is eluted with 0.2 M
ammonium formate-0.1 N formic acid and quantitated by beta counter.
Similar methods were used to assess antagonism at the NK2 receptor, except NKA was used as the stimulating agonist.
The compounds of of Formula I as Exemplified in the EXAMPLES below have been found to displace radioactive ligand for the NK-1 receptor at a concentration range of 0.01 nM to 1.0 ,uM, for the NK-2 receptor, 0.01 nM to S ~M, and for the NK-3 receptor, 1.0 nM to 10 ~lM.
Several methods for preparing the compounds of this invention are illustrated in the following Schemes and Examples.
The compounds of the present invention are prepared by alkylating azacycle 1, in which R1 = H, under appropriate conditions (Scheme 1). The required azacycle starting materials are prepared WO 94/29309 PCT/US94/0554~
2 1 6~ 9 ~
using methods described in the literature; such as described in Ong, H.
H. et al, Journal of Medicmal Chemistry, 1983,26, 981-986, and Nargund, R. e~ al, USSN 08/147,226 (November 3, 1993), EP
93309867.5 hereby encorporated by reference. None of the compounds in these references are claimed to be neurokinin antagonists.
Thus, azacycle 1 (R1=H) is combined with the appropriate aldehyde and the intermediate imine is reduced to the tertiary amine chemically (e.g. using sodium cyanoborohydride) or catalytically (e.g.
using hydrogen and palladium on carbon or Raney nickel catalyst) (Scheme 1). The aldehyde needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention the preparation of a representative aldehyde is described in Hale, J.J.; Finke, P.E.; MacCoss, M. Bioorganic &
Medicinal Chemistry Letters 1993,3, 319-322.
In an alternative embodiment of the present invention, azacycle 1 (Rl=H) can be alkylated with an alkyl halide or alkyl sulfonate ester (with or without an added base to neutralize the mineral acid or sulfonic acid by-product) to give the desired compound (Scheme 1). The alkyl halide or alkyl sulfonate needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention an aldehyde, prepared as described above, can be reduced to an alcohol with sodium borohydride, diisobutylaluminum hydride or lithium aluminum hydride, and the product alcohol converted to either the aL~yl halide using methods described in March J. "Advanced Organic Chemistry", 25 3rd ed., John Wiley & Sons, New York, pp. 382-384 (1985), or alkyl sulfonate ester using methods described in March J. "Advanced Organic Chemistry", 3rd ed., John Wiley & Sons, New York, p. 444 (1985).
In an alternative embodiment of the present invention, 1 (R1 = H) can be acylated to give the tertiary amide and subsequent 30 reduction with a strong reducing agent (e.g. diborane including borane dimethylsulfide; and, lithium alllminllm hydride) will give the desired compound (Scheme 1). The acylating agent needed for this reaction can be prepared by methods generally known in the chemical literature; for ~l 63q95 the purposes of the present invention an aldehyde, prepared as described above, can be oxidized using such commonly used reagents as permanganate in acid or silver oxide, and the resulting acid activated as an acid chloride or mixed anhydride which can be used to acylate I (Rl 5 = H). The product amide can in and of itself be a neurokinin antagonist or can be reduced with a strong reducing agent, such as diborane or lithium aluminum hydride, to give the tertiary amine.
Optionally, compound 1 formed in the alkylation step may be further modified in subsequent reactions. In one illustration of such an approach,the aldehyde fragment contained a t-butoxycarbonylamino group (Example 2). After reductive ~min~tion, the t-butoxycarbonyl protecting group is removed by treatment with a strong acid such as trifluoroacetic acid or formic acid and the resulting amine is acylated to furnish the desired compounds (Example 3). Alternatively, the 5 protecting group may also be present in the azacycle portion as illustrated with a benzyloxycarbonyl group in Example 6. Thus an azacycle cont~ining a benzyloxycarbonylindoline (prepared in Example 4) is alkylated with an aldehyde in the presence of a reducing agent.
Next, the protecting group is removed to liberate a free amine 20 (Example 7) and the amine is further reacted to provide additional analogs (Example 8).
2 1 63~95 SCHEM:E 1 RCHO, [H]
X W R 1 X X' W
~;;z~)m ~
RCO~\ ~trong [H]
~X-Q`W
~ )m O R
~1 63995 In an alternative embodiment of the present invention, the allyl acid 2 (described in Hale et al; see above) can be converted into the N-methyl methoxy amide 3, which is then treated with an alkyl or aryl metal reagent, for example methyllithium or butyllithium, to provide 5 the ketone 4 (Scheme 2). The ketone can be converted into an imine which can then be reduced to secondary amine 5 chemically, (e.g using sodium cyanoborohydride or sodium borohydride), or catalytically (e.g.
using hydrogen and palladium on carbon or Raney nickel catalyst).
Acylation under standard conditions, for example with an acid chloride, provides amide 6. The allyl group in 6 can be oxidatively cleaved to aldehyde 7 with osmium tetroxide followed by sodium periodate or with ozone at low temperature. Reductive ~min~tion of aldehyde 7 with azacycle 1 can then be carried out under the conditions described above.
Substituted spiro(indoline-3,4'-piperidine) derivatives can 5 be prepared as shown in Scheme 3 starting from the appropriately substituted phenylhydrazines. Following the Fischer indole reaction and reduction of the intermediate imine with a mild reducing agent such as sodium borohydride, the indoline nitrogen can be reacted with an electrophile such as an acyl chloride or a sulfonyl chloride. The 20 protecting group on the piperidine nitrogen, for example a benzyloxycarbonyl group, can be removed by treatment with hydrogen in the presence of palladium on carbon or by exposure to trimethylsilyl iodide, to give the deprotected substituted spiro(indoline-3,4'-piperidine).
2 1 63qq5 E DAC O
HOBT-H20 ~N,OMe OH HN(Me)(OMe) HCI - ~e RLi, -78C or Cl' ~ Cl/~3 RMgBr, rt `\ R R6NH3CI ~N,H (BOC)2o Cl/~ C~
Cl 4 Cl 5 1 ) OSO4 N,BOC acetone/ tBuOH/H20 H N,BOC
- R 3:1 CIJ~3 Cl 6 Cl 7 CF3CO2H Amine HCI C ~ ~
anisole, CH2C12 NaBH3CN - R 7 Cl/~
Cl 8 2 1 63~5 O OBn 1) pyridine, toluene ~OBn + ~ 2) CF3CO~H, 60C ~) NH3CI CHO 3) NaBH4, MeOH H
~ OBn N HCI Me3Sil; HCI N
~ ~ H2, Pd/C; HCI
R ~ R
Preparation of spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) derivatives is shown in Scheme 4. Reaction of N-Boc protected 4-piperidone with the lithium salt of methyl phenyl sulfoxide followed by base-mediated elimin~tion-rearrangement and basic cleavage provides the indicated allylic alcohol. The alcohol can be 30 converted to the rearranged allylic chloride with thionyl chloride in toluene in the presence of 2,6-lutidine as a proton scavenger.
Displacement of the chloride with functionalized 2-bromothiophenol provides the allylic sulfide, which can be cyclized under radical conditions to give the illustrated spiro(2,3-dihydrobenzothiophene-3,4'-wo 94/29309 2 1 6 3 9 9 5 PCT/US94/05545 piperidine). Cleavage of the t-butoxycarbonyl group under standard conditions, such as trifluoroacetic acid, then provides the desired spirocycle.
Boc Boc methyl phenyl N
~N~ sulfoxide ~ KOtBu, tBuOH
LDA, THF HO ~ 50C
OC ~S~O
R ~
Boc Boc ~ SH
N N Br ~ ~ SOCI2, PhMe ~ K2CO3, 40C
OH 2,6-lutidine Cl Boc N~ Boc I~J Br Bu3SnH, AIBN ~N~ 1 ) TFA
S~¦~ PhH, 80C ~ 2) HCI, MeOH
H HCI R
N
30 ~
R
2 1 6~9~5 Spiro(2,3-dihydrobenzofuran-3,4'-piperidine) derivatives can be prepared as illustrated in Scheme 5. Treatment of an appropiately substituted ester of 2-fluorophenylacetate with mechloret~mine hydrochloride under basic conditions provides the 5 piperidine product, which on treatment with a strong reducing agent such as lithium aluminum hydride produces the corresponding 4-(hydroxymethyl) compound. Cyclization with base provides the benzofuran derivative, and cleavage of the N-methyl group can then be carried out using l-chloroethyl chloroformate or other suitable N-o demethylating agents.
21 639~5 N NaH
MeO Cl Cl f ~ F
O N
Me ~I LiAlH4, THF
DMF HO ~
R ~ F
Cl ~ Me Me O Cl 1 ,2-dichloroethane, reflux ~NH-HCI
Compounds with alternate arrangements of the amide bond 30 can be prepared as shown in Scheme 6. The illustrated acid can be homologated under Arndt-EisteIt conditions to give the chain-extended acid, which can be derivatized under standard acylating conditions with, for example, an aniline derivative, to give the corresponding amide.
Oxidative cleavage of the olefin with osmium tetroxide or ozone then 21 639~5 provides the aldehyde intermediate suitable for coupling as described earller.
R R
~1 1) (COCI)2 ~OH 2) CH2N2, Et20 ~N2 R
AgN03 ~s~H
H20 o 1) (COCI)2 e` ,~
R
1 ) OSO4, H20, tBuOH
N-Me-morpholine-N-oxide ~\'q 2) NalO4, H20, THF ~ Me O ~5~ N
Me 2 ~ 63~95 In addition, ketone derivatives can be prepared by an extension of the chemistry given above, as shown in Scheme 7. A
second Arndt-Eistert chain extension provides the illustrated heptenoic acid derivative, which after conversion into its N-methoxy-N-methyl 5 amide, can be reacted with an aryl organometallic reagent, such as an aryl magnesium bromide, to provide the ketone. Routine oxidative cleavage then gives the desired aldehyde, which can be coupled with a spiro-piperidine derivative as described above.
R
1) (C )2 ~ 2) CH2N2 ~J~ OH
1) (COCI)2 ~q~
- Me 2) HN(Me)OMe ~ ~N~OMe ~ R' BrMg THF
1 ) OsO4, H2O, tBuOH
N-Me-morpholine-N-oxide R
2) NalO4, H2O, THF ~q '1~ 1~ R' R ~ J
2 ~ O
2 1 6399~
D~ 1) (COC~
s2) C H2N2 ~ ,I~,OH
101) (COc1)2 , ~q ~ Me 2) HN(Me)OMe l I
~N~ OM
BrMgJ3 THF ''' 1 ) OSO4, H20, tBuOH
N-Me-morpholine-N-oxide R
2) NalO4, H20, THF ~\~
,. ~ ~ R' R ~ ~
~ O
~ 1~ R' ~/
O
Alcohol containing antagonists can be prepared according to procedures given in Scheme 8. Formation of the N-methyl-N-methoxy amide of the indicated acid followed by oxidative cleavage of the olefin provides the intermediate aldehyde. Coupling with a spiro(indoline-3,4'-piperidine) derivative followed by addition of an organometallic reagent to the amide provides the illustrated ketone.
Treatment with a hydride reducing agent, such as sodium borohydride, 5 then yields the desired alcohol derivatives.
WO 94/29309 2 1 6 3 ~ ') 5 SCHE~'IE 8 O O
~OH ~N~ Me - 1) (coC1)2 . ,~, OMe l~;~ 2) HN(Me)OMe ~J
1 ) 0sO4,H20, tBuOH ~ N~ Me SO2CH3 N-Me-morpholine-N-oxlde ~ OMe ~< ~
2) NalO4, H20,THF R' R/~ NH HCI
MeOH, NaBH3CN R\,=< O R"MgCI
mol. sieves ~--NI--~`N'Me OMe Sl 02C H3 20 R~N ~--~` R~ NaBH4 R' SO2CH3 so2CH3 N N
R N~ R~ R~--~+ ~1 R' R' Formation of heterocycle substituted antagonists can be carried out according to the procedure given in Scheme 9 for substituted imidazoles. Reduction of the allyl acid with a strong reducing agent such as lithium aluminum hydride followed by in situ 5 formation of the trifluoromethanesulfonate of the formed alcohol allows for displacement of the triflate with a nucleophile such as 2-phenylimidazole. Oxidative cleavage under standard conditions provides the indicated aldehyde which can then be coupled under the conditions described above to the appropriate spiro derivative.
WO 94/Z9309 2 1 6 3 9 9 5 PCT/US94105~4~
LiAlH4 ~--OH (CF~SO2)0 T~F R' 2,6-lutidine R' 1 ) OSO4, H2O, tBuOH
N-Me-morpholine-N-oxide /_\ ~J 2) NalO4, tl2O, THF
HN~f N ~ N)~N
R' ~--N~N
2 0 \=~
R' Spiro(2-oxo- 1,2,3 ,4-tetrahydroquinoline-4,4'-piperidine) and spiro(1-oxo-1,2,3,4-tetrahydroisoquinoline-4,4'-piperidine) can be prepared as shown in Scheme 10. Starting from the indicated spiro(2-oxoindane-3,4'-piperidine) (described in Claremon, D.A. et al, 30 European Patent 0 431 943 943 A2, Ev~ns, B.E. et ~1, U.s. Patent 5~091.387, Davis, L. et al, U,s. Patent 4~420~485, all of which are incorporated by reference, and Parham et al, Journal of Or~anic Chemi~try, 41, 2628 (1976)), deprotection of the piperidine nitrogen is carried out by treatment with acid, for example trifluoroacetic acid, followed by protection as the trifluoroacetamide, and the product is WO 94/29309 ~ 1 ~ 3 q q 5 PCT/US94/05545 exposed to hydrazoic acid in the presence of sulfuric acid. Heating of this mixture effects a Schmidt rearrangement, to provide both the tetrahydroquinoline and the tetrahydroisoquinoline derivatives. These spiro compounds can then be separated and coupled to functionalized 5 aldehydes by the methodology given above.
--N Ot-Bu CF3C02H o~J
HN3, H2S04 rt to 45 deg C
--NH --NH
~~J + HN J
HN`~
Neurokinin antagonists with ether substituents can also be prepared by the route shown in Scheme 11. Thus, the allyl acid discussed earlier can be reduced to the corresponding alcohol with, for example, lithium aluminum hydride. This alcohol can be alkylated by a Williamson ether 30 synthesis, by deprotonation with a strong base such as sodium hydride or sodium hexamethyldisilazide followed by reaction with a benzyl halide such as benzyl bromide. The product can be processed through the oxidative cleavage steps described earlier to provide the aldehyde, which can then be coupled with a spirocycle kunder reductive amination conditions or else by reduction to the corresponding alcohol and conversion to the bromide. the bromide can then be used to alkylate a spirocycle under the conditions detailed above.
OH 4 ~ - OH
R~ R
1 ) OsO4, H20, tBuOH
,, n ~ N-Me-morpholine-N-oxide ~1 2) NalO4, H20, THF
~- ~oJ
2 0 R R' -,~
R
Accordingly in another aspect the invention encompasses a process of making compounds of formula I
21 639q5 X' `W
~Z ~) m as defined above, comprising the steps of:
(a) reacting a compound of formula A
~Q~
X W
~Z~>) m I N
H
A
in a suitable solvent such as acetonitrile or dimethylacetamide with a compound of formula Rl-xl wherein X1 is a leaving group such as bromo, chloro, tosyl or mesyl optionally in the presence of a suitable 2 5 base such as trialkylamine; or (b) reacting a compound of formula A in a second suitable solvent such as methanol or ethanol with a compound of the formula R-CH(O), wherein R-CH2 is R1 as defined above, in the presence of a reducing agent such as sodium cyanoborohydride or hydrogen and a palladium on carbon catalyst; or (c) reacting a compound of formula A in a halocarbon solvent such as methylene chloride with a compound of the formula R-C(O)X2 wherein X2 is a suitable leaving group such as bromo or chloro in the presence of a suitable base such as trialkylamine, to yield a compound of formula I.
3 -(S)-(3 ,4-Dichlorophenvl)-4-(N-(t-butoxycarbonyl)methylamino) butanal A solution of 10 g (41 mmol) of 3-(S)-(3,4-dichloro-phenyl)-4-methylamino-1-pentene in 100 mL of CH2C12 was cooled in an ice bath and treated with 5.8 mL (41 mmol) of triethylamine (Et3N) and 9 g (41 mmol) of di-t-butyl dicarbonate. The cold bath was removed after 5 min and the stirring was continued for 1 h. The reaction mixture was diluted with CH2Cl2 and washed with water, 1.2 15 N HCl, saturated NaHCO3 and brine. The solution was dried over Na2SO4 and concentrated to give 14.58 g of residual oil.
lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) o 1.36 (s, 9H), 2.33 (m, 2H), 2.60 & 2.70 (2s, 3H), 2.8-3.6 (m, 3H), 4.94 (m, 2H), 5.59 (m, lH), 6.9-7.4 (m, 3H).
The residue was dissolved in 80 mL of acetone, 40 mL of t-butanol and 40 mL of water. To this solution 1 mL of osmium tetroxide (4% solution in water) and 5.15 g (44 mmol) of 4-methylmorpholine N-oxide were added. After stirring for 26 h, the reaction was quenched with approximately 5 g of Na2SO3 and 25 concentrated to 25% of the original volume. The residue was partitioned between water and 1:1 ether (Et2o)~ ethyl acetate (EtOAc), the layers were separated and the aqueous layer was extracted with Et2O:EtOAc. Each organic layer was washed with water, brine and dried by filtering through Na2so4. The filtrate was concentrated to 30 afford the crude diol.
A solution of the diol in 120 mL of tetrahydrofuran (THF) and 40 mL of water was treated with 9.42 g (44 mmol) of sodium periodate. After stirring for 2 h, the reaction was diluted with Et2O:EtOAc and washed with water and brine. The organic layer was wo 94/29309 2 1 6 3 9 9 5 PCT/US94/0~545 dried (Na2SO4) and the filtrate was concentrated. The residue was purified by prepLC using 30% EtOAc/hexane to furnish 11.74 g (83%
yield for three steps) of the title compound as a thick oil.
lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) o 1.38 (s, 9H), 2.69 & 2.75 (2s, 3H), 2.6-3.65 (m, SH), 6.95-7.4 (m, 3H), 9.67 (s, lH).
0 1 '-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(t-butoxycarbonyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ~4 '-piperidine) To a solution of 0.76 g (2.2 mmol) of 3-(S)-(3,4-dichlorophenyl)-4-(N-(t-butoxycarbonyl)methylamino)butanal ( from Example 1) in 4 mL of methanol were added 0.608 g (2 mmol) of 1-methane-sulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride and 0.6 g of powdered 4 A molecular sieves. After 15 min a solution of 0.554 g (8.8 mmol) of NaCNBH3 in 8 mL of THF was dropwise added. Some gas evolution was obser~ed. After 2 h, when the reaction was complete by TLC, the mixture was filtered through a pad of celite, the reaction flask and the pad were rinsed with methanol. The filtrate was concentrated to approximately 5 ml and the residue was partitioned between saturated NaHCO3 and Et2o:EtoAc. The organic layer was washed with water, brine and dried over Na2so4. The filtrate was concentrated and the residue was chromatographed on a flash column using a gradient of 49:49:2 to 74:24:2 EtOAc:hexane: triethylamine to furnish 0.94 g (72%) of the title compound as a foam.
lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.37 (s, 9H), 1.6-3.6 (m, 15H), 2.61 & 2.72 (2s, 3H), 2.86 (s, 3H), 3.74 (s, 2H), 6.95-7.4 (m, 7H).
2163~95 1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 ,5-dimethylbenzoyl)(methylamino)) butyl)-1-methanesulfonyl-spiro(indoline-3 .4'-piperidine) Step A: 1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-1-methanesulfonyl-spiro(indoline-3 4'-piperidine) Cold trifluoroacetic acid (TFA, 4 mL) and 0.2 mL of anisole were added to 0.94 g (1.57 mmol) of 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(t-butoxycarbonyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) and the mixture was stirred in an ice bath until all the foam dissolved. After stirring the resulting solution at room temperature for 30 min, it was concentrated in vacuo. The residue was partitioned between 0.5 N NaOH and CH2C12 and the layers were separated. The organic layer was washed with brine, dried over Na2S04 and concentrated to give 0.7 g of foam which was used in the next step without purification.
lH NMR (CDC13, ppm ranges are given because of amide rotomers and line broadening) ~ 1.7-2.7 (m, 10H), 2.64 (s, 3H), 2.88 (s, 3H), 2.9-3.4 (m, SH), 3.70 (s, 2H), 6.8-7.4 (m, 7H).
Step B: 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 4'-piperidine) A solution of 0.12 g (0.52 mmol) of 3,5-dimethylbenzoic acid in 2 mL of CH2C12 containing 1 drop of DMF was treated with 85 ul of oxalyl chloride. (Caution-gas evolution!) After 20 min the solution was concentrated in vacuo and the residue was mixed with 0.2 g (0.4 mmol) of 1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-1-methane-sulfonyl-spiro(indoline-3,4'-piperidine) obtained from Step A, and 0.14 mL (1 mmol) of Et3N in 2 mL of CH2C12. After 1 h the reaction mixture was diluted with CH2C12 and washed with saturated NaHCO3, water, and brine. The CH2C12 solution was dried over Na2SO4, filtered and concentrated. Purification of the residue by prep ~1 639q5 TLC using 2% Et3N/EtOAc afforded 0.238 g (93% yield) of the title compound as a foam.
1H NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.6-2.4 (m, 10H), 2.27 (s, 6 H), 2.6-3.9 (m, 10H), 2.86 (s, 3H), 6.6-7.5 (m, 10H).
The following compounds were prepared by substituting the required acid chloride for 3,5-dimethylbenzoyl chloride in Step B.
1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methylamino)) butyl)-1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Mass Spectrum (FAB) 602 (37Cl + 35Cl isotope), 600 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 ,5-bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-5 spiro(indoline-3 ,4'-piperidine) Mass Spectrum (FAB) 738 (37Cl + 35Cl isotope), 736 (35Cl + 35Cl isotope).
1 '-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 -methylbenzoyl) 2 (methylamino))-butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) 1H NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.6-2.4 (m, 10H), 2.32 (s, 3H), 2.6-3.9 (m, 10H), 2.86 (s, 3H), 6.75-7.5 (m, 1 lH).
25 Mass Spectrum (FAB) 616 (37Cl + 35Cl isotope), 614 (35Cl + 35Cl isotope).
1 '-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 -chlorobenzoyl) (methylamino))-butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-3 piperidine) 1H NMR (CDC13, ppm ranges are given because of amide rotomers and line broadening) o 1.6-2.4 (m, 10H), 2.6-3.9 (m, 10H), 2.86 (s, 3H), 6.75-7.5 (m, 1 lH).
WO 94/29309 2 1 6 3 q 9 5 PCT/US94/05545 Mass Spectrum (FAB) 635 (37Cl + 35Cl isotope), 633 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3 -trifluoromethylbenzoyl) 5 (methyl-amino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 669 (37Cl + 35Cl isotope), 667 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl) (methylamino))-butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.6-2.4 (m, lOH), 2.6-3.9 (m, lOH), 2.86 (s, 3H), 5 6.75-7.5 (m, 1 OH).
Mass Spectrum (FAB) 671 (37Cl + 35Cl isotope), 669 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-trifluoromethylphenylacetyl) 20 (methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 684 (37Cl + 35Cl isotope), 682 (35Cl + 35CI
isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3-isopropyloxyphenylacetyl) 25 (methyl-amino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(benzenesulfonyl) (methylamino))-butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-30 piperidine)lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.65 (m, 3H), 1.8-2.3 (m, 7H), 2.62 (s, 3H), 2.7-3.05 (m, 4H), 2.86 (s, 3H), 3.3 (m, 2H), 3.74 (s, 2H), 7.0-7.7 (m, 12H).
WO 94/29309 2 l 6 3 9 ~ 5 PCT/US94/05545 Mass Spectrum (FAB) 637 (37Cl + 35Cl isotope), 635 (35Cl + 35Cl isotope).
The following compounds were also prepared by using the 5 appropriate acid chloride under the conditions given in Step B above:
1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3,5-difluorobenzoyl)(methyl-amino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Mass Spectrum (FAB) 638(37Cl + 35Cl isotope), 636(35Cl + 35Cl isotope).
1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 -fluoro-5 -(trifluoromethyl)-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Mass Spectrum (CI) 688 (37Cl + 35Cl isotope), 686 (35Cl + 35Cl 5 isotope).
1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-( 1 -naphthoyl)(methylamino))-butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) 1 H NMR (CDCl3, ppm ranges are given because of amide rotomers and 20 line broadening) d Mass Spectrum (FAB) (37Cl + 35Cl isotope), (35Cl + 35Cl isotope).
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(N-(2-chlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3 ,4'-piperidine) 25 Mass Spectrum: 200, 202, 228, 230, 279, 308, 310, 494, 496, 670, 672 (cluster).
1 '-(3-((S)-(3,4-Dichlorophenyl))- 1 -(N-(3-chlorophenylsulfonyl)-(methylamino))-4-butyl)- 1 -methylsulfonyl-spiro(indoline-3 ,4'-3 piperidiIle)Mass Spectrum: 200, 202, 228, 230, 279, 308, 310, 494, 496, 670, 672 (cluster).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-chlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum: 200, 228, 230, 279, 494, 496, 669 (cluster).
1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum: 228, 230, 279, 494, 496, 703, 705 (cluster).
l-Benzvloxycarbonyl-spiro(indoline-3.4'-piperidinium) hydrochloride A solution of 99 g (489 mmol) of 1'-methylspiro(indoline-3,4'-piperidine) (prepared according to Ong, H. H. et al, J. Med. Chem., 1983, 26, 981-986) in 1 L of CH2Cl2 and 82 mL (539 mmol) of Et3N
l5 was cooled to 0-5C with an ice bath and 77 mL (539 mmol) of benzyl chloroformate was added over 30 min keeping the reaction temperature below 10C. After stirring for 2 h 19 mL (136 mmol) of Et3N and 15 mL (105 mmol) of benzyl chloroformate were added since the reaction was incomplete and stirred for 2 h. At this time, additional 19 mL (136 20 mmol) of Et3N and 15 mL (105 mmol) of benzyl chloroformate were added. After 1 h, when a TLC indicated a complete reaction, the solution was concentrated in vacuo and the residue was partitioned between ether and saturated NaHCO3. The layers were separated, the organic layer was washed with saturated NaHCO3 and brine, and dried 25 over MgSO4. The filtrate was concentrated and the residue was chromatographed on 2 kg of silica gel using 1-5% MeOH/CH2Cl2 to obtain 117 g (71 %) of 1 -benzyloxycarbonyl- 1 '-methylspiro(indoline-3,4'-piperidine) as a yellow oil.
The yellow oil was dissolved in 800 mL of 1,2-30 dichloroethane and cooled in ice bath as 50 mL (463 mmol) of 1-chloroethyl chloroformate keeping the tempera~ure below 10C. The resulting solution was heated to reflux. Gas evolution was noticed when the reaction temperature reached 70-75C. After 1 h the solution was cooled, concentrated to ca. 250 mL in vacuo and 700 mL of methanol WO 94/29309 2 1 6 3 ~ 9 5 PCT/US94/05545 was added. The mixture was refluxed for 1.5 h and gas evolution was observed. The reaction was cooled to room temperature and concentrated in vacuo to a wet solid. The solid was slurried with cold methanol, the solid was filtered, washed with cold methanol and dried.
5 The filtrates and the washing were combined and concentrated to a brown foam. The brown foam and the filtered solid were suspended in CH2Cl2, washed with 2.5 N NaOH and the CH2Cl2 solution was dried.
The residue was chromatographed on 2 kg of silica gel using a gradient of 94:5:1 to 89:10:1 CH2Cl2, methanol, NH40H to isolate 91.3 g of free base as a brown oil. The oil was dissolved in 1 L of EtOAc by adding methanol (ca. 10 mL) and HCl gas was passed through the solution.
After stirring the acidic solution for 10 min, it was concentrated to a foam. The foam was triturated with ether and the solid was filtered, washed with more ether and dried to furnish 91.5 g (73%) of title 5 compound as a light yellow solid.
EXAMPLE S
3 -((S)-(3 ,4-Dichlorophenyl))-4-((3 ,5 -dimethylbenzoyl)methylamino)-20 butanal The title compound was prepared using the proceduresdescribed in Example 1 by substituting 3,5-dimethylbenzoyl chloride for di-t-butyl dicarbonate.
lH NMR (CDCl3, ppm ranges are given because of amide rotomers and 25 line broadening) ~ 2.27 (s, 6H), 2.6-3.9 (m, 8H), 6.5-7.5 (m, 6H), 9.73 (s, lH).
1 '-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 ,5 -dimethylbenzoyl)(methyl-3 amino))butyl)- 1 -benzyoxycarbonyl-spiro(indoline-3 ~4'-piperidine) The title compound was prepared from 3-((S)-(3,4-dichlorophenyl))-4-((3,5-dimethylbenzoyljmethylamino)butanal (Example S) and 1-benzyloxycarbonyl-spiro(indoline-3,4'-21 63q~5 piperidinium) hydrochloride (Example 4) following the procedure of Example 2.
lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.6-2.35 (m, 10H), 2.27 (s, 6H), 2.6-3.9 (m, 10H), 5.23 & 5.3 (2 s, 2H), 6.6-7.6 (m, 15H).
Mass Spectrum (FAB) 686 (37Cl + 35Cl isotope), 684 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) (methylamino))butyl )-spiro(indoline-3,4'-piperidine) To a solution of 1.23 g (1.8 mmol) of 1'-(3-((S)-(3,4-dichlorophenyl))-4-(3,5-dimethylbenzoyl(methylamino))butyl)- 1 -benzyoxycarbonyl-spiro(indoline-3,4'-piperidine) (Example 6) in 10 mL of ethanol and 0.8 mL of acetic acid (HOAc) was added 0.15 g of 10% Pd/C. The resulting mixture was hydrogenated on a Parr apparatus for 20 h. The catalyst was filtered and washed with EtOH.
The combined filtrate was concentrated in vacuo and the residue was dissolved in CH2Cl2. The CH2Cl2 solution was washed with dilute (ca 0.5 N) NaOH and brine, and dried by filtering through Na2SO4. The filtrate was concentrated to furnish 1.03 g (quantitative) of the title compound as a foam which was used in the next reaction without purification.
1H NMR (CDCl3, ppm ranges are given because of amide rotomers and 2s line broadening) ~ 1.6-2.45 (m, 10H), 2.27 (s, 6H), 2.6-3.9 (m, 10H), 6.5-7.5 (m, 10H).
Mass Spectrum (FAB) 552 (37Cl + 35Cl isotope), 550 (35Cl + 35Cl isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl) (methylamino))butyl)- 1 -acetvl-spiro(indoline-3.4'-piperidine) 2~ 63~5 Acetyl chloride (16 uL) was added to a solution of 0.1 g (0.18 mmol) of 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)-spiro(indoline-3,4'-piperidine) (Example 7) in 4 mL of CH2Cl2 containing 30 mL of pyridine. After stirring for 5 2 h, the reaction mixture was diluted with CH2Cl2 and washed with saturated NaHCO3, water, brine and dried. ~he residue after concentration of the filtrate was purified by prep TLC using 5%
Et3N/EtOAc as an eluent to afford 90 mg (84%) of the title compound.
lH NMR (CDCl3, ppm ranges are given because of amide rotomers and line broadening) ~ 1.55-2.5 (m, 10H), 2.22 (s, 3H), 2.27 (s, 6H), 2.6-3.9 (m, 10H), 6.6-7.5 (m, 9H), 8.17 (d, lH, J = 12Hz).
Mass Spectrum (FAB) 594 (37Cl + 35Cl isotope), 592 (35Cl + 35Cl isotope).
The following analogs were prepared by substituting the appropriate acylation reagent for acetyl chloride in the above procedure.
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl)(methyl-amino))butyl)- 1 -propionyl-spiro(indoline-3,4'-piperidine) 20 Mass Spectrum (FAB) 608 (37Cl + 35Cl isotope), 606 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) (methylamino)) butyl)-1-formyl-spiro(indoline-3,4'-piperidine) 25 Mass Spectrum (FAB) 580 (37Cl + 35Cl isotope), 578 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl) (methylamino)) butyl)-1-t-butylcarbonyl-spiro(indoline-3,4'-piperidine) 30 Mass Spectrum (FAB) 636 (37Cl + 35Cl isotope), 634 (35Cl + 35Cl isotope).
WO 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl) (methylamino)) butyl)-1-methylaminocarbonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 609 (M+H, 37Cl + 35Cl isotope), 607 (M+H, 5 35Cl + 35CI isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) (methylamino)) butyl)-1-ethoxycarbonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 624 (37CI + 35Cl isotope), 622 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) (methylamino)) butyl)-1-ethanesulfonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 643 (37Cl + 35Cl isotope), 641 (35Cl + 35Cl l 5 isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl) (methylamino)) butyl)-l-i-propanesulfonyl-spiro(indoline-3,4'-piperidine) 20 Mass Spectrum (FAB) 657 (37Cl + 35Cl isotope), 655 (35Cl + 35Cl isotope).
The following compound can also be prepared under the conditions given above:
25 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-fluoro-5-(trifluoromethyl)-benzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) (CI) 652 (37Cl + 35Cl isotope), 650 (35Cl +35Cl isotope).
An alternative method (method B) is given below:
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl)(methyl-amino))butyl)- l -acetyl-spiro(indoline-3,4'-piperidine) l -Acetyl-spiro(indoline-3,4'-piperidine) 2 T ~3~5 Acetyl chloride (1.4 mL, 19.9 mmol) was added to a solution of 5.35 g (16.6 mmol) of 1'-benzyloxycarbonyl-spiro(indoline-3,4'-piperidine) in 33 mL of CH2Cl2 and 3.2 mL (23.2 mmol) of Et3N
5 keeping the temperature between 0-5C by cooling in ice bath. After 10 min the cold bath was removed and reaction was stirred for 30 min at which time a TLC indicated complete reaction. The solution was diluted with CH2Cl2 and washed with water, brine and dried over Na2SO4. The filtrate was concentrated to a thick oil and the oil was dissolved in 40 mL of EtOH. Acetic acid (3 mL) and 0.8 g of 10%
Pd/C were added to the solution and the resulting mixture was hydrogenated on a Parr apparatus for 3 h. The catalyst was filtered and washed with EtOAc and the combined filtrate was concentrated. The residue was partitioned between CH2Cl2 and water and 2N NaOH was 5 added to this mixture until the aqueous layer was basic. The layers were separated and the aqueous layer was extracted with CH2Cl2. The combined organic layer was washed with brine, dried over Na2SO4 and the filtrate was concentrated to give 2.93 g (77%) of the title compound sufficiently pure for use in the next reaction.
1 '-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 ,5 -dimethylbenzoyl)(methyl-amino)) butyl)-1-acetyl-spiro(indoline-3.4'-piperidine) To a solution of 0.284 g (0.75 mmol)of 3-((S)-(3,4-dichlorophenyl))-4-(N-(3 ,S -dimethylbenzoyl)(methylamino))butanal 25 (Example 5) in 2 mL of MeOH were added 0.166 g (0.72 mmol) of 1-acetyl-spiro(indoline-3,4'-piperidine), 0.5 g of powdered 4 A molecular sieves and 10 drops (ca. 0.1 mL) of acetic acid. After stirring the mixture for 1.5 h a solution of 0.189 g (3 mmol) of NaCNBH3 in 3 mL
of THF was added. Some gas evolution was observed. After 30 min 30 when the reaction was complete by TLC the mixture was filtered through a pad of celite, the reaction flask and the pad were rinsed with MeOH. The filtrate was concentrated to approximately 3 mL and the residue was diluted with EtOAc. The EtOAc solution was washed with water, brine and dried over Na2so4. The filtrate was concentrated and 21 639~5 the residue was chromatographed on a flash column using 50% EtOAc-hexane followed by 2% Et3N-EtOAc and finally 93:5:2 EtOAc: MeOH:
Et3N to isolate 0.317 g (74%) of the title compound as a white foam.
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(3,5-dimethylbenzoyl(methylamino)) butyl)- 1 '-methyl- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidinium) iodide A solution of 53 mg (0.084 mmol) of 1'-(3-((S)-(3,4-dichlorophenyl))-4-(3,5-dimethylbenzoyl(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) in 5 drops of MeOH
was diluted with 1 mL of ether and 0.5 mL of methyl iodide was added.
The reaction mixture was stirred overnight while a solid was formed.
5 The yellowish solid was allowed to settle and the supernatent was removed. The solid was washed with ether and dried to furnish 51 mg (78%) of the title compound.
1'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(3-methylbenzoyl) (methyl-amino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 2s Step 1: N-Methoxy-N-methyl-2-(S)-(3,4-dichlorophenyl)-4-pentenamide A mixture of 306 mg (1.25 mmol) of (2S)-(3,4-dichlorophenyl)-4-pentenoic acid (prepared according to the procedure of Hale, J.J.; Finke, P.E.; MacCoss, M. Bioorganic & Medicinal 30 Chemistry Letters 1993,3, 319-322) and 202 mg (1.50 mmol) of 1-hydroxybenzotriazole hydrate in 10 mL of methylene chloride was cooled to 0C and treated with 287 mg (1.50 mmol) of 1-(3-dimethyl-aminopropyl)-3-ethylcarbodiimide. The cooling bath was removed and after 45 min. a solution of 365 mg (3.75 mmol) of N,O-dimethyl-~163~5 hydroxylamine hydrochloride and 522 ~1 (3.75 mmol) of triethylamine in 10 mL of methylene chloride was added via cannula. The mixture was then stirred at 22C for 4 hours and then quenched with 10 mL of water and diluted with 8 mL of methylene chloride. The layers were 5 separated and the aqueous layer was extracted with methylene chloride (2 x 10 mL). The combined organic layers were washed with 10 mL of brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 75 g of silica gel using 1:9 v/v ethyl acetate/ hexane as the eluant afforded 319 mg (89%) of the title o compound as a clear oil.
lH NMR (400 MHz, CDCl3) ~ 2.40 (pentet, lH), 2.75 (pentet, lH), 3.13 (s, 3H), 3.52 (s, 3H), 3.99-4.01 (m, lH), 4.96-5.05 (m, 2H), 5.63-5.70 (m, lH), 7.15 (dd, lH), 7.35 (d, lH), 7.41 (d, lH).
Mass Spectrum (FAB): m/z 290 (M+H, 37Cl + 35Cl isotope, 50%), 288 5 (M+H, 37Cl + 37Cl isotope, 100%).
Step 2: 3-(S)-(3.4-dichlorophenyl)-5-hexen-2-one A solution of 319 mg (1.11 mmoL) of N-methoxy-N-methyl-2-(S)-(3,4-dichlorophenyl)-4-pentenamide (from Step 1 above) 20 in 10 mL of dry tetrahydrofuran was cooled to -70C and treated with 1.0 mL (1.40 mmol) of methyllithium and stirred between -70C to -40C. After 3 hours, the reaction was quenched with 5 mL of water, and diluted with 10 mL of ethyl acetate. The layers were separated and the organic layer was washed with water (3 x 10 mL). The aqueous 25 layers were extracted with 10 mL of ethyl acetate. The combined organic layers were washed with 10 mL of saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 44 g of silica gel using 1:3 v/v ethyl acetate/hexane as the eluant afforded 250 mg (93%) 3 of the title compound as a clear oil.
lH NMR (400 MHz, CDCl3) o 2.07 (s, 3H), 2.36 (pentet, lH), 2.72 (pentet, lH), 3.64 (t, lH), 4.95-5.01 (m, 2H), 5.55-5.65 (m, lH), 7.03 (dd, lH), 7.30 (d, lH), 7.39 (d, lH).
2 1 639q5 Mass Spectrum (FAB): m/z 245 (M+H, 37Cl + 35Cl isotope, 30%), 243 (M+H, 37Cl + 37Cl isotope, 50%), 155 (60%), 119 (100%).
Step 3: N-Methyl 3-(S)-(3,4-dichlorophenyl)-5-hexen-2-(RS)-amine A mixture of 102 mg (0.42 mmol) of 3-(S)-(3,4-dichlorophenyl)-5-hexen-2-one (from Step 2 above), 170 mg (2.52 mmol) of methylamine hydrochloride, and 234 ,ul (1.68 mmol) of triethylamine in 4.0 mL of methanol was treated with 16 mg (0.25 mmol) of sodium cyanoborohydride and stirred at 22C for 20 hours.
Saturated aqueous sodium bicarbonate solution (1.0 mL) was added and the resulting milky mixture was diluted with 5.0 mL of ethyl acetate and 5.0 mL of water. The layers were separated and the organic layer was washed with water (3 x 5 mL). The aqueous layers were extracted with 10 mL of ethyl acetate. The combined organic layers were washed with 10 mL of saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 42 g of silica gel using 10:1 v/v ether/ hexane as the eluant afforded 64 mg of the higher Rf isomer (Isomer A) and 22 mg of a lower Rf isomer (Isomer B) both as yellow oils.
lH NMR (400 MHz, CDCl3); Isomer A: o 1.04 (d, 3 H), 2.29-2.35 (m, 4 H), 2.50-2.68 (m, 3H), 4.86-4.95 (m, 2H), 5.48-5.56 (m, lH), 7.01 (dd, lH), 7.26 (d, lH), 7.34 (d, lH); Isomer B: ~ 0.86 (d, 3H), 2.32-2.50 (m, 4H), 2.51-2.53 (m, lH), 2.68-2.73 (m, 2H), 4.88-4.98 (m, 2H), 5.54-5.61 (m, lH), 6.97 (dd, lH), 7.22 (d, lH), 7.33 (d, lH).
Mass Spectrum (Isomer A) (FAB): m/z 260 (M+H, 37Cl + 35Cl isotope, 70%), 258 (M+H, 35Cl + 35Cl isotope, 100%).
Step 4: N-Methyl-N-t-butoxycarbonyl-3-(S)-(3,4-dichlorophenyl)-5 -hexen-2-(RS )-amine A solution of 1.1 g (4.1 mmol) of N-methyl-(3-(S)-(3,4-dichlorophenyl)-5-hexen-2-(R or S)-amine (Isomer B *om Step 3 above) in lO mL of dry methylene chloride was cooled to 0C and treated with 690 ~l (5.0 mmol) of triethylamine and 1.2 g (5.3 mmol) WO 94/29309 2 1 6 3 ~ 9 5 PCT/US94/05545 of di-tert-butyl dicarbonate. The cooling bath was removed and the reaction was stirred at 22C for 20 hours. The reaction was quenched with 10 mL of water and diluted with 25 mL of methylene chloride.
The layers were separated and the aqueous layer was extracted with 5 methylene chloride (2 x 10 mL). The combined organic layers were washed with 15 mL of brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 72 g of silica gel using 1 :3 v/v ethyl acetate/ hexane as the eluant afforded 1.4 g (95%) of the title compound as a yellow oil.
o l H NMR (400 MHz, CDCl3, ranges are given due to amide rotamers and line broadening) ~ 1.24-5.70 (22H), 6.88-7.40 (3H), 1.50 (s, 3H, N-CH3).
Mass Spectrum (FAB): m/z 358 (M+H, 37CI + 35Cl isotope, 30%), 302 (100%).
Step 5: N-Methyl-N-t-butoxycarbonyl-3-(S)-(3,4-dichlorophenyl)-4- (RS ) -amino-pentanal A solution of 1.4 g (3.9 mmol) of N-methyl-N-t-butoxy-carbonyl-3-(S)-(3,4-dichlorophenyl)-5-hexen-2-(RS)-amine (from Step 4 above) in 20 mL of 2:1:1 v/v/v acetone/t-butanol/water was treated with 30 mg (0.12 mmol) of osmium tetroxide. After 5 min., 691 mg (5.90 mmol) of N-methylmorpholine N-oxide was added and the resulting mixture was stirred at 22C for 4 hours. The reaction was quenched with 491 mg of sodium bisulfite and concentrated in vacuo to 25% of the original volume. The residue was partitioned between 20 mL of methylene chloride and 10 mL of water and the layers were separated. The aqueous layer was extracted with methylene chloride (2 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.
A solution of the crude diol in 24 mL of 3:1 v/v tetrahydrofuran/water was treated with 1.1 g (5.1 mmol) of sodium periodate and stirred at 22C for 20 hours. The reaction mixture was partitioned between 20 mL of ethyl ether and 10 mL of water and the layers were separated. The organic layer was washed with water (2 x 2 1 639~5 15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 68 g of silica gel using 4:1 v/v ethyl ether/hexane as the eluant afforded 372 mg of the higher Rf isomer (Isomer A) and 879 mg of a lower Rf isomer (Isomer B) both as 5 yellow oils.
1H NMR (400 MHz, CDCl3) Isomer B: o 1.19-1.34 (m, 13H), 2.45 (s, 3H, N-CH3), 2.68-2.81 (m, 2H), 3.28-3.34 (m, lH), 4.20-4.50 (m, lH), 6.98-7.32 (m, 3H), 9.60 (s, lH, -CHO).
Mass Spectrum (Isomer B) (FAB): m/z 360 (M+H, 37Cl + 35Cl isotope, 20%), 242 (100%).
Step 6: 1'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(t-butoxy-carbonyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ~4'-piperidine) A mixture of 217 mg (0.60 mmol) of N-methyl-N-t-butoxycarbonyl-3-(S)-(3,4-dichlorophenyl)-4-(RS)-amino-pentanal (from Step 5 above) and 262 mg (0.86 mmol) of 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride in 13 mL of methanol was treated with 115 mg (1.83 mmol) of sodium cyanoborohydride and 20 stirred at 22C for 20 hours. Saturated sodium bicarbonate solution (1.0 ml) was added and the resulting milky mixture was concentrated to 50% of its original volume. The residue was partitioned between 25 mL of ethyl acetate and 15 mL of water and the layers were separated.
The organic layer was washed with water (3 x 10 mL). The aqueous 25 layers were extracted with 20 mL of ethyl acetate. The combined organic layers were washed with 15 mL of brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromato-graphy on 42 g of silica gel using 5:95 v/v methanol/methylene chloride as the eluant afforded 329 mg (89%) of the title compound as a white 30 foam.
1H NMR (400 MHz, CDCl3, ranges are given due to amide rotamers and line broadening) ~ 1.20-2.90 (31H), 3.74 (s, 3H, N-SO2CH3), 7.05-7.41 (m, 8H).
21 63',q5 Mass Spectrum (FAB): m/z 612 (M+H, 37Cl + 35Cl isotope, 70%), 610 (M+H, 37Cl + 37Cl isotope, 100%).
Step 7: 1'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) To a solution of 329 mg (0.54 mmol) of 1'-(3-(S)-(3,4-dichlorophenyl)-4-N((R or S)-(t-butoxycarbonyl) (methylamino))pentyl) 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) (from Step 6 above) in 8.0 mL of dry methylene chloride at 0C was added 117 ~l (1.1 mmol) of anisole and 2.0 mL of trifluoroacetic acid. The cooling bath was removed and the reaction was stirred at 22C for 20 minutes. The reaction was concentrated in vacuo. The residue was partitioned between 10 mL of methylene 5 chloride and 5.0 mL of water. The organic layer was washed with 2N
NaOH (3 x 5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 42 g of silica gel using 5:95:0.5 v/v/v methanol/methylene chloride/ammonium hydroxide as the eluant afforded 221 mg (80%) of the title compound as a clear 20 oil.
1H NMR (400 MHz, CDCl3) ~ 1.05 (d, 3H, J = 6.2Hz), 1.62-2.85 (m, 17H), 2.30 (s, 3H, N-CH3), (7.03-7.37 (m, 7H).
Mass Spectrum (FAB): m/z 512 (M+H, 37Cl + 35Cl isotope, 70%), 510 (M+H, 37Cl + 37Cl isotope, 100%).
Step 8: 1'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(3-methyl-benzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline -3.4' -piperidine) The title compound was prepared from 1'-(3-(S)-(3,4-30 dichlorophenyl)-4-(R or S)-(methylamino)pentyl)-1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) (from Step 7 above) using a procedure identical to Example 3, Step (b), substituting m-toluoyl chloride for 3,5-dimethylbenzoyl chloride.
WO 94/29309 ~ 1 6 3 9 9 5 PCT/US94/05545 lH NMR (400 MHz, CDCl3, ranges are given due to amide rotamers and line broadening) ~ 1.42 (â, 3H, J = 6.7Hz), 1.60-2.30 (16H), 2.54 (s, 3H, Ph-CH3), 2.87 (s,3H, N-CH3),3.74 (s, 3H, N-SO2CH3),7.05-7.79 (m, 1 lH).
Mass Spectrum (FAB): m/z 630 (M+H,37Cl + 35Cl isotope,70%), 628 (M+H, 37Cl + 37Cl isotope, 100%).
1'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(3,5-bis(trifluoromethyl)-benzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) The title compound was prepared from 1'-(3-(S)-(3,4-dichlorophenyl)-4-(R or S)-(methylamino)pentyl)-1-methanesulfonyl-15 spiro(indoline-3,4'-piperidine) (from Example 1, Step 7 above) using a procedure identical to Example 3 Step (b), substituting 3,5-bis(trifluoromethyl)benzoyl chloride for 3,5-dimethylbenzoyl chloride.
lH NMR (400 MHz, CDCl3, ranges are given due to amide rotamers and line broadening) ~ 1.38-3.00 (22H), 3.74 (s, 3H, N-SO2CH3), 6.40-7.41 (m, lOH).
Mass Spectrum (FAB): m/z 752 (M+H,37Cl + 35Cl isotope, 40%),750 (M+H, 37Cl + 37Cl isotope, 60%), 241 (100%).
1'-(3-(S)-(3,4-Dichlorophenyl)-4-(R or S)-(3,5-dimethylbenzoyl(methyl-amino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ~4'-piperidine) The title compound was prepared from 1'-(3-(S)-(3,4-dichlorophenyl)-4-(R or S)-(methylamino)pentyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine) (from Example 1, Step 7 above) using a procedure identical to Example 3, Step (b).
21 63~5 lH NMR (400 MHz, CDCl3, ranges are given due to amide rotamers and line broadening) â 1.37-2.86 (28H), 3.74 (s, 3H, N-S02CH3), 6.24-7.41 (m, lOH).
Mass Spectrum (FAB): m/z 642 (M+H,37Cl + 35Cl isotope, 70%), 644 (M+H, 37Cl + 37Cl isotope, 100%).
(1'-(3-(S)-(3,4-Dichlorophenyl)-4-(R or S)-(3,5-dichlorobenzoyl-(methylamino))pentyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine) The title compound was prepared from 1'-(3-(S)-(3,4-dichlorophenyl)-4-(R or S)-(methylamino)pentyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine) (from Example 1, Step 7 above) using a procedure identical to Example 3, Step (b), substituting 3,5-dichloro-benzoyl chloride for 3,5-dimethylbenzoyl chloride.
lH NMR (400 MHz, CDCl3, ranges are given due to amide rotamers and line broadening) ~ 1.38-2.93 (22H), 3.73 (s, 3H, N-SO2CH3), 6.53-7.42 (m, lOH).
Mass Spectrum (FAB): m/z 684 (M+H,37Cl + 35Cl isotope,70%), 686 (M+H,37Cl + 37Cl isotope, 100%).
1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-bromo-5-methylbenzoyl)-2 5 (methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3.4'-piperidine) Step A: 3-Bromo-5-methylbenzoic acid To a solution of 0.38 g (1.44 mmol) of 3-bromo-5-methyl-benzyl bromide (prepared by NBS bromination of 3,5-dimethyl-3 bromobenzene) in 22 mL of MeCN and 50 mL of water was added 7.8 mL (28.8 mmol) of agueous sodium hypochlorite (13% active Cl). The mixture was allowed to stand in an ultrasonic cleaning bath for 14 h.
The reaction was acidified with HCl to pH 3 and extracted with CH2Cl2. The organic layer was washed with water, brine and dried WO 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 with Na2SO4. The filtrate was concentrated and the residue which was a mixture of the desired acid and the aldehyde was dissolved in 3 mL of acetone. The solution was treated with 6 N Jones reagent until the orange color persisted. After stirring for 20 min the excess reagent was 5 destroyed by adding few drops of i-PrOH. The solution was diluted with water and extracted with CH2Cl2. The CH2Cl2 layer was washed with brine, dried and the filtrate was concentrated. The residue was purified by prep TLC using 0.5:30:69.5 of HOAc:EtOAc:hexane to isolate 0.14 g (45 %) of 3-bromo-5-methylbenzoic acid.
Step B: 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-bromo-5-methylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3.4'-piperidine) 3-Bromo-5-methylbenzoic acid was used in the acylation 5 reaction according to the procedure of Example 3, Step B to obtain the title compound.
Mass Spectrum (CI) 696 (37Cl + 35Cl isotope), 694 (35Cl + 35Cl isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl)-(methvlamino))butyl)- 1 -(2-aminoacetyl)-spiro(indoline-3.4'-piperidine) A solution of 65 mg (0.31 mmol) of carbobenzyl-2s oxyglycine in 3 mL of CH2Cl2 was treated with 82 mg (0.41 mmol) of1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and 56 mg (0.41 mmol) of 1-hydroxybenzotriazole and 42 mg (0.41 mmol) of N-methylmorpholine. After 10 min 123 mg (0.21 mmol) of 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))-30 butyl)-spiro(indoline-3,4'-piperidine) (Example 7) was added and the reaction was stirred.for 2 h. The mixture was diluted with CH2Cl2 and washed with water, brine, dried and concentrated to give 0.184 g of residue. The residue in 10 drops of HOAc was dissolved in 3 mL of EtOH and the solution was hydrogenated on a Parr apparatus for 16 h.
2 1 639q5 The catalyst was filtered and washed with EtOAc. The filtrate was washed with 10% Na2co3~ brine and concentrated. The residue was purified by prep TLC using 30% MeOH-EtOAc to give 80 mg (59%) of the title compound.
Mass Spectrum (CI) 651 (37Cl + 35Cl isotope), 649 (35Cl + 35Cl isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl)-(methylamino))butyl)- 1 -methyl-spiro(indol-2-one-3,4'-piperidine) Step A: 1.1'-Dimethvl-spiro(indol-2-one-3.4'-piperidine) A solution of 0.1 g (0.68 mmol) of N-methyl-2-oxo-indole in 2 mL of THF was added to a well stirred suspension of 0.14 g (3.4 mmol) of NaH in 2 mL of THF with cooling in ice bath. After the gas evolution had stopped the cold bath was removed and the mixture was heated in a 50C bath for another 15 min. The reaction was allowed to cool to room temperature and 0.68 mL of DMSO was added and more gas evolution was observed. After stirring for 10 min, the reaction mixture was cooled in ice bath and 0.144 g of mechloreth~mine hydro-chloride was added. The mixture was warmed to room temperature and stirred overnight. Next morning, the reaction was quenched with water and extracted with EtOAc. The EtOAc extact was washed with brine, dried with Na2so4 and filtered. The filtrate was concentrated and the residue was purified by prep TLC using 89:10:1 EtOAc:MeOH:Et3N to furnish 25 mg (15%) of the title compound.
Step B: l-Methyl-spiro(indol-2-one-3.4'-piperidine) A solution of 25 mg (0.11 mmol) of 1,1'-dimethyl-spiro(indol-2-one-3,4'-piperidine) (from Step A above) in 1 mL of dry dichloroethane was treated with 0.023 mL (0.22 mmol) of 1-chloroethyl chloroformate (ACECl) under a dry N2 atmosphere. After 30 min at room temperature, the solution was kept in a 50C bath for 30 min.
The reaction mixture was cooled to room temperature, 2 mL of MeOH
was added and reheated to 60C. After 30 min the solution was cooled WO 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 and concentrated in vacuo. The residue was partitioned between water and EtOAc and the aqueous phase was adjusted to pH 9 by adding lN
NaOH. The layers were separated and the combined EtOAc solution was washed with brine and dried. The filtrate upon concentration gave 5 34 mg of a residue which was a mixture of the desired compound and the starting material, but was sufficiently pure to be used in the next reaction.
Step C: 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -methyl-spiro(indol-2-one-3 4'-piperidine) A reaction of 49 mg (0.13 mmol) of 3-((S)-(3,4-dichloro-phenyl))-4-(N-(3,5-dimethylbenzoyl)methylamino)butanal (Example 5) with 34 mg of impure 1-methyl-spiro(indol-2-one-3,4'-piperidine) 5 (from Step B) according to the procedure of Example 8, method B
furnished 32 mg of the title compound after purification by prep TLC.
Mass Spectrum (CI) 580 (37Cl + 35Cl isotope), 578 (35Cl + 35Cl isotope).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)-(methylamino))butyl)- 1 -methyl-spiro(isoindol- 1 -one-3.4'-piperidine) Mass Spectrum (CI) 622 (37Cl + 35Cl isotope), 620 (35Cl + 35Cl 25 isotope).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl)-3 (methylamino))butyl)-spiro(2-oxo-tetrahydroquinoline-4.4'-piperidine) Step A: l'-Trifluoroacetyl-spiro(1-indanone-3.4'-piperidine) Cold trifluoroacetic acid (15 mL) and 0.6 mL of anisole were added to 2 g (6.6 mmol) of 1'-t-butoxycarbonyl-spiro(1-indanone-21 63~95 3,4'-piperidine) and the resulting solution was stirred in ice bath for lh.
The reaction mixture was concentrated in vacuo and the residue was partitioned between CH2cl2 and 0.5 N NaOH. The organic layer was washed with brine, dried with Na2so4 and concentrated. The residual orange oil was dissolved in 10 mL of CH2cl2 and 1.92 mL (13.7 mmol) of Et3N, 1 mL (7.1 mmol) of trifluoroacetic anhydride and 3 crystals of DMAP were added. After stirring for 4 h, the reaction mixture was diluted with CH2Cl2 and washed with water, brine and dried. The solution was filtered and the filtrate was concentrated to yield 2.0 g (quantitative) of the desired product as a solid.
lH NMR (CDCl3) ~ 1.65 (d, 2H, J=14Hz), 2.05 (m, 2H), 2.67 (ABq, 2H), 2.89 (m, lH), 3.28 (m, lH), 4.1 l(d, lH, J=14Hz), 4.67 (dt, lH, J=14 and 2Hz), 7.5-7.8 (m, 4H).
Step B: 1'-Trifluoroactyl-spiro-(2-oxo-1,2,3,4-tetrahydro-quinoline-4,4'-piperidine) and 1'-trifluoroactyl-spiro-(1-oxo- 1~2~3 .4-tetrahvdroisoquinoline-4.4'-piperidine) To a mixture of 1.09 g (16.8 mmol) of Sodium azide in 1.2 mL of water and 6.6 mL of CHCl3 was added 0.46 mL of concentrated H2SO4 (36 N) keeping the temperature between 0-5C. (Caution!) After 10 min the cold bath was removed and the reaction was stirred for 3 h, at which time the CHCl3 layer was separated from the aqueous layer. The CHCl3 layer containing HN3 was dried and the filtrate was added to a solution of 2 g (6.7 mmol) of 1'-trifluoroacetyl-spiro(1-2s indanone-3,4'-piperidine) (from Step A) in 7 mL of CHCl3.
Concentrated H2SO4 (1.8 mL) was added to this solution and the reaction was allowed to age for 30 min. The mixture was heated in a 45C bath for 45 min and then stirred at room temperature for 16 h.
Next morning, the reaction mixture was poured into ice and the layers were separated. The aqueous layer was neutralized with aq. NaOH and extracted with EtOAc. The combined organic phases were washed with brine, dried and concentrated. The residue was chromatographed using 50-80% EtOAc-CH2Cl2 to isolate 0.34 g (16%) of 1'-trifluoroactyl-spiro(2-oxo-1,2,3,4-tetrahydroquinoline-4,4'-piperidine) and 0.13 g of WO 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 1 '-trifluoroactyl-spiro(1 -oxo- 1,23,4-tetrahydroisoquinoline-4,4'-piperidine). In addition, 0.72 g (36%) of the starting indanone was recovered.
lH NMR (CDCl3) Isomer A: ~ 1.82 (m, 2H), 1.96 (m, 2H), 2.75 (ABq, 2 H, J=14Hz), 3.16 (t, lH), 3.46 (t, lH), 3.9 (d, lH), 4.42 (d, lH), 6.8-7.3 (m, 4H), 8.49 (br s, lH); Isomer B: ~ 1.9-2.1 (m, 4H), 3.09 (t, lH), 3.42 (m, lH), 3.61 (ABq, 2H), 3.94 (d, lH), 4.45 (d, lH), 6.72 (br s, lH), 7.3-7.6 (m, 3H), 8.11 (d, lH).
Step C: Spiro-(2-oxo-1.2.3.4-tetrahydroquinoline-4.4'-piperidine) To a solution of 0.3 g (0.97 mmol) of 1'-trifluoroacetyl-spiro-(2-oxo-1,2,3,4-tetrahydroquinoline-4,4'-piperidine) (from Step B) in 4 mL of MeOH was added 0.16 g (2.9 mmol) of KOH in 1 mL of water. After stirring the reaction for 16 H the solution was 15 concentrated and the residue was partitioned between EtOAc and water.
The EtOAc layer was washed with brine, dried with Na2SO4 and concentrated to give 0.16 g (76%) of the title compound as a white solid.
lH NMR (CDCl3) ~ 1.6-2.0 (m, 4H), 2.72 (s, 2H), 2.95 (m, 4H), 6.7-20 7.4 (m, 4H), 8.4 (br s, lH).
Step D: 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)-spiro(2-oxo-tetrahydro-quinoline-4.4'-piperidine) The title compound was obtained by reductive ~min~tion of 3 -((S)-(3,4-dichlorophenyl))-4-((3,5-dimethylbenzoyl)methylamino)-butanal (Example 5) by spiro-(2-oxo-1,2,3,4-tetrahydroquinoline-4,4'-piperidine) obtained in Step C according to the procedure of Example 8, method B.
30 Mass Spectrum (CI) 580 (37Cl + 35Cl isotope), 578(35Cl + 35Cl isotope).
WO 94/29309 21 6 3~ q 5 PCT/US94/05545 1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 ,5-dichlorobenzoyl)(methyl-amino))butyl)- 1 -methyl-spiro(2-oxo-tetrahydroquinoline-4,4'-5 piperidine) Step A: 1-Methyl-spiro-(2-oxo-1,2,3,4-tetrahydroquinoline-4,4'-piperidine) To a solution of 0.15 g (0.48 mmol) of 1'-trifluoroacetyl-spiro-(2-oxo-1,2,3,4-tetrahydroquinoline-4,4'-piperidine) (from Example 18, Step B) in 1.7 mL of DMF was added 19 mg (0.77 mmol) of 95% NaH at 0C. After 15 min 0.063 mL (1 mmol) of methyl iodide was added and the reaction was allowed to warm to room temperature.
After stirring for 16 H the reaction was not complete, so an additional 5 0.015 mL of methyl iodide was added and the solution was heated in a 45C bath. After 2 H the reaction was cooled to room temperature and partitioned between EtOAc and water. The EtOAc layer was washed with brine, dried and the filtrate was concentrated. The residue was purified by prep TLC using 33% EtOAc-hexane to provide 1-methyl-2 1 '-trifluoroacetyl-spiro-(2-oxo- 1 ,2,3 ,4-tetrahydroquinoline-4,4'-piperidine). Hydrolysis of this trifluoroacetamide as described in Example 55, Step C furnished 71 mg (64%) of the title compound.
lH NMR (CDCl3) â 1.61 (d, 2H), 1.92 (m, 2H), 2.74 (s, 2H), 2.98 (m, 4H), 3.36 (s, 3H), 7.0-7.4 (m, 4H).
2s Step B: 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichloro-benzoyl)(methylamino))butyl)- 1 -methyl-spiro(2-oxo-tetrahydroquinoline-4 ~4'-piperidine The title compound was prepared by reaction of the amine 30 from Step A and 3-((S)-(3,4-dichlorophenyl))-4-((3,5-dichlorobenzoyl)-methylamino)butanal as described in Example 18, Step D.
Mass Spectrum (CI) 636 (37Cl + 35Cl isotope), 634 (35Cl + 35Cl isotope).
WO 94/29309 PCT/US94/05~45 4-Bromo-2-(S)-(4-fluorophenyl)- 1 -(N-(3,5-bistrifluoromethylbenzoyl)methylamino)butane .
Step A: 3-(S)-(4-Fluorophenyl)-4-(N-(3,5-5 bistrifluoromethylbenzoyl)methylamino)butanol.
A solution of 1.67 g (3.84 mmol) of 3-((S)-(4-fluorophenyl)-4-(N-(3,5-(bistrifluoromethyl)benzoyl)(methylamino))butanal (prepared from 4-fluorophenylacetic acid as described by J. Hale et. al., Bioorganic &
10 Medicinal Chemistry Letters 1993,3, 319-322) in 16 mL of absolute ethanol at 0 C was treated with 172 mg (4.55 mmol) of sodium borohydride. After stirring for 1 h at room temperature, the reaction was quenched with saturated NH4Cl and extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried 15 (MgSO4) and evaporated to give 1.59 of residual oil. Purification on a silica gel flash column (30:70 then 50:50 ethyl acetate:hexanes) provided 1.21 g (72%) of the title compound as a viscous oil.
Mass Spectrum (CI/NH3) M+H= 438.
Step B: 4-Bromo-2-(S)-(4-fluorophenyl)- 1 -(N-(3,5-bistrifluoromethylbenzoyl)methylamino)butane.
To a solution of 1.19 g (2.72 mmol) of 3-(S)-(4-fluorophenyl)-4-(N-25 (3,5-bistrifluoromethylbenzoyl)methylamino)butanol in 20 mL of acetonitrile was added 1.49 g (3.53 mmol) of triphenylphosphine dibromide. After 1.5 h the reaction was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (MgSO4) and concentrated to give 2.33 g of crude white solid.
30 Purification on a silica gel flash column (30:70 ethyl acetate:hexanes) gave 944 mg (69%) of the desired bromide as a viscous oil.
Mass Spectrum (CIJNH3) M+H=S00, 502 (79,81Br isotope).
WO 94/29309 PCT/US94/05~45 ~1 63~95 1 '-(3-(S)-(4-Fluorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine).
To 40 mg (0.08 mmol) of the bromide prepared in Example 20, Step B
and 0.21 ul (0.12 mmol) of N,N-diisopropylethylamine in 0.5 mL of acetonitrile was added 37 mg (0.16 mmol) of 1-acetyl-spiro(indoline-3,4'-piperidine). The resultant mixture was heated in a tightly capped vial at 50 C for four days. The solvent was evaporated and the residue was purified on a 1000 micron silica gel prep plate (93:5:2 ethyl acetate:methanol:triethylamine) to furnish 46.6 mg (90%) of the title compound as a white foam.
Mass Spectrum (CIINH3) M+H=650.
The compounds in Examples 22-26 were prepared as in Example 21 from the requisite bromide, prepared from the corresponding 20 phenylacetic acid as described in Example 20, and the required 1-substituted-spiro(indoline-3,4'-piperidine) .
1 '-(3 -(S )-(3 -Chlorophenyl)-4-(N-(3,5 -bistrifluoromethylbenzoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine).
Mass Spectrum (CI/NH3) M+H= 666, 668 (35,37Cl-isotope).
1 '-(3-(S)-(4-Chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine).
Mass Spectrum (CI/NH3) M+H= 666, 668 (35,37Cl-isotope).
1 '-(3-(S)-(3,4-Difluorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine).
Mass Spectrum (CI/NH3) M+H= 668.
l '-(3-(S)-(3,4-Methylenedioxyphenyl)-4-(N-(3,5-20 bistrifluoromethylbenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) .
Mass Spectrum (CI/NH3) M+H=712.
2s l '-(3-(RS)-(3,5-Dichlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-30 (methylamino))butyl)- l -methanesulfonyl-spiro(indoline-3,4'-piperidine).
Mass Spectrum (CI/NH3) M+H=736, 738 (35,37Cl-isotope).
WO 94/29309 PCT/US94/0~54~
2 1~ 6~995 1 '-(3 -(S)-(4-Chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-5 (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine).
The title compound was prepared as in Example 21 from 4-bromo-2-(S)-(4-chlorophenyl)- 1 -(N-(3,5-bistrifluoromethylbenzoyl)methylamino)butane and spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) hydrochloride except that 3 eq.
of diisopropylethylamine were used.
Mass Spectrum (CI/NH3) M+H=641,643 (35,37Cl-isotope).
1 '-(3 -(RS)-(4-Pyridyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-2 o (methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine).
The title compound was prepared from 3-(S)-(4-pyridyl)-4-(N-(3,5-bistrifluoromethyl-benzoyl)methylamino)butanal (prepared from 4-pyridylacetic acid as described by J. Hale et. al., Bioorganic &
25 Medicinal Chemistry Letters 1993,3, 319-322) by reductive amination as described in Example 2.
Mass Spectrum (CVNH3) M+H=633.
1 '-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(ethylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine).
2 1 639~5 Step A: 4-Bromo-2-(S)-(3,4-dichlorophenyl)-1-(N-(3,5-dimethylbenzoyl)methylamino)butane.
The title compound was prepared as in Example 20, Steps A and B, from 3-(S)-(3,4-dichlorophenyl)-4-(N-(3,5-dimethyl-benzoyl)ethylamino)butanal (prepared from 3,4-dichlorophenylacetic acid as described by J. Hale et. al., (Bioorganic & Medicinal Chemistry Letters 1993,3, 319-322) using ethylamine rather than methylamine to form the intermediate amide).
Mass Spectrum (CI/NH3) M = 454, 456 (79,81Br isotope).
Step B: 1'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(ethylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine).
The title compound was prepared from the bromide prepared in Step A
and 1-acetyl-spiro(indoline-3,4'-piperidine) as described in Example 21.
Mass Spectrum (CVNH3) M+H = 641, 643 (35,37Cl-isotope).
2s 5-Fluoro-spiro(2 3-dihydrobenzofuran-3.4'-piperidine) hydrochloride salt Step 1) 4-(2,5-Difluorophenyl)-4-methoxycarbonyl- 1 -methylpiperidine Methyl 2,5-difluorophenylacetate (4.8 g, 26 mmol) and mechloreth~mine hydrochloride (5.0 g, 26 mmol) in DMSO (15 mL) and THF (50 mL) at 0C was carefully treated with NaH (2.5 g, 104 mmol). The reaction was gradually warmed to reflux over 1 h and WO 94129309 2` 1 6 3 9 9 5 PCT/US94/05545 refluxed further for 1 h. The reaction was cooled to 0C, and 6N HCl (25 mL) was slowly added. The reaction was diluted with lN HCl (200 mL) and washed with hexane (200 mL). The aqueous layer was cooled to 0C and adjusted to pH 12 with solid K2co3. The product was extracted with ethyl acetate (200 mL), washed with brine (100 mL), dried (MgSO4), and concentrated to 4.1 g (59%) of the title compound as an oil.
H NMR (400 MHz, CDCl3) ~ 7.34 (dq, lH), 6.88 (m, lH) 6.78 (ddd, lH) 6.69 (minor NMe invertomer, dm), 6.59 (minor NMe invertomer, dd), 3.69 (s, 3H), 3.80 (minor invertomer, s), 2.71 (d, 2H), 2.48 (d, 2H), 2.38 (t, 2H), 2.25 (s, 3H), 2.10 (t, 2H) ppm.
Step 2) 4-(2,5-Difluorophenyl)-4-hydroxymethyl-1-methylpiperidine EtOH (5.1 mL, 86 mmol) was added to 0.5 M LiAlH4 in glyme (82 mL, 41 mmol) at 0C. 4-(2,5-difluorophenyl)-4-methoxycarbonyl- 1 -methylpiperidine (3.45 g, 12.8 mmol) in glyme (4 mL) was added.
Saturated aqueous sodium potassium tartrate (50 mL) was added along with Celite (10 g), and the mixture was mechanically stirred 1 h at room temp. The slurry was filtered, and the organic layer was extracted with lN HCl. The HCl was washed with EtOAc and then basified with 3N NaOH. The product was extracted with CH2Cl2, washed with 20% brine, dried (MgSO4), and concentrated to a crude solid, which was recrystallized (EtOAc) to yield 1.46 g (52%) of the title compound as colorless crystals.
IH NMR (400 MHz, CDC13) ~ 7.28 (dt, lH, J =7,9 Hz), 6.88 (ddd, lH, J=3,9,9 Hz), 6.81 (ddd, J=3,9,13 Hz), 3.76 (s, 2H), 2.59 (m, 2H), 2.32-2.20 (m, 4H), 2.23 (s, 3H), 1.96 (t, 2H, J=5 Hz) ppm.
WO 94129309 2 1 6 3 9 ~ 5 PCT/US94/0554~
Step 3) 5-Fluoro-1'-methyl-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) NaH (158 mg, 6.56 mmol) was added to 4-(2,5-difluorophenyl)-4-hydroxymethyl-1-methylpiperidine (1.45 g, 6.56 mmol) in DMF (20 mL). The slurry was heated to 90C for 6 h. The reaction was diluted with hexane (200 mL), washed with water (200 mL), brine (50 mL), dried (MgSO4), and concentrated to yield 1.21 g (92%) of the title compound as a white crystalline solid;
1H NMR (400 MHz, CDC13) ~ 6.98 (dd, lH), 6.54 (dt, lH), 6.48 (dd, lH), 4.37 (s, 2H), 2.84 (m, 2H), 2.31 (s, 3H), 1.97 (4H, pentuplet), 1.71 (m, 2H) ppm.
Step 4) 5-Fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) hydrochloride salt 5 -fluoro- 1 '-methyl-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine) (1.21 g, 5.48 mmol) in 1,2-dichloroethane (12 mL) at room temp was treated with 2-chloroethyl chloroformate (1 mL, 9 mmol). A white precipitate formed, and the reaction was refluxed 2 h. MeOH (12 mL) was added and refluxing was continued for 2 h. The reaction was concentrated to a crude solid, which was triturated with EtOAc (5 mL) and filtered to yield 1.27 g (95%) of the title compound as a white crystalline solid.
1H NMR (400 MHz, d6-DMSO) ~ 9.12 (s, lH), 9.04 (s, lH), 7.11 (dd, lH), 7.74-7.66 (m, 2H), 4.53 (s, 2H), 3.26 (d, 2H), 2.95 (t, 2H), 2.08 (t, 2H), 1. 79 (d, 2H) ppm.
Reaction of 5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) hydrochloride with 3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butanal according to the procedure WO 94/29309 2 1 6 3 q q 5 PCT/US94/05545 given in Example 8, Method B gave 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-5 -fluoro-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine). Removal of the BOC group and benzamide formation according to the procedure given in Example 3, 5 Steps A and B afforded the compounds listed in Examples 31-36:
l '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl) -(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) 15 Mass spectrum (CI): m/z = 611.2 (35Cl + 35Cl isotope + H+), 613.2 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-5 -fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 609.3 (35Cl + 35Cl isotope + H+), 611.3 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chlorobenzoyl)-(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) WO 94/29309 PCT/US94/0554~
21 639q5 Mass spectrum (CI): m/z = 575.2 (35Cl + 35Cl isotope + H+), 577.2 (37Cl + 35Cl isotope + H+), 579.2 (37Cl + 37Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-S-fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 569.3 (35Cl + 35Cl isotope + H+), 571.3 5 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-methylbenzoyl)-(methylamino))butyl)-5 -fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) 25 Mass spectrum (CI): m/z = 555.3 (35Cl + 35Cl isotope + H+), 557.3 (37Cl + 35Cl isotope + H+).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(benzoyl)-(methylamino))butyl)-S-fluoro-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine) WO 94/29309 2 1 6 3 ~ 9 5 PCT/US94/05545 Mass spectrum (CI): m/z = 541.3 (35Cl + 35Cl isotope + H+), 543.3 (37Cl + 35Cl isotope + H+).
Preparation of spiro(2,3-dihydrobenzofuran-3,4'-piperidine) hydrochloride was carried out by analogy to the procedure given in Example 30, starting with methyl 2-fluorophenylacetate. Reaction of spiro(2,3-dihydrobenzofuran-3,4'-piperidine) hydrochloride with 3-(S)-(3,4-dichlorophenyl)-4-(t-butoxycarbonyl-methylamino)butanal according to the procedure given in Example 8, Step B gave 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine). Removal of the BOC
group and benzamide formation according to the procedure given in 5 Example 3, Steps A and B afforded the compounds listed in Exarnples 37-43:
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(benzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 523.1 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-methylbenzoyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) 2 1 ~3995 Mass spectrum (CI): m/z = 537.2 (35Cl + 35CI isotope + H+), 539.2 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 551.2 (35Cl + 35Cl isotope + H+), 553.2 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chlorobenzoyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) 20 Mass spectrum (CI): m/z = 557.0 (35Cl + 35Cl isotope + H+).
25 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 591.0 (35Cl + 35Cl isotope + H+), 593.1 (37Cl + 35Cl isotope + H+).
WO 94/29309 PCT/US94/05~45 216~5`
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzofuran-3 ,4 '-piperidine) Mass spectrum (CI): m/z = 591.3 (35Cl + 35Cl isotope + H+), 593.2 5 (37Cl + 35Cl isotope + H+).
1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3 ,4'-piperidine) 15 Step 1) 1-t-Butoxycarbonyl-3-hydroxy-4-methylenepiperidine n-Butyl lithium (9.57 mL, 2.45M in hexane, 23.7 mmol) was added to a -78C solution of diisopropylamine (3.32 mL, 23.7 mmol) in THF (15 mL). After 30 min at -78C, methyl phenyl sulfoxide (3.32 g, 23.7 20 mmol) in THF (4 mL) was added. The solution was warmed to 0C and cooled back down to -78C. 1-t-butoxycarbonyl-4-piperidinone (4.69 g, 23.7 mmol) in TH~ (20 mL) was added. The reaction was warmed to room temp, quenched by addition of solid NH4Cl, concentrated in vacuo, and partitioned between H2O (100 mL) and EtOAc (100 mL).
25 The organic layer was washed with H2O (50 mL) brine (50 mL), dried (MgSO4), and concentrated in vacuo. The resultant oil was heated at 80C in t-butanol (50 mL) with potassium t-butoxide (3.4g, 30 mmol) for 2 h. Solid NH4Cl was added, and the reaction was concentrated in vacuo and partitioned between H2O (100 mL) and EtOAc (100 mL).
3 The EtOAc was washed with brine (50 mL), dried (MgSO4 ), concentrated in vacuo and purified by column chromatography (silica gel 60, 0-50% EtOAc/hexane) to yield 4.47 g (79%) of the title compound as a crystalline solid.
WO 94/29309 PCT/US94/0~45 2~ 6~995 lH NMR (400 MHz, DMSO-d6) â 5.21 (d,lH), 4.96 (s, lH), 4.77 (s, lH), 3.82 (t, 2H), 3.67 (dt, lH), 2.83 (dt, lH), 2.77-2.50 (brd d, lH), 2.26 (dt, lH), 2.01 (ddd, lH), 1.38 (s, 9H) ppm.
Step 2) 1-t-Butoxycarbonyl-3,4-didehydro-4-(chloromethyl)piperidine To 1-t-butoxycarbonyl-3-hydroxy-4-methylenepiperidine (5.329 g, 25.1 mmol) in toluene (120 mL) and 2,6-lutidine (3.1 mL, 26 mmol) at 0C
o was added SOCl2 (2.0 mL, 26 mmol). The reaction was heated at 40C
for 30 min, cooled to 0C, washed with 0C lN HCl (100 mL), 0.1 N
HCl (100 mL), H2O (100 mL), brine (50 mL), dried (MgSO4), and concentrated in vacuo to afford 5.18 g (89%) of allylic chloride as a yellow oil.
1H NMR (400 MHz, CDCl3) ~ 5.78 (s, lH), 4.04 (s, 2H), 3.95 (s, 2H), 3.55 (t, 2H, J=6 Hz), 2.24 (s, 2H), 1.45 (s, 9H) ppm.
Step 3) l -t-Butoxycarbonyl-4-((2-bromophenyl)thio)methyl- 1,2,5,6-tetrahydropyridine The allylic chloride (330 mg, 1.43 mmole) was dissolved in acetone (10 mL) and 2-bromothiophenol (172 ml, 1.43 mmole) and K2CO3 (390 mg, 2.86 mmole) were added. The reaction mixture was heated to 60C
for 1 h and then filtered though silica gel ( ether). The organic layer was concentrated in vacuo and purified by column chromatography (silica gel 60, hexanes/ethyl acetate 10/1) to give the title compound in 84% yield (460 mg).
Step 4) l'-t-Butoxycarbonyl-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine).
WO 94/29309 PCT/US94/0554~
21; ~ 39~5 The intermediate adduct from step 3 above (450 mg, 1.17 mmole) was dissolved in benzene (60 mL) and AIBN (10 mg) and tributyltin hydride (644 mL, 2.39 mmole) were added. This mixture was refluxed for 2 h and concentrated. The residue was dissolved in Et2O and Br2 was 5 added until the reaction solution turned to a brownish color. To this brownish solution at room temp was added DBU (650 mL) dropwise.
The resulting cloudy solution was filtered though silica gel and washed with Et2O. The Et2O solution was concentrated and the residue was purified by radial chromatography (silic gel 60, 10/1 hexanes/EtOAc) to give the title compound (157 mg) in 43% yield.
1H NMR (400 MHz, CDCl3) ~ 7.18 (d, 7 Hz, 1 H), 7.12 (t, 7 Hz, 1 H), 7.06 (m, 2 H), 4.11(m, 2 H), 3.30 (s, 3 H), 2.89 (m, 2 H), 1.79 (m, 4 H), 1.47 (s, 9 H) ppm.
Removal of the BOC group according to the procedure given in Example 3, Step A followed by reaction with 3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butanal 20 according to the procedure given in Example 8, Method B gave 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine). Removal of the BOC group and benzamide formation according to the procedures described in Example 3, Steps A and B
25 gave the compounds listed in Examples 45-46:
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5 -dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) Mass spectrum (CI): m/z = 567.2 (35Cl + 35Cl isotope + H+), 569.2 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(4-Chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) Mass spectrum (CI): m/z = 533 (35Cl + 35Cl isotope + H+), 535 (37Cl + 35Cl isotope + H+).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine)- 1 -oxide.
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) (222 mg, 415 ~mol) in CH2Cl2 (500 ,uL) at -78C was treated with a solution of m-chloroperbenzoic acid (86 mg, 498 ,umol) in CH2C12 (1 25 mL). The reaction was poured into 0C saturated aqueous NaHSO3.
The organic layer was washed with saturated aqueous NaHCO3 (1 mL), brine (1 mL), dried (MgSO4), concentrated in vacuo and purified by column chromatography (silica gel 60, 0-100% acetone/CH2Cl2) to yield 54.3 mg (24%) of the title compound as a white foam.
1H NMR (500 MHz, CDC13) ~ 7.84 (d, lH, J=7.5 Hz), 7.60 (t, lH, J=7.5 Hz), 7.48 (t, lH, J=7.5 Hz), 7.44 (m, lH), 7.39 (dd, lH, J=2.0, 8.5 Hz), 7.32 (m, lH), 7.10-7.04 (rotamer multiplets, lH), 3.6-3.2 (m, 2H), 3.34, 3.32 (two doublets of one diastereomer, lH), 3.16, 3.14 (two WO 94/29309 PCT/US94/05~45 doublets of other diastereomer, lH), 3.1-2.8 (m, 3H), 2.75-2.65 (rotamer singlets, 3H), 2.3-1.7 (m, 10 H), 1.42 (s, 9H) ppm.
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthylmethyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4~-piperidine)- 1 -oxide.
The title compound was prepared by oxidizing 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-5 spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) as described in Example 47 above, and then removing the BOC group and N-benzoylating according to the procedures given in Example 3, Steps A
and B.
20 Mass spectrum (CI): m~z = 623.1 (35Cl + 35Cl isotope + H+).
2 5 1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3 ,4'-piperidine)- 1,1 -dioxide.
To 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-3 (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) (102 mg, 191 ~lmol) in MeOH (0.8 mL) at 0C was added Oxone (176 mg, 287 ~) in water (0.4 mL). After 30 min at room temp, the reaction was filtered through a plug of silica gel and concentrated to yield 39.5 mg (36%) of the title compound as a white foam.
WO 94/29309 2 1 6 3 9 ~ ~ PCT/US94/0~54~
1H NMR (500 MHz, CDCl3) o 7.72 (d, lH, J=7.5 Hz), 7.66 (t, lH, J=7.5 Hz), 7.51 (t, lH, J=7.3 Hz), 7.39 (t, lH, J=8.3 Hz), 3.65-3.25 (m, 2H), 3.38 (s, 2H), 3.15-2.85 (m, 3H), 2.76,2.66 (rotamer singlets, 3H), 2.25 (m, 2H), 2.15-1.95 (m, 3H), 1.95-1.65 (m, 5H), 1.40 (s, 9H) ppm.
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine)- 1,1 -dioxide.
lS The title compound was prepared by removing the BOC group and N-benzoylating (according to the procedures given in Example 3, Steps A
and B) the product from Example 49.
Mass spectrum (CI): m/z = 639.1 (35Cl + 35Cl isotope + H+).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine)- 1,1 -dioxide.
30 To 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) (10 mg, 20 ~mol) in MeOH (0.1 mL) at 0C was added 0.4 M aqueous Oxone (75 IlL, 30 !lmol). The reaction was warmed to room temp and stirred overnight. The reaction was concentrated in vacuo, partitioned WO 94/29309 ~ 3 9 9 5 PCT/US94/05545 between lN NaOH (1 mL) and CH2cl2 (1 mL). The organic layer was concentrated and purified by column chromatography (silica gel 60, 0-100% acetone/CH2Cl2) to yield 9.0 mg (90%) of the title compound as a clear filrn.
Mass spectrum (CI): m/z = 599.1 (35Cl + 35Cl isotope + H+), 601.1 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(4-Chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-15 piperidine)- 1,1 -dioxide.
This compound was prepared according to the procedure given in Example 51 above.
20 Mass spectrum (CI): m/z = 567 (35Cl + 35Cl isotope + H+), 565 (37Cl + 35Cl isotope + H+).
1 '-(3 -((S)-(4-Chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine)- 1 -oxide.
To 1'-(3-((S)-(4-chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) (25 mg, 47 ,umol) in MeOH (1.0 mL) at 0C was added a solution of Oxone (38 mg, 61 ~mol) in H2O (1.0 mL). The reaction was stirred 2 WO 94/29309 2 1 6 3 ~ ~ 5 PCT/US94/05545 min and quenched with 10% aqueous sodium bisulfite. The reaction mixture was diluted with H2O (10 mL), neutralized with sat. aqueous NaHCO3 (15 mL), extracted with CH2cl2 (3 x 25 mL), washed with brine (10 mL), dried (Na2so4)~ concentrated in vacuo, and purified by column chromatography (silica gel 60, 5-8% MeOH/CH2Cl2) to yield 25 mg (99%) of a colorless solid; Mass spectrum (CI): m/z = 549 (35Cl + 35Cl isotope + H+), 551 (37Cl + 35Cl isotope + H+).
l '-(3 -(S)-(4-Chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine), l-oxide.
The title compound was prepared by the oxone oxidation method 15 described in Example 53.
Mass Spectrum (CVNH3) M+H=657, 659 (35,37Cl-isotope).
1 '-(3-(S)-(4-Chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine), l, l-dioxide.
The title compound was prepared by the oxone oxidation method 25 described in Example 51.
Mass Spectrum (CVNH3) M+H=673, 675 (35,37Cl-isotope).
30 Substituted indoline spiropiperidine derivatives were obtained by employing substituted phenyl hydrazines and 1-benzyloxycarbonylpiperidine-4-carboxyaldehyde in the Fisher indole synthesis. Wlhen regioisomers were formed, they were separated as the 1 '-benzyloxycarbonyl- l -methanesulfonyl-spiro(indoline-3,4'-piperidine) derivative by chromatography (silica gel 60, THF/hexane). Preparation WO 94/29309 PCT/US94/05~45 ~1 63~5 of a representative substituted spiro(indoline-3,4'-piperidinium) hydrochloride is described below:
s EXAMPLE 56 1 '-Benzyloxycarbonyl-5 -fluoro-spiro(indoline-3,4'-piperidine) A slurry of 4-fluorophenylhydrazine hydrochloride (6.504 g, 40 mmol), pyridine (6.56 ml, 80 mmol), toluene (360 mL), acetonitrile (40 mL), and N-benzylcarboxy-4-piperidine carboxyaldehyde (9.88g, 40 mmol) was maintained at 0C for 1 h. Trifluoroacetic acid (18.5 mL, 240 mmol) was added, and the reaction was heated 20 h at 60C. The reaction was cooled to 0C, and methanol (40 mL) was added followed 5 by NaBH4 (1.51 g, 40 mmol). The cooling bath was removed and 30%
aqueous NH40H (100 mL) was added. The organic layer was separated, washed with 5% aqueous NH40H (100 mL) brine (50 mL), dried (MgSO4), and concentrated to a crude oil which was purified by column chromatography (SG 60 silica, 0-5% acetone/CH2Cl2) to yield 20 6.48 g (48%) of the title compound as a clear oil.
1H NMR (400 MHz, CDCl3): ~ 7.23-7.36 (m, SH), 6.76-6.71 (m, 2H), 6.58 (dd, lH, J=4.4, 8.0 Hz), 5.14 (s, 2H), 4.12 (br s, 2H), 3.49 (s, 2H), 2.95 (br s, 2H) 1.73 (br s, 4H) ppm.
2s 30 Step 1) l'-Benzyloxycarbonyl-S-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine) To a solution of 1'-benzyloxycarbonyl-5-fluoro-spiro(indoline-3,4'-piperidine) (6.48 g, 19.0 mmol) in CH2cl2 (19 mL) and pyridine (38 21 639~5 mmol, 3.1 mL) at 0C was added methanesulfonyl chloride (19 mmol, 1.52 mL). The reaction was warmed to room temp., diluted with ethyl acetate (200 mL), washed with lN aqueous HCl (100 mL) saturated aqeuous NaHCO3 (100 mL) brine (50 mL), dried (MgSO4), and 5 concentrated to 7.81 g (98%) of the title compound as a red foam.
lH NMR (400MHz, CDCl3) â 7.35 (m, 5H), 7.32 (dd, lH, J=4.2, 9.0 Hz), 6.90 (dt, lH, J=2.7, 8.8 Hz), 6.81 (lH, dd, J=2.6, 8.2 Hz), 5.14 (s, 2H), 4.22 (br s, 2H), 3.84 (s, 2H), 2.92 (br s, 2H), 2.88 (s, 3H), 1.79 (br s, 2H), 1.69 (d, 2H, 13 Hz) ppm.
Step 2) 5-Fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride salt To 1 '-benzyloxycarbonyl-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) (7.81 g, 18.7 mmol) in CHCl3 (18 mL) at room temp.
was added trimethylsilyl iodide (20.5 mmol, 2.93 ml). After 5 min, the rxn was cooled to 0C, and a 5M solution of HCl in methanol/methyl 20 acetate is added with vigorous stirring. The HCl solution was prepared by adding acetyl chloride (190 mmol, 14 ml) to methanol (20 mL) at 0C. 40 ml of EtOAc was added, and the slurry was vigorously stirred at 0C for 4 h. The solid was filtered off under dry nitrogen, washed with 0C ethyl acetate (10 mL) and then with hexane (10 mL), and dried 25 under vacuum to yield 4.77 g (80%) of the title compound as a light pink solid.
1H NMR (400 MHz, DMSO-d6) ~ 8.85 (br s, lH), 8.77 (br s, lH), 7.26 (dd, lH, J=4.4, 8.8 Hz), 7.11 (dt, lH, J=2.8, 8.8 Hz), 7.02 (dd, lH, 30 J=2.8, 8.4 Hz), 3.97 (s, 3H), 3.30 (m, 2H), 3.06 (m, 2H), 3.06 (s, 3H), 2.04 (m, 2H), 1.83 (d 2H, J=14 Hz) ppm.
The substituted 1-methanesulfonyl-spiro(indoline-3,4'-piperidinium) hydrochlorides could be reductively ~min~ted with 3-(S)-(3,4-dichlorophenyl)-4-(t-butoxycarbonyl-methylarnino)butanal according to the procedure described in Example 8, Method B. Removal of the BOC
5 group by the procedure given in Example 3, Step A provided intermediate secondary amine compounds described below which could then be benzoylated under conditions given in Example 3, Step B to give the indicated benzamide derivatives.
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(methylamino)butyl)- 1-methanesulfonyl-5 -methoxy-spiro(indoline-3 ,4'-piperidine) 1H NMR (CDC13, 400 MHz) ~ 7.37 (d, lH, J=8.2 Hz), 7.29 (d, lH), 7.25 (d, lH), 7.04 (dd, lH, J=2.1, 8.3 Hz), 6.72 (m, 2H), 3.76 (s, 3H), 3.73 (s, 2H), 2.87 (m, 2H), 2.82 (s, 3H), 2.78 (d, 2H, J=7.1 Hz), 2.41 (s, 3H), 2.32-2.18 (m, 2H), 2.05-1.85 (m, 5H), 1.7 (m, 3H) ppm.
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(methylamino)butyl)- 1-2 5 methanesulfonyl-5-methyl-spiro(indoline-3 ,4'-piperidine) 1H NMR (CDCl3, 400 MHz) o 7.37 (d, lH, J=6.2 Hz), 7.30 (d, lH, J=2.0 Hz), 7.24 (d, lH, J=10 Hz), 7.05 (dd, lH, J=2.0, 8.2 Hz), 7.00 (d, lH, J= 8.8 Hz), 6.95 (s, lH), 3.71 (dd, 2H, J=16, 5.4 Hz), 2.9 (m, 3H), 30 2.84 (s, 3H), 2.79 (d, 2H, J=7.4 Hz), 2.43 (s, 3H), 2.30 (s, 3H), 2.24 (m, lH), 2.05-1.85 (m, 5H),.1.75-1.60 (m, 3H) ppm.
2 1 63~5 5-Chloro- 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(methylamino)butyl)- 1-methanesulfonyl-spiro(indoline-3 ,4'-piperidine) lH NMR (CDCl3, 400 MHz) ~ 7.39 (d, lH, J=8.2 Hz), 7.29 (d, lH, J=2.1), 7.24 (s, lH), 7.17 (dd, lH, J=2.2, 8.5 Hz), 7.11 (d, lH, J=2.1 Hz), 7.05 (dd, lH, J=2.0, 8.3 Hz), 3.76 (dd, 2H, J=4.5, 25 Hz), 3.18 (p, lH), 2.10-2.85 (m, 4H), 2.87 (s, 3H), 2.61 (s, 3H), 2.47 (m, lH), 2.34 (m, lH), 2.15 (t, lH), 2.04 (m, 2H), 1.95-1.70 (m, SH) ppm.
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(methylamino)butyl)-S-fluoro- 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) lH NMR (CDCl3, 400 MHz) ~ 7.38 (d, lH), 7.3 (m, 2H), 7.05 (dd, lH), 7.91-7.85 (m, 2H), 3.75 (dd, 2H), 3.0-2.8 (m, 3H), 2.81 (d, 2H), 2.43 (s, 3H), 2.42 (m, lH), 2.34 (m, lH), 2.1-1.8 (m, SH), 1.7 (m, 3H) ppm.
1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(methylamino)butyl)-7-fluoro- 1 -2 ~ methanesulfonyl-spiro(indoline-3 ,4'-piperidine) lH NMR (CDCl3, 400 MHz) ~ 7.38 (d, lH), 7.29 (d, lH), 7.05 (m, 2H), 6.95 (m, 2H), 3.99 (dd, 2H), 3.25 (s, 3H), 2.9 (m, 2H), 2.81 (t, lH), 2.45 (s, 3H), 2.38 (m, lH), 2.28 (m, lH), 2.1-1.8 (m, 5H), 1.75 (m, 3H) ppm.
~ 1~ b3~95 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3 ,5-dimethylbenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-5-methyl-spiro(indoline-3 ,4'-piperidine) Mass spectrum (FAB): m/z = 64~.0 (35Cl + 35Cl isotope + H+).
5-Chloro-1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) 15 Mass spectrum (FAB): m/z = 648.1 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 ,5-dimethylbenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-5-methoxy-spiro(indoline-3,4'-piperidine) 25 Mass spectrum (FAB): m/z = 658 (35Cl + 35Cl isotope + H+).
1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(3 -methylbenzoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) WO 94/29309 PCT/US94/05~45 ~1 63995 Mass spectrum (CI): m/z = 632.2 (35Cl + 35Cl isotope + H+), 634.2 (37Cl + 35Cl isotope + H+).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spectrum (FAB): m/z = 688.0 (37Cl + 35Cl isotope + 35Cl +
35Cl isotope+ H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-20 (methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 646.1 (35Cl + 35Cl isotope + H+), 648.1 (37Cl + 35Cl isotope + H+).
2s 30 l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chlorobenzoyl)-(methylamino))butyl)-5-fluoro- l -methanesulfonyl-spiro(indoline-3,4'-piperidine) WO 94/29309 PCT/US94/0554~
21 63'tq5 Mass spectrum (CI): m/z = 652.2 (35Cl + 35Cl isotope + 35Cl + 35Cl isotope + H+), 656.2 (37Cl + 35Cl isotope + 37Cl + 35Cl isotope+ H+), 657.2 (37Cl + 37Cl isotope + 37Cl + 35Cl isotope+ H+),. 658.2 (37Cl +
37Cl isotope + 37Cl + 37Cl isotope+ H+).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-o bis(trifluoromethyl)benzoyl)-(methylamino))butyl)-5-fluoro- l -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 754.1 (35Cl + 35Cl isotope + H+), 756.1 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-20 (methylamino))butyl)-7-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 646.1 (35Cl + 35Cl isotope + H+), 648.1 (37Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-t-butoxycarbonyl)-30 (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) To 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-t-butoxycarbonyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) (1.32 g 2.15 mmol) in toluene (5 mL) at 0C was added WO 94/29309 2 1 6 3 ~ ~ 5 PCT/US94/05545 3.4M Red-Al/toluene (5.1 mL, 17.2 mmol). After 4 h at room temp, the reaction was cooled to 0C and quenched by cautious addition of lN
aqueous NaOH (2 mL). Cold saturated aqueous sodium potassium tartrate (30 mL) was added, and the biphasic mixture was mechanically 5 stirred at 0C for 1 h. The product was extracted with toluene (3 x 10 mL), washed with 50~ saturated aqueous sodium potassium tartrate (10 mL), H2O (10 mL), brine (10 mL), dried (MgSO4), and concentrated to roughly 5 mL volume, and cooled to 0C. Pyridine (705 !lL, 8.6 mmol) and acetic anhydride (410 ,uL, 4.3 mmol) were added. After 16 hours at room temp, the reaction was concentrated and purified by column chromatography (silica gel 60, 0-50% acetone/CH2Cl2) to yield 830 mg (72%) of the title compound as a white foam.
1H NMR (400 MHz, CDCl3) ~ 8.14 (dd, lH), 7.37 (d, lH), 7.28 (m, 15 lH), 7.1-7.0 (m, lH), 6.87 (m, 2H), 3.95, 3.81 (rotamer singlets, 2H), 3.53 (m, lH), 3.36 (m, 2H), 3.22 (m, lH), 3.01 (m, lH), 2.90 (m, lH), 2.82 (m, lH), 2.74, 2.63 (rotamer singlets, 3H), 2.39, 2.20 (rotamer singlets, 3H), 1.89 (m, 4H), 1.65 (m, 4H) ppm.
20 The corresponding 1 -acetyl-spiro(indoline-3,4'-piperidine) compounds were obtained by selectively removing the methanesulfonyl group with Red-Al and then treating with acetic anhydride/pyridine at the stage where the methylamino group is protected with BOC; a representative procedure is given in Example 72 above. The BOC group could be 25 removed using the procedure given in Example 3, step A to give intermediate methylamino compounds which were benzoylated according to Example 3, step B to give the compounds in Examples 73-90:
1 -Acetyl-5-chloro- l '-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-spiro(indoline-3,4'-piperidine) WO 94/29309 PCTIUS94/0~545 2t 639qF~
lH NMR (CDCl3, 400 MHz) ~ 7.83 (d, lH, J=6.6 Hz), 7.12 (d, lH, J=5.2 Hz), 7.09 (d, lH, J=2.0 Hz), 6.87 (dd, 2H, J=2.0, 10.0 Hz), 6.84 (s, lH), 2.81 (p, lH0, 2.75-2.55 (m, 4H), 2.27 (s, 3H), 2.12 (m, lH), 2.04 (m, lH), 1.95 (s, 3H), 1.9-1.7 (m, 3H), 1.6 (t, 2H), 1.5-1.4 (m, 3H) ppm.
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-5-methyl-spiro(indoline-3,4' -piperidine) H NMR (CDCl3, 400 MHz) ~ 8.05 (d, lH)~ 7.38 (d, lH), 7.30 (d, lH), 5 7.05 (dd, lH), 7.00 (d, lH), 6.92 (s, lH), 3.79 (s, 2H), 3.01 (p, 2H), 2.9 (m, 3H), 2.52 (s, 3H), 2.5-2.1 (m, 2H), 2.29 (s, 3H), 2.20 (s, 3H), 2.1-1.7 (m, 6H),. 1.65 (m, 2H) ppm.
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) 25 lH NMR (CDCl3, 400 MHz) ~ 8.14 (dd, lH), 7.38 (d, lH), 7.24 (s, lH), 7.05 (dd, lH), 6.88 (dt, lH), 6.82 (dd, lH). 3.96, 3.83 (rotamer singlets, 2H), 3.13 (p, lH), 3.04 (dd, 2H), 2.92 (dd, 2H), 2.69, 2.66 (rotamer singlets, 3H), 2.50 (p, lH), 2.33 (p, lH), 2.38, 2.20 (rotamer singlets, 3H), 2.13 (t, lH), 2.05 (m, lH), 1.7 (m, 4H), 1.73 (dd, 2H) 30 ppm-wo 94/29309 2 1 6 :~ 9 9 5 PCT/US94/05545 1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-6-fluoro-spiro(indoline-3,4'-piperidine) lH NMR (DMSO-d6, 500 MHz) â 7.76 (dd, lH), 7.58-7.53 (m, 2H), 7.26 (dd, lH), 7.21 (dd, lH), 6.80 (dt, lH), 3.93 (s, 2H), 2.98-2.86 (m, 3H), 2.82 (d, lH), 2.65 (d, lH), 2.38 (s, 3H), 2.19 (m, lH), 2.16 (s, 3H), 2.09 (m, lH), 2.05 (t, lH), 1.90 (t, 2H), 1.78-1.6 (m, 3H), 1.6-1.5 (m, 2H) ppm.
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-4-fluoro-spiro(indoline-3,4'-piperidine) lH NMR (DMSO-d6, 500 MHz) ~ 7.88 (d, lH), 7.63-7.58 (m, 2H), 7.29 (dd, lH), 7.19 (q, lH), 6.79 (t, lH), 3.86 (s, 2H), 3.23-3.13 (m, 3H), 2.97 (m, lH), 2.72 (m, lH), 2.52 (s, 3H), 2.26 (m, lH), 2.16 (s, 3H), 2.09 (t, 4H), 1.97 (p, 2H), 1.76-1.62 (m, 3H) ppm.
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)-(methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 588.2 (35Cl + 35Cl isotope + H+).
? 5 1 -Acetyl- 1 '-(3 -((S)-(3,4-dichlorophenyl))-4-(N-(3,5,-dimethylbenzoyl)-(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 610.2 (35Cl + 35Cl isotope + H+), 612.2 5 (37Cl + 35Cl isotope + H+).
.
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)-(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 582.3 (35Cl + 35Cl isotope + H+).
20 1 -Acetyl- l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5,-dimethylbenzoyl)-(methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 610.3 (35Cl + 35Cl isotope + H+) 1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)-30 (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 582.2 (35Cl + 35Cl isotope + H+).
1 -Acetyl- l '-5-chloro-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-5 dimethylbenzoyl)-(methylamino))butyl)-spiro(indoline-3,4'-piperidine) Mass spectrum (FAB): m/z = 626.0 (35Cl + 35Cl isotope + H+), 628.1 (37Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)-15 (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 616.2 (35Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)-(methylamino))butyl)-5 -fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 650.1 (35Cl + 35Cl isotope + H+).
l -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)-(methylamino))butyl)-5 -fluoro-spiro(indoline-3,4'-piperidine) WO 94/29309 2 1 6 3 9 q 5 PCT/US94/05545 Mass spectrum (CI): m/z = 596.2 (35Cl + 35Cl isotope + H+), 598.3 (37Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 610.2 (35Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3 -((S)-(3,4-dichlorophenyl))-4-(N-(3-isopropoxybenzoyl)-(methylamino))butyl)-5 -fluoro-spiro(indoline-3,4'-piperidine) 20 Mass spectrum (CI): m/z = 640.3 (35Cl + 35Cl isotope + H+), 642.3 (37Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)-(methylamino))butyl)-5-fluoro-spiro(indoline-3,4' -piperidine) Mass spectrum (CI): m/z = 718.2 (35Cl + 35Cl isotope + H+), 720.2 (37Cl + 35Cl isotope + H+).
2 ~ 6 3 ~ ~ 5!
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-5 (methylamino))butyl)-S-methyl-spiro(indoline-3,4'-piperidine) Mass spectrum (FAB): m/z = 606.1 (35Cl + 35Cl isotope + H+), 608.2 (37Cl + 35Cl isotope + H+).
N-Napthoyl- methylamino derivatives (Examples 91 - 101) were prepared by analogy to the benzoyl derivatives, employing commercially available 1-napthoyl chlorides in place of benzoyl 15 chlorides:
1 -Acetyl- 1 '-(3 -((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-S -fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 650.3 (35Cl + 35Cl isotope + H+).
30 1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(1 -napthoyl)-(methylamino))butyl). S-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 632.2 (35Cl + 35Cl isotope + H+), 634.2 (37Cl + 35Cl isotope + H+).
21 ~qq5 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(1 -napthoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 668.2 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 20 Mass spectrum (CI): m/z = 668.2 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) Mass spectrum (CI): m/z = 607.2 (35Cl + 35Cl isotope + H+).
WO 94/29309 PCT/US94/0~45 21 63i~
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- l -napthoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine) sulfone Mass spectrum (CI): m/z = 639.1 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- l -napthoyl)-(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene -3,4'-piperidine) Mass spectrum (CI): m~z = 623.1 (35Cl + 35Cl isotope + H+).
2 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-5 -fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 609.3 (35Cl + 35Cl isotope + H+), 611.3 25 (37Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- l -napthoyl)-(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) 2 1 63~
Mass spectrum (CI): m/z = 591.3 (35Cl + 35Cl isotope + H+), 593.3 (37Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine) o Mass spectrum (CI): m/z = 650.3 (35Cl + 35Cl isotope + H+).
1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 650.3 (35Cl + 35Cl isotope + H+).
Benzylamine derivatives could be synthesized by reducing the benzamide of the 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) 25 derivatives described in some of the Examples. The methanesulfonyl group could be removed by heating with HBr/acetic acid/phenol and then be replaced with an acetyl group by treating with acetic anhydride/pyridine. Representative procedures and compounds are given in Examples 102 and 103 below:
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthylmethyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) (96 mg) was dissolved in lM Dibal-H in toluene (160 uL).
After 1/2 h, saturated aqueous sodium potassium tartrate (5 mL) and EtOAc (5 mL) were added and stirred vigorously for 2 h. The organic layer was washed with H2O (5 mL), brine (5 mL), dried (MgSO4), and concentrated to a crude oil, which was purified by column chromatography (silica gel 60, 0-10% acetone/CH2Cl2) to yield 55 mg (59%) of the title compound as a white foam; 1H NMR (400 MHz, CDCl3) ~ 8.09 (d, lH, J=8.5 Hz), 7.91 (d, lH, J=8.5 Hz), 7.53 (t, lH, 5 J=7.5 Hz), 7.38 (t, lH, J=7.5 Hz), 7.33 (dd, lH, J=4.3, 8,8 Hz), 7.22 (dd, lH, J=5.8, 7.8 Hz), 7.18 (d, lH, J=8.5Hz), 7.09 (d, J=2.0 Hz), 7.04 (dd, lH, J=7.5, 10. 0 Hz), 6.92 (dt, lH, J=2.5, 8.5 Hz), 6.88 (d, lH), 6.77 (dd, lH, J=1.8, 8.3 Hz), 3.85 (dd, lH, J=8.0 Hz), 3.76 (s, 2H), 3.75 (dd, lH, J=8.0 Hz), 2.88 (s, 3H), 2.80-2.66 (m, 3H), 2.62 (dd, lH, 20 J=8.8, 12.3 Hz), 2.51 (dd, lH, J=6.5, 12.5 Hz), 2.28 (s, 3H), 2.18-2.06 (m, 2H), 1.88-1.80 (m,4H), 1.65 (d, 2H, J=10.5 Hz) ppm;
Mass spectrum (CI): m/z = 672.4 (35Cl + 35Cl isotope + H+).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthylmethyl)-30 (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) 1 '-(3 -((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthylmethyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) (45.6 mg) and phenol (19 mg) in 30% HBr/HOAc (270 ~L) WO 94129309 2 1 6 3 ~ q ~ PCT/US94/05~4~
were heated to 70C for 6 h in a sealed vessel. The reaction was concentrated and partitioned between CH2Cl2 (1 ml) and lN NaOH (2 mL). The organic layer was eluted through a 3x3 cm silica gel plug with 0-100% acetonelcH2cl2 to yield 30 mg (74%) of the title 5 compound as a yellow oil.
1H NMR (400 MHz, CDCl3) ~ 8.09 (d, lH, J=8.0 Hz), 7.93 (d, lH, J=8.5 Hz), 7.52 (t, lH, J=7.5 Hz), 7.43 (t, lH, J=7.3 Hz), 7.22 (dd, lH, J=5.5, 7.5 Hz), 7.17 (d, lH, J=8.5 Hz), 7.06 (dd, lH, J=8.8, 10.3 Hz), 7.02 (d, lH, J=1.5 Hz), 6.87 (d, lH, J=3.5 Hz) 6.78 (dd, lH, J=2.3, 8.3 Hz), 6.75 (dd, lH, J=2.3, 7.8 Hz), 6.56 (dd, lH, J=4.0, 8.5 Hz) ppm;
Mass spectrum (CI): m/z = 594.3 (35Cl + 35Cl isotope + H+), 596.3 (37Cl + 35Cl isotope + H+) 2 1 -Acetyl- 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1-napthylmethyl)-(methylamino))butyl)-5 -fluoro-spiro(indoline-3 ,4'-piperidine) 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthylmethyl)-2 5 (methylamino))butyl)-5-fluoro-spiro(indoline-3 ,4'-piperidine) ( 10 mg) in CH2C12 (100 !lL) was treated with one drop acetic anhydride and 1 drop pyridine. After 30 min, the reaction was eluted through a lx2 cm silica gel column using 0-100% acetone/CH2Cl2 plus 1% NH40H to yield 10 mg (93%) of the title compound as a clear film.
1H NMR (CDC13) ~ 8.17 (dd, lH, J=4.3, 8.8 Hz), 8.09 (d, lH, J=8.5 Hz), 7.91 (d, lH, J=8.0 Hz), 7.52 (t, lH, 7.3 Hz), 7.38 (t, lH, J=7.3 Hz), 7.22 (dd lH, 6.8, 7.0 Hz), 7.18 (d, lH, J=8.8 Hz), 7.07 (d, lH, J=2.0 Hz), 7.04 (dd, lH, J=8.0, 10.5 Hz), 6.91 (dt, lH, J=2.0, 9.0 Hz), 6.86 WO 94t29309 ~1 63 ~ ~ ~ PCT/US94/0554~
(dd, lH, J=2.0, 7.5 Hz), 6.76 (dd, lH, J=2.0, 8.5 Hz), 3.96, 3.81 (rotamer singlets, 3H), 3.85 (d, 1 H, J= 13 Hz), 3.75 (d, 1 H, J= 13 Hz), 2.84 (m, 2H), 2.74 (m, lH), 2.61 (dd, lH, J=8.5, 13Hz), 2.51 (dd, lH, J=7.0, 13 Hz), 2.43, 2.35 (rotamer singlets, 3H), 2.24 (s, 3H), 2.3-2.2 (m, 3H), 2.0-1.85 (m, 4H), 1.65 (m, 2H), 1.50 (m, lH) ppm;
Mass spectrum (CI): m/z = 636.4 (35Cl + 35Cl isotope + H+), 638.4 (37Cl + 35Cl isotope + H+).
1 '-(5-Fluoroindolyl-3-(2-ethanoyl))- 1 -methanesulfonyl-spiro(indoline-5 3 4 -piperidine) To a solution of l-methanesulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride (373 mg, 1.23 mmol), 5-fluoroindole-3-acetic acid (500 mg, 2.59 mmol), in DMF (15 mL) at room temp. was added N-methyl 20 morpholine (261 mg, 2.59 mmol), hyroxybenzotriazole (381 mg, 2.82 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (473 mg, 2.47 mmol). The reaction was stirred 48 h, diluted with H2O (250 mL), extracted with EtOAc (3 x 100 mL), washed with H2O (2 x 150 mL), brine (150 mL), dried (Na2SO4), concentrated in vacuo and 25 purified by column chromatography (SG 60 silica, 5% MeOH/CH2Cl2) to afford 486 mg (89%) of the title compound as a colorless oil.
lH NMR (500 MHz, CDCl3) o 8.39 (br s, lH), 7.37 (d, lH, J = 8.2 Hz), 7.34 (dd, lH, J = 9.6, 2.3 Hz), 7.29 (dd, lH, J = 8.9, 4.4 Hz), 7.23 (dt, 30 lH, J = 7.8, 1.2 Hz), 7.14 (d, lH, J = 2.3 Hz), 7.03 (t, lH, J = 7.3 Hz), 6.98 (dt, lH, J = 8.9, 2.5 Hz), 6.87 (d, lH, J = 7.5 Hz), 4.73 (d, lH, J =
13.7 Hz), 3.96 (d, lH, J = 14.0 Hz), 3.82-3.92 (m, 2H), 3.72-3.78 (m, lH), 3.13 (t, lH, J = 13.4 Hz), 2.91 (s, 3H), 2.73 (t, lH, J = 13.5 Hz), ;2 1 ~3995 1.83 (dt, lH, J = 13.5, 4.4 Hz), 1.65-1.75 (m, 2H), 1.52-1.58 (m, lH), 1.40 (dt, lH, J = 13.0, 4.3 Hz) ppm; Mass spec (CI) m/z 441 (M+H).
1 '-(2-(3-(5-Fluoroindolyl))ethyl))- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine).
To a solution of 1'-(5-fluoroindolyl-3-(2-ethanoyl))-1-methanesulfonyl-spiro(indoline-3,4'-piperidine) (100 mg, .226 mmol) in CH2C12 (8 mL) at -70C was added Dibal-H (lM in THF, 0.91 mL, .906 mmol). After 2.5 h the mixture was quenched by addition of 1 M NaOH (20 mL), 15 diluted with CH2cl2 and stirred vigorously for 15 min. The mixture was extracted with CH2Cl2 (3 x 50 mL), washed with brine (50 mL), dried (Na2SO4), concentrated in vacuo and purified by column chromatography (SG60 silica, 5% MeOH/CH2Cl2) to afford 66 mg (68%) of the title compound as a colorless solid.
lH NMR (500 MHz, CDCl3) â 8.20 (br s, lH), 7.42 (d, lH, J = 8.0 Hz), 7.20-7.30 (m, 4H), 7.06-7.14 (m, 2H), 6.93-6.97 (m, lH), 3.84 (s, 2H), 3.08 (d, 2H, J = 11.7 Hz), 2.94-3.00 (m, 2H), 2.93 (s, 3H), 2.71-2.77 (m, 2H), 2.19 (t, 2H, J = 12.3 Hz), 2.07 (dt, 2H, J = 13.2, 3.9 Hz), 1.75 25 (d, 2H, J = 13.0 Hz) ppm; Mass spec (CI) m/z 428 (M+H).
30 4-Fluoro-3,5-dimethylbenzoic acid Step 1) 1-Bromo-4-fluoro-3,5-dimethylbenzene wo 94/29309 21 6 3 q 9 5 PCT/US94/05545 - To a mixture of 4-Bromo-2,6-dimethylaniline (8.3 g, 42 mmol) at 5C
and H2O (50 mL) was added conc H2SO4 (6.25 mL). NaNO2 (4.1 g) was added in portions until an excess was indicated by starch iodide paper. Water (30 mL) was added to make the mixture homogeneous.
After transferring to a plastic container, HBF4 (50%, 13.7 g) was added dropwise with stirring. The resultant white precipitate was collected by vacuum filtration, washed with H2O (30 mL), MeOH (30 mL), and Et2O (60 mL), and dried over P2O5 under vacuum for 16 h. The solid was then heated in a glass flask with an open flame until all the solid had decomposed. The rem~ining liquid was diluted with Et2O (50 mL) and 0.5 M NaOH (30 mL). The organic layer was separated, washed with 0.5 M NaOH (25 mL), H2O (25 mL), brine (25 mL), dried (MgSO4), and concentrated in vacuo yielding 6.06 g (72%) of 1-bromo-4-fluoro-3,5-dimethylbenzene as a pale yellow liquid.
1HNMR(500MHZ,CDCl3)~7.17(d,2H,J=6.2Hz),2.21 (s,6H) ppm.
Step B) 4-Fluoro-3,5-dimethylbenzoic acid To a mixture of magnesium shavings (120 mg, 4.92 mmol) in THF (2 mL) was added a crystal of iodine followed by slow addition of a solution of the bromide (1.0 g, 4.92 mmol) in THF (3 mL). The 2s reaction mixture was heated to reflux for 1 h followed by cooling to room temp. and addition of CO2(s) (excess), stirred 1 h and quenched by addition of lM HCl (10 mL). The mixture was extracted with Et2O
(3 x 25 mL), washed with brine (25 mL), dried (MgSO4), and concentrated in vacuo to afford 0.82 g (99%) of the title compound as a pale yellow solid.
1H NMR (500 MHz, CDC13) ~ 7.81 (d, 2H, J = 6.7 Hz), 2.36 (s, 6H) ppm;
2~3~Y5 Mass spec (CI) m/z 168 (M-H).
The compounds of Examples 108-120 were prepared as per Example 3 5 Step B utilizing the previously prepared amines and the appropriate benzoic or naphthoic acids:
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chloro-4-fluorobenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) 15 Mass spec (CI) 656 (37Cl + 35Cl isotope + H+), 654 (35CI + 35CI
isotope + H+).
1 '-(3-((S)-(3 ,4-Dichlorophenyl))-4-(N-(3-chloro-4-fluorobenzoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Mass spec (CI) 674 (37Cl + 35Cl isotope + H+), 672 (35Cl + 35Cl isotope + H+).
1'-(3 -((S)-(3 ,4-Dichlorophenyl))-4-(N-(4-fluorobenzoyl)-(methylamino))butyl)- l -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Mass spec (CI) 620 (37Cl + 35Cl isotope + H+), 618 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluorobenzoyl)-(methylamino))butyl)-5-fluoro- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 618 (37Cl + 35Cl isotope + H+), 616 (35CI + 35Cl isotope + H+).
1 '-(3 -((S) -(3,4-Dichlorophenyl))-4-(N-(3 -chloro-4-fluorobenzoyl)-(methylamino))butyl)-5-fluoro- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 636 (37Cl + 35Cl isotope + H+), 634 (35CI + 35Cl isotope + H+).
2 s EXAMPLE 113 1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3,5-dimethylbenzoyl)-(methylamino))butyl)-5-fluoro- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 630 (37Cl + 35Cl isotope + H+), 628 (35Cl + 35Cl isotope + H+).
wo 94/29309 21 S 3 9 q 5 PCT/US94/05545 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3,5-dimethylbenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 648 (37Cl + 35Cl isotope + H+), 646 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3 -trifluoromethylbenzoyl)-(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 688 (37Cl + 35Cl isotope + H+), 686 (35Cl + 35Cl isotope + H+).
l '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3,5 -dimethylbenzoyl)-2 5 (methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 612 (37Cl + 35Cl isotope + H+), 610 (35Cl + 35Cl isotope + H+).
21 ~3995 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3-trifluoromethylbenzoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 652 (37Cl + 35Cl isotope + H+), 650 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -naphthoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 634 (37Cl + 35Cl isotope + H+), 632 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -naphthoyl)-(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass spec (CI) 670 (37Cl + 35Cl isotope + H+), 668 (35Cl + 35Cl isotope + H+).
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(1 -naphthoyl)-(methylamino))butyl)- 1 -acetyl-spiro(indolme-3,4'-piperidine) Mass spec (CI) 616 (37Cl + 35Cl isotope + H+), 614 (35Cl + 35Cl isotope + H+).
21 63q95 1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-5(methylamino))-4-phenyl-butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) The title compound was prepared in 6 steps from 2-(S)-(3,4-dichlorophenyl)-4-pentenoic acid using procedures identical to othose in Example 10, substituting phenyllithium for methyllithium in Example 10, Step 2.
Mass Spectrum (FAB): m/z 704 (M+H, 37Cl + 35Cl isotope, 100%), 706 (M+H, 37Cl + 37Cl isotope, 80%).
1 '-(4-(N-(3,5-Dimethylbenzoyl)-(methylamino))-4-(phenyl)butyl)- 1 -20acetyl-spiro(indoline-3,4'-piperidine) The title compound was prepared in 6 steps from 4-pentenoic acid using procedures identical to those in Example 10, substituting phenyllithium for methyllithium in Example 10, Step 2.
Mass Spectrum (FAB): m/z 524 (M+H, 37Cl + 35Cl isotope, 100%), 526 (M+H, 37CI + 37Cl isotope, 50%).
1 '-(3 -((S)-(3,4-Dichlorophenyl))-4-(1 -(2-phenylimidazolo))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) WO 94/29309 PCT/~lS94/0554~
21 b3~9G3 Step 1) 1-(2-Phenylimidazolo)-2-((S)-(3,4-dichlorophenyl))-4-pentene To a solution of 0.178 g (0.77 mmole) of 2-((S)-(3,4-dichlorophenyl))-4-penten-1-ol (prepared in Example 136, Step A) and 0.099 mL (0.85 mmole) of 2,6-lutidine in 1.5 mL of methylene chloride at -53 deg C
under nitrogen was added 0.136 mL (0.81 mmole) of trifluoromethanesulfonic anhydride. The solution was stirred between -30 deg C and -40 deg C for 15 min at which point 0.333 g (2.31 mmole) of 2-phenylimidazole was added. The temperature was allowed o to warm to -20 deg C briefly, and the mixture was then cooled to -60 deg C, stirred at that temperature for 1 hr, stirred at -20 deg Cfor 2 hr, and then held at 4 deg C for 16 hr. After stirring at room temperature for 8 hr, the mixture was treated with 10 mL of saturated sodium carbonate solution and 10 mL of ethyl acetate and the layers were separated. The aqueous phase was extracted with 2x15 mL of ethyl acetate and the combined aqueous layers were dried over sodium sulfate, filtered and concentrated in vacuo. The residue was partly purified by flash chromatography on 36 g of silica eluting with 500 mL
of 3:100 methanol:methylene chloride then 300 mL of 5:100:0.1 methanol:methylene chloride: ammonia water. The partly purified product fractions were flash chromatographed on 66 g of silica eluting with 1.2 L of 83:17 methylene chloride:ethyl acetate to give 85 mg (31%) of an oil.
1H-NMR (400 MHz, CDC13) ~ 2.26 (app. t, 2H), 2.85 (pentet, lH), 4.08 (dd, lH), 4.27 (dd, lH), 4.9-5.0 (m, 2H), 5.45-5.55 (m, lH), 6.59 (dd, lH), 6.79 (s, lH), 6.85 (d, lH), 7.18 (d, lH), 7.23-7.30 (m, 2H), 7.35-7.4 (m, 3H).
Mass Spectrum (FAB): m/z 359 (M+H, 65%), 357 (M+H, 100%), 145 (7%).
Step 2) 1 '-(2-((S)-(3,4-Dichlorophenyl))- 1 -(1 -(2-phenylimidazolo))-4-butyl)- l -methanesulfonyl-spiro(indoline-3,4'-piperidine) The title compound was prepared by employing the chemistry outlined in Examples 1 and 2, using 1-(2-phenylimidazolo)-2-((S)-(3,4-dichlorophenyl))-3-butene in place of 3-(S)-(3,4-dichlorophenyl)-4-methylamino-1-pentene, and beginning with the osmium tetroxide step.
H-NMR (400 MHz, CDCl3) ~ 1.55-2 (m, 8H), 2.08 (t, J = 7.3, 2H), o 2.63 (br d, J = 11, lH), 2.70 (br d, J = 8.3, lH), 2.86 (s, 3H), 2.9-3.0(m, lH), 3.71 (s, 2H), 4.13 (dd, J = 14, 8.8, lH), 4.25 (dd, J = 14, 6.2, lH), 6.66 (dd, J = 6.2, 2.1, lH), 6.79 (d, J = 1.3, lH), 6.94 (d, J = 2.1, lH), 7.03 (d, J = 1.3, lH), 7.05 (d, J = 6.4, lH), 7.15 (d, J = 6.5, lH), 7.15-7.25 (m, 2H), 7.35-7.45 (m, 6H) Mass Spectrum (FAB): m/z 609 (M+H, 25%), 279 (100%), 267 (50%), 212 (30%), 187 (35%).
1'-(3-((S)-(3,4-Dichlorophenyl))-4-((N-(R or S)-(3,5-dimethylbenzoyl)-(methylamino))pentyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) The title compound was prepared in 6 steps from (2S)-(3,4-dichlorophenyl)-4-pentenoic acid using procedures identical to those in Example lO, substituting l-acetyl-spiro(indoline-3,4'-piperidine) for 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) in Example 10, Step 6.
Mass Spectrum (FAB): m/z 606 (M+H, 37Cl + 35Cl isotope, 100%), 608 (M+H, 37CI + 37Cl isotope, 80%).
1'-(3-((S)-(3,4-Dichlorophenyl))-4-((N-(R or S)-(4-fluoro-1-napthyl)-(methylamino))pentyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) The title compound was prepared in 6 steps from (2S)-(3,4-dichlorophenyl)-4-pentenoic acid using procedures identical to those in Example 10, substituting 1-acetyl-spiro(indoline-3,4'-piperidine) for 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) in Example 10, Step 6, and substituting 4-fluoro-1-napthoyl chloride for benzoyl chloride.
Mass Spectrum (FAB): m/z 646 (M+H, 37Cl + 35Cl isotope, 30%), 204 (1 00%).
The following compounds described in Examples 126-129 were prepared by the method described in Scheme II and in Example 10, except that in step 2 ethylmagnesium chloride or - propylmagnesium chloride was used at room temperature instead 20 of methyllithium at -78C.
25 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(R or S)-(N-(3,5-dimethylbenzoyl)-(methylamino))hexyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) 1H-NMR (400 MHz, CDCl3) ~ 0.97 (t, 3H), 2.20 (s, 6H), 2.21 (s, 30 3H), 2.42-2.46 (s+m, 4H), 6.23 (s, 2H), 6.89 (s, lH), 7.04 (t, lH), 7.15-7.21 (m, 3H), 7.39 (t, 2H), 8.18 (d, lH).
Mass Spectrum (FAB) m/z 620 (m+).
WO 94/29309 PCT/US94/05~45 21 639~5 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(R or S)-(N-(3,5-dimethylbenzoyl)-(methylamino))hexyl)- 1 -acetyl-5-fluoro-5 spiro(indoline-3,4'-piperidine) 1H-NMR (400 MHz, CDCl3) ~ 0.96 (t, 3H), 2.20 (s, 9H), 2.45 (s, 3H), 3.81 (s, 2H), 6.24 (s, 2H), 6.84-6.89 (m, 3H), 7.19 (dd, lH), 7.39 (t, 2H), 8.13 (dd, lH).
Mass Spectrum (FAB) m/z 638 (m+).
1'-(3-(S)-(3,4-Dichlorophenyl)-4-(R or S)-(N-(3,5-dimethylbenzoyl)-(methylamino))heptyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine) 20 lH NMR (400 MHz, CDC13) ~ 0.96 (t, 3H), 2.20 (s, 6H), 2.21 (s, 3H), 2.41-2.45 (s+m, 4H), 3.78 (s, 2H), 6.22 (s, 2H). 6.89 (s, lH), 7.03 (t, lH), 7.15-7.21 (m, 3H), 7.39 (t, 2H), 8.18 (d, lH).
Mass Spectrum (FAB): m/z 634 (m+).
1'-(3-(S)-(3,4-Dichlorophenyl)-4-(R or S)-(N-(3,5-3 0 dimethylbenzoyl)-(methylamino))heptyl)- 1 -acetyl-5-fluoro-spiro(indoline-3,4'-piperidine) 1H-NMR (400 MHz, CDCl3) ~ 0.97 (t, 3H), 2.20 (s, 9H), 2.44 (s, 3H), 3.81 (s, 2H), 6.22 (s, 2H), 6.83-6.88 (m, 3H), 7.18 (dd, lH), 7.38 (t, 2H), 8.13 (dd, lH).
WO 94/29309 2 1 6 3 q q 5 PCT/US94/05545 Mass Spectrum (FAB) m/z 652 (m~).
1'-(3-((S)-(3,4-Dichlorophenyl))-4-(R or S)-hydroxy-5-(3,5-dimethylphenyl)pentyl)- 1 -methane-sulfonyl-spiro(indoline-3,4'-piperidine) To a THF (3 mL) solution of 3,5-dimethylbenzylmagnesium chloride (generated from 290 mg (1.9 mmol) of 3,5-dimethylbenzyl chloride and 53 mg (2.2 mmol) of magnesium in THF) was added slowly 1'-(3-((S)-(3,4-dichlorophenyl))-3 -(N-methoxy-N-15 methylaminocarbonyl)propyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) (100 mg, 0.19 mmol, prepared by reacting the product obtained in Example 10, Step 1 under the oxidative cleavage conditions given in Example 1 followed by the coupling procedure given in Example 2) in 1 mL of THF. The reaction 20 mixture was stirred at 60C for 40 min and poured into 20 mL of lN HCl. The solution was extracted with 3 x 10 mL of EtOAc.
The organic extracts were combined, dried, and concentrated.
The product was purified by preparative TLC (30% EtOAc in CH2Cl2) to afford 20 mg of ketone.
25 To a MeOH (3 mL) solution of ketone (19.4 mg) was added sodium borohydride (7 mg). The mixture was stirred at 55C for lh and concentrated. The residue was purified by preparative TLC (4% MeOH in CH2Cl2) to give 15 mg of the higher Rf isomer (Isomer A) and 4 mg of a lower Rf isomer (Isomer B).
1H-NMR (400 MHz, CDCl3), Isomer A: d 1.71 (d, 2H), 1.92-2.12 (m, 6H), 2.23-2.29 (s+m, 9H), 2.50-2.60 (m, 2H), 2.72-2.76 (m, lH), 2.88 (s, 3H). 2.95 (d, 2H), 3.76 (s, 2H), 4.00-4.06 (m, lH), 6.69 (s, 2H), 6.83 (s, lH), 7.05 (d, lH), 7.19-7.24 (m, 3H), 7.37 (t, 2H), 7.44 (s, lH).
Mass spectrum (FAB) Isomer A, m/z 601 (m+), 603 (m++ 2).
lH-NMR (400 MHz, CDCl3), Isomer B: d 1.69 (d, 2H), 1.74-1.79 (m, lH), 1.83-1.90 (m, lH), 1.93-2.05 (m, 2H), 2.07-2.20 (m, 2H), 2.24-2.36 (s+m, 8H), 2.42-2.47 (m, lH), 2.55-2.58 (dd, lH), 2.66-2.72 (d+dd, 2H), 2.87 (s, 3H), 2.86-3.00 (m, 2H), 3.76 (s, 2H), 3.91-3.95 (m, lH), 6.72 (s, 2H), 6.82 (s, 2H), 7.13-7.19 (m, 2H), 7.18-7.21 (m, 2H), 7.36 (t, 2H).
Mass spectrum (FAB) Isomer B, m/z 601 (m+) 603 (m+ + 2).
1 '-(3 -(R)-(3,4-Dichlorophenyl)-5 -(N-3,5 -dimethylphenyl-2 0 methylamino)-S-oxo-pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Step 1) Diazomethyl-(2-(S)-(3,4-dichlorophenyl)-pent-4-en-yl)-ketone.
To a solution of 2-(S)-(3,4-dichlorophenyl)-pent-4-enoic acid (5.04g, 20.6mmol) in 60mL of dichloromethane was added oxalyl chloride 2.15mL (24.6mmol) and dimethylformamide (O.lmL) upon cooling in an ice-water bath. The cooling bath was then removed and 30 the reaction mixture was stirred at rt overnight. The solvent was removed under reduced pressure. The resulting material was diluted in ethyl acetate and concentrated in vacuo in order to remove residual HCl.
The residual crude acid chloride was dissolved in 70mL of ether and was slowly added to a lOOmL ether solution of diazomethane (77mmol).
After stirring for 2hr at rt, the solvent was removed under vacuum.
WO 94/29309 2 1 6 3 q ? ~i PCT/US94/0~545 The resulting yellow oil was chromatographed on silica gel column eluting with a gradient of hexane: ethyl acetate = 20: 1 to 3: 1 to give 4.66g (84%) of diazomethyl-(2-(S)-(3,4-dichlorophenyl)-pent-4-en-yl)-ketone.
H-NMR (CDCl3 400MHz): o 2.44(app. quint. lH), 2.82(app. qunit.
lH), 3.43(br s. lH), 4.98 & 5.02 (d of AB quart., 2H), 5.16 (br s, lH), 5.63(m, lH), 7.09 (dd, J=2.2Hz, 8.3Hz, lH), 7.34(d, J=2.2Hz, lH),7.38 (d J=8.3Hz).
Step 2) 3-(R)-(3,4-Dichlorophenyl)-hex-4-en-oic acid To a solution of the above diazoketone 4.56g (17.0mmol) in 15 340mL of tetrahydrofuran was added 170mL aquous solution of silver nitrate 3.02g (17.8mmol). After stirring at rt overnight, tetrahydrofuran was removed under reduced pressure. The remaining aqueous layer was extracted with two lOOmL portions of dichloromethane. The combined organic phases were washed with 20 brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. The resulting material was purified by silica gel column chromatography. Elution with dichloromethane: methanol = 10: 1 gave 3.94g (90%) of 3-(R)-(3,4-dichlorophenyl)-hex-4-en-oic acid.
25 Step 3) (N-(3,5-Dimethylphenyl)-N-methyl)-((3-(R)-(3,4-dichlorophenyl)-hex-5-en-yl)-amide The carboxylic acid from Step 2 (300mg, 1.16mmol) was dissolved in 5mL of dichloromethane. To it was added 0.131mL
30 (1.50mmol) of oxalyl chloride followed by the addition of a drop of dimethylformamide upon cooling in an ice-water bath. The cooling bath was then removed and the reaction mixture was stirred at rt for 2hr. The solvent and residual HCl was removed as described above.
The resulting crude acid chloride was then dissolved in 5mL of 21 63qq~
dichloromethane. To it was added N-methyl-3,5-dimethylaniline 313mg (3.32mmol) (Prepared from 3,5-Dimethylaniline following the procedure of Barluenga J., Bayon A.M., and Asensio G. J. Chem. Soc.
Chem. Comm. 1984 1334.) followed by the addition of triethylamine 5 0.5mL (3.6mmol) upon cooling in an ice-water bath. Then the cooling bath was removed and the reaction mixture was stirred at rt overnight.
The solvent was removed under reduced pressure. The residual solid material was dissolved in 15mL of ethyl acetate and 5mL of water. The organic phase was separated and aqueous phase was extracted with two o 7mL portions of ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. This crude material was chromatographed on silica gel eluting with a gradient of 10: 1 to 3: 1 hexane-ethyl acetate to give 386mg of (N-(3,5-dimethylphenyl)-N-methyl)-((3-(R)-(3,4-15 dichlorophenyl)-hex-5-en-yl)-amide (88%).
lH-NMR(CDCl3 400MHz): ~ 2.15-2.35 (m., 4H), 2.29 (s, 6H), 3.09 (s, 3H), 3.26 (quint, J=7.2Hz, lH), 4.88 (d, J=7.6Hz, lH), 4.92 (s, lH), 5.5 (m, lH), 6.45 (s, 2H), 6.91 (dd, J=2Hz, 7Hz, lH), 6.93 (s, lH), 7.30 (d, 20 J=g.3Hz, 1 H)-Step 4) 3-(R)-(3,4-Dichlorophenyl)-5-(N-(3,5-dimethylphenyl)-methylamino)-5-oxo-pentanal To 386mg (1.03mmol) of the product from the previous step was oxidized by osmium tetroxide to corresponding diol as described in Example 1 to give 413mg of crude diol. 381mg of this material was then dissolved in lOmL of benzene. To it was added lead tetraacetate 30 452mg (1.02mmol). After stirring for lhr at rt, 5mL of water was added to quench the reaction. The reaction mixture was extracted with two lOmL portions of ethyl acetate. The combined organic phases were dried over anhydrous magnesium sulfate, filtered, and concentrated.
The crude material was chromatographed on silica gel eluting with WO 94/29309 PCTIUS94/05~45 ~1 63995 hexane: ethyl acetate = 2: 1 to give 329mg of 3-(R)-(3,4-dichlorophenyl)-5 -(N-(3 ,5 -dimethylphenyl)-methylamino)-5 -oxo-pentanal (94% overtwo steps).
Step 5) 1'-(3-(R)-(3,4-Dichlorophenyl)-5-(N-3,5-dimethylphenyl-methylamino)-5-oxo-pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Following the procedure described in Example 2, 107mg (0.287mmol) of this aldehyde was treated with 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride to give 1 03mg (58 %
yield) of the title compound .
15 1H-NMR (CDCl3 400MHz): â 2.23 (s, 6H), 2.86 (s, 3H), 3.09 (s, 3H), 3.72 (s, 2H), 6.49 (s, 2H), 6.9-7.2 (s, 8H).
MS(CI): 628 (M++1: 35Clx2), 630 (M++1: 35Cl & 37Cl) 1 '-(3 -(R)-(3 ,4-Dichlorophenyl))-5 -(3 ,5 -dimethylphenyl)-5 -oxo-pentyl)-2 5 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Step 1) (N-Methoxy-N-methyl)-(3-(R)-(3,4-dichlorophenyl)-4-hexenyl)-amide To a solution of 3-(R)-(3,4-dichlorophenyl)-5-hexenoic acid (Example 132, Step 1) 744mg (2.87mmol) was added 1-hydroxybenzotriazole hydrate 465mg (3.44mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloroide 660mg (3.44mmol) with cooling in an ice-water bath. The cooling bath was 21 63~5 then removed. After stirring at rt for lhr, to it was added 5mL
dichloromethane suspension of N, O-dimethylhydroxyl amine hydrochloride 840mg (8.61mmol) and triethylamine 1.2mL (8.6mmol).
After stirring overnight, the solvent was removed under vacuum, 5 diluted with ethyl acetate and water. The organic phase was separated.
Aqueous phase was extracted twice with ethyl acetate. Combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, filtered, concentrated, chromatographed on silica gel eluting on a gradient of hexane: ethyl acetate = 5: 1 to 2: 1 to give o 762mg (88%) of (N-methoxy-N-methyl)-(3-(R)-(3,4,-dichlorophenyl)-4-hexenyl)-amide.
1H-NMR (CDCI3 400MHz): ~ 2.34(m, lH), 2.69 (App. d, 2H), 3.09 (s, 3H), 3.23 (quint. J=7.3Hz, lH), 3.56 (s, 3H), 4.95 (s, lH), 4.98 (app. d, 15 lH), 5.6 (m, lH),7.0 (dd, J=2.1Hz, 8.4Hz, lH),7.28 (d, J=2.1Hz, lH), 7.32 (d, J=8.3Hz, lH).
Step 2) 3-(R)-(3,4-Dichlorophenyl)-(N-methoxy-methylamino)-S-oxo-2 pentaIlal This above material was subjected to the osmium tetroxide oxidation to the corresponding diol as described in Example 1. The crude product was then treated with 1.23g (2.77mmol) of lead 25 tetraacetate as described in example 131, Step 4. Chromatographic purification on silica gel (eluant; dichloromethane: ethyl acetate = S: 1) afforded 618mg (81% two steps)of 3-(R)-(3,4-dichlorophenyl)-(N-methoxy-methylamino)-S -oxo-pentanal .
Step 3) 1'-(3-(R)-(3,4-Dichlorophenyl)-5-(N-methoxy-methylamino)-5-oxo-pentyl)- l -methanesulfonyl-spiro(indoline-3,4'-piperidine) ~ 1 6:~q95 - A sample of 332mg (1.09mmol) of the aldehyde from Step 2 above was subjected to reductive ~min~tion with 1-methanesulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride as described in Example 2 to give 369mg (61%) of 1'-(3-(R)-(3,4-dichlorophenyl)-5-(N-methoxy)-5 N-(methyl)amino)-5-oxo-pentyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine).
1H-NMR (CDCl3 400MHz): ~ 2.87 (s 3H), 3.10 (s, 3H), 3.60 (s, 3H), 7.0-7.4 (m, 7H).
Step 4) 1 '-(3-(R)-(3,4-Dichlorophenyl))-5-(3,5-dimethylphenyl)-5-oxo-pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) To a 1.2mL THF solution of the amide from Step 3 above (73mg, 0.13mmol) was added l.lmL of 0.7M 3,5-dimethylphenylmagnesium bromide solution in THF (prepared from 5-bromo-m-xylene and magnesium turnings in THF). Then the reaction mixture was heated to 500C. After stirring for 1.5hr, the reaction mixture was allowed to cool 20 down to rt and the reaction was quenched by sat NH4Cl aq solution.
THF was removed under reduced pressure, diluted with ethyl acetate.
The organic phase was separated and the aqueous phase was extracted twice with ethyl acetate. Combined organic phases were dried over anhydrous magnesium sulfate, filtered, concentrated, chromatographed 25 on silica gel eluting with a gradient of dichloromethane: ethyl acetate =
10: 1 to 1: 1 to give 55mg (70%) of the title compound.
lH-NMR (CDCl3 400MHz): â 2.34 (s, 6H), 2.86 (s, 3H), 3.23 (m, 2H), 3.74 (s, 2H), 7.0-7.5 (m, lOH).
MS (CI): 599 (M++1;35Clx2), 601 (M++1: 35Cl& 37Cl).
2l 63~5 1 '-(3-(R)-(3,4-Dichlorophenyl)-6-(3,5-dimethylphenyl)-5-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 70mg (0.126mmol) of 1'-(3-(R)-(3,4-dichlorophenyl)-5-(N-methoxy)-N-(methyl)amino)-5-oxo-pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4r-piperidine) (Example 132, Step 3) was treated with 0.8M THF solution of 3,5-dimethyl benzylmagnesium chloride as in the case of Example 132. The crude material was chromatographed on silica gel in the same solvent system to afford 33mg of the title compound (43%).
1H-NMR (CDCl3 400MHz): ~ 2.24 (s, 6H), 2.86 (s, 3H), 3.47 (s, 2H), 3.72 (s, 2H), 6.64 (s, 2H), 6.8-7.4 (m, 8H).
MS (CI): 613 (M++1: 35Clx2), 615 (M++1: 35CI& 37CI).
1 '-(3-(S)-(3,4-Dichlorophenyl)-6-(3,5-dimethylphenyl)-6-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 3-(R)-(3,4-Dichlorophenyl)-4-hexenoic acid (Example 131, Step 2) was converted into 4-(S)-(3,4-Dichlorophenyl)-5-heptenoic acid as in Example 131, Steps 1 and 2. 4-(S)-(3,4-dichlorophenyl)-4-heptenoic acid was converted to (N-methoxyl-N-methyl)-(4-(S)-(3,4-dichlorophenyl)-6-heptenyl)-amide followed by treatment with 3,5-dimethylphenylmagnesium bromide as described in Example 132, Step 4 to give the title compound.
1H-NMR (CDCl3 400MHz): ~ 2.32 (s, 6H), 2.80 (s, 3H), 3.74 (s, 3H), 7.0-7.4 (m, lOH).
WO 94/29309 2 1 6 3 q ~ j PCT/US94/05545 MS (CI): 613 (M++1: 35Clx2), 615 (M++1: 3~Cl& 37Cl).
1 '-(3-(S)-(3,4-Dichlorophenyl)-6-(3,5-dimethylphenyl)-5-(RS)-methyl-6-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) Step 1) 4-(S)-(3,4-Dichlorophenyl)- 1 -(3,5-dimethylphenyl)-hept-6-ene-1 -one 1.42g (4.50mmol) of (N-Methoxy-N-methyl)-(4-(S)-(3,4-dichlorophenyl)-6-heptenyl)-amide (prepared in Example 134) was dissolved in 20mL of dry THF. To it added 10mL THF solution of 3,5-5 dimethylphenylmagnesium bromide prepared from 1.8g (9.6mmol) of 5-bromo-m-xylene and 463mg of magnesium turnings. After stirring for 2hr at rt, the reaction was quenched with saturated aqueous ammonium chloride solution. THF was removed under reduced pressure. The residual material was diluted with ethyl acetate. The 20 organic phase was separated, aqueous phase was extracted twice with ethyl acetate. Combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, filtered, concentrated, chromatogrpraphed on silica gel eluting with a gradient of hexane:
ethyl acetate = 10: 1 to 5: 1 to give 1.57g of 4-(S)-(3,4-25 dichlorophenyl)-1 -(3,5-dimethylphenyl)-hept-6-ene-1 -one (97%).
Step 2) 4-(R)-(3,4-Dichlorophenyl)-1-(3,5-dimethylphenyl)-2-(RS)-methyl-hept-6-ene- 1 -one Hexamethyldisilazane (0.108mL, 0.512mmol), and 0.089mL of hexamethylphosphoramide were dissolved in 2mL of dry THF. To it was added 0.306mL (0.49mmol) of n-butyllithium (1.6M hexane solution) after cooling in an ice-water bath. After stirring for 20min, WO 94129309 2 1 6 3 ~ ~ 5 PCT/US94/05545 the ice-water bath was replaced by a dry ice-acetone bath and 2mL of a dry THF solution of 4-(S)-(3,4-dichlorophenyl)-1-(3,5-dimethylphenyl)-hept-6-ene-1-one (154mg, 0.426mmol) was added via syringe. After stirring for lhr, 0.066mL (1.06mmol) of iodomethane 5 was added . The cooling bath was removed and the mixture stirred at rt overnight. The solvent was then removed under reduced pressure and the residual material was diluted in ethyl acetate and water. The organic phase was separated. The a~ueous phase was extracted twice with ethyl acetate. The combined organic phases were washed with o brine, dried over anhydrous magnesium sulfate, filtered, concentrated, and chromatographed on silica gel eluting with a gradient of hexane:
ethyl acetate = 10: 1 to 7: l to give l50mg of 4-(R)-(3,4-dichlorophenyl)- l -(3,5-dimethylphenyl)-2-(R &S)-methyl-hept-6-ene- 1 -one (94%). This was a 1 to 1 mixture of two diastereomers as revealed 5 by proton NMR.
H-NMR (CDCI3 400MHz): ~ 1.06 ( d, J=7Hz, l.5H), 1.14 ( d, J=6.7Hz, l.5H), 2.30, 2.31 (s, 6H), 2.5 (m, O.5H), 2.6 (m, O.5H), 3.1-3.2 (m, lH), 4.9 (m, 2H), 5.5 (m, lH), 6.8-7.4 (m, 6H).
Step 3) 3-(S)-(3,4-Dichlorophenyl)-5-(RS)-methyl-6-(3,5-dimethylphenyl)-6-oxo-hexanal The product from Step 2 above was subjected to osmium tetroxide oxidation followed by the treatment with sodium periodate as described in Example 1 to give 3-(S)-(3,4-dichlorophenyl)-5-(RS)-methyl-6-(3,5 -dimethylphenyl)-6-oxo-hexanal.
Step 4) l '-(3-(S)-(3,4-Dichlorophenyl)-6-(3,5-dimethylphenyl)-5-(RS)-methyl-6-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine) 21 6~qq5 This product from Step 3 above was subjected to reductive amination with 1-methanesulonyl-spiro(indoline-3,4'-piperidine) as described in Example 2 to give the title compound.
1H-NMR (CDCl3 400MHz): ~ 1.05 (d, J=7Hz),1.08 (d, J=6.7Hz), 2.30 & 2.32 (s, 6H), 2.89 (s, 3H), 3.72 (S, 2H), 6.8-7.0 (m, 10H).
MS (CI): 627 (M++1: 35Clx2), 629 (M++1: 35Cl& 37Cl).
1 '-(3 -(S )-(3,4-Dichlorophenyl)-4-(3,5 -(bistrifluoromethyl)benzyloxy)-l -acetyl -spiro(indoline-3,4 ' -piperidine) Step A: 2-(S)-(3,4-Dichlorophenyl)-4-penten-1-ol To a solution of 2-(S)-(3,4-dichlorophenyl)-4-pentenoic acid (7.0 gm) (prepared as described by J. Hale et. al., Bioorganic & Medicinal Chemistry Letters 1993,3, 319-322.) in ether (50 mL) at r.t. was added portionwise over 5 min solid lithium aluminum hydride (700 mg). The reaction was heated to 40 C for 3 hr and then stirred at r.t. for 16 hr.
The reaction was poured into water cont~ining 25 mL of 2N NaOH and extracted twice with ether. The ether layers were washed with brine, combined and dried over Na2SO4. Flash chromatograghy afforded the title compound (4.5 gm) as an oil. [a]D = +14 (EtOH, c = 1.5).
Step B: 2-(S)-(3,4-Dichlorophenyl)-1-(3,5-(bistrifluoromethyl)benzyloxy)-4-pentene To a solution of 2-(S)-(3,4-dichlorophenyl)-4-penten-1-ol (1.0 gm) in DMF (25 mL) was added sodium hydride (175 mg) while cooled in an ice bath. After 1 min, 3,5-(bistrifluoromethyl)benzyl bromide (2.0 gm) was added followed by a second portion of sodium hydride (175 mg).
After 1 hr, the reaction was poured into water and extracted twice with ether. The ether layers were washed with brine, combined and dried over Na2SO4. Flash chromatograghy (hexanes, then 2 and 5% ethyl acetate/hexanes) afforded the title compound (2.0 gm) as an oil.
2 1 6399~
NMR (CDCl3): ~ 2.30-2.40 and 2.50-2.60 (2 m, 2 H), 2.90-3.00 (m, l H), 3.55-3.65 (d of AB q, 2 H, J = 6 and 9 Hz), 4.54 (AB q, 2 H, J = 13 Hz), 4.90-5.00 (m, 2 H), 5.55-5.70 (m, 1 H), 7.04 (dd, I H, J = 2 and Hz), 7.30 (d, 1 h, J = 2 Hz), 7.36 (d, 1 h, J = 8 Hz), 7.64 (s, 2 h), 7.76 (s, 1 H).
Step C: 3-(S)-(3,4-Dichlorophenyl)-4-(3,5-(bistrifluoromethyl)benzyloxy)butan- 1 -ol o A solution of 2-(S)-(3,4-dichlorophenyl)-1-(3,5-(bistrifluoromethyl)benzyloxy)-4-pentene (1.5 gm) in methanol (50 mL) was cooled to -70 C in a dry ice/acetone bath and ozone bubbled thru for 15 min until a blue coloration was seen. The solution was purged with N2 for 10 min and sodium borohydride was added. The reaction was allowed to warm to r.t. and was stirred for 2 hr. The volatiles were removed in vacuo and the residue was flash chromatograghed (30 then 50% ethyl acetate/hexanes) to give the title compound as a clear oil.
NMR (CDCl3): ~ 1.78-1.88 and 2.00-2.10 (2 m, 2 H), 3.05-3.15 (m, 1 H), 3.45-3.55 (m, 1 H), 3.55-3.68 (2 m, 3 H), 4.55 (AB q, 2 H, J = 13 Hz), 7.04 (dd, 1 H, J = 2 and 8 Hz), 7.32 (d, 1 h, J = 2 Hz), 7.36 (d, 1 h, J = 8 Hz), 7.65 (s, 2 h), 7.76 (s, 1 H).
Step D: 4-Bromo-2-(S)-(3,4-dichlorophenyl)-1-(3,5-(bistrifluoromethyl)benzyloxy)butane 3-(S)-(3,4-Dichlorophenyl)-4 (3,5 (bistrifluoromethyl)benzyloxy)butan-1-ol from Step C (500 mg) was converted to the title compound (530 mg) with Ph3P-Br2 as described in Example 20, Step B.
Step E: 1'-(3-(S)-(3,4-Dichlorophenyl)-4-(3,5-(bistrifluoromethyl)benzyloxy)- 1 -acetyl-spiro(indoline-3,4r-piperidine).
4-Bromo-2-(S)-(3,4-dichlorophenyl)- 1 -(3,5 -(bistrifluoromethyl)benzyloxy)butane (30 mg) from Step D was converted to the title compound (42 mg) as described in Example 20, Step C.
2 1 ~39~5 NMR (CDCl3): ~ 1.48-2.05 (m,10 H),2.14 and 2.34 (2 s,3 H),2.10-2.25 (m,2 H),2.70-2.85 (m,2 H),2.90 (m, l H),3.48-3.58 (m,2 H), 3.70 and 3.84 (2 s,2 H),4.55 (AB q,2 H, J = 13 Hz),6.90-7.15 (m,4 h),7.33 (d, l h, J = 2 Hz),7.37 (d, l h, J = 8 Hz),7.66 (s,2 h),7.76 (s,1 H),8.18(d,1 h,8Hz).
Claims (20)
1. A compound of formula I
I
or a pharmaceutically acceptable salt thereof, wherein the nitrogen expressly shown above is optionally quaternized with C1-4 alkyl or phenyl C1-4 alkyl or is optionally present as the N-oxide (N+O-), and wherein:
l and m are each independently 0, 1, 2, 3, 4, or 5, with the proviso that 1 + m is equal to 1, 2, 3, 4, or 5;
R1 is selected from a group consisting of:
( 1 ) hydrogen, (2) linear or branched C1-8 alkyl, linear or branched C2-8 alkenyl, or linear or branched C2-8 alkynyl, wherein the C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl is di or tri or tetra substituted, the substitutents independently selected from:
(a) hydroxy, (b) oxo, (c) cyano, (d) halogen which is defined to include Br, Cl, I, and F, (e) trifluoromethyl, (f) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) C1-3 alkyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (7) -NR6COR7, wherein R6 and R7 are independently selected from:
(a) hydrogen, (b) C1-6 alkyl, or mono or disubstituted C1-6 alkyl, the substitutents independently selected from (1) phenyl,unsubstituted or substituted with hydroxy, C1-3 alkyl, cyano, halogen, trifluoromethyl or C1-4 alkoxy, (2) hydroxy, (3) oxo, (4) cyano, (5) halogen, (6) trifluoromethyl, (c) phenyl, pyridinyl or thiophene or mono, di or trisubstituted phenyl, pyridinyl or thiophene, the substitutents independently selected from (1) hydroxy, (2) C1-4 alkyl, (3) cyano, (4) halogen, (5) trifluoromethyl, (d) C1-3 alkyloxy, or R6 and R7 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or disubstituted, the substituents independently selected from (a) hydroxy, (b) oxo, (c) cyano, (d) halogen, (e) trifluoromethyl, (8) -NR6CO2R7, (9) -NR6CONHR7, (10) -NR6S(O)jR7, wherein j is 1 or 2, (11) -CONR6R7, (12) -COR6, (13) -CO2R6, (14) -OR6, (15) -S(O)kR6 wherein k is 0, 1 or 2, (16) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) benzimidazolyl, (2) benzofuranyl, (3) benzoxazolyl, (4) furanyl, (5) imidazolyl, (6) indolyl, (7) isoxazolyl, (8) isothiazolyl, (9) oxadiazolyl, (10) oxazolyl, (11) pyrazinyl, (12) pyrazolyl, (13) pyridyl, (14) pyrimidyl, (15) pyrrolyl, (16) quinolyl, (17) tetrazolyl, (18) thiadiazolyl, (19) thiazolyl, (20) thienyl, and (21) triazolyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from, (a) hydroxy, (b) oxo, (c) cyano, (d) halogen, (e) trifluoromethyl, (g) -NR6R7, (h) -NR6COR7, (i) -NR6CO2R7, (j) -NR6CONHR7, (k) -NR6S(O)jR7, (l) -CONR6R7, (m) -COR6, (n) -CO2R6, (o) -OR6, (p) -S(O)kR6, (q) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) benzimidazolyl, (2) benzofuranyl, (3) benzoxazolyl, (4) furanyl, (5) imidazolyl, (6) indolyl, (7) isoxazolyl, (8) isothiazolyl, (9) oxadiazolyl, (10) oxazolyl, (11) pyrazinyl, (12) pyrazolyl, (13) pyridyl, (14) pyrimidyl, (15) pyrrolyl, (16) quinolyl, (17) tetrazolyl, (18) thiadiazolyl, (19) thiazolyl, (20) thienyl, (21) triazolyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from (1) phenyl, (2) hydroxy, (3) oxo, (4) cyano, (5) halogen, (6) trifluoromethyl, wherein the nitrogen of definition R1 2(g) as defined above is optionally quaternized with C1-4 alkyl or phenyl C1-4 alkyl or is optionally present as the N-oxide (N+O-);
W is selected from the group consisting of (1) a covalent bond (2) C1-3 alkyl, unsubstituted or substituted with (a) oxo, (b) OR6, (c) halogen, (d) trifluoromethyl, (e) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) hydroxy, (2) cyano, (3) halogen, (4) trifluoromethyl, (3) S(O)k, (4) (C1-3 alkyl)-S(O)k, (5) S(O)k-(C1-2 alkyl), (6) S(O)k-NH, (7) S(O)j-NH(C1-2 alkyl), (8) S(O)j-NR6, (9) S(O)j-NR6-(C1-2 alkyl), (10) CONH, (11) CONH-(C1-2 alkyl), (12) CONR6, (13) CONR6-(C1-2 alkyl), (14) CO2, (15) CO2-(C1-2 alkyl);
Q = NR2, O, S, S(O), or SO2, with the proviso that when W is a covalent bond and X is C1-3 alkyl, then Q must be NR2;
R2 is selected from a group consisting of:
(1) hydrogen, (2) C1-8 linear or branched alkyl,unsubstituted, monosubstituted or multiply substituted with (a) -OR6, (b) = O, (c) -NHCOR6, (d) -NR6R7, (e) -CN, (f) -halogen, (g) -CF3, (i) -phenyl, unsubstituted or substituted, wherein the substitutents are selected from the group consisting of (1) hydroxy, (2) cyano, (3) halogen, (4) trifluoromethyl, (3) S(O)R8, wherein R8 is C1-6 linear or branched alkyl, unsubstituted, mono di or trisubstituted with (a) hydroxy, (b) oxo, (c) cyano, (d) -OR6, (e) -NR6R7, (f) -NR6COR7, (g) -halogen, and (h) -CF3, (i) -phenyl or mono, di or trisubstituted phenyl, the substituents independently selected from (1) hydroxy, (2) oxo, (3) cyano, (4) -NHR6, (S) -NR6R7, (6) -NR6COR7, (7) -halogen, (8) -CF3, and (9) C 1-3 alkyl, (4) SO2Rg, or (5) COR8, (6) CO2R8;
(7) CONR7R8;
X is selected from the group consisting of (1) a covalent bond (2) C1-3 alkyl, unsubstituted or substituted with (a) oxo, (b) OR6, (c) halogen, (d) trifluoromethyl, (e) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) hydroxy (2) OR6, (3) halogen, and (4) trifluoromethyl, (3) S(O)k, (4) (C1-3 alkyl)S(O)k, (5) S(O)k(C1-2 alkyl), (6) NHS(O)j, (7) NH(C1-2 alkyl)S(O)j, (8) S(O)jNR6, (9) S(O)j-NR6-(C1-2 alkyl), (10) NHCO, (11) NHCO-(C1-2 alkyl), (12) NR6CO, (13) NR6-(C1-2 alkyl)CO, (14) O(CO), and (15) (C1 -2 alkyl)O(CO), Y-Z considered together are 2 adjoining atoms of the ring said ring being an phenyl, naphthyl or heteroaryl group, with the heteroaryls selected from the group consisting of:
(1) benzimidazolyl, (2) benzofuranyl, (3) benzoxazolyl, (4) furanyl, (5) imidazolyl, (6) indolyl, (7) isoxazolyl, (8) isothiazolyl, (9) oxadiazolyl, (10) oxazolyl, (11) pyrazinyl, (12) pyrazolyl, (13) pyridyl, (14) pyrimidyl, (15) pyrrolyl, (16) quinolyl, (17) tetrazolyl, (18) thiadiazolyl, (19) thiazolyl, (20) thienyl, (21) triazolyl, and wherein the aryl or heteroaryl group is unsubstituted, mono, di or tri substituted, the substitutents selected from:
(a) hydrogen, (b) C1-6 alkyl, branched or unbranched, unsubstituted or mono or disubstituted, the substituents being selected from hydrogen and hydroxy, (c) oxo (d) OR6, wherein R6 is as defined immediately above, (e) halogen, (f) trifluoromethyl, (g) nitro, (h cyano, (i) NR6R7, (j) NR6COR7, (k) NR6CO2R7, (1) NHS(O)jR6, (m) NR6S(O)iR
(n) CONR6R7, (o) COR6, p) CO2R6, (q) S(O)jR6, (r) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(a) benzimidazolyl, (b) benzofuranyl, (c) benzoxazolyl, (d) furanyl, (e) imidazolyl, (f) indolyl, (g) isoxazolyl, (h) isothiazolyl, (i) oxadiazolyl, (j) oxazolyl, (k) pyrazinyl, (l) pyrazolyl, (m) pyridyl, (n) pyrimidyl, (o) pyrrolyl, (p) quinolyl, (q) tetrazolyl, (r) thiadiazolyl, (s) thiazolyl, (t) thienyl, (u) triazolyl, and wherein the heteroaryl is unsubstituted mono or di substituted, the substitutents selected from (1) hydrogen, (2) C1-6 alkyl, branched or unbranched, unsubstituted or mono or disubstituted, the substituents being selected from hydrogen and hydroxy, (3) oxo (4) OR6, (5) trifluoromethyl, (6) nitro, (7) cyano, (8) NR6R7, (9) NR6COR7, (10) NR6CO2R7, (11) NHS(O)jR6, (12) NR6S(O)jR7, (18) CONR6R7, (19) COR6, (20) CO2R6, (21) S(O)jR6, and (22) phenyl.
I
or a pharmaceutically acceptable salt thereof, wherein the nitrogen expressly shown above is optionally quaternized with C1-4 alkyl or phenyl C1-4 alkyl or is optionally present as the N-oxide (N+O-), and wherein:
l and m are each independently 0, 1, 2, 3, 4, or 5, with the proviso that 1 + m is equal to 1, 2, 3, 4, or 5;
R1 is selected from a group consisting of:
( 1 ) hydrogen, (2) linear or branched C1-8 alkyl, linear or branched C2-8 alkenyl, or linear or branched C2-8 alkynyl, wherein the C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl is di or tri or tetra substituted, the substitutents independently selected from:
(a) hydroxy, (b) oxo, (c) cyano, (d) halogen which is defined to include Br, Cl, I, and F, (e) trifluoromethyl, (f) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) C1-3 alkyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (7) -NR6COR7, wherein R6 and R7 are independently selected from:
(a) hydrogen, (b) C1-6 alkyl, or mono or disubstituted C1-6 alkyl, the substitutents independently selected from (1) phenyl,unsubstituted or substituted with hydroxy, C1-3 alkyl, cyano, halogen, trifluoromethyl or C1-4 alkoxy, (2) hydroxy, (3) oxo, (4) cyano, (5) halogen, (6) trifluoromethyl, (c) phenyl, pyridinyl or thiophene or mono, di or trisubstituted phenyl, pyridinyl or thiophene, the substitutents independently selected from (1) hydroxy, (2) C1-4 alkyl, (3) cyano, (4) halogen, (5) trifluoromethyl, (d) C1-3 alkyloxy, or R6 and R7 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or disubstituted, the substituents independently selected from (a) hydroxy, (b) oxo, (c) cyano, (d) halogen, (e) trifluoromethyl, (8) -NR6CO2R7, (9) -NR6CONHR7, (10) -NR6S(O)jR7, wherein j is 1 or 2, (11) -CONR6R7, (12) -COR6, (13) -CO2R6, (14) -OR6, (15) -S(O)kR6 wherein k is 0, 1 or 2, (16) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) benzimidazolyl, (2) benzofuranyl, (3) benzoxazolyl, (4) furanyl, (5) imidazolyl, (6) indolyl, (7) isoxazolyl, (8) isothiazolyl, (9) oxadiazolyl, (10) oxazolyl, (11) pyrazinyl, (12) pyrazolyl, (13) pyridyl, (14) pyrimidyl, (15) pyrrolyl, (16) quinolyl, (17) tetrazolyl, (18) thiadiazolyl, (19) thiazolyl, (20) thienyl, and (21) triazolyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from, (a) hydroxy, (b) oxo, (c) cyano, (d) halogen, (e) trifluoromethyl, (g) -NR6R7, (h) -NR6COR7, (i) -NR6CO2R7, (j) -NR6CONHR7, (k) -NR6S(O)jR7, (l) -CONR6R7, (m) -COR6, (n) -CO2R6, (o) -OR6, (p) -S(O)kR6, (q) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) benzimidazolyl, (2) benzofuranyl, (3) benzoxazolyl, (4) furanyl, (5) imidazolyl, (6) indolyl, (7) isoxazolyl, (8) isothiazolyl, (9) oxadiazolyl, (10) oxazolyl, (11) pyrazinyl, (12) pyrazolyl, (13) pyridyl, (14) pyrimidyl, (15) pyrrolyl, (16) quinolyl, (17) tetrazolyl, (18) thiadiazolyl, (19) thiazolyl, (20) thienyl, (21) triazolyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from (1) phenyl, (2) hydroxy, (3) oxo, (4) cyano, (5) halogen, (6) trifluoromethyl, wherein the nitrogen of definition R1 2(g) as defined above is optionally quaternized with C1-4 alkyl or phenyl C1-4 alkyl or is optionally present as the N-oxide (N+O-);
W is selected from the group consisting of (1) a covalent bond (2) C1-3 alkyl, unsubstituted or substituted with (a) oxo, (b) OR6, (c) halogen, (d) trifluoromethyl, (e) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) hydroxy, (2) cyano, (3) halogen, (4) trifluoromethyl, (3) S(O)k, (4) (C1-3 alkyl)-S(O)k, (5) S(O)k-(C1-2 alkyl), (6) S(O)k-NH, (7) S(O)j-NH(C1-2 alkyl), (8) S(O)j-NR6, (9) S(O)j-NR6-(C1-2 alkyl), (10) CONH, (11) CONH-(C1-2 alkyl), (12) CONR6, (13) CONR6-(C1-2 alkyl), (14) CO2, (15) CO2-(C1-2 alkyl);
Q = NR2, O, S, S(O), or SO2, with the proviso that when W is a covalent bond and X is C1-3 alkyl, then Q must be NR2;
R2 is selected from a group consisting of:
(1) hydrogen, (2) C1-8 linear or branched alkyl,unsubstituted, monosubstituted or multiply substituted with (a) -OR6, (b) = O, (c) -NHCOR6, (d) -NR6R7, (e) -CN, (f) -halogen, (g) -CF3, (i) -phenyl, unsubstituted or substituted, wherein the substitutents are selected from the group consisting of (1) hydroxy, (2) cyano, (3) halogen, (4) trifluoromethyl, (3) S(O)R8, wherein R8 is C1-6 linear or branched alkyl, unsubstituted, mono di or trisubstituted with (a) hydroxy, (b) oxo, (c) cyano, (d) -OR6, (e) -NR6R7, (f) -NR6COR7, (g) -halogen, and (h) -CF3, (i) -phenyl or mono, di or trisubstituted phenyl, the substituents independently selected from (1) hydroxy, (2) oxo, (3) cyano, (4) -NHR6, (S) -NR6R7, (6) -NR6COR7, (7) -halogen, (8) -CF3, and (9) C 1-3 alkyl, (4) SO2Rg, or (5) COR8, (6) CO2R8;
(7) CONR7R8;
X is selected from the group consisting of (1) a covalent bond (2) C1-3 alkyl, unsubstituted or substituted with (a) oxo, (b) OR6, (c) halogen, (d) trifluoromethyl, (e) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) hydroxy (2) OR6, (3) halogen, and (4) trifluoromethyl, (3) S(O)k, (4) (C1-3 alkyl)S(O)k, (5) S(O)k(C1-2 alkyl), (6) NHS(O)j, (7) NH(C1-2 alkyl)S(O)j, (8) S(O)jNR6, (9) S(O)j-NR6-(C1-2 alkyl), (10) NHCO, (11) NHCO-(C1-2 alkyl), (12) NR6CO, (13) NR6-(C1-2 alkyl)CO, (14) O(CO), and (15) (C1 -2 alkyl)O(CO), Y-Z considered together are 2 adjoining atoms of the ring said ring being an phenyl, naphthyl or heteroaryl group, with the heteroaryls selected from the group consisting of:
(1) benzimidazolyl, (2) benzofuranyl, (3) benzoxazolyl, (4) furanyl, (5) imidazolyl, (6) indolyl, (7) isoxazolyl, (8) isothiazolyl, (9) oxadiazolyl, (10) oxazolyl, (11) pyrazinyl, (12) pyrazolyl, (13) pyridyl, (14) pyrimidyl, (15) pyrrolyl, (16) quinolyl, (17) tetrazolyl, (18) thiadiazolyl, (19) thiazolyl, (20) thienyl, (21) triazolyl, and wherein the aryl or heteroaryl group is unsubstituted, mono, di or tri substituted, the substitutents selected from:
(a) hydrogen, (b) C1-6 alkyl, branched or unbranched, unsubstituted or mono or disubstituted, the substituents being selected from hydrogen and hydroxy, (c) oxo (d) OR6, wherein R6 is as defined immediately above, (e) halogen, (f) trifluoromethyl, (g) nitro, (h cyano, (i) NR6R7, (j) NR6COR7, (k) NR6CO2R7, (1) NHS(O)jR6, (m) NR6S(O)iR
(n) CONR6R7, (o) COR6, p) CO2R6, (q) S(O)jR6, (r) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(a) benzimidazolyl, (b) benzofuranyl, (c) benzoxazolyl, (d) furanyl, (e) imidazolyl, (f) indolyl, (g) isoxazolyl, (h) isothiazolyl, (i) oxadiazolyl, (j) oxazolyl, (k) pyrazinyl, (l) pyrazolyl, (m) pyridyl, (n) pyrimidyl, (o) pyrrolyl, (p) quinolyl, (q) tetrazolyl, (r) thiadiazolyl, (s) thiazolyl, (t) thienyl, (u) triazolyl, and wherein the heteroaryl is unsubstituted mono or di substituted, the substitutents selected from (1) hydrogen, (2) C1-6 alkyl, branched or unbranched, unsubstituted or mono or disubstituted, the substituents being selected from hydrogen and hydroxy, (3) oxo (4) OR6, (5) trifluoromethyl, (6) nitro, (7) cyano, (8) NR6R7, (9) NR6COR7, (10) NR6CO2R7, (11) NHS(O)jR6, (12) NR6S(O)jR7, (18) CONR6R7, (19) COR6, (20) CO2R6, (21) S(O)jR6, and (22) phenyl.
2. A compound according to Claim 1 wherein:
1 + m is equal to 2, 3, or4;
Y and Z are each individually a carbon atom;
R1 is selected from a group consisting of:
C1, C2, C3, C4, C5, C6, C7 or C8 linear or branched alkyl, di, tri or tetra substituted, the substitutents independently selected from:
(a) hydroxy, (b) Cl or F, (c) trifluoromethyl, (d) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) C1-3 alkyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (7) -NR6COR7, wherein R6 and R7 are independently selected from:
(a) hydrogen, (b) C1-6 alkyl, or mono or disubstituted C1-6 alkyl, the substitutents independently selected from (1) phenyl,unsubstituted or substituted with hydroxy, C1-3 alkyl, cyano, halogen, trifluoromethyl or C1-4 alkoxy, (2) hydroxy, (3) oxo, (4) cyano, (5) halogen, (6) trifluoromethyl, (c) phenyl, pyridinyl or thiophene or mono, di or trisubstituted phenyl, pyridinyl or thiophene, the substitutents independently selected from (1) hydroxy, (2) C1-4alkyl, (3) cyano, (4) halogen, (5) trifluoromethyl, (d) C1-3 alkyloxy, or R6 and R7 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring contaiining 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or disubstituted, the substituents independently selected from (a) hydroxy, (b) oxo, (c) cyano, (d) halogen, (e) trifluoromethyl, (8) -NR6CO2R7, (9) -NR6CONHR7, (10) -NR6S(O)jR7, wherein j is 1 or 2, (11) -CONR6R7, (12) -COR6, (13) -CO2R6, (14) -OR6, (15) -S(O)kR6, (16) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(a) pyrazinyl, (b) pyrazolyl, (c) pyridyl, (d) pyrimidyl, and (e) thienyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from, (a) hydroxy, (b) oxo, (c) cyano, (d) halogen, (e) trifluoromethyl, (e) -NR6COR7, (f) -NR6CO2R7, (g) -NR6CONHR7, (h) -NHS(O)jR6, (i) -COR6, (i) -OR6, (k) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) pyrazinyl, (2) pyrazolyl, (3) pyridyl, (4) pyrimidyl, and (5) thienyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from (a) phenyl, (b) hydroxy, (c) oxo, (d) cyano, (e) halogen, and (f) trifluoromethyl, W is selected from the group consisting of (1) a covalent bond (2) C1-3 alkyl, unsubstituted or substituted with oxo, and (3) S(O)2;
Q = NR2, S, S(O) or SO2, with the proviso that when W is a covalent bond and X is C1-3 alkyl, then Q must be NR2;
R2 is selected from a group consisting of:
( 1 ) hydrogen, (2) C1, C2, C3, C4, C5, C6, C7 or C8 linear or branched alkyl, unsubstituted, monosubstituted or multiply substituted with (a) -OR6, (b) = O, (c) -NR6R7, (3) SO2Rg, wherein R8 is C1-4 linear or branched alkyl, unsubstituted, mono or disubstituted with (a) -OR6, (b) -NHCOR6, (c) -NR6R7, (d) -halogen, (e) -phenyl;
(4) COR8, or (5) CO2R8;
(6) CONR7R8;
X is selected from the group consisting of (1) a covalent bond, and (2) C1-3 alkyl;
Y-Z considered together are 2 adjoining atoms of the ring said ring being an phenyl, naphthyl or heteroaryl, with the heteroaryl selected from (1) pyrazinyl, (2) pyrazolyl, (3) pyridyl, (4) pyrimidyl, and (5) thienyl.
1 + m is equal to 2, 3, or4;
Y and Z are each individually a carbon atom;
R1 is selected from a group consisting of:
C1, C2, C3, C4, C5, C6, C7 or C8 linear or branched alkyl, di, tri or tetra substituted, the substitutents independently selected from:
(a) hydroxy, (b) Cl or F, (c) trifluoromethyl, (d) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) C1-3 alkyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (7) -NR6COR7, wherein R6 and R7 are independently selected from:
(a) hydrogen, (b) C1-6 alkyl, or mono or disubstituted C1-6 alkyl, the substitutents independently selected from (1) phenyl,unsubstituted or substituted with hydroxy, C1-3 alkyl, cyano, halogen, trifluoromethyl or C1-4 alkoxy, (2) hydroxy, (3) oxo, (4) cyano, (5) halogen, (6) trifluoromethyl, (c) phenyl, pyridinyl or thiophene or mono, di or trisubstituted phenyl, pyridinyl or thiophene, the substitutents independently selected from (1) hydroxy, (2) C1-4alkyl, (3) cyano, (4) halogen, (5) trifluoromethyl, (d) C1-3 alkyloxy, or R6 and R7 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring contaiining 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or disubstituted, the substituents independently selected from (a) hydroxy, (b) oxo, (c) cyano, (d) halogen, (e) trifluoromethyl, (8) -NR6CO2R7, (9) -NR6CONHR7, (10) -NR6S(O)jR7, wherein j is 1 or 2, (11) -CONR6R7, (12) -COR6, (13) -CO2R6, (14) -OR6, (15) -S(O)kR6, (16) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(a) pyrazinyl, (b) pyrazolyl, (c) pyridyl, (d) pyrimidyl, and (e) thienyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from, (a) hydroxy, (b) oxo, (c) cyano, (d) halogen, (e) trifluoromethyl, (e) -NR6COR7, (f) -NR6CO2R7, (g) -NR6CONHR7, (h) -NHS(O)jR6, (i) -COR6, (i) -OR6, (k) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) pyrazinyl, (2) pyrazolyl, (3) pyridyl, (4) pyrimidyl, and (5) thienyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from (a) phenyl, (b) hydroxy, (c) oxo, (d) cyano, (e) halogen, and (f) trifluoromethyl, W is selected from the group consisting of (1) a covalent bond (2) C1-3 alkyl, unsubstituted or substituted with oxo, and (3) S(O)2;
Q = NR2, S, S(O) or SO2, with the proviso that when W is a covalent bond and X is C1-3 alkyl, then Q must be NR2;
R2 is selected from a group consisting of:
( 1 ) hydrogen, (2) C1, C2, C3, C4, C5, C6, C7 or C8 linear or branched alkyl, unsubstituted, monosubstituted or multiply substituted with (a) -OR6, (b) = O, (c) -NR6R7, (3) SO2Rg, wherein R8 is C1-4 linear or branched alkyl, unsubstituted, mono or disubstituted with (a) -OR6, (b) -NHCOR6, (c) -NR6R7, (d) -halogen, (e) -phenyl;
(4) COR8, or (5) CO2R8;
(6) CONR7R8;
X is selected from the group consisting of (1) a covalent bond, and (2) C1-3 alkyl;
Y-Z considered together are 2 adjoining atoms of the ring said ring being an phenyl, naphthyl or heteroaryl, with the heteroaryl selected from (1) pyrazinyl, (2) pyrazolyl, (3) pyridyl, (4) pyrimidyl, and (5) thienyl.
3. A compound according to Claim 2 wherein:
1 + m is equal to 2, 3, or 4;
R1 is selected from a group consisting of:
C1, C2, C3, C4, C5 or C6 linear or branched alkyl, di or tri substituted, the substitutents independently selected from:
(a) hydroxy, (b) Cl or F, (c) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) C1-3 alkyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (d) -NR6COR7, wherein R6 is hydrogen or C1-3 alkyl and R7 is phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, wherein the phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, is optionally substituted with Cl, F, CF3 or C1-3 alkyl, (e) -NHS(O)jR6, (f) -COR6, (h) -OR6, W is selected from the group consisting of (1 ) a covalent bond, and (2) C1-3 alkyl, unsubstituted or substituted with oxo;
Q is NR2, S, S(O) or S(O)2;
R2 is selected from a group consisting of:
(1) hydrogen, (2) C1, C2, C3 or C4 linear or branched alkyl, unsubstituted, monosubstituted or disubstituted with oxo, OR6, NR6R7 or phenyl, (3) SO2R8, (4) COR8, or (5) CO2R8;
(6) CONR7R8;
X is selected from the group consisting of (1) a covalent bond, and (2) methylene or 1-ethylene or 2-ethylene;
Y-Z considered together are 2 adjoining atoms of the ring said ring being phenyl.
1 + m is equal to 2, 3, or 4;
R1 is selected from a group consisting of:
C1, C2, C3, C4, C5 or C6 linear or branched alkyl, di or tri substituted, the substitutents independently selected from:
(a) hydroxy, (b) Cl or F, (c) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) C1-3 alkyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (d) -NR6COR7, wherein R6 is hydrogen or C1-3 alkyl and R7 is phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, wherein the phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, is optionally substituted with Cl, F, CF3 or C1-3 alkyl, (e) -NHS(O)jR6, (f) -COR6, (h) -OR6, W is selected from the group consisting of (1 ) a covalent bond, and (2) C1-3 alkyl, unsubstituted or substituted with oxo;
Q is NR2, S, S(O) or S(O)2;
R2 is selected from a group consisting of:
(1) hydrogen, (2) C1, C2, C3 or C4 linear or branched alkyl, unsubstituted, monosubstituted or disubstituted with oxo, OR6, NR6R7 or phenyl, (3) SO2R8, (4) COR8, or (5) CO2R8;
(6) CONR7R8;
X is selected from the group consisting of (1) a covalent bond, and (2) methylene or 1-ethylene or 2-ethylene;
Y-Z considered together are 2 adjoining atoms of the ring said ring being phenyl.
4. A compound according to Claim 3 wherein:
1 + m is equal to 2 or 3;
R1 is selected from a group consisting of:
C1, C2, C3, C4, C5 or C6 linear or branched alkyl, di or tri substituted, the substitutents independently selected from:
(a) hydroxy, (b) Cl or F, (c) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) methyl or ethyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (d) -NR6COR7, wherein R6 is methyl and R7 is phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, wherein the phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1 3 alkyl or thiophenel C1-3 alkyl, is optionally substituted with Cl, F, CF3 or C1-3 alkyl, W is selected from the group consisting of (1) a covalent bond, and (2) C1-3 alkyl, unsubstituted or substituted with oxo, and Q is NR2;
R2 is selected from a group consisting of:
(1) hydrogen, (2) C1, C2, C3 or C4 linear or branched alkyl,unsubstituted, monosubstituted or multiply substituted with oxo, OR6, NR6R7 and phenyl (3) SO2R8, (4) COR8, or (5) CO2R8;
(6) CONR7R8;
X is selected from the group consisting of (1) a covalent bond, and (2) methylene or 1-ethylene or 2-ethylene;
Y-Z considered together are 2 adjoining atoms of the ring said ring being phenyl.
1 + m is equal to 2 or 3;
R1 is selected from a group consisting of:
C1, C2, C3, C4, C5 or C6 linear or branched alkyl, di or tri substituted, the substitutents independently selected from:
(a) hydroxy, (b) Cl or F, (c) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) methyl or ethyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (d) -NR6COR7, wherein R6 is methyl and R7 is phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, wherein the phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1 3 alkyl or thiophenel C1-3 alkyl, is optionally substituted with Cl, F, CF3 or C1-3 alkyl, W is selected from the group consisting of (1) a covalent bond, and (2) C1-3 alkyl, unsubstituted or substituted with oxo, and Q is NR2;
R2 is selected from a group consisting of:
(1) hydrogen, (2) C1, C2, C3 or C4 linear or branched alkyl,unsubstituted, monosubstituted or multiply substituted with oxo, OR6, NR6R7 and phenyl (3) SO2R8, (4) COR8, or (5) CO2R8;
(6) CONR7R8;
X is selected from the group consisting of (1) a covalent bond, and (2) methylene or 1-ethylene or 2-ethylene;
Y-Z considered together are 2 adjoining atoms of the ring said ring being phenyl.
5. A according to Claim 4 wherein:
1 + m is 3;
R1 is ;
where B is (a) phenyl or mono di or trisubstituted phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3;
(b) -CH2phenyl or mono or disubstituted -CH2phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3;
(c) pyridyl or mono di or trisubstituted pyridyl wherein the substitutents are independently chloro, methyl, phenyl or CF3; and (d) thiophene or mono or disubstituted thiophene wherein the substitutents are independently chloro, methyl, phenyl or CF3.
1 + m is 3;
R1 is ;
where B is (a) phenyl or mono di or trisubstituted phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3;
(b) -CH2phenyl or mono or disubstituted -CH2phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3;
(c) pyridyl or mono di or trisubstituted pyridyl wherein the substitutents are independently chloro, methyl, phenyl or CF3; and (d) thiophene or mono or disubstituted thiophene wherein the substitutents are independently chloro, methyl, phenyl or CF3.
6. A according to Claim 5 wherein:
where B is (a) phenyl or mono di or trisubstituted phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3.
where B is (a) phenyl or mono di or trisubstituted phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3.
7. A of formula I according to Claim 1 I
wherein the group is an optionally mono di or trisubstituted group selected from the optional substitutents residing at 1, 2, or 3 of the unsubstituted positions on the above groups, the substituents selected from the group consisting of (a) hydroxy, (b) oxo, (c) cyano, (d) -NR6R7, (e) -NHCOR6R7, (f) -halogen, (g) -CF3, (h) -phenyl or mono, di or trisubstituted phenyl, the substituents independently selected from (1) hydroxy, (2) oxo, (3) cyano, (4) -NR6R7, (5) -NHCOR6R7, (6) -halogen, (7) -CF3, and (8) -C1-3 alkyl.
wherein the group is an optionally mono di or trisubstituted group selected from the optional substitutents residing at 1, 2, or 3 of the unsubstituted positions on the above groups, the substituents selected from the group consisting of (a) hydroxy, (b) oxo, (c) cyano, (d) -NR6R7, (e) -NHCOR6R7, (f) -halogen, (g) -CF3, (h) -phenyl or mono, di or trisubstituted phenyl, the substituents independently selected from (1) hydroxy, (2) oxo, (3) cyano, (4) -NR6R7, (5) -NHCOR6R7, (6) -halogen, (7) -CF3, and (8) -C1-3 alkyl.
8. A compound according to Claim 7 wherein:
R1 is selected from a group consisting of:
C1, C2, C3, C4, C5, C6, C7 or C8 linear or branched alkyl, di, tri or tetra substituted, the substitutents independently selected from:
(a) hydroxy, (b) Cl or F, (c) trifluoromethyl, (d) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) C1-3alkyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (7) -NR6COR7, wherein R6 and R7 are independently selected from:
(a) hydrogen, (b) C1-6 alkyl, or mono or disubstituted C1-6 alkyl, the substitutents independently selected from (1) phenyl,unsubstituted or substituted with hydroxy, C1-3alkyl, cyano, halogen, trifluoromethyl or C1-4 alkoxy, (2) hydroxy, (3) oxo, (4) cyano, (5) halogen, (6) trifluoromethyl, (c) phenyl, pyridinyl or thiophene or mono, di or trisubstituted phenyl, pyridinyl or thiophene, the substitutents independently selected from (1) hydroxy, (2) C1-4 alkyl, (3) cyano, (4) halogen, (5) trifluoromethyl, (d) C1-3alkyloxy, or R6 and R7 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or disubstituted, the substituents independently selected from (a) hydroxy, (b) oxo, (c) cyano, (d) halogen, (e) trifluoromethyl, (8) -NR6CO2R7, (9) -NR6CONHR7, (10) -NR6S(O)jR7, wherein j is 1 or 2, (11) -CONR6R7, (12) -COR6, (13) -CO2R6, (14) -OR6, (15) -S(O)kR6, (16) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(a) pyrazinyl, (b) pyrazolyl, (c) pyridyl, (d) pyrimidyl, and (e) thienyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from, (a) hydroxy, (b) oxo, .
(c) cyano, (d) halogen, (e) trifluoromethyl, (e) -NR6COR7, (f) -NR6CO2R7, (g) -NR6CONHR7, (h) -NHS(O)jR6, (i) -COR6, (j) -OR6, (k) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) pyrazinyl, (2) pyrazolyl, (3) pyridyl, (4) pyrimidyl, and (5) thienyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from (a) phenyl, (b) hydroxy, (c) oxo, (d) cyano, (e) halogen, and (f) trifluoromethyl.
R1 is selected from a group consisting of:
C1, C2, C3, C4, C5, C6, C7 or C8 linear or branched alkyl, di, tri or tetra substituted, the substitutents independently selected from:
(a) hydroxy, (b) Cl or F, (c) trifluoromethyl, (d) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) C1-3alkyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (7) -NR6COR7, wherein R6 and R7 are independently selected from:
(a) hydrogen, (b) C1-6 alkyl, or mono or disubstituted C1-6 alkyl, the substitutents independently selected from (1) phenyl,unsubstituted or substituted with hydroxy, C1-3alkyl, cyano, halogen, trifluoromethyl or C1-4 alkoxy, (2) hydroxy, (3) oxo, (4) cyano, (5) halogen, (6) trifluoromethyl, (c) phenyl, pyridinyl or thiophene or mono, di or trisubstituted phenyl, pyridinyl or thiophene, the substitutents independently selected from (1) hydroxy, (2) C1-4 alkyl, (3) cyano, (4) halogen, (5) trifluoromethyl, (d) C1-3alkyloxy, or R6 and R7 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or disubstituted, the substituents independently selected from (a) hydroxy, (b) oxo, (c) cyano, (d) halogen, (e) trifluoromethyl, (8) -NR6CO2R7, (9) -NR6CONHR7, (10) -NR6S(O)jR7, wherein j is 1 or 2, (11) -CONR6R7, (12) -COR6, (13) -CO2R6, (14) -OR6, (15) -S(O)kR6, (16) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(a) pyrazinyl, (b) pyrazolyl, (c) pyridyl, (d) pyrimidyl, and (e) thienyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from, (a) hydroxy, (b) oxo, .
(c) cyano, (d) halogen, (e) trifluoromethyl, (e) -NR6COR7, (f) -NR6CO2R7, (g) -NR6CONHR7, (h) -NHS(O)jR6, (i) -COR6, (j) -OR6, (k) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) pyrazinyl, (2) pyrazolyl, (3) pyridyl, (4) pyrimidyl, and (5) thienyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from (a) phenyl, (b) hydroxy, (c) oxo, (d) cyano, (e) halogen, and (f) trifluoromethyl.
9. A compound according to Claim 8 wherein:
R1 is selected from a group consisting of:
C1, C2, C3, C4, C5 or C6 linear or branched alkyl, di or tri substituted, the substitutents independently selected from:
(a) hydroxy, (b) Cl or F, (c) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) C1-3alkyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (d) -NR6COR7, wherein R6 is hydrogen or C1-3 alkyl and R7 is phenyl, pyridinyl or thiophene, phenylC1-3alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, wherein the phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, is optionally substituted with Cl, F, CF3 or C1-3 alkyl, (e) -NHS(O)jR6, (f) -COR6, (h) -OR6-
R1 is selected from a group consisting of:
C1, C2, C3, C4, C5 or C6 linear or branched alkyl, di or tri substituted, the substitutents independently selected from:
(a) hydroxy, (b) Cl or F, (c) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) C1-3alkyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (d) -NR6COR7, wherein R6 is hydrogen or C1-3 alkyl and R7 is phenyl, pyridinyl or thiophene, phenylC1-3alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, wherein the phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, is optionally substituted with Cl, F, CF3 or C1-3 alkyl, (e) -NHS(O)jR6, (f) -COR6, (h) -OR6-
10. A compound according to Claim 9 whereinwherein the group is an optionally mono di or trisubstituted group selected from the substitutents residing at 1, 2, or 3 of the positions 1, 2, 3, 4, 5, 6 or 7 of the above groups, the substituents selected from the group consisting of (a) hydroxy, (b) oxo, (c) cyano, (d) -NHR6, (e) -NR6R7, (f) -NHCOR6R7, (g) -halogen, (h) -CF3, (i) -phenyl or mono, di or trisubstituted phenyl, the substituents independently selected from (1) hydroxy, (2) oxo, (3) cyano, (4) -NHR6, (5) -NR6R7, (6) -NHCOR6R7, (7) -halogen, (8) -CF3, and (9) -C1-3 alkyl.
11. A compound according to Claim 10 wherein:
R1 is selected from a group consisting of:
C2, C3, C4 or C5 linear or branched alkyl, di or tri substituted, the substitutents independently selected from:
(a) hydroxy, (b) Cl or F, (c) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) methyl or ethyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (d) -NR6COR7, wherein R6 is methyl and R7 is phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, wherein the phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, is optionally substituted with Cl, F, CF3 or C1-3 alkyl.
R1 is selected from a group consisting of:
C2, C3, C4 or C5 linear or branched alkyl, di or tri substituted, the substitutents independently selected from:
(a) hydroxy, (b) Cl or F, (c) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl, (2) hydroxy, (3) methyl or ethyl, (4) cyano, (5) halogen, (6) trifluoromethyl, (d) -NR6COR7, wherein R6 is methyl and R7 is phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, wherein the phenyl, pyridinyl or thiophene, phenyl C1-3 alkyl, pyridinyl C1-3 alkyl or thiophenel C1-3 alkyl, is optionally substituted with Cl, F, CF3 or C1-3 alkyl.
12. A according to Claim 11 wherein:
R1 is where B is (a) phenyl or mono di or trisubstituted phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3;
(b) -CH2phenyl or mono or disubstituted -CH2phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3;
(c) pyridyl or mono di or trisubstituted pyridyl wherein the substitutents are independently chloro, methyl, phenyl or CF3; or (d) thiophene or mono or disubstituted thiophene wherein the substitutents are independently chloro, methyl, phenyl or CF3.
R1 is where B is (a) phenyl or mono di or trisubstituted phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3;
(b) -CH2phenyl or mono or disubstituted -CH2phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3;
(c) pyridyl or mono di or trisubstituted pyridyl wherein the substitutents are independently chloro, methyl, phenyl or CF3; or (d) thiophene or mono or disubstituted thiophene wherein the substitutents are independently chloro, methyl, phenyl or CF3.
13. A compound according to Claim 12 wherein B is phenyl or mono di or trisubstituted phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3.
14. A compound according to Claim 1 selected from the group consisting of (a) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-t-butoxycarbonyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(b) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(c) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methyl-amino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(d) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-bistrifluoro-methylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(e) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(f) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(g) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-trifluoromethyl-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(h) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichloro-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(i) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-trifluoromethyl-phenylacetyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(j) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-isopropyloxy-phenylacetyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(k) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzenesulfonyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(l) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -benzyoxycarbonyl-spiro(indoline-3 ,4'-piperidine);
(m) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)-spiro(indoline-3 ,4'-piperidine);
(n) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -propionyl-spiro(indoline-3 ,4'-piperidine);
(o) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino)) butyl)-1-formyl-spiro(indoline-3,4'-piperidine);
(p) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -t-butylcarbonyl-spiro(indoline-3 ,4'-piperidine);
(q) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -methylaminocarbonyl-spiro(indoline-3,4'-piperidine);
(r) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -ethoxycarbonyl-spiro(indoline-3 ,4'-piperidine);
(s) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -ethanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(t) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -i-propanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(u) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)-1 '-methyl-1 -methanesulfonyl-spiro-indoline-3,4'-piperidinium iodide;
(v) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3-methylbenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(w) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5-bis(trifluoromethyl)benzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(x) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5-dimethylbenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro-(indoline-3 ,4'-piperidine);
(y) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5-dichlorobenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro-(indoline-3 ,4'-piperidine);
xs (aa) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-difluorobenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(ab) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-fluoro-5-(trifluoromethyl)benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(ac) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(1-naphthoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(ad) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(2-chlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3 ,4'-piperidine);
(ae) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3 ,4'-piperidine);
(af) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-chlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3 ,4'-piperidine);
(ag) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3 ,4'-piperidine);
(ah) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-fluoro-5-(trifluoromethyl)benzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine);
(ai) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine).
(aj) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-bromo-5-methylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(ak) 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -(2-aminoacetyl)-spiro(indoline-3,4'-piperidine);
(al) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -methyl-spiro(indol-2-one-3,4'-piperidine);
(am) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)(methylamino))butyl)- 1 -methyl-spiro(isoindol- 1 -one-3 ,4'-piperidine);
(an) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2-oxo-tetrahydroquinoline-4,4'-piperidine); and (ao) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)(methylamino))butyl)- 1 -methyl-spiro(2-oxo-tetrahydroquinoline-4 ,4 '-piperidine) .
15. A compound according to Claim 1 selected from (a) 1'-(3-(S)-(4-fluorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (b) 1'-(3-(S)-(3-chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine), (c) 1'-(3-(S)-(4-chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-1-acetyl-spiro(indoline-3,4'-piperidine), (d) 1'-(3-(S)-(3,4-difluorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-1-acetyl-spiro(indoline-3,4'-piperidine), (e) 1'-(3-(S)-(3,4-methylenedioxyphenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine), (f) 1'-(3-(RS)-(3,5-dichlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (g) 1'-(3-(S)-(4-chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine), (h) 1'-(3-(RS)-(4-pyridyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-1-acetyl-spiro(indoline-3,4'-piperidine), (i) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)(ethylamino))butyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (j) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)(methylamino))butyl)-5-fluoro-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine), (k) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)(methylamino))butyl)-5-fluoro-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine), (l) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-5-fluoro-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine), (m) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)(methylamino))butyl)-5-fluoro-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine), (n) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)-(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3 ,4'-piperidine), (o) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine), (p) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzofuran-3 ,4'-piperidine), (q) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine), (r) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzofuran-3 ,4'-piperidine), (s) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine), (t) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(4-fluoro- 1-napthoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzofuran-3 ,4'-piperidine), (u) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3 ,4'-piperidine), (v) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3 ,4'-piperidine), (w) 1'-(3-((S)-(4-chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene -3 ,4'-piperidine), (x) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3 ,4'-piperidine)- 1 -oxide, (y) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1-napthylmethyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3 ,4'-piperidine)- 1 -oxide, (z) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine)- 1,1 -dioxide, (aa) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3 ,4'-piperidine)- 1 ,1 -dioxide, (ab) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine)- 1,1 -dioxide, (ac) 1'-(3-((S)-(4-chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3 ,4'-piperidine)- 1 ,1 -dioxide, (ad) 1'-(3-((S)-(4-chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3 ,4'-piperidine)- 1 -oxide, (ae) 1'-(3-(S)-(4-chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine), 1-oxide, (af) 1'-(3-(S)-(4-chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine), 1, 1-dioxide, (ag) 1 '-benzyloxycarbonyl-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (ah) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)- 1 -methanesulfonyl-5-methoxy-spiro(indoline-3 ,4'-piperidine), (ai) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)- 1 -methanesulfonyl-5-methyl-spiro(indoline-3 ,4'-piperidine), 5-chloro- 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(methylamino)butyl)- 1-methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (ak) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-5-fluoro-1 -methanesulfonyl-spiro(indoline-3,4'-piperidine), (al) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-7-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (am) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-1-methanesulfonyl-5-methyl-spiro(indoline-3,4'-piperidine), (an) 5-chloro-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)(methylamino))butyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (ao) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-1-methanesulfonyl-5-methoxy-spiro(indoline-3,4'-piperidine), (ap) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (aq) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (ar) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (as) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (at) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)-(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (au) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-7-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (av) 1 -acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-t-butoxycarbonyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (aw) 1-acetyl-5-chloro-1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-spiro(indoline-3,4'-piperidine), (ax) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-5-methyl-spiro(indoline-3,4'-piperidine), (ay) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (az) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-6-fluoro-spiro(indoline-3,4'-piperidine), (ba) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-4-fluoro-spiro(indoline-3,4'-piperidine), (bb) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methylamino))butyl)-4-fluoro-spiro(indoline-3 ,4'-piperidine), (bc) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5,-dimethylbenzoyl)(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine), (bd) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine), (be) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5,-dimethylbenzoyl)(methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine), (bf) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (bg) 1-acetyl-1'-5-chloro-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5,-dimethylbenzoyl)(methylamino))butyl)-spiro(indoline-3,4'-piperidine), (bh) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (bi) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (bj) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3 ,4'-piperidine), (bk) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-5 -fluoro-spiro(indoline-3 ,4'-piperidine), (bl) 1 -acetyl- 1'-(3 -((S)-(3 ,4-dichlorophenyl))-4-(N-(3 -isopropoxybenzoyl)(methylamino))butyl)-5 -fluoro-spiro(indoline-3 ,4'-piperidine), (bm) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3 ,4'-piperidine), (bn) 1 -acetyl- 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3 ,5-dimethylbenzoyl)(methylamino))butyl)-5-methyl-spiro(indoline-3 ,4'-piperidine), (bo) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3 ,4'-piperidine), (bp) 1 -acetyl- 1'-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-( 1-napthoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3 ,4'-piperidine), (bq) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-( 1 -napthoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (br) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (bs) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3 ,4'-piperidine), (bt) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3 ,4'-piperidine) sulfone, (bu) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine), (bv) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthyl)(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine), (bw) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthyl)(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine), (bx) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthoyl)(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine), (by) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthoyl)(methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine), (bz) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1-napthylmethyl)(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (ca) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1-napthylmethyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (cb) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthylmethyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (cd) 1'-(5-fluoroindolyl-3-(2-ethanoyl))-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (ce) 1'-(2-(3-(5-fluoroindolyl))ethyl))-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (cf) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chloro-4-fluorobenzoyl)(methylamino))butyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (cg) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chloro-4-fluorobenzoyl)(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (ch) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluorobenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine), (ci) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluorobenzoyl)(methylamino))butyl)-5-fluoro- 1 -acetyl-spiro(indoline-3,4'-piperidine), (cj) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chloro-4-fluorobenzoyl)(methylamino))butyl)-5-fluoro- 1 -acetyl-spiro(indoline-3,4'-piperidine), (ck) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3,5-dimethylbenzoyl)(methylamino))butyl)-5-fluoro- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (cl) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (cm) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3-trifluoromethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (cn) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine), (co) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3-trifluoromethylbenzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine), (cp) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-naphthoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (cq) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(4-fluoro- 1-naphthoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (cr) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(1-naphthoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (cs) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))-4-phenyl-butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (ct) 1'-(4-(N-(3,5-dimethylbenzoyl)(methylamino))-4-(phenyl)butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (cu) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-( 1-(2-phenylimidazolo))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (cv) 1'-(3-((S)-(3,4-dichlorophenyl))-4-((N-(3,5-dimethylbenzoyl)(methylamino))-4-(methyl)butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (cw) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-((N-(4-fluoro- 1-napthyl)(methylamino))-4-(methyl)butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (cx) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(R and S)-(N-(3 ,5 -dimethylbenzoyl)(methylamino))hexyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine), (cy) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(R and S)-(N-(3 ,5-dimethylbenzoyl)(methylamino))hexyl)- 1 -acetyl-S-fluoro-spiro(indoline-3 ,4'-piperidine), (cz) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(R and S)-(N-(3,5-dimethylbenzoyl)(methylamino))heptyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine), (da) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(R and S)-(N-(3,5-dimethylbenzoyl)(methylamino))heptyl)- 1 -acetyl-5-fluoro-spiro(indoline-3 ,4'-piperidine), (db) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(R and S)-hydroxy-5-(3,5-dimethylphenyl)pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (dc) 1'-(3-(R)-(3,4-dichlorophenyl)-5-(N-(3,5-dimethylphenyl)(methylamino))-5-oxo-pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (dd) 1'-(3-(R)-(3,4-dichlorophenyl))-5-(3,5-dimethylphenyl)-5-oxo-pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (de) 1'-(3-(R)-(3,4-dichlorophenyl)-6-(3,5-dimethylphenyl)-5-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (df) 1'-(3-(S)-(3,4-dichlorophenyl)-6-(3,5-dimethylphenyl)-6-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), and (dg) 1'-(3-(S)-(3,4-dichlorophenyl)-6-(3,5-dimethylphenyl)-5-(R&S)-methyl-6-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine).
(dh) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(3,5-(bistrifluoromethyl)benzyloxy)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine)
(b) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(c) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methyl-amino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(d) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-bistrifluoro-methylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(e) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(f) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(g) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-trifluoromethyl-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(h) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichloro-benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(i) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-trifluoromethyl-phenylacetyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(j) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-isopropyloxy-phenylacetyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(k) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzenesulfonyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(l) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -benzyoxycarbonyl-spiro(indoline-3 ,4'-piperidine);
(m) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)-spiro(indoline-3 ,4'-piperidine);
(n) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -propionyl-spiro(indoline-3 ,4'-piperidine);
(o) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino)) butyl)-1-formyl-spiro(indoline-3,4'-piperidine);
(p) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -t-butylcarbonyl-spiro(indoline-3 ,4'-piperidine);
(q) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -methylaminocarbonyl-spiro(indoline-3,4'-piperidine);
(r) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -ethoxycarbonyl-spiro(indoline-3 ,4'-piperidine);
(s) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -ethanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(t) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)- 1 -i-propanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(u) 1'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)(methylamino))butyl)-1 '-methyl-1 -methanesulfonyl-spiro-indoline-3,4'-piperidinium iodide;
(v) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3-methylbenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(w) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5-bis(trifluoromethyl)benzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(x) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5-dimethylbenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro-(indoline-3 ,4'-piperidine);
(y) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5-dichlorobenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro-(indoline-3 ,4'-piperidine);
xs (aa) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-difluorobenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(ab) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-fluoro-5-(trifluoromethyl)benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(ac) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(1-naphthoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine);
(ad) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(2-chlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3 ,4'-piperidine);
(ae) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3 ,4'-piperidine);
(af) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-chlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3 ,4'-piperidine);
(ag) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulfonyl-spiro(indoline-3 ,4'-piperidine);
(ah) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-fluoro-5-(trifluoromethyl)benzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine);
(ai) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine).
(aj) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-bromo-5-methylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine);
(ak) 1'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -(2-aminoacetyl)-spiro(indoline-3,4'-piperidine);
(al) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -methyl-spiro(indol-2-one-3,4'-piperidine);
(am) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)(methylamino))butyl)- 1 -methyl-spiro(isoindol- 1 -one-3 ,4'-piperidine);
(an) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2-oxo-tetrahydroquinoline-4,4'-piperidine); and (ao) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)(methylamino))butyl)- 1 -methyl-spiro(2-oxo-tetrahydroquinoline-4 ,4 '-piperidine) .
15. A compound according to Claim 1 selected from (a) 1'-(3-(S)-(4-fluorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (b) 1'-(3-(S)-(3-chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine), (c) 1'-(3-(S)-(4-chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-1-acetyl-spiro(indoline-3,4'-piperidine), (d) 1'-(3-(S)-(3,4-difluorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-1-acetyl-spiro(indoline-3,4'-piperidine), (e) 1'-(3-(S)-(3,4-methylenedioxyphenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine), (f) 1'-(3-(RS)-(3,5-dichlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (g) 1'-(3-(S)-(4-chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine), (h) 1'-(3-(RS)-(4-pyridyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-1-acetyl-spiro(indoline-3,4'-piperidine), (i) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)(ethylamino))butyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (j) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)(methylamino))butyl)-5-fluoro-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine), (k) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)(methylamino))butyl)-5-fluoro-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine), (l) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-5-fluoro-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine), (m) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)(methylamino))butyl)-5-fluoro-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine), (n) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)-(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3 ,4'-piperidine), (o) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine), (p) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzofuran-3 ,4'-piperidine), (q) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine), (r) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzofuran-3 ,4'-piperidine), (s) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzofuran-3,4'-piperidine), (t) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(4-fluoro- 1-napthoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzofuran-3 ,4'-piperidine), (u) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3 ,4'-piperidine), (v) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3 ,4'-piperidine), (w) 1'-(3-((S)-(4-chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene -3 ,4'-piperidine), (x) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3 ,4'-piperidine)- 1 -oxide, (y) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1-napthylmethyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3 ,4'-piperidine)- 1 -oxide, (z) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine)- 1,1 -dioxide, (aa) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3 ,4'-piperidine)- 1 ,1 -dioxide, (ab) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3,4'-piperidine)- 1,1 -dioxide, (ac) 1'-(3-((S)-(4-chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3 ,4'-piperidine)- 1 ,1 -dioxide, (ad) 1'-(3-((S)-(4-chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3 ,4'-piperidine)- 1 -oxide, (ae) 1'-(3-(S)-(4-chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine), 1-oxide, (af) 1'-(3-(S)-(4-chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine), 1, 1-dioxide, (ag) 1 '-benzyloxycarbonyl-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (ah) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)- 1 -methanesulfonyl-5-methoxy-spiro(indoline-3 ,4'-piperidine), (ai) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)- 1 -methanesulfonyl-5-methyl-spiro(indoline-3 ,4'-piperidine), 5-chloro- 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(methylamino)butyl)- 1-methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (ak) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-5-fluoro-1 -methanesulfonyl-spiro(indoline-3,4'-piperidine), (al) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-7-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (am) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-1-methanesulfonyl-5-methyl-spiro(indoline-3,4'-piperidine), (an) 5-chloro-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)(methylamino))butyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (ao) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-1-methanesulfonyl-5-methoxy-spiro(indoline-3,4'-piperidine), (ap) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (aq) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (ar) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (as) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (at) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)-(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (au) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-7-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (av) 1 -acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-t-butoxycarbonyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (aw) 1-acetyl-5-chloro-1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-spiro(indoline-3,4'-piperidine), (ax) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-5-methyl-spiro(indoline-3,4'-piperidine), (ay) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (az) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-6-fluoro-spiro(indoline-3,4'-piperidine), (ba) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-4-fluoro-spiro(indoline-3,4'-piperidine), (bb) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methylamino))butyl)-4-fluoro-spiro(indoline-3 ,4'-piperidine), (bc) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5,-dimethylbenzoyl)(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine), (bd) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine), (be) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5,-dimethylbenzoyl)(methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine), (bf) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (bg) 1-acetyl-1'-5-chloro-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5,-dimethylbenzoyl)(methylamino))butyl)-spiro(indoline-3,4'-piperidine), (bh) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (bi) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (bj) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3 ,4'-piperidine), (bk) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butyl)-5 -fluoro-spiro(indoline-3 ,4'-piperidine), (bl) 1 -acetyl- 1'-(3 -((S)-(3 ,4-dichlorophenyl))-4-(N-(3 -isopropoxybenzoyl)(methylamino))butyl)-5 -fluoro-spiro(indoline-3 ,4'-piperidine), (bm) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3 ,4'-piperidine), (bn) 1 -acetyl- 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3 ,5-dimethylbenzoyl)(methylamino))butyl)-5-methyl-spiro(indoline-3 ,4'-piperidine), (bo) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3 ,4'-piperidine), (bp) 1 -acetyl- 1'-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-( 1-napthoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3 ,4'-piperidine), (bq) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-( 1 -napthoyl)-(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (br) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (bs) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3 ,4'-piperidine), (bt) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthoyl)(methylamino))butyl)-spiro(2,3 -dihydrobenzothiophene-3 ,4'-piperidine) sulfone, (bu) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine), (bv) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthyl)(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine), (bw) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthyl)(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine), (bx) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthoyl)(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine), (by) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthoyl)(methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine), (bz) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1-napthylmethyl)(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (ca) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro- 1-napthylmethyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (cb) 1-acetyl-1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-napthylmethyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (cd) 1'-(5-fluoroindolyl-3-(2-ethanoyl))-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (ce) 1'-(2-(3-(5-fluoroindolyl))ethyl))-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (cf) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chloro-4-fluorobenzoyl)(methylamino))butyl)-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (cg) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chloro-4-fluorobenzoyl)(methylamino))butyl)-5-fluoro-1-methanesulfonyl-spiro(indoline-3,4'-piperidine), (ch) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluorobenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine), (ci) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluorobenzoyl)(methylamino))butyl)-5-fluoro- 1 -acetyl-spiro(indoline-3,4'-piperidine), (cj) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chloro-4-fluorobenzoyl)(methylamino))butyl)-5-fluoro- 1 -acetyl-spiro(indoline-3,4'-piperidine), (ck) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3,5-dimethylbenzoyl)(methylamino))butyl)-5-fluoro- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (cl) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (cm) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3-trifluoromethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (cn) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3,5-dimethylbenzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine), (co) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3-trifluoromethylbenzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine), (cp) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-1-naphthoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (cq) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(4-fluoro- 1-naphthoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (cr) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(1-naphthoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (cs) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))-4-phenyl-butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (ct) 1'-(4-(N-(3,5-dimethylbenzoyl)(methylamino))-4-(phenyl)butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (cu) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-( 1-(2-phenylimidazolo))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (cv) 1'-(3-((S)-(3,4-dichlorophenyl))-4-((N-(3,5-dimethylbenzoyl)(methylamino))-4-(methyl)butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (cw) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-((N-(4-fluoro- 1-napthyl)(methylamino))-4-(methyl)butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine), (cx) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(R and S)-(N-(3 ,5 -dimethylbenzoyl)(methylamino))hexyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine), (cy) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(R and S)-(N-(3 ,5-dimethylbenzoyl)(methylamino))hexyl)- 1 -acetyl-S-fluoro-spiro(indoline-3 ,4'-piperidine), (cz) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(R and S)-(N-(3,5-dimethylbenzoyl)(methylamino))heptyl)- 1 -acetyl-spiro(indoline-3,4'-piperidine), (da) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(R and S)-(N-(3,5-dimethylbenzoyl)(methylamino))heptyl)- 1 -acetyl-5-fluoro-spiro(indoline-3 ,4'-piperidine), (db) 1'-(3-((S)-(3,4-dichlorophenyl))-4-(R and S)-hydroxy-5-(3,5-dimethylphenyl)pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (dc) 1'-(3-(R)-(3,4-dichlorophenyl)-5-(N-(3,5-dimethylphenyl)(methylamino))-5-oxo-pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (dd) 1'-(3-(R)-(3,4-dichlorophenyl))-5-(3,5-dimethylphenyl)-5-oxo-pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (de) 1'-(3-(R)-(3,4-dichlorophenyl)-6-(3,5-dimethylphenyl)-5-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), (df) 1'-(3-(S)-(3,4-dichlorophenyl)-6-(3,5-dimethylphenyl)-6-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine), and (dg) 1'-(3-(S)-(3,4-dichlorophenyl)-6-(3,5-dimethylphenyl)-5-(R&S)-methyl-6-oxo-hexyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine).
(dh) 1'-(3-(S)-(3,4-dichlorophenyl)-4-(3,5-(bistrifluoromethyl)benzyloxy)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine)
15. A pharmaceutical composition for antagonizing the effect of substance P in a patient in need of such treatment comprising a pharmaceutically acceptable carrier and a non-toxic threapeutically effective amount of the compound of Claim 1.
16. A pharmaceutical composition for the antagonizing the effect of neurokinin A, in a patient in need of such treatment comprising a pharmaceutically acceptable carrier and a non-toxic threapeutically effective amount of the compound of Claim 1.
17. A method for antagonizing the effect of substance P
in a patient in need of such antagonizing which comprises the administration to the patient of a non-toxic therapeutically effective amount of the compound according to Claim 1.
in a patient in need of such antagonizing which comprises the administration to the patient of a non-toxic therapeutically effective amount of the compound according to Claim 1.
18. A method for antagonizing the effect of neurokinin A in a patient in need of such antagonizing which comprises the administration to the patient of a non-toxic therapeutically effective amount of the compound according to Claim 1.
19. A method of treating or preventing asthma in a pateint in need thereof which comprises the a-lministration to the patient of a non-toxic therapeutically effective amount of the compound of Claim 1.
20. A process of making compounds of formula I
according to Claims 1 to 14 I
comprising the steps of:
(a) reacting a compound of formula A
I
in a suitable solvent with a compound of formula K1-X1 wherein X1 is a leaving group optionally in the presence of a suitable base such as trialkylamine; or (b) reacting a compound of formula A in a second suitable solvent with a compound of the formula R-CH(O), wherein R-CH2 is R1 as defined above, in the presence of a reducing agent; or (c) reacting a compound of formula A in a halocarbon solvent with a compound of the formula R-C(O)X2 wherein X2 is a suitable leaving group such as bromo or chloro in the presence of a suitable base;
to yield a compound of formula I.
according to Claims 1 to 14 I
comprising the steps of:
(a) reacting a compound of formula A
I
in a suitable solvent with a compound of formula K1-X1 wherein X1 is a leaving group optionally in the presence of a suitable base such as trialkylamine; or (b) reacting a compound of formula A in a second suitable solvent with a compound of the formula R-CH(O), wherein R-CH2 is R1 as defined above, in the presence of a reducing agent; or (c) reacting a compound of formula A in a halocarbon solvent with a compound of the formula R-C(O)X2 wherein X2 is a suitable leaving group such as bromo or chloro in the presence of a suitable base;
to yield a compound of formula I.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7290493A | 1993-06-07 | 1993-06-07 | |
| US072,904 | 1993-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2163995A1 true CA2163995A1 (en) | 1994-12-22 |
Family
ID=22110458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002163995A Abandoned CA2163995A1 (en) | 1993-06-07 | 1994-05-17 | Spiro-substituted azacycles as neurokinin antagonists |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0702681A1 (en) |
| JP (1) | JPH08511522A (en) |
| AU (1) | AU680020B2 (en) |
| CA (1) | CA2163995A1 (en) |
| HR (1) | HRP940337A2 (en) |
| IL (1) | IL109836A0 (en) |
| WO (1) | WO1994029309A1 (en) |
| ZA (1) | ZA943946B (en) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589489A (en) * | 1993-12-15 | 1996-12-31 | Zeneca Limited | Cyclic amide derivatives for treating asthma |
| US5434158A (en) * | 1994-04-26 | 1995-07-18 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin-3 antagonists |
| GB9408872D0 (en) * | 1994-05-03 | 1994-06-22 | Zeneca Ltd | Heterocyclic compounds |
| GB9415996D0 (en) * | 1994-08-08 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
| TW432061B (en) * | 1994-08-09 | 2001-05-01 | Pfizer Res & Dev | Lactams |
| US5998444A (en) * | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
| DE69534213T2 (en) * | 1994-10-25 | 2006-01-12 | Astrazeneca Ab | Therapeutically effective heterocycles |
| US6008223A (en) * | 1994-10-27 | 1999-12-28 | Zeneca Limited | Therapeutic compounds |
| GB9502644D0 (en) * | 1995-02-10 | 1995-03-29 | Zeneca Ltd | Heterocyclic derivatives |
| WO1996033189A1 (en) * | 1995-04-19 | 1996-10-24 | Merck & Co., Inc. | Process for the preparation of spiroindolines |
| GB9508786D0 (en) | 1995-04-29 | 1995-06-21 | Zeneca Ltd | Substituted heterocycles |
| US5719156A (en) * | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5795894A (en) * | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| US5696267A (en) * | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US5654316A (en) * | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
| US5892039A (en) * | 1995-08-31 | 1999-04-06 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| EA199800337A1 (en) * | 1995-10-27 | 1998-10-29 | Мерк Энд Ко., Инк. | METHOD OF OBTAINING GROWTH HORMONE GROWTH STRENGTHEN THE SECRETION |
| US6028196A (en) * | 1995-10-27 | 2000-02-22 | Merck & Co., Inc. | Process for the preparation of a growth hormone secretagogue |
| GB9523526D0 (en) * | 1995-11-17 | 1996-01-17 | Zeneca Ltd | Therapeutic compounds |
| EP1019410A1 (en) * | 1995-11-23 | 2000-07-19 | MERCK SHARP & DOHME LTD. | Spiro-piperidine derivatives and their use as tachykinin antagonists |
| RU2135494C1 (en) | 1995-12-01 | 1999-08-27 | Санкио Компани Лимитед | Heterocyclic compounds and composition on said showing antagonistic effect with respect to tachykinin receptors |
| GB9601724D0 (en) * | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
| GB9603137D0 (en) * | 1996-02-15 | 1996-04-17 | Merck Sharp & Dohme | Therapeutic agents |
| GB9603136D0 (en) * | 1996-02-15 | 1996-04-17 | Merck Sharp & Dohme | Therapeutic agents |
| US5869488A (en) * | 1996-05-01 | 1999-02-09 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5691362A (en) * | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| WO1997049710A1 (en) * | 1996-06-21 | 1997-12-31 | Merck Sharp & Dohme Limited | Spiro-piperidine derivatives and their use as therapeutic agents |
| US6046333A (en) * | 1996-10-25 | 2000-04-04 | Merck & Co., Inc. | Convergent process for the preparation of a growth hormone secretagogue |
| ES2202481T3 (en) * | 1996-10-28 | 2004-04-01 | Schering Corporation | ARILALQUILAMINAS SUBSTITUTED AS ANTAGONIST OF NEUROQUININA. |
| US5789422A (en) * | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
| US5945428A (en) * | 1996-11-01 | 1999-08-31 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US5962462A (en) * | 1996-12-13 | 1999-10-05 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| US5783579A (en) * | 1996-12-20 | 1998-07-21 | Schering Corporation | Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists |
| DK0987269T3 (en) | 1997-05-30 | 2003-10-06 | Sankyo Co | Salts of optically active sulfoxide derivative |
| US6013644A (en) * | 1997-12-12 | 2000-01-11 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| US6063926A (en) * | 1998-11-18 | 2000-05-16 | Schering Corporation | Substituted oximes as neurokinin antagonists |
| GB9907571D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Compounds |
| AU2002259147A1 (en) | 2001-05-08 | 2002-11-18 | Schering Corporation | Use of neurokinin receptor antagonists to treat androgen-dependent diseases |
| BR0212378A (en) | 2001-09-06 | 2004-10-19 | Schering Corp | 17betahydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| CA2463626C (en) | 2001-10-17 | 2011-05-24 | Schering Corporation | Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| GB0213715D0 (en) | 2002-06-14 | 2002-07-24 | Syngenta Ltd | Chemical compounds |
| CA2503720A1 (en) * | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Gamma-aminoamide modulators of chemokine receptor activity |
| TW200524868A (en) * | 2003-07-31 | 2005-08-01 | Zeria Pharm Co Ltd | Benzylamine derivatives |
| US7091211B2 (en) | 2003-07-31 | 2006-08-15 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| GB0328908D0 (en) | 2003-12-12 | 2004-01-14 | Syngenta Participations Ag | Chemical compounds |
| GB0328907D0 (en) | 2003-12-12 | 2004-01-14 | Syngenta Participations Ag | Chemical compounds |
| US7479496B2 (en) | 2004-02-19 | 2009-01-20 | Bristol-Myers Squibb Company | Substituted spiro azabicyclics as modulators of chemokine receptor activity |
| US7288563B2 (en) | 2004-02-19 | 2007-10-30 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
| US7381738B2 (en) | 2004-02-19 | 2008-06-03 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
| US7230022B2 (en) | 2004-02-19 | 2007-06-12 | Bristol-Myers Squibb Company | Substituted fused bicyclic amines as modulators of chemokine receptor activity |
| US7354925B2 (en) | 2004-03-29 | 2008-04-08 | Pfizer Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists |
| KR101412339B1 (en) | 2004-07-15 | 2014-06-25 | 알바니 몰레큘라 리써치, 인크. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| MX2007011079A (en) | 2005-03-08 | 2007-10-08 | Janssen Pharmaceutica Nv | Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists. |
| US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
| CN101495184A (en) | 2005-07-15 | 2009-07-29 | Amr科技公司 | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| SI2805945T1 (en) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| CA2690191C (en) | 2007-06-27 | 2015-07-28 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| CA2717509A1 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| GB0808030D0 (en) * | 2008-05-01 | 2008-06-11 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| UA105182C2 (en) | 2008-07-03 | 2014-04-25 | Ньюрексон, Інк. | Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity |
| WO2010027567A2 (en) | 2008-07-23 | 2010-03-11 | Schering Corporation | Tricyclic spirocycle derivatives and methods of use thereof |
| EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | Inhibitors of akt activity |
| US9034899B2 (en) | 2009-05-12 | 2015-05-19 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| US8815894B2 (en) | 2009-05-12 | 2014-08-26 | Bristol-Myers Squibb Company | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| CA2760837C (en) | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| WO2011095581A1 (en) | 2010-02-05 | 2011-08-11 | Intervet International B.V. | S piroindoline compounds for use as anthelminthi cs |
| US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
| US8518907B2 (en) | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
| EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| WO2012143879A1 (en) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| WO2013017678A1 (en) | 2011-08-04 | 2013-02-07 | Intervet International B.V. | Novel spiroindoline compounds |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| US20130310435A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
| US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
| US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
| US9855286B2 (en) | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
| AU2013323508B2 (en) | 2012-09-28 | 2017-11-02 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
| ES2651347T3 (en) | 2012-11-28 | 2018-01-25 | Merck Sharp & Dohme Corp. | Compositions and methods for cancer treatment |
| CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP2881391A1 (en) | 2013-12-05 | 2015-06-10 | Bayer Pharma Aktiengesellschaft | Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof |
| ES2748694T3 (en) * | 2014-11-21 | 2020-03-17 | Esteve Pharmaceuticals Sa | Spiroisoquinolin-1,4'-piperidine compounds with multimodal pain relief |
| EP3525785A4 (en) | 2016-10-12 | 2020-03-25 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3301857A (en) * | 1963-08-26 | 1967-01-31 | Hoffmann La Roche | Spiro |
| JPS54109983A (en) * | 1978-02-13 | 1979-08-29 | Sumitomo Chem Co Ltd | Novel spiroamine derivative and its preparation |
| EP0360390A1 (en) * | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
| IL96507A0 (en) * | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| CA2037287A1 (en) * | 1990-03-02 | 1991-09-03 | Ben E. Evans | Spirocyclic oxytocin antagonists |
| NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
-
1994
- 1994-05-17 EP EP95901979A patent/EP0702681A1/en not_active Ceased
- 1994-05-17 WO PCT/US1994/005545 patent/WO1994029309A1/en not_active Application Discontinuation
- 1994-05-17 AU AU72011/94A patent/AU680020B2/en not_active Ceased
- 1994-05-17 JP JP7501802A patent/JPH08511522A/en active Pending
- 1994-05-17 CA CA002163995A patent/CA2163995A1/en not_active Abandoned
- 1994-05-31 IL IL10983694A patent/IL109836A0/en unknown
- 1994-06-06 ZA ZA943946A patent/ZA943946B/en unknown
- 1994-06-06 HR HR08/072,904A patent/HRP940337A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HRP940337A2 (en) | 1997-04-30 |
| ZA943946B (en) | 1995-01-20 |
| JPH08511522A (en) | 1996-12-03 |
| AU680020B2 (en) | 1997-07-17 |
| WO1994029309A1 (en) | 1994-12-22 |
| IL109836A0 (en) | 1994-08-26 |
| AU7201194A (en) | 1995-01-03 |
| EP0702681A1 (en) | 1996-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU680020B2 (en) | Spiro-substituted azacycles as neurokinin antagonists | |
| US6013652A (en) | Spiro-substituted azacycles as neurokinin antagonists | |
| US5869496A (en) | Spiro-substituted azacycles as tachykinin receptor antagonists | |
| KR930009441B1 (en) | Substance p antagonists | |
| US7902366B2 (en) | NK1 antagonists | |
| JP2500279B2 (en) | Azabicyclic compounds, pharmaceutical compositions containing them and methods of use for therapy | |
| US5604252A (en) | Azanorbornane derivatives | |
| US5434158A (en) | Spiro-substituted azacycles as neurokinin-3 antagonists | |
| US5877191A (en) | Phenyl spiroethercycloalkyl tachykinin receptor antagonists | |
| JP4212112B2 (en) | Non-peptidyl vasopressin V1a antagonist | |
| JP2005535659A (en) | 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1 (NK-1) antagonists for the treatment of vomiting, depression, anxiety and cough | |
| JPH06501267A (en) | Fused ring analogs of nitrogen-containing non-aromatic heterocycles | |
| JP2006523692A (en) | (Piperidinyloxy) phenyl, (piperidinyloxy) pyridinyl, (piperidinylsulfanyl) phenyl, and (piperidinylsulfanyl) pyridinyl compounds as 5-HT1F agonists | |
| JP4458853B2 (en) | NK1 antagonist | |
| CHENG et al. | PYRROLIDINE AND PIPERIDINE DERIVATES AS NK1 ANTAGONISTS | |
| Paliwal et al. | NK 1 antagonists | |
| NZ615293B2 (en) | Novel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |